CA2142707C - Benzo-fused lactams promote release of growth hormone - Google Patents

Benzo-fused lactams promote release of growth hormone

Info

Publication number
CA2142707C
CA2142707C CA002142707A CA2142707A CA2142707C CA 2142707 C CA2142707 C CA 2142707C CA 002142707 A CA002142707 A CA 002142707A CA 2142707 A CA2142707 A CA 2142707A CA 2142707 C CA2142707 C CA 2142707C
Authority
CA
Canada
Prior art keywords
methyl
amino
oxo
biphenyl
tetrahydro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA002142707A
Other languages
French (fr)
Other versions
CA2142707A1 (en
Inventor
Richard J. Bochis
Matthew J. Wyvratt
William R. Schoen
Robert J. Devita
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of CA2142707A1 publication Critical patent/CA2142707A1/en
Application granted granted Critical
Publication of CA2142707C publication Critical patent/CA2142707C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D223/00Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/16Benzazepines; Hydrogenated benzazepines
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23KFODDER
    • A23K20/00Accessory food factors for animal feeding-stuffs
    • A23K20/10Organic substances
    • A23K20/116Heterocyclic compounds
    • A23K20/132Heterocyclic compounds containing only one nitrogen as hetero atom
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23KFODDER
    • A23K20/00Accessory food factors for animal feeding-stuffs
    • A23K20/10Organic substances
    • A23K20/116Heterocyclic compounds
    • A23K20/137Heterocyclic compounds containing two hetero atoms, of which at least one is nitrogen
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/25Growth hormone-releasing factor [GH-RF] (Somatoliberin)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/28Insulins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/29Parathyroid hormone (parathormone); Parathyroid hormone-related peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/30Insulin-like growth factors (Somatomedins), e.g. IGF-1, IGF-2
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D281/00Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D281/02Seven-membered rings
    • C07D281/04Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D281/08Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D281/10Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06008Dipeptides with the first amino acid being neutral
    • C07K5/06017Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06008Dipeptides with the first amino acid being neutral
    • C07K5/06017Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06008Dipeptides with the first amino acid being neutral
    • C07K5/06017Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/0606Dipeptides with the first amino acid being neutral and aliphatic the side chain containing heteroatoms not provided for by C07K5/06086 - C07K5/06139, e.g. Ser, Met, Cys, Thr
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06008Dipeptides with the first amino acid being neutral
    • C07K5/06017Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/0606Dipeptides with the first amino acid being neutral and aliphatic the side chain containing heteroatoms not provided for by C07K5/06086 - C07K5/06139, e.g. Ser, Met, Cys, Thr
    • C07K5/06069Ser-amino acid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06008Dipeptides with the first amino acid being neutral
    • C07K5/06078Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06139Dipeptides with the first amino acid being heterocyclic
    • C07K5/06147Dipeptides with the first amino acid being heterocyclic and His-amino acid; Derivatives thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06139Dipeptides with the first amino acid being heterocyclic
    • C07K5/06156Dipeptides with the first amino acid being heterocyclic and Trp-amino acid; Derivatives thereof

Abstract

There are disclosed certain novel compounds identified as benzo-fused lactams which promote the release of growth hormone in humans and animals. This property can be utilized to promote the growth of food animals to render the production of edible meat products more efficient, and in humans, to increase the stature of those afflicted with a lack of a normal secretion of natural growth hormone. Growth promoting compositions containing such benzo fused lactams as the active ingredient thereof are also disclosed.

Description

- WO 9~/0~634 2 1 ~ 2 ~ O ~ PCI/US93/~-7791 .' ' ' TITLE OF THE ~VENTION
BENZO-FIJSED LA~TAMS PROMOTE RELEAS~ OF GROWTH
HORMONE~
., 5 BACKr~'ROI,~ T~ ~rVEN~O~
Growth ho~rnone, which is secreted ~rom the pituitary, slim~ tes growth of all tissues of the body ~a~ are capable of growing.
II1 ad~i~on, gro~ norm~ is ~mQY~ ~O hav~ me rC)l~QW~g aa~lc e~fects on the metabolic process of the body:
1 . Increased rate of protein synthesis in all cells of the body;
2. Decrcased rate of carbohydrate utilization in cells of the :~
body;
3 Increased mobilization of ~ree fatty acids and use of ~atty :: acids for energy.
A de~lciency in growth hoImone secre~ion can result in :various medical disorders, such as dwarf~sm.
Yarious ways are ~own to release growth ho~mone. ~or exampIe, che~rL~caIs such as arginine, L-~,4~diny~ro~phenyl~e (L-DQPA), glucagon, ~asopressin, and insulin induced hypoglycemia~ as ~; ~ 20 well as activities such as sle~,p and exercise, indirectly cause grow~
ho~one to be released from the pituitary by actiIIg in some fashion on the hypoth~ml-s perha~s either ~o decrease somatostatin secretion or to increase the secre~ion of the kllowIl secretagogue grow~ hormone ; ~ releasing fa tor (G~) ~r an un~nown endogenous growth hormone-:~ 25 releasing hormone or all of these.
In cases where increased levels of growth hormone were desired, the problem was generally solved by providing exogenous growth horTnone or by ~ini.~tering an agent which stimulated growth bo~none production and/or release. ln either case the peptidyl nature 30 of the compound necessitated ~hat it be ~rlmini~tered by injection.
IIlitially the source of growth hoImone was ~he extraction of the pituitary gl~Ilds of ~adavers. This resulted in a very expensive product and canied with it the risk that a disease ~ssociated with the source of the pituitary gland could be transmitted to the recipient of the growth :
,:

214270 ~
WO 94t05634 PCI /US93/07791 -~
), ~

ho~none. Recently, recombinant growth hormone has become available ~;.
which, while no longer carrying any risk of disease tr~n.~mi.~sion, is still a ve~ e~pensive .product which must be given by injection or by a nasal spray. ...
Oth~r cor~po~nds ha~ n d.,~,~lop~d ~hich stim~ e ~hc release of endogenous growth horrnone such as analogous peptidyl compounds related to.(3RF or the peptides of U.S. Patent 4,411,890.
dd~s, ~.m~ cnn~ iy cm~ r tnan g~o~ hn~n~n~s a:~
still susceptible to various proteases. As with most peptides, their potential for oral bioavailability is low. The iIlstant compounds are non-peptidyl agents for promoting the release of growth hormone which may be ~ministered parenterally, nasally or by the oral route. ~.

SUMMARY OF THE INVE~ON
Ihe instant inven~ion covers certain ben~o-fused lactarn compounds which have dle ability to s~imulate the release of natural or eIldogenous growth hoImone. The compou3~ s have the ~bili~y to d to tr~at corl~tions wnich requir~ ~e s~imuianon of growth ho~none production or secretion such as in hum~s with a deficiency of ; 20 nat~r~ growth ho~one: or in ~nim~l.s used for ~od production where ~e s~imu~a~iOn of grow~ ho~none will result in a larger, more:
productive ~nim~l. Thus, it iS an object of the instant inven~ion to describe the beIlzo-fused l~ct~m compou~lds. It i~ a filrther object of this inventiorl to describe procedures fo~ the prepara~ion of such 25 compounds. A still further object is to describe the use of such compounds to increase the secretion of growth hoImone in humans and ~nim~ls A still fur~her object of this inven~ion is to describe compositions cont~ining ~e ben~o-fused lactam compo-mds for the use of t~ating hllm~n.~ and ~nim~ so as to irlcrease the level of growth 30 hoImone secretions. Further objec$s will become apparent from a :: ~ re~-ling of ~he following description.

wo 94/05634 21 4 2 7 () ~ PCr/US93/07791 DES(: RIPTION 0~ THE INVENTION
The novel benzo-fused lac~ns of ~he ins~nt invention are .. best descnbed in ~e following structllral formula I:
R,W (X)n-(C-~2)p 4 ~, I */--N--C--A--N :;
~,~ r O R6 ~ ~R
(~H2)q 1 0 (~)w R1R~R3a here L is ~ ~ 20 r~' R3b : ~ R R
.

;~ 5 ~ n iS O or 1;
1~ pîsOto3;
q is O to 4;
w is O or I; ~ ;

(:)H R10 ~ I I
X is C-O, O, S(O)m, -ClH-, -N-, ~H~CH-;
m is O to 2;
R1 R2 ~la R2a Rlb and R2b are ~r~depend~Iltly hydrogen, halogen, Cl-C7 alkyl, C1-C3 perfluoroalkyl, Cl-C3 perlluoroalkoxy, 21~27~J
4 PC~rJUS93/0779~

', ~ . ': ' '.

-S(o)mR7a, cyano, nitro, R7bo(cH2)v-~ R7bCoo(CH2)V-, R7boCo(CH2)V, R4RSN(CH2)V-, R7bCoN(R4)(CH2)"-, '' R4RSNCQ(CH2)V-, phenyl or substituted phenyl where the substituents s are from 1 to 3 of halogen, Cl-C6 alkyl, Cl-C6 alkoxy, or hydroxy; .:.
R7a and R7b are independently hydrogen, Cl-C3 perfluoroalkyl, Cl-C6 alkyl, substituted Cl-C6 alkyl, where the substituents are phenyl or substit~ted phen~l: phPnyI or subs~ ed phenyl ~here the phen~l ;
subs~ituents ~ rom 1 ~o 3 of haIogen, Cl-C6 aIkyl, Cl-C6 alkoxy, or 10 hydroxy a~d v is~ O to 3;

R3a and R3b are independentl~ hydrogen, R9, Cl-C6 alkyl substituted with R9, phenyl substi~uted with R9, or phenoxy substi[uted with R9 ::~ : wi~ the proviso that ei~er R3a or R3b must be a substituent other than 5 hydrogen;

;: R9 is R4bRl2bNcoN(Rl2a)(cH2)v-9 ~,4bR12b~ .12~}~C~2 ~ R4bRl2~(Rl2b)csN(Rl2a)((~H2) R4bRl2cN~ 2b)coN(Rl2a)(~H7) R4bR l 2CNN(R l 2b)Coo(cH2)v-7 R4bR l ~-bNcoo(cH2) or Rl30CoN(R12a)(CH2)~-, where v is O to 3.

25 Rl2a, R12b aIld R12C ar~ independently RSa, ORSa, or CoR5a. R12a d R12b or Rl~b and R12c, or ~12a and R1~C, or Rl2~ and R4b, or R12C and R4b or R1~3 and Rl2a can be talcen together to form -(~H2)~B~CH2j~;- where B is CHRl, O, S(~)m or NR10, m is 0, 1 or 2, r and s are independently O to 3 and Rl and R10 are as de~med.
3 o ~
~: : R13 is Cl-C3 perfluoroalkyl, Cl-C6 alkyl, substi~ted Cl-C6alkyl, where the substitutents are hydroxy, NRlOR1 l, carboxy, phenyl or substituted phenyl; phenyl or substi~uted . WO94/~S~34 214~'70~ PCI/US93/07791 phenyl where the substi~ents on ~e phenyl are from 1 to 3 of halogen, Cl-C6 alkyl, C1-C6 alkoxy or hydroxy.
., ' ;
and v is as de~ined above;
5 R4, R4b, RS aIld Rsa are independerltlY h~dro~en. phenyl. substituted phenyl, C1-C1s) alkyl, substituted ~1-( 10 alkyl, C3-Clo alkenyL
subs~ihlte-l C3-Clo aLkenyl, C3-Clo allcynyl, or substl~ted C3-Clo a~ky~ wk~re t~ s~ nt ~ r!h~'ny~ y~ y~ ;~Y~
are f~m 1 to 5 of hydroxy, Cl-C6 alkoxy, 1:~3-C7 cycloalkyl, fluoro, Rl, R2 indepeIldently disubstituted phenyl C1-C3 alkoxy, R1~ R2 indeperl~ently disul~sli~u~d phenyl, C1-C20-a~canoyloxy, Cl-C5 alko~ycarbonyl, ca~boxy, formyl or ~ OR1 1 where R10 and Rl 1 are independently hydrogen, Cl-C6 alkyl, phenyl~ phenyl Cl-C6 alkyl7 : ~ ~ C1-Cs-alkoxycaIJoonyl or Cl-Cs-~lk~noyl-Cl-C6 alkyl; or R4 ~d RS
can be taken toge~er to fo~n ~CH2)r-B~CH2)S- where B is CHRl, : O, S(O)m or N~R10, r and s are ~dependently 1 to 3 and R~ and R10 are as def~ed abov~;

20 R6 is hydrogen, C1-CIo alkyl, phenyl or phenyl Cl-C1o alkyl;

~ A is ~ ~
:: : R8 . -(CH2)x~C~(CH2)y~
~ ~ Fl8a ;~ where x and y are i~dependently 0-3;
: ~ ~30 R8 aIld R8a are indepe~dently hydroPen. Cl-Clo alkyl, trifluoromethyl, phenyl, substituted Cl-Clo alkyl where the substituents are ~rom 1 to 3 of imida~olyl, indolyl, hydroxy, fluoro, S(o)mR7a~ Cl-C6 alkoxy? C3-- ~C7 cycloalkyl, Rl, R2 independently disubs~ituted phenyl C1-C3 alkoxy, Rl, R2 independen~ly disubstituted phenyl. Cl-Cs-alkanoyloxy, Cl--Cs 21~2707 WO 94/05634 ' . PCI/US93/0779,~

i :,' ,', .'; .

alkoxycarboIlyl, carboxy, formyl, or ~ OR 1 ~ where R1 0 and R1 1 are as de~ed above; or R8 and R8a can be taken together to ~orm (CH2)r where t is 2 to 6; and R8 and R8a can independently be joined to one or both o~ R4 and R5 to ~oIm alkylene bridges between the 1e. . ~ $trog~r~ a~d t~e allcyl ?o~;oIl of ~ A g~oup wh.,rem the bridge conta~l~s ~rom 1 to 5 carbon atoms; and pharmaceutically acceptable salts thereoS
Tn ~ à~ove ~ m~ d mro~Lgnou~me i:ns speci~ication, ~e following te~ns have the indicated me~nin~
Ihe all~yl groups specified abo~e are inten~ed to include ~ose aLkyl groups o~ the designated length in either a straight or branched co~figuratiorl. Exemplary of such alkyl groups are me~yl, ethyl, propyl, isopropyl, blltyl, sec~butyl, tertiary butyl, pentyl, ~isopentyl, hexyl, isohexyl, and ~e like.
e alkoxy groups specified:abo~e are inte~ded to include those alkoxy groups of the desigIlated length in eîther a straight or branched configuratioIL Exemplary OI such alko~y groups a~
metho~y, etho~y, propo~cy, isopropoxy, ~uto~y, iSoDUto~y, temary butoxy, pentoxy, isopentoxy, hexoxy, isohexoxy and the like.
The ter~ "halogen" i~ intended to include ~e halogen atom fluorine, chlor~ne, l~lon~ e and iodine. ~ ~ :
Cer~in :of ~e above defined terms may occur more than ~ ~nce iIl the above fo~a and upo~ such occullence each term shall be defined independently of the other.
Preferred compounds of the instant invention are realized whenin the above structural ~olmu}a:

n is O or 1;
p iS 0 to 3;~
q iS 0 ~O 2;
w'is O or l;

X is 0, S(O)m~ , ~H=CH-;

.

.. . . . . .... ..

WO 94/0~634 2 1 ~ 2 7 0 ~ Pcr/us93/~77sl ~
.

.: misOto2;
R1, ~2, :R1a~ R2a, Rlb and R2b are independently hydrogen, halogen, C1-C7 alkyl, Cl-C3 perfluoroalkyl, -~(0)mR7a, R7bo(CH2)V-, R7bCoo(CH2)V-, R7boco(cH2)v-~ phenyl or substituted phenyl 5 where ~e substituents are from 1 to 3 of halo~en, C1-C6 alkyl, Cl-C~
a1koxy or hydroxy; : ~
R7a and R7b are independently hydrogen, Cl-C3 perfluoroalkyl, Cl-C6 U~;;~ d~ 6 ~ s~s~ ;L~ 2he}~ ;
10 and v is O to 2;
R3a:and~R3b are independently hydrogen, R9, C1-C6 alkyl sulu~ ed wi~ R9, phenyl: substicuted wi~ R9, or phenoxy substituted with R9 wi~ the proviso ~at ei~er R3a or R3b must be a substi~ent other than ; hydroOoe~

Rg is~ R4bR12bNCoN~.12a)(CH2)V-, R4bR12~CSN(R12a)(CH2)v~~
: R4bRl~2 ;NN~l2b~coN(~l2a)tcH ~) 0 ~; R4b~12CNN~I~b)C00(CH2)~-, R4bR12bNCOO(CH2)~- or R130CON(R12a)(CH~,)v-, : : where;v is O to 3. ~ :

R12a ~R12b a~d R12C are~depen(lentiy R~a, 0RSa, or ~o~Sa. R1'~2 "'~ 2s ~ :and RI2b ~r Rl2b~ d Rl2c~ or Rl2a and Rl2c~ or R12b aI~d R4b, or R12C~and R4b ~ or R13 and R12a can be ~aken together to fo~rm (CH2)r-B{CH2)S- where B is C~Rl, O~ S(O)m or NR10, m is 0, 1 or 2, r and s are iI~dependently 0 to 3, R1 is as~defined above and R10 is hYdrogen~ cl-c6 alkyl~:phenyl cl-c6~aL~yl or c~-cs ~lk~noyl~l-c6 : 3~ alkyl.

R13:is ~ C:l-C3 perfluoroalkyl, Cl-C6 alkyl, sllbstituted~Cl-C6 alkyl, where ~e substituents are hydroxy, NR10Rl 1, carboxy~ phenyl or subshtuted phenyl; phenyl or substituted ; ~ ~
~: : : :

WO 94/05634 P~/US93/0779~
'.

phenyl where the substit~ents on ~e phenyl are from 1 to 3 ~ ;
of halogen, Cl-C6 alkyl, Cl-C6 alkoxy or hydroxy, where v is as defined above;

5 R4, R4b~ R5 and RSa are independently hydrogen, phenyl, substituted ~; phenyl, Cl-Clo alkyl, subs~ituted Cl-Clo alkyl, where ~e substituents on the allcyl or phenyl are from 1 to 5 of hydroxy, Cl-C6 alkoxy, C~-C7 cycloalky~ ~lu~ro~ Rl~ R2 indepen~ntly disllhstihlted phenvl :~ ~ Cl C3 alkoxy, RI, R2 indepen~3e~tly disubstituted phenyl, C1-C20- 7,' alkanoyloxy, Cl-C5 aL~coxycarbonyl, carboxy or ~olmyl;
R4 and R~ can be talcen together to form -(CH2)r-B-(CH2)S- where B
is CHRl, O, S(O)m or N-R10, r and s are independelltly 1 to 3 and and RlO are as de~ned above;
R6 is hydrogen, C1~Clo alkyl or phenyl C1-C1o alkyl;
~: :
is ~: : R8 ~ ~ ~ .
(C H2)X-( ~-(C H2)y-- - R8a :

2s~ ~1vhere x and y :are indepen~ently O-2;
R8 and R8a are independently hydrogen, C1-CIo alkyl, sul)s~i~u~ed C1-Cl~ alkyl where ~e substituents are frorn 1 to 3 of imida~olyl, ~ndolyl, hydroxy~ fluoro, S(o)mR7a, Cl-C6 alkoxy, Rl, R2 ~; ~ independently disubstituted phenyl,~ C1-~s-alkanoyloxy, Cl-Cs 1) 1 a~ y fomlyl ~ 1 where R10 andlRl1 are dependently hydrogen, C1-C6 alkyl or C1-Cs alkanoyl~'I-C6 alkyl;
or R8 and: R8a can be taken toge~er to fo~ CH2)~- where t is 2 to 4;
and R8 and R8a can independently be joined to one or both of R4 and - R5 to folm alkylene bridges between the terrninal nitrogen and the alkyl -~~ WO 94/05634 2 1 4 2 7 ~ 7 PCI'/US93/07791 portion of the A group wherein the bridge contains from 1 to 5 carbon atoms; ~:
and pha~aceutically acceptable salts thereof.
Additional preferred compounds are realized in the above 5 structural fo~nula when:
n is O or l;
p is O to 2;
aisO~2:
w is O or l;
10 X is S(~)m or -CH=CH-;
misOorl; : :
R1 R2 ~ a R2a, Rlb, and R2b are irldependently hydrogen, halogen, Cl-C7 alkyl, Cl-C3 perf~uoroalkyl, -S(o)mR7a, R7bo(CH2)V-, R7bCOO(CH~)v-, R7bC)CO(CH2)v-, phenyl or subs~ituted phenyl 5 where ~e substi~ents are from 1 to 3 of halogen, C1-C6 alkyl, C1-C6 alkoxy, or hydroxy;
R7a and~ R7b ~e ~depen(1~n~1y hYdlo2ell~ Cl -C6 a31cyl or substituted Cl-C6 a~ where t~ sul~liLu~ s are p~ d ~ ~ O to 2;
20 R3a and R3b are independently hydrogen, R9, C1-C6 alkyl substituted h R9, phenyl subs~iluted wi~ R~ or phe~o~y subs~in~ted wi~ R9 wi~ the proviso ~at ei~er R3~ or R3b must be a substituent other than ~:
hydrogen;

R9 is R4bR12bNCON(R12a)(C~I2)V~
~,4bR12bNCSN(R12a)(CH2)v~~
R4bRl2cNN(Rl2b)coN(Rl2a)(cH2) R4bR l2cNN(RI2b~coo(cH2)v-~
R4bR12bNCOO(CH2)v- or Rl30CON(Rl2a)(CH2)v-, whe~evisOto2.

R12a, R12b and R12C are indcpendently RSa, ORSa, or CoR5a. R12a and R12b, or R12b and R12C, or R12a and R12C, or R12b and R4b or R 1~c and R4b or R13 and R. 12a can be takerl together to ~orm ;

2 1 ~ 2 7 0 7 pcr/usg3~o771 . . .
. .

-(CH2)r-B~(: H2)S- where B is CHRl, O, S~~)m or NR 10, m is 0, 1 or 2, r and s are independeIltly O to 2, R1 is as defined above and R10 is hydrogen, Cl-C6 alkyl or C1-Cs alkanoyl-Cl-C6 alkyl;

5 R13 ~; C~-C~1 alkyl, sLbs~ d C1~6 ~ ;yl, w~le t~e substituents are phenyl or substituted phenyl; phenyl or :~: substituted phenyl where ~e substituents on the phenyl are ~m I to 3 o~ nalo_en, Cl -C6 a~;i C1-~6 a~Q~7 Qr o hydroxy;
R4, R4b, RS and R5a are independently hydrogen~ Cl-C1o alkyl, substituted Cl-Clo alkyl, where the substituents on ~e alkyl are from 1 y o~y, Cl-C6 alkoxy, fluoro, Rl, R2 ir~dependentl disubstituted phenyl, C1-C20-alkarloyloxy~ C1-Cs alkoxycarbonyl or 1 5 carboxy;

:~ R6 is hydrogen or Cl Clo alkyl;
A is 2o R8 -(CH2)x-c-(cH2)~

R8a : ~
25 wh x and y:are indepenrlP.ntly ~2;
: R8 and R8~ are indepenrlçntly hydrogen, C: l-Clo ~lkyl, substituted Cl-Cl~ alkyl where the substituents are from 1 ~o 3 of iinidazolyl, indolyl, hydroxy, fluoro, S(o)mR7a~ Cl-C6 aLkoxy, Rl, ~2 independently disul)~liLuled phenyl~ C1-Cs-alkanoylo~y, C1-C5 alkoxycarbonyl9 carboxy; or R8 and R8a can be taken together to form ~CH2)r where t : ~ : i s 2; or R8 and R8a can independently be ioined to one or bo~ of R4 and R5 to folm alkylene bridges between ~e terminal nitrogen and the alkyl portion of the A group wherein the bridge ~ontains from 1 to 5 carbon atoms; ~
.

~ ' WO 9~ns634 21~ 2 7 0 ~ PCI'/U~;93/07791 ";, and phannaceutically acceptable salts thereof. ::
Still fur~er preferred compounds of the instant invention are realized in the abo~e structural ~ormula when;
nisOorl;
5 pisOto2;
qisl;
w is l; , :~
X is S(~)m or -CH=CH-;
; misOorl;
10 Rl~ R2, Rla, R2a, Rlb aIld R2~ are independently hydrogen, halogen, ~ .
7 alkyl, C1-C3 perflu~alk~ S(~ mR , R ~(~
R7bCoo(cH2)v-~ phenyl or substituted phenyl where ~e subs~icueIlts are from 1 to 3 of halogen, Cl:-C6 al~;yl, C~ 6 alkoxy or hydroxy;
lS R7a and~R7b a~e independently hydrogen, C1-C6 alkyl, substituted C1-C6 alkyl, where the substituents are phenyl and v is O or 1; ~:
R3a arld R3b are Lndependently hydrogen, R9, or C1-C6 alkyl subs$itut~d ~i~ ~9 w~t~ t~e pro~iso ~at either R3a or R3b must be a :::: : substi~lent o~er thaIl hydrogen;
~ , R9 is R4bR1~CON(R12a)(CH2)V-~
4bRl2c~ 2b)coN(Rl2a)~cH2)~
R4bR12CNN(R12b)COO(CH?)V-, 2s bNC~~(CH2)v~ or R1 30CoN~R12a)(CH2) wh~e v is O or l.

Rl:2a, R12b and R12C are independently RSai oR5a, or CORSa. R12a and R12b or R12b and R12C, or R12a and R12C, or R12b aI~d R4b, or ~;
~ 12c and~R4b 0r R13: and Rl2a carl be taken together to ~olm -(CH2)I--B-(cH2)s- w~ere B is CHRl, O, S(O)m or NR10, m is O, 1 or 2, r and s are independently O to 2, Rl is as defined above and R10 is ydrogen, Cl-C6 alkyl or Cl-Cs alkanoyl~l-C6 alkyl; ;~

.

.
,.:

U~O 94/~634 2 1 ~ 2 ~ 0 7 PCI'/l IS9~/0779,~
,:

; .,, ' .' R13 is Cl-C6 alkyl, substituted C1-C6 allcyl, where the substituents are phenyl or substituted phenyl; phenyl or . :
sul,sli~,lled phenyl where the substituents on ~e phenyl are from 1 to 3 of halogen, C1-C6 alkyl. Cl-C6 alkoxy or hydroxy;

R4, R4b, RS and R5a are independently hydrogen, Cl-Clo alkyl, s~ CIQ a~ ;he SubS*t~
10 to 3 of:hydro~y, C1-C3 alkoxy, fluoro, R1, R2 independently : . disubstituted phenyl, C1-C20 alkanoyloxy, C1-Cs alkoxycarbonyl or carboxy;
, .
R6 is hydrogen;
A is : I .
H2)%-C-lCH2)y- '' R8a ':~
where x and~y are independently 0~
R~ and~R8a ale ~depen~lently hydrogen~ C~ o aLkyI~ su~s~ 1 : ~ 25 C1o aLkyl where the substituents are from 1 to 3 of imida~olyl, indolyl, hydroxy, fluoro, S(o)mR7a~ Cl-C6 alkoxy, Rl, R~ dependently disubsti~ted phenyl, Cl-Cs-alkanoyloxy, Cl-Cs alkoxycarbonyl, carboxy; or R8 and R~a can be taken together to form -(CH2)r where t 0: is 2; and R8 and~R8a can independently be joined to one ~r both of R4 and R5 to ~orm al~ ne ~ridges between ~e te~ al ni~rogen and the alkyl portion of the A group wherein the bridge contains ~~om 1 to 5 carbon atoms;
and pharmaceutically acceptable salts thereof.

r~~~ wo 94/05634 2 1 4 2 7 ~ 7 PCr/US93/07791 ~:

Representative preferred growth hormone releasi~g compounds of the present inven~on include the ~ollowing: 1 1. N~ [2'-[(Metihoxycarbonyl)amino~ biphenyl]-4-yl~methyl]- :
2,3,4,5-tetrahydro-2-oxo-lH-1-benzazepirl-3(R)-yl] 3-arnino-3- j:
methylbllt~n~mide; ' ' 2. N-~ 2'-~(Me~yl2mino~a~bonvl~aminol~1.1'-biDhenyll~4-yl]-me~ylJ-2,3,4,5-~etrahydro-2-oxo-1H-l-~n~a~epin-3(~)-yl~-3- ;;
amino-3-me~ylbllt~n~m~

3. N-~ 2'-~Et~yl,~ninocarbonyl)amino]~1,1'-bphenyl]4-yl]-methyl]-2,3,4~5-tetrahydro-2-oxo-lH-1-benza~epin-3(R)-yl]-3-amino-3-me~ylb~lt~n~mi~le;

4. N-L1-~E2'-[(2-Propylaminocarbonyl)amino][ 1,1 '-biphenyl]-~-yl~-methylJ-2,3,4,5-tetrahydro-2-oxo-lH- 1 -benzazepin-3(~)-yl]-3-~minr~3~m~.~ylbllt~n~mi~
:
:: 20 5~. N-[1-~2'-[(An~inocarbonyl)amino][1,1'-biphenyl~-4-yl] methyl]-'~,3,4,~-te~hydro-2-o~co-lH-l-be~za~epin-3(R)-yl]-3-amino-3-r~ethylbllt~n~mide;
:
: ~ 6. N-[1-~[2'-[(Morpi~oli~ocarbonyl~r~ino~ ph~nylJ-~-yl]-me~hyl]-2,3,4,5-~trahydro-2-oxo-lH-l-b~.n~7epirl-3~R)-yl]-3-mino-3-methylb~ n~mide;

7. N-[1~2'-~(Piperazinocarbonyl)amiLno][l,l'-bipherlyl3-4-yl3-me~yl~-2,3,4,5-tetrahydro-2-oxo-lH-1-berlzazepin-3(R) ylJ-3- :
3 ~ amin~3-me~yibllt~n~mi~e;

8. N-[1-~2'-[~(2-Hydroxye~ylamino)carbonyl]amino]~1,1'-biphenyl]-4-yl]methyl] -2,3 ,4,5-tetrahydro-2-oxo- 1 H- 1 -benza~epin-3(R)-yl~-3-amino-3-methylbllt~n~mide;

21~270 ~
WO 94/05634 PCI /VS93/û779~ ~

. . .

9. N-[1-[[2'-[[(2-Hydroxypropylamino)carbonyl]amino][l,l'-biphenyl~-4-yl]methyl]-2,3,4,5-tetrahydro-2-oxo-1~
'nenzazepin--:3(R)-ylJ-3-amiTlo-3-methylb~ n~mide; /:
. ~ ~
10. ~-[1-E[2'-[(Methyl~minocarbonyl)oxy~[l,l'-biphenyl]~-yl]- ,,:.
me~ylJ-2,3,4,5-tetrahydro-2-oxo-lH-l-benzazepin-3(R)-yl]-3-ami~o-3-m~thYlbllt~n~mi~e;
1:
1 1. N-~ 1 -[~2'-[(Dimethyl~minocarbonyl)amino] [ 1,1 '-biphenyl]-4-yl] -memy~]-2,J~4,3-te~ahydro 2-oxo-lH l-benzazepin-3(R)-yl]-3 arnino-3-me~ylbllt~n~mide;

12. _-[1 ~2'-[[(2(R)-Hydroxypropylamino)car~onyl]amino]~l ,1'-~: lS biphenyl]~-yl]me~hyl~-2,3,4,5-tetrahydro-2-oxo-lH-l-benz~epin-3(R~-yl3-3-amino-3-methylbllt~n~mitle;

13. N~ r(~2(~-~ydr~opvl~min~)carbc~yl~ o][l,1'~
biphenyl]~-yl]methyl3-2,3,4,5-~e'~rahydro-2-o~o-1H~
2 0 be~zazepill-3(R)-yl3-3-amino-3-methylb-lt~n~mitle;
.
14. N-[1-[[2'~[~[[1-Hydroxyprop-2(R)-yl3aIrlino~carbonyl]amino~- -[1,1'-biphenyl]-4-yl]methyl]-2,3,4,5-tetrahydro-2-oxo-lH-1-~n7~7epin 3(~)-yl~-3-amino-3-me~hyIbllt~n~mifle;

15. N-~1-[~2'-[4-[(Medlylaminocarbonyl)amino]phenoxy][1,1'-biphenyl]-4-yl]methyl]-2,3,4,5-tetrahydro-2-oxo-lH~
ben7~7epin-(R)-yl~-3-amino-3-methylb~ n~mide;

3 ~ 16. N-[ 1 -[L2'-[2-~(Me~yl~minocarbonyl)am~rlo]phenoxy] [ 1,1 '-~: biphenyl]-4-ylJmethyl~-2,3,4,5-tetrahydro-2-oxo lH-1-benzazepin-3(R)-yl3-3-amino-3-methylbl1t~n~mide;

:, ' .

:

~' ' WO 94~05634 2 1~ 2 7 0 7 P~/US93/07791 '~

17. N-[1-~2'-[(Amirlocarbonyl)~rninQ]~l,l'-bipheIlyl]~-yl]methyl]-2,3,4,5-tetrahydro-2-oxo-lH~ 1-benzazepLn-3(R)-y1]-3-[2(R)- ~.
hydroxypropyl~amino-3-methylbl-t~ mide; ,.

5 18. N~ r2'-J(Amino~arbon~l)amino][l.l'-biphenyl~4-yl~me~yl]-2,3~4,5-tetrahydro-2~oxo-lH-l~benzazepin-3(R)-yl]-3-~2(S),3-dih.ydroxypropyl~amino-3 -methylbut~n~mide;

19. N~ 2'-~(MeJ~hylaminocarbonyl)amino]~l,l'-bipheny}]-4-yl]-me~yl~-2,3,4,5-tetrahydro-2-oxo-lH-l-beIl~azepin-3(R)-yl]-3-rz(}~-hydroxypropyl~amino-3-me~hylbut~n~mide;

20. N-[1-~[2'-~(Me~yl~minoc~rbonyl)amino~1,1'-biphenyl~-4-yl]-me~yl]-2,3,4~5-te~ahydro-2-oxo-1H-l~benz~epin-3(R) yl]-3-[2(S)-hydro~ypropyl]amino-3-methylbllt~n~mide;

21. N-[1-~2'-~(Me~ylaminocarbonyl)amino]~1,1'-biphenyl] 4-yl]-m~yl~-~~,4,5-~s~yd~2~x~1H~1-~n7.~7.epin-3~R)-yll-3-[2(S)~3-dihydroxypropyl3amino-3-methyIbut~n~mide;
~: ~ 2 0 , ~
22. N-~1-[~2'-~(MoIpholir~ocaroonyl)~ino~1,1'-biphenyl3~-yl]-me~yl]-2,3~4,5-tetrahydro-2-oxo-lH-l-benz zepin-3(R)-yl~-3-[2tR~-hyd~o~yl~o~yl]~ml~-3-ml~ylbllt~n~m;de;

2s 23. N-[1-~2'-~(MorpholLT3ocar~nyl)amino]El,l'-bi~henyl~yl]-methyl]-2,3,4,5-tetrahydro 2-oxo-1H-1-benzazepin-3(R)~yl]-3-. [2(S),3-dihydroxypropyl3amino-3-methylbut~n~mide;

24. ~ N-~ 2'-~[(2~Hydroxye~ylamino)carbonyl]amino][1,1'~
:: 30 biphenylj-4-yl~methyl]-2,3, ',5-~etr~hydro-2~xo-1H-1-benzazepin-3(R)-yl]-3-~2(R)-hydroxypropyl]amino-3-methyl-bi~t~n~mide;:
~ .
' 21~270~
W{) g4/~563~ PCI/U~i93/0779 ~ ~ . - 16-25. N-~1 -[[2'-[[(2-Hydroxyethylarnino)carbonyl]amLno][1,1'-biphenyl]-4-yl]methyl]-2,3,4,S-tetrahydro-2-oxo-lH~
benzazepin-3(R)-yl]-3-[2(S)-hydroxypropyl]amino-3-methyl-bllt~n~mifle;

26. N-[1-~[2'-[~(2-Hydroxyethylamino)carbonyl]amino]~1,1'-biphenyl3~-yl]methyl~-2,3,4,5-tetrahydro-2-oxo-lH-1-p~-3(R)-y~ -r~s~3-d;~yd~yp~py~
me~ylbnt~n~mide; '' 27. N-~1-[~2'-~(MernylaminocarbonyI)amino][1,1'-biphenyl]-4-yl]-me~yl~-2,3,4,5-tetrahydro-2-oxo-lH-1 -'benzazepin-3(R)-yl~-2-amino-2-methylpropaIlamide;

5 28. N-[1-[[2'-[(~inocarbonyl)amino][1,1'~biphenyl]-4-yl3-methyl]~
2,3,4/5-tetrahydro-2-oxo-lH-l-benzazepin-3(R)-yl]-2-a~xlino-2-methylpropanamide;
.
. :, . . .
29. N-~ 1 -[[2'-[(Morpholiwcarbonyl)aIrlmo] [ 1 ,1 '-biphenyl]~4-yl; -2 0 me~yl] -2~3 ~4,5-tetrahydro-%-oxo- l H- 1 -benzazepin-3(R)-yl] -2- :
~nino-2-methylpropanamide;

3û. N-[1-[[2'-~Piperazinocarbonyl)amino]~1,1'-biph~nyl]-4-yl]-methyl]-2,3,4,5-tetrahydro-2-oxo-lH-l ~ben7~7epin-3(R)-yl~-2-am~2-methylpropanamide;
:
31. N-[1-~[2'-~(2-Hydroxyethylamino)carbonyl]amino][l,1'-biphenyl]-4-yl]methyl]-2,3,4,5-tetrahydro-2-oxo- lH-l -benz-azepin-3(R)-yl] -2-amino-2-methylpropanamide;
~ 30 32. N-~1-[~2'-[(Methylaminocarbonyl)o~y~[l,l'-biphenyl~-yl]-methyl]-2,394,5-tetrahydro-2-oxo-lH-1-benzazepin-3(R)-yl~-2-:~ ~ amino-2~methylpropanamide;
: ~ .

WC~ 94/0~6~4 2 1 4 2 7 1) 7 PCrlUS93iO7791 33. N-~1-[~2'-[[(Me~oxycarbonylme$hylamino)carbonyl]amiIlo][1,1'- :~
biphenylJ-4-yl]me~ylJ-2,3 ,4,5-tetrahydro-2-oxo- lH-1 -benz-~ . azepin-3(R)-yl]-2-aIr~Lno-2-me~ylpropana~nide;

34. N-~1-[[2'-[(Hydroxyam~nocarbonyl)aII~ino~1,1'-biphenyl]-4-yl3-me~yl3-2,3,4,5-tetrahydro-2-oxo-lH-1 -benzazepin-3(R)-yl]-2-am~o-2,-methylprop~n~mi~e;

35. ~-[1-~2'-[(~ethoxycarbonyl)~ino]~l,l'-biphenyIJ~-yIl-methyl3-0 7 -fluoro 2 ,3 ,4,5 -tetrahydro-2-oxo- 1 H- 1 -ben~azepin-3 (R)-yl] -3-ammo-3-me~ylorlt~n~mide; ;' 36. ~ 2'-~(Me~ylaminocarbonyl~amino]~1,1'-biphenyl]-4-ylJ-:: methyl]-7-fluoro-2,3,~,5-tetrahydro-2-oxo-1H-1-be~7~7epin-3(R)-yl3-3-amino-3-methylbllt~n~mide;

37. N-[1-[[2'-[(Me~ylami~ocarbonyl)amino]~1,1'-biphenyl]-4-yl]- :~
:~ : me~ -7-~i~Qrome~ ?.3~4~5-~etr~hydr~--oxo-lH~~en7.~7.epin-3(R)-yl~-3-almîno-3-methylb~lt~n~mide; '.
20:
38- N-{1-[[2'-t(~IoIpholinocarbonyl)amino~[171'-biphenyl~-4-me~yl]-7-trifluoromethyl-2~3,4,5-te~rahydro-2-oxo-lH-1- i n7~7epirL-3(R)-yl~-3-am~3-methylbllt~n~m;de;
~,; ~ ..
39 ~1-[~2'-[[(2-Hy~oxyethyl~mino)carbonyl]amino][1,1'- :biphenyl] -4-yl]methyl] -7 -trifluoromethyl-2,3 ~4,5 -tetrahydro-2-., , oxo-lH-I-~ ~epin-3(R)-yl]-3-aIr~ino-3-methylbllt~n~mide;

40. . N-[1 -[[2'-[[(2-Hydroxye~ylamino)carbonyl]aII~ino] [ 1,1'-3 0 biphenyl~yl]methylJ-7-fluor~2,3 "4,5-te~r~ydro-2-oxo- lH- 1-benzazepin-3(R)-yl]-3-amino-3-methylbllt~n~mide;
,.

,.

WO 94/~5634 2 1 4 2 7 0 ( PCr/lJS93/~779t~ ~
.~

.

- 18- ;
41. N~ 2'-[(Methylam~ocarbonyl)oxy]~1,1'-biphenyl]~-yl]- .
methyl]-7-fluoro-2,3 ,4,5-tetrahydro-2-oxo- lH- 1 -benza~epin- ;:
3~R)-yl~-3-amino-3-methylbllt~n~mide;

42. N-[1-[~'-[2-[(Methylaminocarbonyl)amino]phenoxy]~1,1'-biphenyl3-4-yl]methyl~-7 trifluorornethyl-2,3,4,5-tetrahydro-2-oxo lH-I-ber~azepin-3(X)-yl~-3-amino-3-methylbut~n~mide;

43- N-r1-~2'-~(Methyl~r~inocarbonyl)amino~[1,1'-biphenyl~-4-yl]-methyl]-7-fluoro-2,3,4,5-tetrahydro-2-oxo-lH-1-ben7.~7epin-3(~)~yl] 3-~2~R~-hydroxypropy~no-3-methylDllt~n~mide;

44. N-[1-[[2'-[~Me~yl~minocarbonyl)amino]~l,l'-bipheIlyl]-4-yl]-methyl]-7-fluoro-2~374,5-tetrahydro-2-oxo 1H-1-bçn7~7epin-lS 3(R)-yl]-3-[2(5),3-dihydroxypropyl]amino-3-methylbutanamide;

45. N-[1-[[2'-[(Morp~olinocarbonyl)~o][1,1'-biphenyl~-4-yl]-meghyl~-7-fluor~2.3,4.5-tetrahydro-2-oxo-l~-l -bç.n7.~7.epin-3(R)-yl]-3-[2(R)-hydro~yF ropylJarnino-3-methylbllt~n~mide;

46. N-[1~ '-[(MoIpholinocarbonyl3a~inoj~1,1'-biphenyl]-4-yl]-methyl~-7-fluoro-2,3,4,5-tetrahydro-~-o~o- lH-1 -ben~azepin-3(R)-yl~-3-[2(S),3-d~hydroxypropyl~amillo-3-methylbllt~n~mide;

25 47. N~ 2'-[~(2-Hydroxyethyl~minr)~carbonyl]~mino] ~lsl ~~
biphenyl]~-yl]methyl]-7-fluoro-2,3,4,~-tetrahydro~2-oxo-1H-l-benzazepin-3(R)-yl] -3-~2(R)-hydro~y~ropyl~amino-3-me~hyl-bllt~n~mide;

30 48. N-[1-~[2'-[(Me~yl~minocarbonyl)~ir~o][l,1'-biphenyl]~yl]-methyl]-7-fluoro-2,3,4,5-~etrahydro-2-oxo-lH- l -benzazepin-3(R)-yl~-2-amino-2-me~ylpropanamide;

s~ wO 94/05634 2 1 4 2 7 0 ~ PC~/US93/~7791 - 19- :~
49. N-~1-[[2'-[(Morpholi~ocarbonyl)aminoJ[1,1'-biphenyl]-4-yl]-methylJ-7-fluoro-2,3,4,5-tetrahydro-2-oxo-1H-l-ben7~7epin- ::
3(R)~yl]-2-~o-2-methylpropaIlamide;

: ~ 5 SO. N~ 2'-[(Pipera.zinocarbonyl)amino][1,1'-biphenyl]-4-yl]-methyl~-7-fluoro-2,3,4,5-tet~ahydro-2-oxo-lH-1-benzazepin-3(R)-ylJ -2-a~L~no-2-me~ylpropanamide;
'~
~1. N-El-rr2'-~'(2-Hydroxyethylam~no)carbonyIlam~no~l,l'- ",'.
0 biphenyl]~-yl]methyl]-7-fluoro-2,3,4,5-tetrahydro-2 oxo-lH~
l~~ epi,l-3~ ylj-2~ ~ino-2-m:~ yl~ mide; ''., ".
52. N-[1-[[2'-[(Me~yl~minocarbonyl)oxy][1,1' biphenyl]~-yl]-: methyl3-7-fluoro-2~3,4,$-tetrahydro-2-oxo-lH-1-bçn~7epin-~ 3(R)-yl~-2-~mino--methylpropan~de;

53.: ~ 2-Amin~-2-methyl-N-[2,3,4,5-tetrahydro-1-[[2'-~[[(methylamino)-car~onyl]~mino7m&~ylll1,1'-biphenyl yl~me~hyl3-2-oxo-I~- i ben7~7ep~n-3(R)-yl3proparlamide;

:~ : 54. ~ 2-Amino 2-methyl-N-[2~3,4,5-tetrahydro-1-~[2'-[[[(methylamino)-carb~nyl]amino]me~yl][1,1'~biphenyl3~-yl~methyl]-7-fluoro-2-oxo-lH-ben7~7erin-3(R~yl]proparlamide;
.. .
2s~ ~ :55~ ~ 2-Am~2-methyl-N-~2,3,4,5-te~ahydro-1-[~2'-L[[~methylamiTlo)-: carbonylJamino]me~yl]~l~1'-biphenyl]-4-ylJme~hyl~-7-methoxy-2-oxo-lH-~n7~7epLn-3(R)-yl]propanamide;

: ~ ~: : 56. 2 -Amino-2-methyl-N-~2,3,4,5-tetrahydro-1~[[2'-[[[(methylamino~-~:: 30 carbonyl]amino]me~hyl][l,l'-biphenyl]~-yl~me~yl~-7-methylthio~
2-oxo-lH-ben7~epin-3(R)-yl]proparlamide;
,~, , :

WO 94/05~34 2 1 ~ 2 ~ 0 7 P(~/US93/0779i'-' ~

~- ~-57~ 2-Amino-2-methyl-_-~2,3,4,5-tetrahydro-1-[[2' [[[(methylamino)-carbcnyl~amino]methyl][l ,1 '-bîphenyl]4-yl]me~yl]-7-tIifluoro-methyl~2-oxo-lH-benzazepin-3(R)-yl]propanam~de;

58. 3-~nino-3-methyl~N-[2,3,4,5-tetrahydro-1-L[2'-LL[(methylamino)-carbonyl]aT~LinoJmethyl][l ,1 '-biphenyl]~-yl]methyl]-2-oxo-lH-benzazep~n 3(R?-yl]bllt~n~mide;
,::
~9. 3-Amino-3-methyl-N-[2,3,4,5-tetrahydro-1-[[2'-[[~(methylaIxlino~-ca~bonyl]~mino]methyl] [ 1,1 '-biphenyl]~-yl]methyl] -7-:fluoro-2-~co-l~-benza~epin-3~R)-yl]~lt~n~mide;

60. 3-Amino-3 methyl-N-[273,4,5-tetrahydro-1-~[2'-[[[(methylamino)-~; : carbonyl] amirlo]me~yl3 [ 1, 1 ' -biphenyl] -4-yl~me~yl] -7 -me~oxy-2-lS oxo-lH-beIlza~piIl-3(R)-yl~bllt~n~mide;

61. 3-Amino-3-methyl-~-[2,3,4,5-tetrahydro 1-[[2'-~[[~methylamino)-carbo~ll~mirlolm~yl]~ birh~rlyl~-4-yl}methylJ,-7-methylthi~
2-o~o-1H-b~.n~7.epin-3(R)-yl]bllt~n~mide;
6?. 3-~ino-3-methyl-N-[2,3,4,5-tetrahydro 1-[~2'-[[[(methylamino)- I
carbonyl]amino]~methyl][1,1'-bipheTlyl]~-yl]methyl]-7-trifluoro- I' me~yl-2-oxo-lH be~7.~7epin-3(R)-ylJbllt~n~mide;
,:
2s 63. 3-[2~R~HydrQxypropyl~ o-3-me~yl-N-~,3,~,$-tetrahydro-1 ~[2'-[[[(methyl~o)carbonyl]amino]me~yl][l,l'-biphenyl]-4-yl~-medlyl~-2 oxo-lH-~enzazepin~3~ yl]bllt~narnide;

: 64. 3-~2(R)-Hydroxypropyl]am~no-3-methyl- -[2,3,4,5-tetrahydro- l -: [[2'~ (me~ylamino)c~onyl]aII~ino~me~hyl][1,1' ~iphenyl] A yl~-methyl~-7-fluoro-2-oxo-lH-benzazepin-3(R)-yl]bllt~n~mide;

, - WO94/05634 21~27117 PCI/US93/07791 65 . 3-[2(R)-Hydrox~ropyl3amino-3-methyl-N~2,3,4,5-tetrahydro- 1-~[2'~[[(me~hyl~mino)carbonyl~ ~ino]methylJ[l,l'-biphenyl]-4-yl~- ,~'.';, me~yl]-7-methoxy-2-oxo-lH-ber~zazepin-3(R)-yl]but~n~ e;

66. 3-~2(~)-Hydro~ypropyl3amino-3-methyl~ 2,3~4,5-tetrahydro-1-[[2' -[[[~methyl~minQ)carbonyl]a~ino]methyl] [ 1~1 '-biphenyl]-4-yl]-me~yl3-7~methyl~io~2-oxo-lH-b~n~7epirl-3(R)-yl]b~lt~n~m~; }

67~ 3-~2(R~-H~droxypropyl]aIrlino-3-me~yl-N ~2,3,4,5 tetrahydro-l- /.
0 [~2 ' -[ [[(methyla~ino)carbonyl]am~no]methyl] [ 1,1 ' -biphenyl] -4-y}] -rnethylJ-7-trifluorome~yl-2-oxo-lH-benzazepin-3(~)-yl]-bllt~n~mide; ''., .

68. 3-~2(S)~3-D~ydroxypropyl]amino-3-me~hyl N-[2,3,4,S-tetra-15 : ' ~hydro~ [2'-C[~(methylamino)call,ollyl~amiIlo]methyl][1,1'-biphenyl3~yi]me~yl]-2-oxo-1H-b~r~azepin-3(R)-yl}but~n~mide;
!i, 9. ~[2~S~,3-~3 propy~minQ-3-m~thyl-N-~2~3~4~-tetra-hydro-1-~2'-~[[(me~ylamino)carbonyl]ammo~me~yl~1,1'-: biphenyl~4~ylJmethyl]-7-fluoro-2-oxo-1H-benzazepin-3(R3-yl]~ 2-ide; '.' 70. 3 -~2(S),3-Di~yd~ y~ivo~l]a~ino~3-methyl-N-~273,4,5-tetr~-hydro-1-~2'-~[[~me~yla~o)carbonyl~aminoJme~yl][l,l'-biphenyl]~yl]me~yl~ methoxy-2-oxo-lH-ben7~7epi~-3(R)-yl]but~n~mide;
, 71. 3 [2(S),3-Dihydroxypropyl~amino-3-me~hyl-N-[2,3,4,5-tetra- :
hydro-1-[[2'-~[[(methylarnino)carbonyl]amirlo~methyl][l ,l '-bIphenyl] 1 yl]me~yl]-7-m~ylthio-2~x~1H-ben~azepin-3(R)-yl~b~lt~n~nide; ~

72. 3-l2(S),3-Dihydroxypropyl]amino-3-me~hyl-N-~293,4,5-tetra-hydro~ 2'-~[[(me~hy}amino)carbonyl~amino]me~yl]~1~1'-.

WO 94/05~34 2 1 ~ 2 7 0~ PCI/U~;g3/0779~

'"'' , ::

. .
biphenyl]-4-yl]me~ylj-7-trifluoramethyl-2-oxo-lH-benzazepin- ~ .
3(R)--yl]bllt~n~mi-le; ~., '. ,, 73. 2-Am~o-2-me~hyl-N-[2,3,4,$-tetrahydro-1-[[2'-[[(amino-S carbonyl)ami~o]methyl3~1,1'-biphenyl3~-yllme~yl3-2-oxo~1H-benzazepin-3(R)-yl3propana~ide;
, , 7~ -~o-'~-m~hyl-~ -tP~ y~1 ~{~ (2m~Q-c~rbonyl)amino]methyl] [ 1,1 '-biphenyl~-4-yl]methyl~ -7-fluoro-2-~ oxo-lH-ben~.~7.epin-3(R)-yl]propanamide;

75. 2-Aminor2-methyl-N-~2,3,4,5-tetrahydro-1-[~2'-[[(amino-car'oonyl)~nino]methyI] ~1, I '-biphenyl34-yl]methyl]-7-methoxy-2-o~o-lH-benza~epin-3(R)-yl]propanamid~
. .
~: 76. 2~ ino-2-methyl-N-[2,3,4,5-tetrahydro-l-[~ [(amino-carbonyl)~mino]methyl] [ 1,1 ' -biphenyl~-4-yl]me~yl]-7-methyl- ~ ' iQ-2-Qx~lH-ben7~7Pp~n-3(R)-ylJpr~p~m;Ae;

77 2-Amino-2-methyl-N-[2,3,4,5-tetrahydro 1-[[2'-[[(amino-~' ca~ony~ r~ino]methyl]E 1,1'-biphenyl]~yl~methyl]-7-trifluoro-~m:ethyl-2-oxo-lH-ben~azepin-3(R)-yl]propa~ ide;

78. 3-Amîno-3-methyI-N-~2,3,4,5-tetrahydro-1-r[2'-~[(amino-2~s ca~ yl3amino]me~yl~1,1'~iphenyl]~yl~methyl]-2~x~1H- ;
ben~epin-3(R)-yl3bllt~n~mide; '','~

79. 3~AIr2ino-3~methyl-N-[2,3,4,5-tetrahydro-1-[[2'-~ o-carbonyl)amL~o]methyl] [I, l '-biphenyl]-4-yl]methyl]~7-fluoro-2-oxo-lH-ben7~epirl-3(R)-yl]but~n~mide;

80. 3-Amino-3-methyl-N-[2,3,4,5-tetrahydro- 1 -[[2'-L[(amino-:~ : carbonyl~amino]methyl][1,1'-biphenyl~4-yl]me~hyl]~7-methoxy-2-oxo-lH-benzazepin-3(R)-yl]but~n~mide;

'~
:.

.. . - -- -.. . ~ .. . .

~ WO 94/05634 2 1 ~ 2 7 ~ ~ PCI/US93/~7791 ., ..:

~, 81. 3-Amirlo-3-methyl-.N-[2,3,4,S-tetrahydro-1-[[2'-~[(amino- ;
carbonyl)~mino]me~yl]~l,1'-biphenyl]-4-yl]methyl]-7-methyl-thio-2-ox~-lH-berl~7epin-3(R)-yl]bllt~n~mide; , "' s ., 82. 3-Amino-3-methyl~ -[2,3,4,5-tetrahydro- 1 -r~2~-[~(amino-carbonyl)~mLno~methylJ~1,1 '-biphenyl]-4-yl~methyl]-7-trifluoro-m,~fhYl-7-Qxt3- l~-~en7~7e~i~-3(R)-yl3~l~t~n~mid~; .""
. ,.
0 83. 3-~2(R)-Hydroxypropyl]amino-3-methyl-N-~293,495-tetrahydro-l- ;
~[2'-[[(aII~Lnocarbonyl)aII~ino~me~nyl3[i ,I '-biphenyl3~-yl3me~lyl]- ','', 2-oxo~l~-ben7.~7epin-3(R)-yl]bllt~n~mifle;

84. 3-[2(R)-Hydro~ypropyl]amino~3-methyl-N-~,3,4,5-tetrahydro~
5 - [[2 ' - ~ ~(aminocarbonyl)amino]methylJ [ 1, 1 ' -biphenyl] ~-yl]methyl~ -7-fluoro-2-oxo~ be~7~7epLn-3(R)-ylJbllt~n~mi~le;

:: 85. 3-~2(R~Hyd~oxy~ro~yl~aminQ-3-me~yl-N-~2.3,4.5-tetrahydro-1-[~'-[~(aminocar~onyl)~mo]me~yl~[1~1'-biph~nyl] '-yl]methyl~-7-methoxy~2-o~o-lH-ben7~7epin-3(R)-yl3b1lt~n~mide;
: : ~
86. 3-[2(R)-Hydroxypropyl]amino-3-methyl-N-~2t3,4,S-tetrahydro- 1-[~2'-~(aminoc~onyl)amino]methyl][1~1'-biphenyl3-4-yl]methyl3-: 7-me~yl~io-2-oxo-lH-ben7.~7epin-3~)-yl]bllr~n~mi~e; ,' 87. 3-~2(R)-Hydroxyp~opylJamino-3-methyl-N-[2,3,4,~-tetrahydro- 1 -[[2'-[[(aminocarbonyl)aInino]methyl]~1 ,1 9-biphenyl]~-yl]methyl]-7-trifluoromethyl-2-oxo-lH-benzazepin~3~R)-yl]bllt~nami~le;

30 88. 3-[~(S),3-Dihyd~ox~propyl]amino-3-m~hyl-N-['~,3,4,5-tetra-hydro-1-[[2'~[(amirlocarbonyl)amLno3methyl]~1,1'-biphenyl]-4-yl]methyl]-2-oxo-lH-ben7.~7e.pin-3(R)-yl]bnt~n~mide;
1~
, .
, ',:
1:

wo g4/0s634 2 1 ~ 2 7 0 7 PCI'/US93/07791---. .
':

. . .

89. 3-[2(S),3wDihydroxypro~yl~amino-3-me~yl-N-[2,3,4,5-tetra- . :
hydro-1 [[2'-~(aminocarbonyl)amino]me~hyl]~1,1'-bipheny1~-4-yl]methyl~-?-fluoro-2-oxo-lH-benzazepin-3(R)-yl]bu~n~mi~le;

5 90. 3-~2(S)3-Dihydroxypropyl~amino-3-methyl-N-[23~4.5-tetra-hydro~ 2'~[[(aminocarbonyl)amino]meth~,rl][1,1'-biphenyl]-4-yl]r~ethyl]-7-methoxy-2-oxo-lH-ben~azepin 3(R)-yl]bl~t~n~mide;

91. 3-[2(S~,3-Dihydro~ypropyl~amino-3-methyI-~-[2,3,4,S-tetra-hydro-1-[[2'~[[(aminocarbonyl)~mino]methyl][1,1~-bipherlyl]-4-yI~me~yIJ-7~methylthio-~-oxo-lH-beIlzazepin-3(R)-yl]-, bl-t~n~mi~e;
,"
92. 3-[2(S),3-Dihydroxypropyl]amino-3-methyl-N-[2,3,4,5-tetr~-~ hydro-1-[~2'-[~aminocarbonyl)amirlo]Ine~yl][1,1'-biphenyl]-~-~: yl]methyl~-7 trifluoromethyl~2-oxo-1H-benzazepin-3(R)-ylJ-~; b~lt~n~mi~
:: ... . .
93. 2-Amirlo-2-metbyl-N-[2,3,4,5-te~rahydro-1-~2'-[[[(ethylaminoj-20 ~ carbollyl~amino]me~hyl~[1,1'-biphenyl]~-yl]methyl]~2~oxo-1H- 7epin-3(R)-yl]propanamide;

:~ : 94. 2~ lno-2-methyl~ 2,3,4,5-tetrahydro~ [~'-[~[(e~ylam;~o)- ~
car~onyl3~mino]me~yl~rl,19-biphenyl~-yl~methyl~-7-fluoro-2- .' ~5 ~ oxo~ en~?7s~pill-3(R)-yl]~ ~de;

;~ ~ 95. 2-Amino-2-methyl-N-[2,3,4,5-tetrahydro-1-[[2~-[~[(ethylamino)-carbonyl]amino~methyl] [ 1 ,1 '-biphenyl~-4-yl]methyl]-7-methoxy-2-oxo-lH-be~7,~7epin-3(R)-yl~propanamide;

96. 2-Arnino-2-methyl-N-[2,3,4,5-tetrahydr~ [2'~[~[~ethylamino)-carbonyl]aII~ino3methyl] [1, I '-biphenyl]-4-yl]methyl]-7-methylthio-2-oxo-lH-benzazepin-3(R)-yllpropanamide;

, , -- WO 94/05634 2 1 4 2 7 0 ~ P~/US93/1)779t 97. 2-Amino-2-methyl~N-t2,3,4,5-tetrahyd~o-1 ~[2'-~[[(e~hylamino)-carbonyl~amino3methyl3 [ 1, I '-biphenyl]~-yl]methyl~ ~7 -trifluoro-methyl-2-oxo~ ben7~7ep~n-3(R)-yl]propanamide;

98. 3-Amino~3-methyl-N-~2t3,4,5-tetrahydro-1-E[2'-~[~ethylarniDo)-ca~bonyl]amino]methyl~[1,1 '-biphenyI]~-yl]methyl]-2 oxo-lH-en~a~pirl-3(R)-yl]b-ltAn~mi~le;

99. 3-Am~no-3-methyl-~-~2,3,4,5-tetrahydro- l -~E2i-[[[(ethylamino)-carbonyl]ami~o]methyl] [ 1,1 ' -biphenyl] ~-yl]Inethyl] -7 -fluoro-2-oxo-lH-benzazepin-3~R~-yIJb~lt~n~mide;

100. 3-~nino~3-methyl-N [2,3,4,~-tetrahydro-1-~[2'-[~[(ethylamino)-calbonyl3am~no]me~yl]~1,1'-biphenyl]~-yl~methyl]-7-methoxy-2-oxo-lH-~ ea~ep~n-3(R)-yl3bllt~namide;

101. 3-Amino-3-m~thyl-~-[2,3,4,5-tetrahydro-1-[[2'-~[(ethylamino)-a~yl~in~hyl~E1~ bi~hPtlYll~yl]met:hyl]-7-me~yl~io-2-oxo-1H-ben7~7epiIl-3(R)-yl~bllt~n~mide;

1~02. 3-Amino-3-methyl-N-[2,3,4,5-te~hydro- 1 -[[2'-[~[(ethylamino)-~: carbonyl] amino]methyl] [ 1 ~1 ' -biphenyl] 4-yl]me~yl] ~7 -trifluoro me~yl-2-ox~lH-ben7~7epin-3(R)-yl]bl~t~n~mide;

25: 103. 3-[2(R~Hydroxypropyl]amino-3-me~yl-~-~2,3,4,5-te~ahydro-1-: ~ [~2'-[~[(e~yl~o)carbonyl]amino]me~yl3~1,1'-biphenyl~-yl~-:; me~yl]-2-oxo-lH-benzazep~-3(R)-yl]but~n~mide;

104. 3-[2(R)-HydroxypropylJarnino-3-me~yl-N-~2,3,4,$-tetrahydro-1-~2'-~[[~ylammo)c~d~ yl]amino]me~yl3~1,1'-biphenyl]~yl~-methyl]-7-fluoro-2-oxo-lH-berlzazepin-3(R)-yl]bl-t~n~mide;

Wo 94/~5634 2 1 4 2 7 0 7 PCI'/US93tO779~-- ~

105. 3-[2(R)-Hydroxypropyl]amino-3-methyl-N-E2,3,4,5-tetrahydro-1-~[2'-~[[(e~ylamino)carbonyl]amino]methyl][1 ,1 '-biphenyl~-yl]-me~yl]-7-methoxy-2-oxo-1H-benzazepin-3(R)-yl}but~n~mide;

106. 3-~Z(R)-Hydroxypropyl~amino-3-methyl- -[23,4,5-te~rahydro-1-~[2'-~[[(e~yla~ino)carbonylJaIx~ino]methyl][1 ,1 '-biphenyl]4-yl]-me~yl]-7~meth~rlthio-2-oxo-lH-benzazepin 3(1~)-yl~bllt~n~mi~e;

107. 3-~2(R)~Hydroxypropyl]amiIlo-3-me~yl-~-[2,3,~,5-tetrahydro-1-0 ~[2'-[[[(e~yl~mino)carbonyl~amino]methyl][1,1 '-biphenyl]~-yl]-metnyi3-7-trL~uorome~yl-2-oxo-1H-benzazepin-3(R)-yl]-bllt~n~mi~le;

108. 3-[2(S),3-Dihydroxypropyl~amino-3-me~yl-~-[2,3,4,5-tetra-hydro-1-[~2'-[[~(ethylam~no)carbonyl]~o]methyl~[1,1'-biphenyl]4-yl]methyl~-2-oxo-lH-ben7.~7,epin-3(R)-yl~bl~t~n~mide;

,.... lQ9. 3-E2(~ )ihydrQxypro~yl]~min~-3-methyl-N-[2~3,4~ a~
: ' hydro-l-r~2'-[[[(ethylamino)carbonyl]amino]m0~yl]~1,1'-~ ~ 20 biphenyl]~-yl]methyl~-7-fJluoro-2-oxo 1H-benzazepin-3(R)-yl3-blls~n~mide;
.
1 10. 3-[2(S),3~Dihydroxypropyl]amino-3-meshyl-M~[~,3,~,5-te~ra-hydro-1~[~2~-r[[(ethyl~nino)carbonyl~amirlo]me~yl][ l ,l ' 2s biphenyl3-~yl3methyl3~7-methoxy-2~x~1H-ber~azDpin-3(R)-yl3-but~n~mide;
. , j . , 11 1. 3-[2(S),3-Dihydroxypropyl]amino-3-methyl-N-~2,3,4,~-tetra-hydrn-1-[[2'-[~[(ethylarnino)carbonyl~arr~ino]methyl][1,1'-biphenylj A yl3methyl] 7-methylthio-2-oxo-lH-be~ epin-3(R)-yl]~ ide;

~;~ 112. 3-[2(S),3-Dihydroxypropyl]amino-3-me~yl-N [2,3,4,5-tetra-hydro-1-[[2'~[[[(ethylamino)carbonyl]amino]me~yl][1,1'-~- WO 94/0~ 2 1 ~ 2 7 0 ~ PCI/US93/07791 biphenyl]-4-yl~me~ylJ-7-trifluoromethyl-2-oxo-lH-ben~azepin-3(R)-yl~bllt~n~mide;
..
1 13. 2-Amino~2-methyl-N-~2,3,4,5-tetrahydro-1-~[2~[[[[~hydroxy-e~yl)amino~carbonyl3amino]me~hylJ~1,1 ' biphenyl]~-yl]methyl]-2-oxo-lH-benzazepin-3(R)-yl]propanamide;

114 2~ o-2-me~yl-N-~23.4~-~etrahvdro-l-r!2'-~r~(hydroxy-e~yl)~o~cal~ollyl3amillo]methyIJrl,l ~-biphenyI~-yI~me~yl~-7-fluora-2-oxo-lH benzazepin-3(R) yl]propanamide;

1 15. 2-Amino-2-methyl-N-[2,3,4,5-tetrahydro-1-~2'-[[~[(hydroxy-e~yl)amino]car~onyl~a~ino]methyl]~1 ,1 '-biphenyl]~-yl]me~yl]-7-met~oxy-2-oxo-lH-b~n7.~7epin-3(R)-yl]propan~de;
I S
116. 2 Amino-2-me~hyl-~-[2,3,4,5-tetrahydro-1~[[2'-[[[~(hydroxy-ethyl)~o]carbonyl]aminoJme~yl][1,1 '-biphe~13~-yl]me~yl]-7-meth,Yl~bio-2~xo-lH-ben7.~.epin-3~)-yllpropanamide;
, ..
~:~ 20 117. 2-Amino-2-methyl-N-[2,3,4,5-tetrahydro-1-[[2'-~[~hydroxy-e~yl)amino~ca~ yl]aminoJme~hyl~E1,1'-biphenyl] 4-ylJmethyl]-: 7-trifluorome~yl-2-oxo-lH-benza~epin-3(R)-yl]propaIlamide;

118. 3-Amino~3 methyl-~-[2,3,4,5-tetrahydro-1-[~2'~ (hydro~y-2s e~hyl)~minolca~ yl]~oJmethyl~ 1'-biphe~ylJ~-yl]mefhyl~-2-oxo-lH-ben7~7,epin-3(R)-yl]b~lt~n~mide;
, , . ~ . .
119. 3-Amirlo-3-me~yl-~-[2,3,4,5-tetrahydro-1-~2'-~E[~hydroxy-ethyl)2m;no]carbonyl]amino~methyl]~1,1'-biphenyl~ yl~methyl~-7-fluor~2-oxo-lH-ben7~7epiIl~3(R~yl]bllt~n~mide; ' 120. 3-Amino-3-me~yl-N-~2,3,4,5-te~rahydro-1-[[2'-[[~[~hydroxy-e~yl)amino~carbonyl]amino]methyl~ biphenyl] 4-yl]methyl~-7-me~oxy-2-oxo-1H-~enzazepin-3~R)-yl]but~n~mide, 2142713~
WO94/05634 P~/US93~07791~-.
121. 3~ ino-3-methyl-N-[2,3,4,5-tetrahydro-1-[~2'-~[[L(hydroxy-e~yl)amino~carbonyl]amino]me~yl][1 ,l '-biphenyl]~-yl]methyl]-7-methyl~io-2-oxo-lH-benzazepin-3(R)-yl]bllt~mide; '' .:
122. 3-~nino-3-methyI-~-~2,3,4,5-tetrahyd~o-1-[~2~-~[[[~hydroxy-ethyl)a~ino]carboIlyl]amino]methy~][1 ,l '-biphenyl]~-yl]methyl]-7-t~l~oI~methvl-2-oxo-lH-b~.n7~7e~L~-3(R)~vl]bl-t~n~m;d~;

0 123 . 3-~2(R)-Hydroxypropyl]amino-3-methyl-N-[2,3,4,5~t~trahydro- 1-[~2'-~ ydro~yeinyl)~o~carbonyl~a~ino]me~hyl][1 91~-bipben~l]~-yl~methyl]-2-oxo-lH-be~azepin-3(R)-yl]b~ n~mirle;
.
124. 3-[2(R)-Hydrox~ropylJamino-3-methyl-N-~2,3,4~-tetrahydro-1-[[2'-[~[~ydroxyethyl)amino]carbonyl]amLno]methyl]~1,l'-bipherlylJ~-yl]methyl]-7 fluoro-2-oxo-lH-ben7~7epin-3(R)-yl]-.~ bllt~n~mit~e;

-. 3-~2(R)-Hydr~y~rol,yl~amino-3-me~yl-N-~2,3,495-tetrahydro-1-~[2'-[~[~ydroxyethyl)amino]carbon~ ]amino]rnethyl]~l,l'-biphenylj~-yl]methyl]-7-methoxy-2-oxo-lH-ben~azepLn-3(R)-yl]-: : :
126. 3-~2(R)-Hydroxypropyl]amino-~-me~hyl-N-[2,3,4,~-~etrahydro-l-2s [~2~ yd~oxyethyl)amillo]ca 1~ yl3~mino~me~hyl~ bi-phenyl]-4-yl]me~yl]-7-me~ylthio-2-oxo-lH~ pin-3(R~-yl]-: i; bllt~n~mide;

:; 127. 3-[2(R)-Hydroxypropyl]amino-3-methyl-N-~2,3,4,5-te~rahydro-~-3 ~ E[2'-[[[[(hydroxye~yl)~mino]carbo~yï]amino]me~yl~ bi-phenyl3-4-yl]methyl]-7-trifluoromethyl-2-oxo-1H-benzazepin-3(R)-yl~b~ n~mide;
' -~'WO 94/05634 21 ~ 2 7 0 7 PCI~/US93/û7791 - 2g -128. 3-~2(S),3-Dihydroxypropyl]amino-3-me~yl-N-[2,3,4,5-tetra-hydro-1 -[[2'-[~[[~ydroxye~yl)amino]carbonyl]amino]methyl]-[1,1'-biphenylJ-4-yl]me~yl]-2-oxo-lH-benzazepin-3(R)-yl]l~ ide;

129. 3-[2(S),3-Dihydro~cypropyl]annino-3-methyI~ 2,3,4,5-tetra- ;
hydro-1 -[[2'-[[[[~ydroxyethyl)~minQ]carbonyl]amino]me~hyl]-rl.l'-bi~h~nyl~-yl~met~vl~-7-fl~Qro-2-ox.o-t~-l~.n7~7e.pin-~
yl~ ""i,i~e;

130. 3-~2~5),3-l3îhydroxypropyi~am~o-3-me~yl-~-~2,3,4,j-t2rra-hydro-1 -~2'-[~[~ydroxye~yl)~mino]carbonylJ~o]methyl]-~1 ,1 '-biphenyl]~-yl]me~yl]-7-methoxy-2-oxo-lH-ben7~7epin-3~)-yl]bllt~n~ e;
:: :
131. 3-[2(S),3-Dihydro~ropyl~amino-3-me~yl-;~[2,3,4,5-tetra-hydro-1-[[2'-[[[[(hydroxyethyl)amino]carbonyl]amino]me~yl]-'~irh~,nyl~yl~yl~-7~n~:hyl~ 2-oxQ-lH-ben7.~7.epin-;: 3(R~-yl]bllt~n~mi~le;

132. 3-[2(S),3-Dihydroxypropyl~amino-3-methyl-~-[2,3,4,5-tetra-hydro-1 -~2'-[[~[(hydroxyethyl)am~oJcarboIlyl3amino3methYl l-~1,1 '-biphenyl]-4-yl]me~yl]-7-trifluoromethyl-2Doxl) ~ lH-:: ben7~Yepin-3~)-yl3bllt~n~mide;
:: :
133. N-[5-[~2'-[(Me~oxycarbonyl)amino3[1,1'-biphenyl~4-yl]me~yl]-~ ~ 2,3,4,5-tetrahydro-4-oxo-1,5-benzo~iazepiIl-3(S)-yl]-3-amino-3-': me~ylbl1t~n~mide;

30 134~ N-[5-~2'-[(Me~.ylaminoc~l~lyl)amino][1,1'-biphenyl~yl]-: methyl]-2,3,495-tetrahydro-4 oxo-175-benzothiazepin-3(S)-yl]-3-amirlo-3-me~ylbllt~n~mide;

.

21 4 2 7 0 ~
WO 9~/05634 P~US93/0779'~

l 35. N-[5-[[2'-[(MoIpholinocarbonyl)aminoJ [l ,1 '-biphenyl]~4-yl]-methyl~-2,394,5-tetrahydro~-oxo-~1,5--benzothia~epin-3~S)-yl]-3-am~no-3-me~ylb~ n~mi-le,;

136. N-ES-[L2'-[[(2-Hydroxyethyl ~nino)carbonyl~o1~l,1'-biphenyl]-4~yl~methyl]-2,3,4~5-te~rahydro-4-oxo-1,5-ben~o-thiazep~n-3(S)-yl]-3-~irlo-3-methy'lbllt~n~mi~e;

137. ~-[5-[~2'-~(Methy1~minocarbonyl)amino~[1,1'-biphenyl]-4-yl]-methyl]-293,4,5-tet~hydro-4-oxo-1,5-benzothiazepin-3(S)-yl~-3-~2(R)-hydroxypropyI~ ino-3-methylb~t~n~m;de;

138. -~5-[[2'-[(MorphoIinocarbonyl)aII~ino~[~ biphenyl]-4-yl]-methyl]-2,3,4,5-tetrahydro~-oxo-1,5-benzot:hiazepin-3~S)-yl~-3-[2(R)-hydrox~ropyl]amirlo-3-me~ylbu~n~mide;
~, 139. N-[5-~2'-[~(2-HydroxyethyIamino)carbonyl]amirlo]~1,1'-h~nyl~3rl]m~e,~hyl~-2~,4~5-t~rahyd~ o-1 ,5-berlzo-~iazepin-3(s)-yl3-3-~2(R)-hydro~yyroyyl]amino~3-meth b~7t~n~m1de;
:: :
~: : 140. N-~5-~[2'-~(Me~laminocarbony1)amino]~1,1'-biphenyl]4-yl]-~,~ me~hyl]-2,3,4,5-~etrahydro~-oxo-I,5-ben~o~hia~epin-3(S)-yl~-3-2(S),3-dihydroxypr~pyl~o-3-methylbllf~mirle;
2s ~:: : 141. 2-Amino-2-methyl-N-[2,3,4,5-tetrahydro-5-L[2'-[[[(methylamino)-:, car~onyl]a~ o~rnethyl]~ biphenyl~-4-yl]methyl]-4~oxo-1,5-ben~othiazepin-3(S)-y~]propanamide;
:: :
3~ 1~2. 2~ o-2-me~yl-N-~2,3,4,5-tetrahydro-5-[[2'-[[[(methylamino)-carbonyl]amino]me~yl3[ 1,1 ~-biphenyl3~ yI]methyl]-8-fluoro~-oxo-1,5-ben~othiazepin-3(S)-yl]propanamide;

...... -. - - , -. -; .. . , . ,- --~ WO 9'~/05634 2 1 ~ 2 7 0 7 PCI'/U~i93/07791 . .
143. 2-f~nn m o-2-m ethyl-N-[2,3,4,5-tetraihydro-5-[[2'-[[[~m ethylann~no)-carbonyl]aII~ino]me~yl} [ 1,1 '-biphenyl]-4-yl]methyl] -8-methoxy-4-oxo-1 ~5-benzothiazepin-3(S)-yl]propanamide; .

5144. 2-Amino-2-methyl- -~2,3,4,5-tetrahydro-5-~[2'~ (me~hylamino)-carbonyl]am~no3me~yl]~1,1'~biphenyl]-4-yl]methyl~-8-methylthio-4-oxo-1,5-ber~o~iazep~n-3(S)-yl]propanamide;

145. 2~A~nino-2-methyl-~-[2,3,4,5-tetrahydro-5-[[2'-[~(methylarnino)-carbonyl]amino]methyl] [ 1,1 ' -biphenyl] ~-yl]methyl] -8-tri fluoro-me~yl~-oxo-1~3-ben~o~a~epiIl-3~S)-yl3propanamide;

146. 3-Amino-3-methyl-N-[2,3,4,5-tetrahydro-5-~2'-~[[(methylamino)-::~ car~onyl~amino3me~hy}][171'-biphenyl~-yl]met:hyl~-4-oxo-1,5-benzo~liazepin-3(5)-yl]bllt~n~mi(le;

147. 3~nino-3-1nethyl-~-[2,3,4,5-~etrahydro-S-[[2'-~[~(methylaIxl~o)-. r~.~knn~ minn~ .hyllEll'-hi~h~n,~ll~ylJmethyI]-8-fluoro~-o~o-1~5-beIIzo~iazepin-3(S)-yl~lu~ ,,.ide;
2~ :
~ j ;~ 148. 3-An~ino-3-methyl-~-[2,3,4,5-tetrahydro-5-[[2'-[[[(methylam~o)-carbonyl~amino]me~yl~[1,19-biphenyl]-4~yl~rne~yl]-8-me~oxy-4-oxo-1,5-be~o~ epin-3(S)-yl~bllt~n~mide;
~::
2~~ 14g ~3~ ~3-methyl-N-[2,3,4,~tet~ahydIo 5-E~2'-~{[(met~lyl~o)-calluo~yl~ o3methyl] [ 1~1 '-biphenyl3-4-yl]me~iyl] -8-methyl~io-. , . 4-oxo-1,,5-beD~othiazepin-3(S)-ylJbllt~r~mide;

150. 3-Amino-3-methyl-N-[2,3,4,5-tetrahydro-5-[[2'~[~(methylamino)-: ~ yl]amino~methyl~l,l'~iphenyl]~yl~me~hyl]-8-trifluoro-': ~ me~yl~-oxo-1,5-benzo~iazepin-3(S)-~l]bllt~n~mide;

:
:

~: :

21~2707 WO ~4/05634 PC~U~i93/0779 , ,,' , ' ' ':
151. 3-[2(R)-Hydro~yprop~1~arnino-3-methyl-N-[2,3,4,5-tetrahydro-S- .
~[2'-[[[~methylamino)ca~bonyl]amirlo]me~yl]~1,1 '-biphenyl]-4-yl]- :
methyl]4-oxo-1,S-b~nzot~ epirl-3(S)-ylJbut~n~mide;

1~2. 3-~2(R)-Hydroxypropyl]amino-3-methyl-N-~2,3,4,5-tetrahydro-S-[[2'-[[[(methylaT~no)carbonyl]amiTlo]me~yl~ biphenyl]-4-y~-me~lyl~-8 fluo~-4-oxo-l~5-benzothiazepin-3(s)-ylJbllt~n~mide;

153. 3-~2(R)-Hydr~xypropyl]amirlo-3-me~yl-N-~2,3,4,S-tetrahydro-S-0 ~[2 '-L [[(me~y'l~mino)c~rbonyl~mino~methyl~ [ 1,1 ' -biphenyl}~-yI~methyI~-8-methoxy-4~oxo- 1 ,S-ber~othiazepin-3(S)-yl]-. bllt~n~mi~le,;

:~ ~ 1S4. 3-[2~R)-Hydroxypropyl~mino-3-methyl-N-[2,3,4,~-te~rahydro-5-~2'-~[(me~ylamîno)caIbonylJamino]methyl~ biphenyl]~-yl]me~yl]-8-methylthio~-oxo-1,5-ben~o~iazepin-3(S)-yl]-lt~n~rnide;

15~ 3-[2(R)-Hydro~ypropyl]aI;~ino-3-me~yl-N-~2,3,4,5-tetrahydro-5-[~2$-[C[(methyl~o)c~rbollyl]amino]me~yl}~1,1'-biphenyl~4-:: yl]me~yl]-8-trifluorome~hyl~-oxo-1 ,5-benzo~iazepin-3(S)-yl~ -b~lt~n~mide;

:: 156. 3-r2~S),3-Dihyd~o~ypropyl~am~Q-3~methyl-N-~2,3,4,5-tetra-hydr~5-~2'-~[~(me~yl~mino)car~oonylJamino]methyl]~l,l'-:' ' biphenyl]~-yl]me~yl~-oxo-1,5-be~o~iazepin-3(S)-yl~-:~; . b~lt~n~mi~e;

157. 3-[2(S),3-Dihydroxypropyl]amino-3-methyl-N-[2,3,4,5-tetra-3 0 hydro-S-r~2~-[[~(me~yl~mino)call,o~yl]amino]me~yl][ 1,1 ' -biphenyl3-4-ylJmethyl3-8-fluoro-4-oxo-1 ~5-benzothia~epin-3~S)-: . yl]bllt~n~mide;

'~- ' WO 94/0S634 2 1 ~ 2 7 0 7 PCI'/US93/07791 . .

158. 3-[2(S),3~Dihydroxypropyl]a~ino-3 me~yl~-~2,3,4,5-tetra- , hydro-5-~[2' -[[[(methylamiIlo)carbonylJamino]methyl] [ 1,1 ' -biphenyl~-4-yl~methyl]-8~methoxy~-oxo-l,5~benzo~iazepi~-3(S)-' yl~ 1e;

1 59. ~-[2(S),3-Dihydroxypropyl]amino-3-methyl-N-~2,3,~,5-tetra-hydr~-5-[~2'-~[[(methyla~r~no)carbonyl]am~no]methyl]~
he~s~l~-a-y~ v~ -methv~ ~- oxo-l5-~othi~epin-: ~ ~ 3(S)-yl]bllt~n~m1de; .

160. 3-~2~S),3-D~ydroxypropyl~amino-3-me~yl-N-~2,3,4,5-tetra-hydr~-s-[~-[c[(me~ly~ o)carbony~ ~ino~me~y~
biphenyl]~-yl]methyl]-8-trifluorome~yl-4-oxo-1,5-benzo-epin-3(S)-yl~b~ n~mi~

161. 2-Amino-2-met~yl- -[2,3,4,5-tetrahydro-1-[[2'-[[(amirlo-caioonyl)am~o]methyl~ 1'-biphenyl~-4-yl]methyl]4~oxo-1,5-ben7~thi~ 3~ yll~p~n7mi~

20 162. 2-Amino-2-methyl-N-[2~3,4,5-~etrahydro-5-[[2'-[[(amino-' ': ca~bonyl).~mmo~me~yl]~1,1'-biphenyl]~-yl]methyl]~8 fluoro4-oxo-1,5-benzot~iazepin-3~S3-yl]prQparl~nide;

163. ~2-Amino-2-methyl-_-[2~3,4,5-te~rahydro-;-~[2'-[[~amino-25: ~ ca~yl)ami;no~m~yl]E~ bipheIIyl~-ylJme~hyl]-8-:me~oxy-4-oxo-1,5-beD~o~hiazepin-3(S)-yl]~rop~n~mi~;
~: :
164. 2-Amino 2-methyl-N-~2,3,4,~-~etrahydro-5-~2'-[[(amirlo-carbonyl)amirlo3methyl~ biphenyl]-4-yl]me~yl3-8-methyl-3D thio~ zot~azepin-3(S)-yl]propanaInide;

165. 2-Amino 2-me~yl-N-~2,3,4,5-tetrahydro-1-[~2'-[~(amillo-carbonyl)amino]methyl~[1,1'-biphenyl]-4-yl~methyl]-8 trifluoro-methyl-4-oxo-1,5-ben~o~iazepin-3(S)-yl~propanamide;

::~

21~707 WO 94/05634 PCr/US93/û779 1 66. 3-Amino-3-methyl-N-[2,3,4,5-tetrahydro-5-~[2'-~[(amino-earbonyl)amino]me~yl][1,1'-biphenyl]-4-yl]methyl]~-oxo-1,$-lzothia~epin-3(S~-yl~b-it~n~mide; : -s 167. 3-Amino-3-me~yi-N-[2,3,4~5-tetrahydro-.$-[[2'-[[(amino-carbonyl)amiIlo]me~yl][1 ,1 '-biphenyl]-4-yl]me~hyl]-8-fllloro~
o~Q-l5-be~:Q~i~7pp~-3(s)-yllh~t~3n~

168. 3 Amino-3-me~yl~ -[2,3,4,5-tetrahydro-5-[[2'-[[(amino-car~onyljamino~me~yl~1,1 '-biphenyl~-yl~methyl]-8-me~oxy-4-oxo-1,5-ben~othi~epir~-3(S)-yl]but2n~mide;

169. 3-Amino-3-me~yl-N-[2,3,4,5-tetrahydro-5-[~2'-[[~amino-calbonyl)~mino]me~yl][1,1'-biphenyl~yl]me~yl]-8-methyl-io~oxo-i,5~ zothiazepin-3(S)-yl]but~n~mide;

170. 3-~milln-3-m~thyl-N-~ 4,5-tetrahydr~ EE~a~o-car~onyl)amirlo3methyl] [ 1 ,1 '-biphen~lJ-4-yl~methyl]-8-~Tifluoro-methyl~-oxo-1,5-ben~othia~pin-3(S)~yl~bllt~n~mide;

171. 3-[2(R)-Hydroxypropyl]amino-3-me~yl-N-E2,3,4,5-te~rahydro-5-~; ~ [~2'-~[(an~inocaioonyl)a~no]methyl~[1,1'-biphgnyl3~-yl]me~yl~- 4-oxo-1,5~beIlzo~iazepin-3(S)-ylJbllt~?n~mide;

172. ~ 3-[2(R)-Hydroxypropyl~amino-3-me~yl-N-[2,3,4,5-tetrahydro-5-' ~ ~[2'-[[(aminocarbonyl)amino]me~yl] [ 1,1 '-biphenyl~-ylJme~yl]-~; 8-fluoro~-oxo-1,5-ben~o~iazepin-3(S)-yl]but~n~mide;
~ .
30 173. 3-[2(R~Hydro~;ypropyl]amino-3-me~yl-N-[2,3,4,5-tetrahydro~
:: : [[2'-[[(aminocarbonyl)aminoJme~hyl]~1,1'-biphenyl]4yl]methyl]-8-methoxy~4-oxo-1,5-benzo~iazepirl-3(S)-yl]bllt~n~mide;

--' WO 9~/~56~4 PCr/US93107791 21~707 ~

-35- ;
174. 3-[2(R) Hydroxypropyl]amillo-3-me~yl-N-[2,3,4,5-tetrahydro-5-[[2'-[[(aminocar~onyl)amino]methyI]~l,1'-biphenyl]~-ylJmethyIJ- :
8-methyl~io~-oxo-1 ,5-berLzothiazepin-3(S)-yl]but~n~mi~le;

175. 3-~2(R)-Hydroxypropyl]amino-3-me~yl-N-~2,3,4,5-tetrahydro 5-[~ [(aminocarbonyl)a~ o]me~yl~rl,I'-biphenyl]~-yl]me~yl]-8~trifluoromethyl~-oxo-1,s-benzothiazepin-3(s)-ylJbllt~n~ e;

176. 3-r2(S),3-Dihydroxypropyl~amino-3-me~yl-N-r2,3,4~5-tetra-hydro 5~[2'-[~(aminocarbonyl)amirlo]me~ylJ[l,1'-biphenylJ-4-yl~me~ylJ~-~o-1,5~ o~ epirl-3(s)-y~ t~n~ e;

177. 3-~2(S),3-l:)ihydroxypropyl]amino-3-methyl-~-[2~3,4~5-tetra-hydro-S-[[2'-[~(amitloc~rbonyl)aIr~ino~methyl~[1,17-biphenyl]~
yl]methyl]-8-fluoro~-oxo-1,5-benzothia~epin-3(S)-yl]-;~ bllt~n~mide;

;~ 178.~ 3-~S~3-~hydroxy~ropyl~ o-3-me~yl-. -~2,3,4~ -te~ra-hydro-5-~[2'-[[~ ocarbonyl)amino]me~yl]~1,1'-biphenyl]~
yl]methyl]-8-~e~oxy-4-oxo~1,5-be~othiazepiIl-3(S)-yl]-':~ b lt~n~3mirle;

179. 3-~2(~),3-DihydrOXypropyl]amillo-3-methy~ 2~3?4~s-tet hy~ro-5-~[2;'-C[(~oc~l~ollyl)amino3me~yl][1~ ~h~nylJ-4-yl]methyl]-8-me :hylthio~oxo-1,~-benzothia~epiIl-3~S)-yl~-bllt~n~mide;
: . !
180. 3-r2(S),3-Dihydroxypropyl]amino-3-methyl N-~2,3,4,S-tetra-hydro-5-[~2'-[~(ani~nocarbonyl)a~ o~me~hyl][l,l'~iphenyl]-4-3 D yljme~yl]-8~rifluoromethyl~oxo-1 ,5-be~othiazepin-3(S)-yl3-bllt~ mi-le;

..

wo 9q/~5634 Pcr/uss3/~779,t~

,- , ........... , :
181. 2-Amino-2-methyl-N-~2,3~4,5-tetrahydro-5-[~2'-[[~(ethylamino)-carbonyl]amiIlo]methyl~[I,l'-biphenyl]4-yl]methyl]-4-oxo-l,S-be~zothiazepin-3(S)-yl]~r~ mirle;
', ~;; 5 182. 2-Amino-2-methyl- ~2~3,4.5-tetrahydro-5-~2'-~r~(e~hylarnino)-carbonyl]amino]Insthyl][1 ,1 '-biphenyl]~-ylJmethyl~-8-fluoro4-: ~ oxo-l,S-benzothi~epin-3(S)-yl]propanamide;

183. 2-Amino-2~methyl-N-[2,3,~,5~tetrahydro-$-[[2'-~[[(ethylamiIlo)- ;
: 10 carbo~l]~mir~o]me~yl]~ biphenyl]-4-yl]methyl]-8-tne~oxy-4-o~o-1 ,5-belLzothi~epin-3(S)-yI]prop~n~mi~le;

1 84. 2-Amino-2-methyl-~-[2,3,4,5-tetrahydro-5-~[2'-[~[(ethylamino)-ca~bo~yl~aDm no] m e~hyl][1,1'-biphenyl]~4-yl]m e~hyl]-8-m e~hyl~hio-4-o~o-1,5- ~ rLzothiazepDn-3(S)-yl~propanannide;

185. 2-AIriino-2-methyl-N~[2,3,4,~-tetrahydro-5-~2'-~E~(ethylamiIlo)- ;
~yl}~mino~ iphe~yl]~-yl~ hyl~-~ifluo~
me~yl~-o~o-1 ,5-be~o~ epi~-3(S)-yl]prop~n~mi~e;

186. 3- ~ I~o-3-m e~hyl-N-[2,3,4,5-tetrz3hydro-5-[~2'-~[(e~hylarn~no)-~arboIlyl]arnino]methyl][1,1 '-biphenyl] '1-yl]methyl34-oxo-1,5-hi~epin-3(S)~l~but~n~mi~;

2s 187. 3~ ino-3-~nethyl-N-[2,3,4,5~te~rahydr~5-~[2'-~[[(e~ylaII~ino~
carbonyl]amLno]methyl~ [ l, l ' -biphenylJ ~-yl~methyl] -8 -fllloro4-~, oxo-1,5i-berlzot~iazepin-3(S)-ylJbut~n~mide;
:: :
188. 3-Amino-3-methyl-N-[2,3,495-tetrahydro-~ 2'-[[~(ethylamino)-3 ~: ca.l~ollylJamir~o]me~yl] ~1 , 1 '-biphenyl]-4-yl]me~yl] -8-me~oxy~
oxo~l,5-ben~o~iazepin-3(S)-yl~bllt~n~mide; ::

.. . . . ... . . ....

~'~'- WO 94/05634 2 1 4 2 7 0 ~ PCI'/lJS93/07791 :

1 89. 3-~nino-3-methyl-N-~2~3,495-tetrahydro-5-[~2'-[~[(ethylamino)-carbonyl]amino]methyl][1,1 '-biphenyl]-4-yl]methyl]-8-methylthio~
4-oxo- 1 ,5-benzo~iazepin-3(S)-yl~b~lt~n~mide;

190. 3-Amino-3-methyl-N-[23,4,5-tetrahydro-5-[~2'-[[[(e'thylaIr~irlo)-carbonyl]amino3methyl][ 1,1 '-biphenyl]4-yl~methyl~-8-trifluoro-methyl~-oxo-l ,S~benzothiazepin-3(S)-yI]but~n~nlide;

191. 3-[2(R)-Hydroxypropyl~amino-3-me~yl-N-r'~,3,4,5-tetrahydro-5-[[2'~[[[(ethyl~mino)carbonyl]amino]methyl]Ll,l'-biphenyl]4-yl]-me~hyI]4-o~o~ -benzocniazepirl-3(S)-yl]b~ n~mide;

192. 3-[2(R)-Hydroxypropyl]amino-3-methyl-N-~2,3,4,5-tetrahydro-5-~[2~-~[E(e~hylamino)carbonyl]amino]methy~ -biphenyl]~-yl]
methyl]-8-fluoro~-oxo-1,5~ o~iazepin-3(S)-yl~bl:lt~n~mide;

193. 3-[2(R)-Hydroxypropyl~amino-3-methyl-N-~2,3,4,S-tPtrahydro-5-2'-~r(~y?~mino)carbonyl~amino~methyllrI.l'-biphenYIl-4-ylJmethyl~-8~methoxy '-oxo-1,~-benzothiazepLn-3(S)-yl]-ide;

.
1 94. 3-~2(R)-Hydro~ypropyl]amino-3-methyl-N-[~,3,4,5-te~rahydro-5-'7'~ (ethy!~min~Q)carbonyl]amino]methyl]~1,1 '-biphenyl]-4-yl~methyl]-8-me~ylthio-4-oxo~ -benzo*liazepm-3(S~-yl3-~ e;

.
! ~ 1 95 . 3--~2~R)--Hydro~ypropyl]amino--3--me~yl-- --~2,3,4,5--tetrahydro 5 2'-~(e~ylamin~)carbonyl]amino]me~lyl]~1,17~biphenyl]~-yl]-:' : methyl~-8-trifluoromethyl-4-oxo-l,S-bgn~othia2epin-3(S)-yl]-~,lt~n~1"~1e;

1 96. 3-~2~S),3-Dihydroxypropyl~amino-3-methyl-N-[2,3,4,5-tetra-- hydro-5-[[2'-[~(ethylamLno)carbonyl]amino]me~yl~[1,1'-W~ 94/05~34 2 1 4 2 7 0 ~ Pcr/usg3/0779r biphenyl]~-yl]me~yl]4-oxo-1 ,5-~othiazepin-3(S)-yl]-b~ n~mi(le; , '.'' 197. 3-~2(S)~3-Dihydroxypropyl]arnino-3-me~yl-N-~2,3,4,5-tetra-hydro-5-[[2~L~(ethylamino)carbonyl]amino]methyl] ~1,1 '-biphenyl]~4-yl]methyl]-8-fluoro-4-oxo-1,5-benzt)~iazepin-3~S)~
yl]bllt~n~mide.;

198. 3-[2(S),3-Dihydroxypropyl]amiIlo-3-methyl-N-[2,3,A,5-te~ra-hydro-5-~[2'-[[~(ethylamino)carbonyl]amino]methyl][l,l'-~Tphenyi3-4-yI]me~yl3-8-me~oxy4-oxo-1,5-benzothiazepin-3(S)-yl]bllt~n~mi(lc;

1 99. 3-[2(S),3-Dihydrox~rpropyl]amiIlo-3-methyl-N-[2,3,~,5-tetra-hydro-5-~[2'-[[[(ethylamino)carbonyl]al~o3methyl][1,1'-pherlyl]~4-yl]methyl]-8-methylthio~-oxo-l,S-benzothiazepin-3(S)-yl]b lt~n~mi(le;

00. 3~2(~),3-Dihydr~ypropyl]amino-3-me~yl-N-~2,3,475-tetra-hydro-5-[[2'-[~[(ethylamino)carbonyl]~o~methyl}[l,l'-::: biphenyl]-4-yl3me~yl]-8-tnfluorome~yl-4-oxo-1,5-benzo-~iazepin-3(S)-yl~ . .ide;

20I. 2-~ninG-2-me~yI-N-r2,3,4,5-tetrahydro-5-~2'-[~[[(hydroxy-ethyl~ o~carbo~yl~arnino]me~hyl~ biphenyl~-yl]me~yl~-4-oxo-1,5-benzo~ epin-3(S)-yl]proparlamide;

20~. 2-Amino-2-methyl-N-[2,3,4,5-tetrahydro-5-[[2'-[[[[(hydroxy-e~hyl)amino]carbonyl]amino]me~yl][l,1'-bipherlyl]~-yl]methyl]-8-fluoro~ox~1,5-benzothia~epiIl-3(S)-yl]pr~panamide;

203. 2-~nino-2-methyl-N-[293,4,5-tetrahydro-S-~2'-[~[(hydroxy-e~yl3aII~ino]carbony1]amino]methyl]~1,1'~biphenyl]4-yl~me~hyl]-8-methoxy-4-oxo-1,5-benzothiazepin-3(S)-yl]propanamide;

' WO 94/05634 2 1 ~ 2 7 1~ 7 PCr/US93/077~1 ~ ':

204. 2~ nino-2-m e~hyl-N -~2,3,4,5-tetr ~ ydro-5~[[2'-[~[(hydroxy-e~hyl)a m ~no]carbonyl~am 1noJm e~hyl][l,1'-biphenyl~-4-yl] m e~hyl~-8-me~ylthio-4-oxo-1,5 benzo~ia~epin-3(S)-yl]propanamide;
~
205. 2-~mino-2-me~yl~ 2,3,4,5-tetra:hydro-5-[[2'~[[~(hydroxy-: e~yl)amino]carbonyl]amino]methyl~1,1'-bipheIlyl]~-yl]methyl]-orome~hyl-4-oxo-15-~e~o~epiD-3~S)-vl~proDanamide:

0 206. 3-Amlino-3-me~yl~-[2,3,4,5-tetrahydro-5-[~2'-~[~[(hydro~y-e~hyl3aminoJca~onyl]amino]medlyl~ iphenyi]-4-yl3 m e~hyl]-4-oxo- 1 ,5-be~Lzothi~epin-3(S)-yl3bllt~ mide;

207. 3-Amino-3-methyl-N-[2,3,4,5-tetrahydro-5-[~2'-[[~[(hydroxy-e~yl)amino~carbonyl]amino]methyl]~1,1'-biphenyl~-yl]me~yl~-~: 8-fluoro~-oxo-1,5-berLzothiazepin-3(S)-yl]bllt~n~mide;

:: : 2~ 3-A}ni~3-~fhyl-N-E23,4.5-tetrahydr~5-[~2'-~[[~hydroxy-e~yl)ami~oJcar~orlyl~ammo~methyl3[1,1'-biphenyl]~-yl~me~hyl~-8-methoxy~-oxo-1,5-benzothiazepLn-3(S3-yl~b~ n~mide;
:' :
209. 3-An~ino-3-me~yi-N-~2,3~4,5-te~rahydro-5-[[2'-[~[[(hydroxy-e~yl)a~o~carbonyl3amino]methyl]~1,1'-biphenyl~-yl]methyl]-8-me~yl~io~4-oxo 1,~-berlzothiazepin-3~S)-yl~b-lt~n~mide;

210. 3-Ami~o-3-me~yl-_-~2,3,4,5-tetrahydro-5-[[2'-~[[~(hydroxy-:~ e~yl)amino] carbonyl] amino]me~yl] ~1 ? 1 ' -bîphenyl~ ~-yl]me~yl] -8-trifluoromethyl~-oxo-1,5-benzo~hiazepin-3(S)-yl]b~lt~n~mide;

30 211. 3-~2(R~Hydroxypropyl~amino-3-me~hyl-N-[?,3~4,5 tetrahydro-S-: [[~ [[(hydroxye~yl)amino]carbonyl3aIr~ino]me~yl][1,1'-biphenyl3~-yl]methyl3~-oxo- 1 ~5-beIlzo~iazepLn-3(S)-yl~-but~n~mide;

:::

. , . . .. .. .. . . . , .... . , . , . -WO 94/~5634 2 1 ~ 2 ~ cr/U~93/0779j~

212. 3-[2(R)-Hydroxypropyl]amino-3-methyl-N-[2,3,4,5-tetrahydro-5-[[2' [[[~ydroxyethyl3am~no~carbonyllamirlo3me~hyl]~l,1'-biphenyl]-4-yl]me~hyl]-8-fluoro-4-oxo~ ben~o~ia~epin-3(S)-yl]b1lt~n~mi~e;
~: . 213. 3-[2(R)-Hydroxypropyl3amino 3-methy~-N-[2,3,4,5-tetrahydro-5-~: ~[2'-[[~[~ydroxye~yl)am~ o]carbonyl~amirlo]methy~
~iph~nyll -4-yl~me~yl} -g metkoxy-4-oxo- 15~ oth;a 7epin-3 (~-yl~bnt~n~mi~e;

214. 3-[2~R)-Hydroxypropyl]amino~3-methyl-N-~2,3,4,j-tetrahydro-5-[[2~-[L[[~ydro~ye~yl)?min~]carbonyl]amino]methyl]~ l ,l '-biphenyl]~-yl]methy!~-8-methylthio~-oxo-l,S-berlzotbiazepin-3(S)-yl~bllt~n~mide;

. 15. 3-~(R)-H~droxypropyI]~xlino-3-methyl-N-~2,3,4,5-tetrahydro-5-[2'-[[[[~ydroxyethyl)~nirlo]carbomyl]a~ino]me~yl][l,l'-biphenyl~l~e~yl~ triflllorc m~thyl~xo-l,S-be~
iazepin-3(S)-yl31,~ ni~1e;
~ :.
216. 3-[2(S)?3-Dihydro~ypropyl~amino-3-me~hyl-N-~2,3,4,S-tetra-hydro-5-[~2'-[~[~(hydroxyethyl)amino]carbonyl~amino]me~yl]-biphenyl]~-yl]me~yl]-4-oxo-1,5-b~o~ epin-3(S~-yl3bllt~n~mi~1e;

17. ~3-[2(S),3-Dihydroxypropyl]~nino-3-me~hyl-N-~2~3,4,5-tetra-hydro-5-[[2'-~E~(hydroxyethyl)amino]carbonyl]aIT~ino~methyl]-~l ,l '-biphenyl]-4-yl]methylj-8-fluoro-4-oxo-1 ,5-benzo-thiazepin-3(S)-yl]b~ n~mille;
3 o ~; 218. 3-~2(S),3-~3ihydroxypropyl~amino-3-methyl-N-~2,3~4,5-tetra-hydro-5-[[2'-[[[[~hydroxye~yl)amino]carbonyl]amino]methyl]-: ~ [1,1'-biphenyl]~4-yl]methyl]-8-methoxy~-oxo-1,5-berLzo-:: thiazepin-3(5)-yI]bllt~n~mide;

... . . ..... .. , . . . . ~ . . . .

~: WO 94/05634 2 1 ~ 2 7 ~ ~ PCl'/US93/07791 -41- ;

: ~ 219. 3-~2(S),3-Dihydro~ypropyl]amino-3-me~yl-N-[2,3,4,5-tetra-hydro-5-[~2'-~[~(hydroxye~yl)amillo]carbonyl]amino]me~yl]-~1,1 '-biphenyl]-4-yl]methyl~-8-methylthio~-oxo-1,5-ben~-thiazepin-3(S)-yl]blls~n~mide;

, .
220. 3-[2(S),3-Dihydroxypropyl~amino-3-methyl-N-~2,3,4,5-tetra- ~.
:: hy~-s-~r2~-rrr~hy~roxyethy~)~m;no}~arbon~ minolm~[l,~'-biphenyl~-4-yl~methyl~-8-tnfluoromethyl ~-oxo~ -benzo-iazepin-3(S)-yl~b~ n~micle;

221. 2-Amino-2-methyl-N-[2,3,4,5-tetrahydro-1-[~2'-[2-[[(methyl-~: amino)carbonyl]a~ino]prop-2-yl]~ biphenyl]4-yl]methyl]-2-ox~-lH-ben7~7epin-3(R:)-yl]prop~mi~

' ~ ~ t 222. 2-An~ino-2-methyl-N-~2,3,4,5-tetrahydro-1-~2'-[1-[[(methyl-amino)carbonyl]amino3e~yl][1,1'-biphenyl]4yl]methyl]-2-oxo-l~n7~7~pin 3~R)-yllprop~n~mi~;

20 ~ 223.~ 2-Amino-2-me~yl- -[2,3,4,5-tetrahydro-1-[~2'-[[(me~oxy-carboIlyl)~mmo3methyl~ biphenyI~4 ;yl]me~yl~-2-oxo- 1~-epin-3(R)-~l]propan~nide;
:: ~
224. 3-Amino-3-me~yl-N-[2,3,4,~-tetrahydro-1-~2~-[~(me~oxy-2 5 c ar~onyl3~in~]me~yl3 [ 1,1 ' -biphenyl]~ylJme~yl]-2-oxo-lH-' ~ ben~.~7epin-3(~)-yl]b lt~n~mide;

~: 225. 3-[2(R)-Hydroxypropyl]amino-3~methyl-N-[2,3,4,5-tetrahydro- 1 -[[2'-~[(me~oxycarbonyl)amino]me~yl][1,1'-biphenyl~-yl]-:~ 30 ~ me~yl~-2~x~1H-benz~zep~-3(R~-yl]b~ n~mide;

226. 3-[~(S),3-DihydroxypropylJamino-3-me~hyl~N-~2,3,4,S-tetra-: hydro-1-[[2'-[[(methoxycarbonyl)amino]methyl~[1,1'-biphenyl]~-yl]methyl]-2-oxo-1H-benzazepin-3~)-yl]but~n~m;de;

' ~1~2707 WO 94/OS634 PCI'/US93/0779 227. 2-Amino-2-me~yl~ 2,3,4,5-tetrahydro-5-[[2'-[[(methoxy-car~onyl)amino]methyl][l,1'-biphenyl]-4-yl]me~yl]4 oxo-1,5-benzothiazepin-3~S)-yl~prop~n~mi~e;

228. 3-Amino-3-methyl-N-[2,3,4,5-t~trahydro-5-[~2'-~[(methoxy-carbonyl)~ino]me~yl] ~1,1 '-biphenyl3-4-yl]methyl]~-oxo-1,5- I' ber~zo.~ 7~pi~.-3(S~-yl~b~lt~n~mi~3~

0 229. 3-[2(R)-Hydroxypropyl]amino-3-methyl- -[2,3,4,5-tetrahydro-5-Z'-~[(metho%ycarbonyl)~mino]me~yl][1,1'-biphenyl~-yI~-methylJ~oxo-l,S-benzo~iazepin-3(S)-yl]but~n~mide;

230. ~3-[2(S~,3-Dihydro~ypropyl]amino-3-methyl-N-~2,3,4,5-tetra-L 5 hydro-5-[~2' -[[(methoxycar'oonyl)amino~me~yl3 [ 1,1 ' -biphenyl] ~-yl]me~yl]~-oxo~1 ,5-benzothiazepin-3(s)-ylJbllt~n~mit3e;

231. 2-Ami~o-2-me~hyl~ 3,4,5-te~ahyd~o~ E'~ {(~e~hyl~n~no~
~ carbonyl]o~y3me~yl~1, 1 '-biphenyl~-4-yl3me~yl~-2-oxo-lH-benzazepin-3(R)-yl~propanamide:

; 232. 3 ~nino-3-methyl-N-[2,3,4,5-tetrahydro-1-[[2'-[[~(methylaIr~ino)-c~bonyl]oxy]methyl]~1,1'-biphenyl]~yl]me~yl~-2-oxo-lH-be~7~7epin-3(R)-y~ t~n~mide;

233. 3-[2(R)-Hydroxypropyl]amino-3-me~yl-N-[2,3,4,5~tetrahydro-1-[[2'-~[~me~ylamino)carbonyl]oxy]me~yl][1 ,1 '-biphenyl]-4-yl]-, me~yl]-2-oxo- lH-ben7.~7epin-3(R)-yl]bllt~n~mi~e;

30 234. 3-~2(S),3-Dihydlo~y~lolJyl]a~ o-3-me~yl-N-[2,3,4,5-tetr~-:~ hydro- 1-[[~ [[(me~ylamino)carbonyl]oxy]methyl] [ 1,1 ' -biphenyl]4-yl]me~yl~-2-oxo-lH-benzazepiIl-3(R)-yl]bllt~n~mide;

:

:

~ - WC) 9~/05634 2 1 4 2 7 0 ~ PCT/lJS93/07791 ~,~. , .
q3 235. 2-Amino-2-methyl-N-~2,3,4,$-tetrahydro-5-[[2'-E[[(methylamino)-carbonyl~oxy]me~hyl~[1,1 '-bîphenyl~-4-yl]methyl]4-oxo-1 ,5-benzothiazepin-3(S)-yl]~ro~ misle;

236. 3~Amino-3-methyl-N-[2,3,4~5 tetrahydro-5-[[2'-[~[(methylamino)-carbonyl~oxy]me~yl]~ 1,1 '-biphenyl]-4-yl]rne~yl]-4-oxo- 1,~-benzot hiazepin-3(S)-yl]bllt~n~mi~e;
- ,.
237. 3-[2(R)-Hydroxypropyl~amino-3-me~yl-N-~7,3,4,5 tetrahydro-5~
[[2'-~[~(methylamino)carbonyl]oxy]methyl~[l,l'-biphenylJ-4-yl]- .' metnyl3~-oxo~ beIlzo~iazepin-3(S3-yl~but~n~de;

238. 3-[2~S),3-Dihydroxypropyl]amino-3-methyl-N-[2,3,4,5-tetra-hydro-5-[~2'-~[(methylaIrino)carbonyl]oxy]me~hylJ~1,1 '-l 5 biphenyl~-yl]medl~l]~-oxo-1 ,5-benzothi~epin-3(S)-yl]-t~n~m;de.
.
,:
Re~resentati~e examples of the nomenclature employed are given below:

N-[1 -[[2'-[(Methylaminocarbonyl)amino]~ 1 ? 1 '-biphenyl~-yl]methyl~ -~: : 2,3,4,5-te~rahydro-2-oxo-1H-1-benz~epin-3(R)-yl~3-ami~o-3-methyl-~: bl1t~n~mide ~5 : : 1I CH3 /CH3 ~ ~ NH-C-CH2-C-NH2 ~ 11 ~C-NHCH3 , .
. . , WO 94~0S634 2 1 ~ 2 7 0 7 P~IUS93/0779.~

N~ [~2'-[(Methyl~inocarbonyl)o~y][1,1'-biphenyl]~-yl]me~yl]-7-methyl-2,3,4,5-tetrahydro-2-oxo-1H-1 -benzazepin-3(R)-yl]-2-arr~ino-2-methylpropanamide . -CH3~NH- ICl-C NH2 ~-NHCH3 ;:
:~ 15 N-[1-[~2'-[(Me~yIaminocarbonyl)amino~ 1'-bi~h~y1~-4-yIl~hyl~-2 ,3,4,5-tetrahydro-2-oxo-1H-1 -benza~pin-3(R)-yl]-3-[2(R)-hydroxy-20 propyl]amino-3-methylbllt~n~mide : .
: 1I C~ ~ H3 H,~ pH
--\~NH-C-(:;H~-G~NH-CH2-C-CH3 'H

~C-NHCH3 31~

~- WO 94/05634 2 1 ~ 2 7 0 7 PC~/U593/07791 3-[2(S),3-Dihydroxypropyl]amino-3~methyl-N-~2,3,4,5-tetrahydro-5-[~2'-~2-~-morpholLnocarbonyl]amino~ethyl~1,1' biphenyl~-4-yl]methyl]-7-me~yl4-oxo-1 ,5-be~zothiazepin-3(S)-yl]bllt~n~mide Ol CH3 CH3 h~ ~OH
CH~ kNH-C-CH2-C-NH-CH2-C CH20H

H2CH2NH-CN~O

: 1 5 ':

The ~ ounds of ~e instant inve~ion all have at least one asymmetric center as noted by ~e astensk in the structural FoImula I
20 above. Addit:ional asymmetr~c ce~ters may be present on the molecule depenllin~, upon t~e Ilahlre of ~he various substituents on the molecule.
ach such as~etric center will produce two optical isomers and it is intçn~led ~a~ ~11 such optical isomers, as separated, pure or partially ' ~ puri~ied op~cal isomers: or: ~cemic mi~tures thereof, be mcluded wi~
~: 25~ ~he ambit of ~he in~t~nt ~v~ntion ~ the case of the asymmetnc ce~er represented by ~e asterisk in Formula I, it has been found that ~e :~ ~ compourld in which the 3-amino substituen~ is above the plane of the structure? as seen in Formula Ia, is more active and thus more preferred over ~e compound in which the 3-amino subs~ituen~ is below the plane 30 Of the s~ucture. In the substi~ n~ (X)n, when n = 0, the asymme~ic center is ~le~ ted a~ the R-isomer. When n - 1, this center will be designated according to ~e R/S rules as ei~er R OF S depending upon ~:~ : the value of X.

WO ~,/05634- 2 1 ~ 2 7 0 7 PCI/US~3/0779,'-~ '~

' R1(X)n-(CH2)p F~ ~R4 R r O
(~ 12)q ~.

(L)w lo Rla ~-- 3 , The instant compounds are generally isolated in the forrn of heir p7~ ceutically acceptable acid addi~ion salts, such as the salts den~ed from us~ng inorga~ and organic ac.ids. Examples of such : acids are hyd~ochlQric, ni~ric. sulfuric, phosphoric. fo~c ace~c.
uo~oet~ propiomc, ~lla~ic, ~-ucc~c~ ma}o~lic a~ ~e ~ce. ~n ' addition, certain compounds co.~i..i"g an acidic ~cnon such as a carboxy can ~e is~la~ed in ~e fo~m of theLr inorg~nic salt in ~hich the counterion can be selected ~rnm sodium, potassium, lithium, calcium, m~nesium and ~e like, as well as from organic bases.
:The c~mpounds (I) of the present invention are prep~red rom ~olactam i~ nediates such as those of ~lmula II. The ion ~ ~ese i~ e~iates is described m ~e following reac~ion ~: S~en~es.
R1 (X)n~(CH2)p ~ NHz R2 H ~

II

~: ;

. .

WO 9~/05634 2 1 ~ 2 7 0 7 PCr/U~i93/07791 Benzo~filsed lactams 3 wherein the lactarn is a seven~
mernbered ring are convemently prepared from substituted tetralones 2 using known procedures. The subs~i~uted tetralones are, in some cases, com~ercially available or are prepared from a suitably substituted 5 der~va~ve of 4-phenylbutync acid 1. CyclizatioIl of l canbe achîeved by a number of methods well known în the literatNre including trea~neIlt with polyphosphoric acid at ele~ated temperarures as shown in Sch me 1.

[ Polyphosphoric [\~
Acid /~
~2 O=~OH 50-1 50~t: R2 O

:
: , . :: 20 : R~
[ HN3 RZ ~ CHCI3 zi~N~
.

': 30 Conversion of substituted tetralones 2 to benzolactams 3 can be achîeved by a number of methods f~milî~r to those skilled in the art. A suîtable method involves the use of hydrazoic acid (Schmidt or Cur~ius reactîons) to fo~n the subs~ituted ber~olactam 3.
:

WO 94/~5634 2 1 ~ 2 ~ 0 7 PCI'/US9~/077~

Benzo-fused lactams wherein the l~ct~m i5 an eight-membered ring (O are prepared as descri~ed by D. H. Jones, et al, J.
Chem. Soc~ C, 2176-21%1 (1969) by a ser~es of analogous transformations starting ~rom a substituted derivati~e of S-phenyl-5 ~e..,t~.oic acid 4 as shown in Scheme 2.

SCHE~E 2 R~
\~.f ~ Polyphosphonc [~
~1 J Acid /~/
R2C)=~< 50-1 50~C: R2 . OH

~: , ~ :

/~ ~ CHC13 RZ N~J

As illus~rated in Scheme 3, an ~alogous sequence is employed in ~e construction of benzo-fused lactams con~ining nine-membe~ed rings. The requisite berlzocyclooctanone inteImedia~e 8 is obtained by acid-catalyzed cyclization of ~e substibuted 6-phenyl-h~noic acid precursor 7 using ~e a~oremen~ioned conditions.
Elaborahon to the desired nine-membered lactam product: 2 can be achievcd directly, through the use of hydrazoic acid (Schmidt reaction) using conditions described by R. ~Iuisgen, et al, Ann., ~, . ~

: WO 94/0~634 2 1 4 2 7 0 I PCI/VS93/07791 30-51 (19~4); or, via Beckm~nn rearrangement of an intelmediate oxime, as demons$ra$ed by W.M. Schubert~ et al, J. Amer. Chem.
So~., ~, 5462-546~ (1954).

S ScHEME 3 ., 1 ' i R1 ,, r~ 50 150DC ~) R2 COOH R2 O ~.
:Z. ' ~' "' , lS R1 R
[~/~ ~ HN3, CHGI3 , / "~
/~ ~ or; 1. Nl 120H / N~' Ra~ O 2. H25~ R2 H O
~ : ~

As shown in Scheme 4, 3-aminobeDzol~&t~m analogs whereirl the lact~m: is a six-membeired riIlg ~ are prepared from a 2s ~ :substitilted denvative~ of 2-nitrobenzyl chloride (or bromide~ 10 by the method oi A.L. Dav;s, ~et al, Arch. Biochem. Biophys., ~, 48-~1 :: (1963) ~d references cited therein.
:

, :

~ .

wo 94/~5634 - ~ 1 'I 2 7 o 7 PCl /U~93/~77gf~

' ., ,, . ..

~ ~ s o ?j S C~HEhIlE 4 R \~CH2CI ~ I HCOCH3 ~,~. 5 2 N~2 C2H5O2C-CH-C02~2H!;
R NaOC2H5, C2~t5OH

''' ' : 10 , . ..
~ ~ ~ Rl N~iCOCH3 HCI
~ CO2C ~H~; r ~J\ co2G2Hs NO
5 ~

NHz ~2 ~ ~NH2 2~0 COOH PdtC COOH

1 Z l 3 13 HCI ~NH~

R H
: 3 0 . ~ :
Benzo ised aminiolactarn analogs cont~;ning a five-: membered lactam are prepared by an analogous sequence fromi :: :

w0 94/05634 21~ 2 7 Q ~1 PCI~/US93/07791 a~ ro~lia~ely subs$i~u$ed derivatives of e~yl o-nitrom~n~lelate 15 by ~e procedure of A.L. D~vis, et al, J. Med. Chem., 1~~ 1043-104S (1973), as shown in Scheme S.

S(: HEME 5 [~COzC2Hs 1. PBr3 L~ ~N K~

: ~

R1 ~ N O RiNH2 ~ ~ CO2C2H5 1- HC~, CH3COOH ~f CO
/~NO2 2. NaOH /~NO2 : R2 ~ ~2 16 ~

2s ~ R~ NH2 R1 NH2 ~N~2 Conversion of substituted benzo-fused lactams to the requisite 3-amino der~vatives can be achieved by a number of methods f~mili~r to those skilled in the art~ including ~hose described by .

wo 94,056~l ~ 2 7 0 ~ P(:~/US93~0779~

Watthey, e~ al, J. Med. Chem., 2,~., 1511-1516 (1985) and references cited there~n. One eommon route proceeds via ~e inte~nediacy of a 3-~: halo ~chloro, bromo or iodo) intermediate which is subsequently displaced by a nitrogen nucleophile, typically azide. A useful method of ~: 5 i~)rmiIlg ~e 3~iodoben~olactam intermediate 20 in-~olves treating ~e benzolactam wi~ two equivalents each of iodotrimethylsilarle and îodine at low temperablre, as illustrated in Scheme 6 i~or the seven-membered in analog 3~
~ ~ .
. . ~
, . ~ ~ : : :

~:
. ~ , ..
:: .

~: 2~ :
: : , :: :
':

.

~:

~7'' ' WO 94~05634 2 1 4 2 7 ~ 7 Pcr/US93/~7791 ~:. SCHEME 6 3)3Sil~ l2 !~
RZ H O (c2Hs)3N~ -1 ~CC

~ ' Fl'~_ NaN3, DMF, '~ ~ R2 N o Tetramethylguanidinium H azid~. CH2C12 lS 2:

N tl2, PUC
~ or PPh3, H2O
R2 H ~

~ :

: ~ ~NH2 ~ :~
3a ~ 22 , ; : ~
Elaboration of the iodobenzolactams to the de~ired c ~
:: amLnolactam i"te~ te Il is achieved by a two-step procedure illustrated in Scheme 6. Typically, iodobenzolactam 2Q is trea~ed wi~h :
:: :

;. :
,, ~

W~:) 94/05634- ~ 1 4 2 7 o JS PCI'/US93/0779~'~ ;

- ~;4 -- .,, ' ':
sodium azide in N,N-dimethylformamide at 50-100 C to give the 3- -azido derivative 21. Altematively, tetramethylguanidinium azide in a solvent such as methylene chloride c~n be employed to ac~ieve similar results. Hydrogenation wi~ a metal catalyst, such as pl~tinllm on carbo~ or al~r~2~vely, ~re~trn~.nt with ~riphenylphosph~e i~ w~
toluene, results in PormatioIl of ~he amine derivative 22. Formation of the ~nalogous derivatives of the eigh~- and nine-membered benzolactams is ~so ac~;e~d ~ ~he ~~ sho~ in Schem~, 6.
O Chiral ~inobenzolactams are obtained by resolution of the racemates by classical me~hods farniliar to those skilled in ~e art. For e~cample, ~esolution can be achi ved by formation o~ diastereomeric salts of ~e racemic amirles wi~h optically active acids such as D- and L-taltaric acid. Determin~hon of absolute stereochemistry can be ~: achieved Ln a number of ways including X-ray analysis of a suitable crystall~ne derivatiYe.
: A use~ul preparation of the chiral intermediate 27 is shown in Scheme 7.

: 30 wo 94/~634 2 1 4 2 7 ~) 7P~r/US93/07791 ss S~E 7 H2NOH ~ HCI [~

O ~
OH

H ~ 2 1. NH3 ~N~ 2. D-tartarlc acid H ~

~: .

25:::
; : :
' ~' ' 26 ~N~

H ~
3u ~ ~ 7 , ~r Conversion of 1-tetralone to the seven-membered : benzolactam 24 is achieved by Beckm~n rearrangement of the e~ ediate oxime 23. Trea~nent of 24 with iodine and , ~ , wo 94/05634 2 1 ~ 2 7 ~ ~ PCr/U~93/0779~

hexamethyldisilazane gives the 3-iodo derivative 25 which is se~uentially treated with arn~non:ia and D-tar~ic acîd to give the diastereomeric D-tartrate salt 26 a~ter recrystallization. Liberation of ~e free amine 27 is achieved by neutr~lization of the D-tar~rate salt 5 wi~h potassium carboDate followed by extra~tive isolatio~
Ir~e~ne~i~tes of Formula II wherein X is a sulfur atom are prepared by methods deseribed in the lilterature and known to those ~lledi~ &~ AS i~ ed in Sc~eme 8~ t:he se~ membered r'~2 analog 35 is prepared from a protected deAvadve of cysteine ~2 by the method of Slade, et al, J. Med. Chem., ~, 1517-1521 (1985) and references cited therein (C~Bz is benzyloxycarbonyl).

' ~; 20 : :

.

~ ~ 3t) WO 94',,/0,5634 214 2 7 0 7 PCI'/US93/07791 SCHE,~IE, 8 ~NO2 HOC NH~,~z ' ~ .
: 10 ~: ~ . NaHCO, R~S~r, NHCB~
C2HsOH/H"~O R2~N~ )2 COOH
lS

n ~ S ~NHC,~,7.
NH4CI ~1~ COOH

: 2 ~

!: ~ :
., '~.! . I ' ~ i 30~
, ~ :

; ~

: ~ .

~1~2707 wo 94/0s634 P~r/uss3/0779l--SCHEME ~ (Con't~

R1 ( ~)m ;~:LDi~ycloh~xyl~ S~
. carbodiimide R2 N~
H

~ m=0, ~ m=1, 34 m=2 : .
t ~)m CHH3BrOOH ' ~5 H ~

;: : ~ m-0, ~ m=1, 37 m-2 Sulfoxide and sulfone intermediates 36 and ~Z are p~epared by oxid~ti~n of 32 w ith various oxidants such as sodium periodate or meta-chloroperbe~Lzoic acid. Elght-membered ring L~temledia~s of Formula II wherein X is sulfilr can be prepared by an analogous route ~5 star~,, frGm derivatives of homo~cyst ~e.
InteImediates of Fo~mlla Il wherein X is an oxygen atom prepared by methods described in the literature and 1~OWn to those skilled in ~e art. For e~mrle, the seven membered I~ng analog 39 can ~:: be prepared from a su~stitu~ed derivative of 3-~2-~itrophenoxy~
30: ~r~yalloic acid ~ by ~e method of J. O~t9 Arch. Pharm. ~Wcir~eirrl, : Ger.), ~(9j, 601-603 (1990).
' ... ... ...... .. . . . ~ .. . . ~ . .... ...

- WO 94/05634 2 1 4 2 7 0 7 Pcr/usg3/o77gl ~ME 9 ,;

R\~(~~ Zn Dicyclohexyl-~2 NH4Ci carbodiimide R~

3~ ~ :

~Six-membèred nng allalogs wherein X is oxyge~ (~L ) may be prepared by rea~tion o~ a sllbs~ituted derivative of 2-amirlophenol 40 th chloroacetyl chlonde by the me~od of Huang and Chan, Synthesis, H ~ 51 (1984) and references cited ~ere~. Subsequent incol:poration : of an an~ino group at the 3 posîtîon of either ~2 or 41 is achieved by ~e 5 me~ods des~nbed i~ SG~Çn1e 6.
~ .
I' , ' SC~IEME 10 .
.

Z~ H2 2 N O

~Q ~

~ .
:

WO94/0563q ~ 707 PCI/US93/0779,~
.

Seven-membered ring analogs of Formula Il wherein X is C-O can be prepared from derivatives of tryptophan as described in the Australian J. Chem., ~, 633-640 (1980). Seven-membered ring analogs of Formula II wherein X is CH-CH can be prepared from ~e S aforementioned analogs wherei~ X is C=O. Tre~tme~t of 42 with ch~mical redwcing agents such as sodiurn borohydride in a polar solvent such as meth~rlol or ethanol results in reduction to give the secondary :~ alcohol~i~,r~tivç ~ (X-CHOH).

R1 R~ OH
[~/~ NH2 NaBH4 ~ ~ NH
: N~ CH3C)H N~
~ 15 p(2 ~ ~ R2 H o : ~ :
Dehydration o~ 43 can be achieved by several methods decIibed in the literature and familiar to those skilled in ~e art. For e.x~m~le~ treahnPnt of 43 in an inert solvent~ such as b~n7e.nP, with a strong acid such as p-toluenesulf~I~ic acid, can result in dehydra~ion to 25 the nn.c~ red analog 44.
:

~NH2 p-TsOH ~NH2 3~ 2/ ~ N C6H6 R2 N O
~: . ' , . , . . ., .. . ..... , . .... , , ., . . .. ~ ~ ,.. ..

'~ WO 94/05634 2 1 4 2 7 0 ~ PCl'/US93/07791 Intelmediates of foImula II can be further elaborated to new intelmediates (fomlula m) which are substituted on the amino group (Scheme 11). Reduetive allcylation of II with an aldehyde is canied out urlder conditions known in the ~; ~or example, by catalytic 5 hyd~o_en~ion wi~h hydro~e~ he presence of pl~tinllm~ p~ lm or nickel catalysts or wi~ chemical reducing agents such as sodium cyarloborohydride Ln an ~ert solvent such as methanol or ethanol.

S~H~ME 1 1 1~ , R~ X)n- (~H2)p NH2 Aldehyde ; /~N--~ sodium cyano-R2 H ~ borohydrid~

': l[I
, ~
X)n- (CH2)o [~ NHFl6 ,, , < : m Att~ehment of ~e aIr~ino acid sidechain to intermediates of folmula m is accomplished by the rout shown in Scheme 12.
Coupling is conveniently caITied out by the use of an appropriately protec~ed amino acid derivative, such as that illustrated by folmula IV, 30 and a couplillg rea~ent such as be~otri~ol-1-yloxytris(dimethyl-axnino)phosphonium hexafluorophosphate ~"BOP") or benzotriazol-1-yloxytnpyr~olidinophosphonium hexafluorophosphate ("PyBOP") in an iner~ solvent suoh as methylene chloride. Separation of unwanted side ,! products, and puri~lcation of intermediates is achieved by ch~omato-graphy on silica gel, employing flash chromatography (W.C. Still, M.

WO 94/05634 21~ 2 10 7 PCI~US93/0779~

~ - 62 -Kahn and A. Mitra, J. Org. Chem., ~., 2923 (1978)) or by medi~
pressure liquid chromatography SC~IE~ 1 2 ;.
s Rl (X)n~ (CH2)p ~ ~1~ ~ HO-C A-N-G

F~2 H C ) II~ IV

BOP G = t-butoxycarbonyl CH2CI2 orbenzyloxycarbonyl :
1 5 ~ "
~ .: ' R (X)r~~ (CH~p o R5 N--C-A--N~G
2 0 /~ N--~o F~

V

2s ~e protected amino acid denvatives IV are, L~ many c~ses, co~ercially available in t-butoxycarbonyl (B(:)C) or be~yloxy-carbonyl (CBz) ~oIms. A useful method to iprepare ~e preferred sidechain 49 is shown in Scheme 13.
, 3 û

:

: WO 94/~563~ 2 1 4 2 7 0 7 PCr/US93/07791 SC~EME 13 /CH3 ~ ~H3 CH2~C~ + ~=C=Nsc)2cl alherr F~CH3 ~,H3 45 S(:)~CI
: .: ~ :

CH3 ~H3 Na2SO3F~ CH3 BOC~O ~FN~ 3 H20 O \H ~ BOC

l S:
; ~ ~

~; ~ LiOH C-CH2-C-NHBOC

20 ~

s ~
: : Reachon of isobutylene Wi~l N-chlorosulfonylisocyanate 45 in diethyl ethe~ gives the azetitlinone deriYative 46. Remov~l o~ the s: chlorosul~onyl group with aqueous sodium sulfite ~ollowed by reaction with di-t-bu~rldicarbonate gives the BOC-pro~ected intelmediate 48.
lk~line hydrolysis gives the protected ~ino acid derivative 49 in good t' ~'" ! overall yield- ;
Intermediates of folmula V~ are p~epared as shown in 30 Scheme 14 by trea~nent of the desired lactam intermedia~e V with an al~ylating agent VI, wherein Y is a good leaving group such as Cl, Br, I, O-methanesulforlyl or O-(p-toluenesul~onyl). Alkylation of :: intermediates of ~ormula V is conveniently caITied out in anhydrous dimethyl forrn~mide (DMF) in the presence of bases such as sodium hydride or po~assium t-butoxide for a period of 0.5 to 24 hours at 21~2707 wo 94/0s63q ~Cr/US93/077~
. : . , - 6~ -tempera~res of 20-100~C. Substituents on the aLky}ating agent VI may need to be protected during alkylation. A descnption of such protectirlg groups may be found in: Protective Groups in Organic Synthesis. T.W.
Greene, John Wiley and SOI1S, New York, 1981.
:~ ~ SC~Ml~ 14 R\,~,X)~- ~CHa~
N--C-A-N--G

R2 ~ ~

V
1. NaH/DMF
2. R1a ~ 2?~ ~
~- ~ 20 ' R

R1 (X)n~ (CH2)p 0 R~
~q/ \ N--C-A--N G
/~N--~ R6 R2 I ~
(C72)q 3 o (L)w R3a Y is a leaving group \~
G is t-butoxycarbonyl /~\
i ~ or banzyloxycarbonyl R1a R2a ,'.'': ~JII

,~, .. . . .. . .

''' WO 94/05634 2 1 4 2 7 0 7 PCI'~US93/07791 AlkylatLng agents Vl are in some cases commercially available or may be prepared by methods desc~ibed in the litera~ure and ~mili~r to one skilled in the art. Compounds of formula I where R3a or R3b is a carbamate, semicarbazide or u~ea derivative, whereirl this fi~nrtion~ tt~ch~ to ~he phenyl ~ by a nitrogen atom are prepared from interrne~ e 5~, obtained by allcylation with a derivative ~ of fo~nula VI where~n R3a or R3b is a n~tro group as shown in Scheme :~ ~5.

1 0 , , . .

~:~ 15 .

,, :

.

~: 3C

' .

21~2~0 ~
WO ~4/05634 P~/~S93/077 ~' .
s C-A--N-G

~-; 1. NaHt~MF
: 10 ~ R1a \'=\ (L
: ~ i 2i,~'~1D~ q NO2 V~
~: 1 5 R1 (x)n- (cH2)p ~ Rs ~N--~ R

:1 ~ (CH2)q Y is a leaving group (l~w NO2 Gist-butoxy~arbon~
: 2s or benzyloxycarbonyl ~ R1a R2a .
, : ~ .
:

: : :

wo 94/05S34 21~ 2 7 0 7 Pcr/uss3/077s1 . .
A useful method of synthesiz~g a preferred alkylating agent 54 is shown in reaction Scheme 16.

SC~lE~ 16 .
CH3 Br 1 0 B(OH)2 ~1 Pd(PPh3)4, ~JaOH, ~
J
~;: 2~propanol, T
benz~ne, hea~ ~NOz ~: CH3~ CH2Br N-bromosuccinimida ~
~: 25 ~ l~;~l ~ C~14,AIBN, heat I~J

¢~N~2 ~ ~,NO2 , ~ : ~ 30 - 53 :: ~ Reaction of 4-~olylboronic acid 5 ~ with 2-bromonitro-~en~ene 52 in the presence of a ~ransi~ion metal catalyst such as (tetrakis3triphenylphosphine palladium (O) in a mixed solYent system ~ .

WO 94/05634 2 1 ~ 2 ~ ~ ~'' PCI'/US93/0779'.'--cont~ining aqueouS sodi~n hydroxide, water, 2-propanol and benzene at elevated temperatureS for several hours giveS ~e coupled product 53 in good overall yield. Chromatographic puri~icativn and separation of unwanted by-products is conveniently'~performed on silica, eluting with common or~anic ~olvents such as hexane, ethyl ace~ate and methylene chloride. Conversion of,~, to the bromide derivative 54 is accomplished by~tre~tmeIlt wi~ N-bromosuccinimille in refluxing :~ c~o~ tetr~hlQ~ide in ~h~ presenre o~ a ~di ;nit;?itn~ such 2s benzoyl peroxide 01; 2,2'-az~bisisobutyronitrile (A~3N).
As shown in Schemç 17, reduction of the nitro group of 50 is achieved by hydrogenation in the presence of a metal catalyst, such as palladium on carbon, in a protic solvent such as methanol or ethanol. It may be appreciated by one skilled in the art that for certain compounds where catalytic:hydrogena~ion is incompatible with existing 15 functionality, alternative methods of reduction are indicated, such as '' ~ ch~ al reduction wi~h stannous chloride under acidic conditiorls. It should also be noted ~at ~e protecting group G in intermediate 50 must cnmp~ le With~ e,~ t~l CC~O}~ ~pa~d ~
redllction. For example, intem~ediate ~Q wherein G is t-butoxy-20 carb~yl (130C) is stable to ~e conditio~s of cat~lytic reduction employed in the conversion to ~. Interrnediate ~j may also be fur~er elaborated to a new inte~nediate 56 by reductive alkylation with an aldehyde by ~e ~folel~entiorled proced~res.
: : ~5 : ~: ' 30 :: :

WO 94/0~634 2 1 ~ 2 7 0 7 PCI'/U!~;~3/07791 : - 69 -SC~EME 17 . .
R1 ~X)n~(~ ti2)p 0 R~
~ NI--C-A--N-G

(C12)q w N~2 H rd/C
~ CH30H

T::t 1 a 1:~2a 5 ~ ~Q G is t-butoxycarbonyl , ~
~: ' (CH2)p O R5 ~ I \~N~ A--N-(;
~N~ Fl6 (C~q :: ~
)w NH2 ~:~ 25 \~

R1a R2a :: , 21~2707 WO 94/1~5~34 PCl'/US~3/0779~ ;

SCHEME 17 (Cont'd~
X)n_ ~CH2)p o R5 '~A--N--G

(CH2)~ aldehyde sodium cyanoborohydride (L~NH2 R 1 a R2a X)n--~C~2~P 11 : (C 12)q (L)w NHR
2s \~

.: ~ R1~ R2a : 30 '~:

~: wo 94/0s634 2 1 4 2 7 () ~ P~:T/VS93/07791 Elaboration of 56 to ~arbamate compound 57 is achieved by reaction with the a~ro~Uliate ohloro~ormate reagent in pyridine or in methylene chlorlde wi~ trie~hyl~mine as shown i:n Scheme 18.
S SC~IF~E 1~

R\~X)n~(CH2)p C-A--N-G
R2 1 o ~6F~13,Q~C,GI
(C 1 2)q 0 (L)w NHR12a pyridin~ or \~ methylene chlonde/Et3N
p~1a R2a ~; 20 R~X~n- (~ H~)p O F~s J~N-~ R5 RZ l G
: ~ 25 (CH2)q 12a O
R~ ll 13 R1a R~a WO 94/05634 PCr/US93/0779t . - 72 -TransfoImatiorl o-f amine intermediate 56 to urea derivatives is accomp1ished in severa1 ways. Termin~lly disubstituted compounds carl be ob~ained directly by reac~io~ of~ with a disubstituted carbamoyl chloride 58 in an inert solvent such as 5 me~y1ene chloride in the presence sf triethyl~min~ or 4-dimethy1-aminopyridirle. In addition, mono-substituted compound 61 wherein either R4b or R12b is hydrogen is obtained from 56 by reaction with an isocv n~e 50 as ShQW~ Ln S~hPm~ 19~ T~;n?l~Y ~ubs~d ~ q 61, wherein R1Zb is hydrogen, is also prepared from amine 56 by reaction wi~ trirne~ylsilyl isocyanate (~Q; R12b is (CH3)3Si).

': :
:' .

., ~ .

:

'; , ' ~: '?: WO 94/05634 2 1 4 2 7 0 ~ PCI ~US93tO7791 SCHE~, 19 X)n~ H2)p o ~5 F~2/ I--~RS 4~
(C72)~. R12b~ CI
(~)w NHRt2a 0 ~..
\~/ rnethylene chloridr~/Et3N

R1a R2a 4-dim~thylaminopyridin~

. ~ : R1 (X)n~ 2~p 0 R

~J~N ~RB

(CHI 2)q R12a ~

\~ 4b ~1a ~,2a n ;; ~ ~ ':
' 3 0 .

, ~

21~270~
W~ ~4/0~63~ PC~/US93/0779 ~
, 1 .
.
~ ' . - 74 SCHEME 19 ~Cont'd) 1,~ R1 (X)n~ (CH2)p ~ i~6 !~ S ~ N-C-A-N-G
R2 1 O R12b-N=C=C) (C 12~q . ~Q
)w NHR~3 merhylan~ cniande/Ei~N
0 \¢~ or ~; p~1a R2a L~ 15~ ~6 : : :

R1 ~X)n~(~)p Q E~
NI C-A--N-G

R2 ~ ~ O
(c72~q R1~a ~
)w N~C'N~

\~ H
,,~ j , Rla R2a ::':: :

~-~;: Alternatively, amine 55 is conver~ed ~o an isocyanate 62 by treatment with phosgene or an equivalent reagen~ such as bis(trichloro-methyl)carbonate (triphosgene) as indicated in Scheme 20. Subsequent .~ ~ reaction of 62 with primary or secondary arnines in an inert solvent L~ ,' ,.,.,~"~ ' , wo 94/0s634 2 1 ~ 2 7 0 7 PCr/USg3/07791 -75- :
such as methylene chloride gives the colTesponding urea deriva~ive ~2 :
in good yield. Isocyanate ~ is also converted to substituted semi~arba~ides ~ or hydroxy- or alkoxyureas 64 by reactioIl with substit~ted hydrazines or hydroxy- or alkoxyl~mines, respectively.

SCHEME 20 !;

(C~ c,s NI -C-A--N-G

R (CH2)q (CbCO)2Co (1~ NH methyl2n~chlor~de triethylamin~

R1a R2a G is t-butoxycarwnyl or 2 0 ~ benzyloxycarbonyl R~X)n- (CH2)p R ~5 ,[~'d'N ~R=
(C 12)q (L)w N--C~
3~
/~
R1 a R2a ~ ~ 62 w094/05634~14270 ~ P~/US93/0779, SCHEME 20 ~Cont'd) R1 (X)n (CH2)p O Rs s ~,\~,/ \ 11 1 . .
NI--C-A--N-G

o ~L)w N--C=O R4b~l2bNH
me~hylsne chloride 'R1a R2a ':', ~ ~ 15 Ç2 ~ , : ., R~x)n- (c H2)p 8 N--C-A-N-G

H\ 1~l 'f~ R4b Rla ~2a G is t-butoxycarbonyl benzyloxycarbonyl : .
' :

:

--- wo s4/0s634 21 4 2 7 0 7 PCr~US93/07791 SCHEME 20 (Cont'd) . .
~; ~ R~X)n-(CH2~p s R2 I O R~ 2CNN(R12b)H
~1: . (CH )q m~thylsne chlonde (L)w I~J--C_O

R l a R2a R\ (~ )n-(CH2)F~ O ~5 , ~ C_~--N-G
/~N--~ R6 R2 1 ~

N C'N~ ~R12c 2s~ R
R1a R2a G iS t-~utoxycarbonyl . or benzyloxycarbonyl , , , .

WO 94/056342 ~L 4 2 7 0 7 PCI'/US93/07791 ~

- 78 - ~
:~ , SCHEME ~0 ~Cont'd) ' R~(~xjn-(CH2)p o 1 5 ,~ NI--C-A-N-G ~-R2 1 0 Pl4b~R5aO)~
(CH2?q ~ ' mqthylene chlorid~ ~-(L)w N--C=O
~ , ...

R1~ R~a ~, 15 R1 (X)"-(CH2)D O R~
i~ NI--C-A-N-G
~ t o R~
72)q o :~

~L~w N_c~N, ~R5a ~ 4b R1a R2a G is t-butoxycarbonyl or benzyloxycarbonyl Compounds of formula I where R3a or R3b is a carbazate or carb~m~te derivative wh~re attachment to the phenyl r~ng is through ~e~oxyge~ atom of ~e carbazate or carbamate lirlkage are prepared from acetophenone intermediate 65 as indicated in Scheme 21.

.

;::
; ~~ WO ~4/0~34 2 1 4 2 7 0 7 PCr/US93/07791 ' .

',:

- 79 - ::

.
R1 (X)n~ (CH2)p~ Rs -~ N--~-A--N~
m-chloroporb~nzQic acid (5~2~ O
\\ methylene chloride (L~C-C~3 ~: : R1a p~2a G is t-butoxycarbonyl benzyloxycarbonyl R1 (X)n- (CH~)p N ~ R5 : R2 1 ~ ,:
~: ~ (CH2)q ~ ;
:~: :
~ ~ 25 (L~SO--C-CH3 R 1a R2a .
:~ : 30 : ~

W O 94/og~34 214 2 7 0 1 PCr/US93/0779~

~.
SC~ME ~l (Cont'd) - ~

R~n-(CH~ 5 H2O I ~~O R
(CH2)q (L)w OH
'''~ /~

i R1a R2a ~ 7 Rl2b-N=C=O Fl1 (X)n- (C~l2)p ~ R5 N--~-A~
: ~ 20 CH2C:12/Et3N: /J~N~O R6 DMAP ~ (CH2)q O

w o~

25; \~ H
R~a R2a ;: : G is t-butoxycarbonyl ;~ ! Gr ~ ~ ~
benzyloxycarbonyl 68 ~ .
, :~: ~ :

~ :

WO 94/05634 P~/US93/07791 - 2142707 ~

81 :
-- :, SCHEME 21 (Cont'd) R\,~X)n- (CH2)p ~ Rs NI--C-A-N-G

~2 I O 1. N,N'-carbonyldiimidazole (CH2)q ~4bf: 12CNN~R12b~H

lO: (L~f~OH methylenechloride "
; R1a R2a :
' 15 R~X)n-(ÇH2)p ;N~--C-A--N--G
~C~ ~N;
\Ç~ 2b R1a R2a G is t-butoxycarbonyl or benzyloxycarbonyl : 69:
3 o C)xidative rea~rangemerlt of 65 through the use of a peroxy-carboxylic acid (Baeyer-Villager reaction) such as m-chloro-: pe~benzoic acid gives the ester 66 which is hydrolyzed ill ~he presenceof a strong base such as sodium or li~ium bydroxide to give phenol 67.

WO ~4/0563'~ 2 7 0 7 PCI'/US93/0779~.

Reaction of 67 wi~ an isocyana~e leads directly to carbamate 68 -Additionally, treatment of 67 with N,N'-carbonyldiimidazole in dime~ylfo~namide can form an activated intermediate which will react with substituted hydrazine reagents to give a carbazate product 69.
Compou~ds of formula I wherein Ii~a Qr R3b is R4bRI2bNCo~ 2a)cH2-~ R4bl~ 2bNCSN(R12a)CH2-R4bRl2cNN~Rl2b)~s~ 2a)~H2-~ R4b~l2c~ 2b)-CO~(R~ ~ or ~1 30Co~ )C~2- 5~ prep~Pd ~om ~e t-butyl ester illte~ ediate 70 as described in Scherne 22. Remc)val of the t-butyl ester through the u~e of tr;Iquoroace~c a~id will give the carboxylic acid 71. It may be appreciated by one skilled in the art ~at ~e protecting group G in 70 must there~ore be compatible with the strongly acidic conditions employed for ester cleavage; hence G is taken as benzyloxycarbonyl. Conversion of the carboxylic acid to the benzyl~rninP, derivative 72 can be achieved by a ~ive-step sequence consisting OI: 1) formation o~ a mixed anhyd}ide with isobuty}
hlo~fo~mate; 2) r~duc~ion wi~h sodium bolohydride ~o the b~nzyl alcohol; 3) forma~ion of the mesylate with methanesulfonvl chloride;
4) ~orm~on of ~e azide by reaction wîth sodium azide, and finally, 5) reduc~ion of ~e azide wi~ tin(II) chloride. The benzylami~e inte}mediate 72 can be further elaborated to 73 by the aforementioned reductive amina~ion procedure.

.

-- W0 ~4105634 2 1 4 2 7 0 7 Pcr/VS93/07791 SC~IEME 22 , ~,, Rt (X)n~ (cH2)p ~ R5 .

(CH~
CF~COC:)H
0 (L)w COOtBu b methylen~ chlorid~
;' : ' /~

R1a R2a :

~)n-- (CH~ C~ R5 ~ N--C-A--N-G

CH2)q a is benzyloxycarbonyl I
(L)w COOH
\5~

5 ~la R2a 71:

21~2707 WO 94/05634 PCl /U~;93~07791, _ '.
:~: SC~ME 22 (Co~t'd) 1.IBu-O-C CI, N-m~thylmorpholine 2. sodium boro'nydride 3. CH3SO2CI
4. sodium azide . Sn~l~, aqueous dioxane :~ R~)n~(CH2)p 11 ~ ", ~N--~ R 6 (CH2)q - (L)~ GH2N~

R '~R2a 2 ~ ~ ~
G is benzyloxycarbonyl : :
, 30 ~

: ~
~: :

:~ . ' : ::

~: :

wO 9410~634 2 14 2 7 0 7 PCllUS93tO7791 .

SCHEME 22 (Cont'd) .. ..

s ;, , n\~xjn~~cH2)p O l ~ ' /J~N~ I ~
o ~CH2)q aldehyde " , I
~: ~L )w CH Nll sodiumcyanoboronydnde 5 ~ Rta R2a : :
R\ (/)n~(CH2)p 0 Rs 20 1;: ;1 [~ N~l~ A-N-G

2 ~ ~ R6 (G l 2)q 2'i (L~H2NHRiza / \J
~' ! ~, I ' : ' ' ' j/ \
R 1 a R2a :~ G is benzyloxycarbonyl - , Reactions of amine 73 with the ~propriate reagents to ~orm urea-linked compounds 74 and 7~ and carbamate~ ed : ~

wo9~oS~ 270 ~ PCI/US93/07791-. J

.
compound 76 are illustrated in Scheme 23. Terminally ILnsubsti~uted urea 74, wherein R12b is hydrogen, is also prepar~d from amine 73 by reaction with trimethylsilyl isocyanate ~~Q; R12b is (CH3)3Si). ~

S SCH~ 3 . .
. .

P~ (X)n~(( H2)p 0 R~
~ N--C-A--N~
~N--~ I 6 Rl~b-NaC=O
R2 ~ O 60 (C l 2)g m~thylene chloride/Et3N

:~ 15 ' (Llw jCH2NHRl2a 4-dimethylerninopyridine ~; R1a ~
, ~ " , Rl (X)n- (CH2)p O P~5 ~5 R2~ ~ I_C_A_N--G

:: ~ (CH2)q O
(L)w fH2N--c'N

3~0 : ~ ~ R12a H
R1a R2a :~ :

G isbenzyioxycarbonyl ~ :

- wo g4/OS~34 2 1 ~ 2 ~ () 7 PCr/US93/077gl ':, ~: SCHEME 23 (Cont'd) ,.

R~X)n~ (CH2)P o ~5 ~4b X--C-A-N-G Rl2b,N~CI

lo (C l2)q methyl0n~ chloride/Et3N
~ ~ (L)w C~ N~12a 4-dim0thylarninopyridine : ' - , \~,~

Rla/~ 2a ~, : ; R1 (X~n_ ~cH2)p ~ ~ R5 ; ~ C_A_N_G
: R~ / I ~~O R6 ~: : (CH2)q O

W ~ CH2N'C'N"
~~ 25 ~ 12c 1 4b : R1a R2a , 3c - G is benzylaxycarbonyl ':~

W094/05634 214270 ~ P~/US93/07791,--~

, .

SCHE~aE 23 (Cont'd) X3n~~CH2)p O I a 13,0 Cl N~--C-A--N-G R 'C' ", pyridine or lo ~72)q m~thylen~ chloride/Et~N

(L~,~CI IzNHR12a 5 ~ 1 a R 2a ~ ' (X)n~ (CH2Jp ~ R5 C-A--N-G
2' I ~~0 R6 (CH2)q 0 ~: 2s ~ w CH

F~1a R2a : ~

: , ~
: 3 0 G is benzyloxycarbonyl As shown in Scheme 24, hydrazide compound 77 can be prepared from mtermediate 73 by a two-step procedure consisting of - wo 94/Q5634 2 1 4 2 7 0 7 PCr/USg3/07791 89 ' activation of ~e ~nine via treatment with N,N'-carbonyldiirni~7.01e ~llowed by tre~tment with the appropriately substituted hydraz~e deriva~ve R4bRl2cN~ 2b~H.

S SCH:E~E 24 ;.

i.
R~ X)n-(CH;~, ~ ~15 R2 ~ ~ 6 1. N,N'~arbonyldlimidazolg ~ r~ 4b r~ 1 2c~ r~ 1 2b "
(~H2)q ~. n n ~ n n methylen~ chloride :~ 15 (L)w CH2NHR12a .

F~1a ~ ~2a : ~ 0 ;, F~ ()n~ ~H2~P N ~ R5 /~ ~ i 6 7 o R4b (~ CH2N'~'N~ ~ R12C ' ~ R 1 2a R 1 2b R1a F~2a G is benzyloxycarbonyl 7 ~ ~
WO 94/~5634 PCl/US93/07791~

,'.' ,~
A useful preparation of ~e protected beIlzylamine in~ermediate 8~ is shown in Scheme 25. Metallation of 4-bromoben~yl t-butyldiphenylsilylether 78 with n-butyllithium ~oIlowed by trea~nent with triisopropyl borate gives the aryl boronic acid Z~. Reaction of 79 5 with 2-bromo-N~(t-butoxycarbonyl)benzylamine 80in~heprese~ce of tetrakis(triphenylphosphine)p~ m(O) and sodium hydroxide in a m~xed solvent system at eleva~ed temperature gives the coupled product 81 in good yiel~ Desilyla~ ~d c~n~ersion to ~he O-methanesulfonate 82 is achieved by treatment with tetrabutyl-ammonium fluoride followed by methanesulfonyl chloride. Reaction of 82 with compounds of ~ormula ~ is ca~ried ou~ using ~e conditions described in Scheme 14.

:~: 15 ~ .

~5 .

-' wo g4/0s634 2 1 4 2 7 0 ~ PCl/US93/07'791 ,;

H2 :)H ~ lH20Si(Ph)~tBu ¢~ t~auph2sicl ~ ¢~
Et3N, DMF 1' : Br Br ~ ~ ~10 CH20Si(Ph)2tBu ~ CH20Si(Ph)2tBu ~ 1. n-C4HgLi, THF ¢~

Br ~ 3 aq HCI ~ B(OH)~ :
: ~ 78 : ~
. . ~, .
20 :~
Br : Br ~CH2NH2 di~t-butyldicarbonate ~CH2NHBOC
methylene chlorida .

. ' ' ' ~lll270'~
wo s4/~s634 Pcr/U~93/0779 - 92 - .

SCHEME 25 (Cont'd~ - :

CH205i(Ph)2tBu Br ~,CH2NHBOC

~GH~ 80 7~ : ~ CH2OSi(Ph)2tBu :; Pd(PPh3)4, 5~LNaOH
isopropanal, wa~er, ~CH2NHBOC
b~nz~ne, r~flux ~

;:

CH2OSi(Ph)2tBu C H2OSO2CH3 1 . (n-C4Hg)4NF
. Cti~S~2CI, ~
~,CH NHBOC Et3N, CH2CI2 ~CH2NHBOC

: Conversion to the final prodllcts o~ fo~nula I wherein R4 is : hydrogen, is camed out by simlllt~neous or sequential removal of all protectiDg groups ~rom intermediate VII as illustrated in Seheme 26.

:: :

.

-~ wo g4/05634 2 1 4 2 7 0 7 P~/US93/~7791 ~

S~ 26 R~X)n-(CH2)p 0 1 5 2~ R6 (CH2)q Rernovalof ~r~
(~ R3a groups R1a R2a ; ~
s R1 (X)n-(CH2)p ~ R5 N~--C-A-N--H

2Q ; R2 1 ~
(C HI 2)7 :: :
(L )w F~3a ~: 25 R1~ Rza ; ~ ~': : : Removal oI ben~yloxycarbonyl (CBz) aroups can be 3o achieved by a number of methods known in the ar~; for example, catalytic hydrog~natiQn wi~ hydrogen in the presence of a pl~1imlm or ~: ~ palladium cat~lyst ~ a protic solvent such as methanol In eases where catalytic hydrogenation is contra~dicated by the presence of o~he~
potenti~lly reactive functionality, removal of ber~yloxycarbonyl groups : ' carl ~Iso be aehieved by treatmen~ wi~h a solution of hydrogerl bromide : :

2i~270~i WO 94/05634 PCI'/US~3/0779 , - 94-in acetic acid. Removal of t-butoxycarbonyl (BOC) protecting groups is carried out by trea~nent of a solution in a solvent such as methylene ..
~: chloride or methanol, with a strong acid, such as hydrochloric acid or trifluoroacetic acid. Conditions required to remove other protecting 5 groups which may be present can be found in Protecti~e Groups in Organic Syn~esis T.W. Greene, John Wiley and Sons, NY. 1981.
As shown in Scheme 27, compourlds of formula I wherein ~4 and RS a~e each hYdro~en can ~e ~er el~o~ed by reductive ~: alkyla~ion with an aldehyde by ~e a~orementioned procedures or by: 10 alkylations such as by reaction with various epoxides. The products, ~: obtained as hydrochioride or tri~luoroacetate salts, are conveniently purified by reverse phase high performance liquid chromatography (HPLC) or by recryst~lli7.~tion. :

~ .

~ ::
:: ~ 25 ~ : .

i~ 3 0 :;~ : : :::

~ .

- wo 94/0~634 214 2 7 0 7 Pcr/us93/0?791 ' .

~ 95 - . , SC~EME 27 ' ~N~ Rs : p~2 1 OAld~hyde,sodium (CH2)q cyanoborohydride Il ~ D3a or ~ $n epoxicie Rla F~2a ; .
R1 ~X)n~ (~H2)p O H

) N~C - A - N--R4 ' (c72)9 ~: (L)w R~a R~a R2a It is noted that the order of carrying out t~e foreco~g reaction schemes is not sig~ificant and it is within the skill uf one skilled in th~
~: art to vary ~e order of reactions to facilitate the reaction or to avoid 30 unwanted reaction products.
The growth hormone releasing compounds of Fonnula I
are useful in vitro as unique tools ~or understanding how growth hoIm~ne secretion is regulated a$ the picuitary level. This includes use in ~e evaluation of many factors thought or known to influence growth horrnone secretion such as age, sex, nutritlonal ~actors, glucose~ arnino WO94/05~ 21'~2~ I P~/U~i93/07791~

: .
acids, fatty acids, as well as fasting and non-fasting states. In addition, the compounds of ~his invention can be used in ~e evaluation of how other hoImones modify grow~ ho~none releasing activity. For ~ ~
example, it has already been established ~àt somatostatin inhibits ~:
5 growth ho~none release. Other hotmnn~s tha~ are impo~ant and i~
need of study as to their e~fect on growth honnone release include the gonadal hormoIles, e.g., testosterone, estradiol, and progesterone; the ~n~l ho~mo~es, e.~., co~sol ~d o~er ~ 0~1~31~s. ep~ephr~e a~d norepinep~e; the pancreatic and gastrointestinal hormones, e.g., insulin, glucagon, gas~rin, secretin; the vasoactive intest~nal peptides, e.g., bombesin; and ~e thyroid hormones, e~g., thyroxine and triiodothyron~ne. The compounds of Formula I can also be employed to investigate ~e possible negative or posi~ive ~eedback eff~cts of some of ~e pituitary hormones, e.g., grow~ ho~none and endoIphin peptides, on the pituitaI~ to modi~y grow~ hormone release. Of particular scientilSc iuxlportance is the use of ~ese compounds to elucidate the subcellular mech~ni~m~ media~ing ~e release of growth hormone.
om}ds ~ mu}a I c~t~ m;ni~te~d to 20 ~nim~ , including mall, to release growth hormone in vivo. For examplet the compounds can be ~mini~tered to comTnP,rcially important ~nim~ls such as swine, cattle, sheep and the like to acceler~te and increase their rate ~d extent of growth, and to increase milk prod~c~on m such ~nnn~l.c. In addition, ~hese compounds can be ~mini~tered to hllm~n~ in vivo as a diagnostic ~ool to direct}y 5 dete~ e whe~er ~e pi~uilary is capable of releasing growth hoImone. F~r exarnple, the compounds o~ Formula I can be ~(lmini~tered in vivo to children. Serum samples taken be~ore and after such ~mini~tration can be assayed ~or growth hoImone. Comparison 3 0 of ~e amounts of growth hormone in each of these samples would be a means for ~irectIy dett;~ g tne ability of ~e pa~ent's piruitary to release grow~ hormone.
AGcordingly, ~e present inven~ion includes within its scope phalmaceutical compositions comprising, as an active ingredient, at least one of the compounds of Folmula I in association with a pharmaceutical W094/0~634 21~ 2 7 0 7 PC~/US93/07791 calTier or diluent. ~ptionally, the active ingredient of the ph~Tm~ceutical compositions can comprise a growth promoting agent in addition to at least one of ~e compounds of ~oImula I or another ::
compositiorl which exhibits a dirr~r,~lt activity, e.g., an antibiotic or other ~h~rrn~ceutically active m~teri~l .
Growth promoting agents include, but are not limited to, I~H, die~ylstilbesterol, theophylline, enkeph~lins, E series pros~g~n~in~, compou}lds ~sclosed tn U.s. P2~1:~ ~C~. 3 ')~93~5. e.g.
zeranol, alld compounds disclosed in U.S. Paten~ No. 4,036,979, e.g., sulbenox or peptides disclosed in U.S. Patent No. 4,41 lt890.
A still further use of ~e disclosed novel benzo~ sed lac~
grow~ hormone secretagogues is in combination ~rith other growth hormone secretagogues such as GHRP-6, GHRP-1 or GHRP-2 as described in U.S. Patent Nos. 4,41 1,890; and publica~ons WO 8~/07110 ,.
and WO 89/0711 1 and:B-HT 920 or in combination with grow~
hoxmone releasing factor arld its analogs or grow~ hormone and its analogs. A s~ll further use of ~e disclosed novel benzo-fused l~ct~m grow :h hnrmr~n~ s~rr~t~ s is in combin~tinn wi~h a~ adrenergic agonists or ,B3 adreIlergi~ agonists in the trea~nent of obesity or in combination with para~yroid hormone or bisphosphonates, sueh as ~-217 (alendronate), in ~e treatment of osteoporosis. A still fur~her use of the disclosed novel benzo-fused lactam grow~ hormone secretago~ues is in :combinatior~ w~h IGF-1 to reve~se the ~at~bolic effe~ts of nitrogen wasting as descn~ed by Kupfer, et al, J. Clin.
In~es~ 3~1 :(1993).
As is well l~own to those skilled in the ar~, the known and potential uses of growth hormone are vaIied and mul~itudinous. Thus, ~e ~ ni~tra~ion of the compounds of this inven~ion for purposes of stim~ tin~ the release of endogenous grow~ hormone can have the same~ effects or uses as g~WIll hormon~ itself. These varied uses of grow~ homlone may be sllmm~rized as follows: s~imulating growth hoImone release in elderly hllm~n.~; preven~ion of ca~bolic side effects of glucocorticoids; trea~nent of osteoporosis; stirn~ tion of the imrmlne system; treatment of retardation; acceleration of wound healing;

21~270 ~
WO 94~05634 PCr/US93t~7791i.~
9~- ;
accelerating bone ~racture repair; treatment of growth retardation, treating renal failure or insufficiency resulting in growth retardation;
tre~tment of physiological short stature, including growth hormone :; deficient ehildren; treating short stature associated w~th chronic illness;
treatment of obesity and ~row~ retarda~ion associated ~ith obesitv;
treating growth retardation associated wi~ Prader-Willi syndrome and Turner's syndrome; accelerating the recovery and reducing hospit~li7~tion of bu~ p~ nt~ nt Cf m~ant~eA ,_rowth ~ ~ retardation, skeletal dysplasia, hypercortisolism and C~ in~.s syndrome; inductîon of pulsatile growth hormone release; replacement of growth hormone in s~ressed pa~ients; tre~tment of osteochondro-dysplasias, Noonans syndrome, schi~ophrenia, depression, Alzheimer's disease, delayed wound h~.~lin~, and psychosocial depr~vation; treatment of pulmonary dysfunction and ventilator dependency; attenuation of :: ~ prote~n catabolic response after a major operation; reducing cache~ia ~: and protein loss~ due to chronic illness such as cancer or AII)S.
Tr~atment of hyperinsulinemia including nesidioblastosis; adjuvant tre~tm~nt ~or o~ tion infl-1ctio~; ~o ~im~ tP thy~nic de~elopment and prevent ~e age-related decline of thymic func~ion; treat:ment of immlmosuppressed patien~s; improvement in muscle strength, mobility, inten~nce of skin thicl~ness, metabolic homeostasis, renal hemeostasis :~e frail elderly; s~ulation of osteoblasts, bone Temodelling, and cartilat,e ~row~h; s*mnl~tioll of ~e immune system in companion nim~l~ and trea~nent of disorders of aging in companioIl ~nim~ls;
Drowdl p~motant in livestock and s*m~ tion of wool growth in she~p.
The compounds of this invention can be ~ ninistçred by oral, parenteral (e.g., intramuscular, intraperitoneal, intravenous or subcutaneous injection or implant), nasal, vagirlal, rectal, sublingual, or topical routes of ~mini.~tration and can be ~o~nulated in dosage ~o~ns ~ ,, al,~roL,~ia~e for each rou~e of ~mini.~tration, Solid dosage folms for oral ~rlministration include capsules, tablets, pills, powders and granules. In such solid dosage forms, the active compound is admixed with at leas~ one inert ph~
ceutically accep~able~ c~Tier such as sucrose, lactose, or sta~h. Such ;::

WO ~4/05634 2 1 ~ 2 7 ~ 7 PCI/US93/07791 dosage ~o~ns can also compIise, as is normal prac~ice, additional substarlces other ~an inert diluents, e.g., lubIicating agents such as ~.
m~nesium stearate. In the case of capsules, tablets and pills, ~e dosage forms may also comprise l~urre~ g agents. Tablets and pills can additionally be prepared with enteric coatings.
Liquid dosage forms for oral ~-lministration include ph~ ceutically acceptable emulsions, soIutions, suspensions, syrups, the e~i~s Col~t~ ~ i~rt ~ihl~n~s commo~ sed in the a~ .such as water. ~esides such inert diluents, compositioIls can also include .
adjuvaIlts, such as wetti~g agents, emulsifying and suspending agents, and sweete~g, flavoring and pem~ing agents. i.
Preparations according to this invention for parenteral ~min;.ctration ~nclude sterile aqueous or non-aqueous solutions7 suspensions,oremulslons. Examplesofnon-aqueoussolventsor vehicles a~e:propylene glycol, polye~ylene glycol, ~eaetable oils, such as oli~e oil a~d co~ oil9 ~elatin, and injectable organic esters such as ethyl olea~e. Such:dosage foIms may also contain adjuvants such as p~g,wet~inc~ ci~yirlg,aIlddispe~ ga~en~s. Iheymaybe sterilized by, for example, ~ltration ~rough a bac~eria-retai~ing filter, by incoIp~rating steri1i7.in~ agents into the compositions, by irr~ in~
the composi~ons, or by he~in~ ~e composi~io~s. They can also be marlufac~d in the form of sterile solid compositions which can be dissolved ~ s~enle w~ter, or some other steri}e ~ectable medium immediately before use.
Compositions for rectal or vaginal ~lmini~ka~ion are pre~erably suppositories which may contain~ in addition to the actiYe substance, excipients such as cocQa butter or a suppository wax.
Compositions for nasal or sublingllal ~ministration are also prepared wi~ standard exripients well known in the art.
The dosage of active ingredient in ~e compositions of this invention may be varied; however, it is necessary tha~ the amount of the active ingredient be such that a suitable dosage form is obtained. The selected dosage depends upon ~e desired ~erapeui~c effect, on the route Of ~(lmini~tration~ and on the duration of the trea~nenlt. Generally, 21~270;~
WO 94/05634 P~/US93/07791r~

dosage le~els of between 0.0001 to 100 mg/Kg of body weight daily are ~mini~ered to patients and ~nim~ , e.g., m~mm~ls, to obtain ef~ective release of growth hormone. .:
The following exaIxlples are provided ~or ~he purpose of fil~ther illustration only and are not intended to be limit~lions on ~e : disclosed invention ,~ .

;: FX.~,,I~L~ 1 0 N-[1-[[2'-[(Methoxycarbonyl)aIT~ino][1,1'-biphenyl]-4-yl]me~yl]-2,3,4,3-~etrahydro-2-o~o-lH-l -be~7.~7.epin-3(0-yI3-3-amino-3-methvlbutanamide. tnfluoroacetate : StepA: l-Tet~alone oxime :; ~ 1S To 4~.6 L of water at room temperature in a ~-neck 50 L
: flask sitting in a ste~ ba~ apparatus eqwipped wi~ an overhead sti~Ter, a temperature probe and reflux co~denser was added 3.72 K~
(2736 mQl~ of s~ r~t~ h s~g, foll~wed by 1.9 Kg ~
hydroxylamme hydrochioride (27.36 mol). To this slurry at raom temperature, 12 L of ethanol was ~dded ~ollowed by 1.994 Kg (13.68 mol) of l-te~ralone. Additional ethanol (1.7 I,) was used to rinse o~f the funnel and added to ~e reaction mixture. The resulting light orange : sl~lTry was he~t~d to: 75~C over 40 minlltes and m~int~in d at 75-85~C
~: ~ for another 75 minutes. ~e reaction mixture was cooled with the aid o~ ice packed around the flask. When the ~ al temperablre reached 32~C, the reaction ~ ure was pumped over 15 mi~utes into 60 L of ~: ~ ice contained in a 200 L vessel. The reaction vessel was washed with an additional 2 L of water whiGh was added to the 200 L vessel. When the 30 ice mel~ed, the mixture was filtered ~hrough a filter pad and the wet c~e washed with ~ I, of water. Th~ wet cake was suction dried for 1 ho~r then transfe~red to two trays and dned under vacuum at 40~C ~r 2 days to give 2.094 Kg (13.01 mol, 95%) of product. lH NMR (250 MHz, CDCl3): ~ 1.90 (m, 2H), 2.80 (t, 6Hz, 2H), 2;88 (t, 6Hz, 2H), 7.1~-7.35 (m, 3H), 7.90 (d, 8Hz, lH~, 8.9 (br s, lH).

;,1 , .~ .

- WO 94105634 2 1 4 2 7 0 7 PCI'/US93/07791 - 101 - .

Step B: 2.3~4~5-Tetrahydro-lH-l-benzazepin-2-one To 10 L of methanesulfonic acid in a 22 L 3-neck flask equipped with an overhead stirrer, a temperat~re probe, nitrogen inlet alld reflux condenser, was added 2.6 Kg (18.61 mol) of phosphorus pentoxide. A~ addi~onal 1.6 L of me~anesulfonic acid was used to wash all the phosphorus pentoxide into ~e vessel. The m~xture was hea~d ~ 90~C fol ~ houls ~n eooled ~Q 50~C llSina ~ ;ce ba~fh and treated with 2.00 Kg (12.41 mol) of l-tetralo~e oxime in several po~ions over 15 minlltes. The mixture was heated at 63~C for 10 mimltes ~en slowly heated ~o 80~C ana l~ept a~ 80~C ~or 3 hours. ~e reaction m~re was p~ped into 70 L of ice ~hen treated slowly wi~
11.2~ L of 50~ a~ueous sodium hydroxide over 90 minutes at such a rate so as to m7~in~;n ~e tempera~ure below 28~(:. The mix~e was filtered and 4 L of ~e fil~ate was used to rinse ~e vessel. The wet cake (pink) was washed ~ith 8 L of water then suction dried for 45 mim~tes ~d transferred to two trays and dried under vacuum at 40~C
f~ 2 days t~ 19 Kg ~ mol,gS%~ of produc~ 1~1~ (250 MHz,CDCl3): â 2.2~ (m~ 2H), 2.38 (t, 6Hz, 2H), 2.82 (t, 6Hz, 2H), 7.03 (d, 8Hz, lH), 7.13 (m, lH), 7.24 (m, 2H), 8.63 (br s, lH).

Ste~ C: 3-Iodo-2~3.4.5-tetrahvdro-lH-l-benzazepiIl-2-one A sus~er.sion of 1.8 Kg (11.17mol) of 2,3,4,5-tetr~hydro-1H-1-ben7~epi~l-2-one in a mixture of 22.33 L of methylene chloride ~d 11.78 L (S~.83 mol) of hex~methyldisi~ n~ w~s hP~tel~ at reflux for 10 minlltes~ then cooIed to 30~(: and treated with 80503 K~ (33.5 mol) of iodine in one portion. The mix~ure was heated a~ reflux for 2.5 hours, ~en cooled to room temperature. Aqueous sodium sulfi~e cont~ining 4.926 Kg o~ sodium sullSte in 44 L of water was cooled to 0~C and i~to it was poured the reac~io~ ure in se~eral portions with vigorous stining while m~int~inin~ the temperature below 10~C. The reaction vessel was rinsed with 22.33 L of me~ylene chloride and the washing trans~rred to the quenching mixture. The quenching mixture was s~i~ed vigorously and the layers allowed to separate. The aqueous .. ,; .

; ~

21~2707 WO 94/05634 PCI'/US93/07791j,_ layer was removed and reextracted with 22.33 L of methylene chloride.
~he combzIled organic layers were washed with 11 L of water and co~centrated under vacuum to a final volume of approxima~ely S L.
The residue was t~eated with 55 L of toluene and concentrated under vacuum to a final volume of 10 L. The resul~a slurrv was isolated by filtration and the ~llter cal;e washed wi~ an additional 5 L of toluene and dried under vacuum at ambient temperature for 2,4 hours to give 10842 ~ (6.42 mol~ 57~o) of p~d~c~ lH ~ (200 ~ CDCl ,):
~ 2.6-2.8 (m, 3H), 2.93 (m, IH), 4.64 (t, 8Hz, lH), 6.97 (d, 8Hz, lH), 7.10-7.35 (m, 3H), 7.~5 (br s, lH).

Step D: 3(R3-Amino-2,3,4,5-tetrahydro-lH-l-ben~azepin-2-one, D-tartaric acid salt 3~Iodo-2,3,4~5-tetrahydro-lH-1-ben~azepin-2-one (1.79 Kg, 6.24 mol) was slurried in 6.2 L of me~anol and the slurry charged into an autoclave. Condensed ammonia ~155 L) was added and the a~toclave closed~ wi~h s~rring. and heat~d to 100~C over 1 hou~.
~eai~g ~t 1 ~C ~s ~ollLi,~ued for 2 h~urs ~en ~e ~ut~a~e w~s allowed to cool to room te~ elalule over 1 hour, during which time the in~ernal presslLre was 150-155 psi. The reaction n~L-~ was tr~ns~elTed to a polyethylene jug and the autoclave nnsed with 2x8 L of me~anol. The w~hinc~ were concentrated under vacuum at 30~C then combined w~ the reaction mixture ~d concentrated to near dr~ness under vacuum at 30~C. The resulting residue was dissolved in 4 L of e~yl acetate ~en conce~lLl~L~d to dryness ~lder vacuum at 303C.
Sodium chloride (712 g) was dissolved in 2 L of water and 1.0 Kg of sodium carbonate was dissolved in 6 L of water. Two liters of ~e sodium carbonate solution was added to the c~ncentrated residue and the resulting slurry transferred to aIl extraction flask. Anolher 2 L
por~ion of dle sodium carbonate solution was added to ~e residue flask and ~e solution transfeITed to the extrac~ion flask. The rem~îning sodium ~arbonate solution was used in the same way. The sodium chloride solution was added to the sodium carbonate/aminolactam emulsion and the resulting mix~ure stirred for 10 minutes then extracted WO 94/05634 PCl'tUS93/~7~91 21~2707 with four 6 L portions of me~hylene chloride. The combined methylene ehloride layers were concentrated to dryness; ~e residue was ~reated with 2 L of 2~0 proof ethallol a~d the resulting slurry concentrated to dryness ur~der vacuum to give 1.171 Kg of crude product.
The c~ude product was slurried in 8 L of etha~ol and treated with 900 g of I)-tartaric acid in one portion. Water (7 L) was added and the mix~ure heated to 77~t:, then additional ethanol (45 ~) vas added and h~.~tin~ con~in~ed~ The soluriorl was cnoled to 43~C and treated wi$h the seed slurry. (The seed slurry was prepared by the route described above st~g wi~ 10.50 g of crude product and 9.1 g or D-t~anc acid.) The so~u~ion was aged at room tempeTamre for 4g hours. The slurry forrned was removed by ~lltration and ~e we~ cake washed ~th 1.8 L of ethanol. The r~sulting filter cake was suction dried~with nitrogen bleeding for 20 hours, then transfelTed into a drying tray a~d 'dried under vacuum for 24 hours to ~ive 354 g (1 085 mol, 17.4%) of the product lH NMR (250 M~l~, CDCl3): ~ 2.13 (m, lH), 2.51 (m, 2H), 2073 (m, 2H), 3.68 (t, 6Hz, lH), 3.98 (s. 2Hj, 7.05 (d,~ 8~, ~>, 70~6 ~ ~" ?~, 7 ~ s, 5H~ .2~ f~r s, lH)-.

/' :: Z5 :

,~.j .
:' 30 .i i', :
~ .

;~lL~ J'U ~
W~ 94/0~634 P~/US93/0779~_~
- 10~-Step E: 3(R)-Amino-2~3~4~5-tetrahydro-lH-l-ben~azepin-2-one A solution of 229.23 g (0.700 mol) of 3(R)-a~Lino-2~3,4,5-tetrahydro-lH-l-ben~azepin-2-orle, D-tartrate in 4.1 L of water was treated wi~h 194 g (1.~0 mol) of potassium carbonate. Subsequent portions of 100 g and 135 g of potassium carbonate were added until the pH was 10.5. The mixture was extracted with four 4 L portions of meL~ylene chloride which were then combined and dr~ed over m~esium sulfa~. The aaueous la~er wa~ tre~ed with 1.4 Ka ~f :~ sodium chloride and reextracted with four ¢ L portions of me.hylenechloride which were then combined and dried over m~gnesium sulfate.
e two 16 L batches of e~rracts were combined, filtered and concentra~ed to dryness lmder vacuum to give 115.5 g of product which contained 1.6~o of an impurity identified as 7-iodo-3(R)-amino-2,3,4,5-tetrahydro-1H-1 be~zazepin-2-one.
~:~ A solution of 107.02 g (0.607 mol) of the intermediate obtained above in 10712 L of ethanol was hydrogenated at room temperature and 40 psi over 4.ûO g of 10% palladium on carbon ~or 4 hollrs~ The cataI,Ys~ was r~oved by ~iltr~ion ~rou~ solkaflok a~d t~e ~lltrate co~centrated to dry~ess under vacuum to give 101.08 g (0.57 mol, 94.4%) of product.

Step P: 4.~-Dimethvlazetidin-2-one A 3-~ec~ 3 L round bottom flask equipped with a magnetic s~i~rer, the~nomel~r, cold fin;,er condenser and nitrogen bubbler was 25 charged wi~h 1 L of ether. l~e flask was cooled to -65~C and into it was c~ndensed 500-600 ~ of isobu~ylene. The cold finge~ condenser was replac~d wi~ a d~oppLng funnel and 200 mL (325 g9 2.30 mol) of chlorosulfonyl isocyanate was added dropwise over 1.5 hours. The mixture was m~int~ined at -65~C for 1.5 hours then the dry ice/acetone , ~ 3 coolingbath replaced u~thme~anol/ice arld ~e inte2nal temperature slowly increased to -5~C at which time the reaction Lr~tiated and the inte~nal te~perature rose to 15~C with evollltiorl of gas. The intemal temperature resnaLned at 15~C for several minutes ~hen dropped back down to -5~C and ~e mixture stirred at -5~C for 1 hour. The r WO 94/05634 2 1 ~ 2 7 0 7 PCIIUS93/07791 me~anol/ice ba~ was ~moved and ~e reaction mi~ture warmed to room temperature and stirred overnight.
~ e reaction mi~lre was transferred to a 3-neck 12 L
round bottom flask fitted with a mechanical stirrer alld diluted with 2 L
of ether. The well stirred reaction mixture was treated with 2 I~ of satllrated aqueous sodium sul~ite. After 1 hour, an additional 1 L of saturated aqueous sodium sulfite was added followed by sufficierlt sod~ arbo~ adjust the l)H to a~proxim~telv 7. The Lllixlure was sti~Ted another 30 minlltes then ~e layers allowed to separate. The ether layer was removed and the aqueous layer reextracted with 2xl L
or e~er. The combined ether e~trac~s were wasned once wi~ ~00 mL
of saturated aqueous sodium bicarbonate and once with 500 mL of saturated aqueous sodium chloride. The ether layer was removed, dried over m~gsium sulf~te, ISltered and concentrated under vacuum to ~i~e 33 g of a pale yellow oil. Th~ aqueous layer w~s made basic by the addition of solid sodium bicarbonate and extracted with 3xl L of ether.
The comb~rled e~er extracts were washed and dried as described above, then cnm~jn~ wi~h~e n~ g o~j?ale y~ w Qil and conce~trated under vacuum to give 67.7 g of product. Pur~er extraction ~of the aqueous layer with 4xl 1, of methylene chloride and w~.~hin~ and drying as before gave an additional 74.1 g of product. Still er extraction of ~e aqueous layer with 4x l L o~ methylene chlonde Dave an addition~l 21.9g o~ product. The- ~ombined product (163.7 g, 1~6~ moI, 72%) was used in Step G wi~out purific~tion. lH
N~R (200 ~ CDCl3): ~ 1.45 (s, 6H), 2.7S (d~ 3Hz, 2H), 5.~ ~br s.

Step G: N-(t-Butoxycarbonyl)-4~4-dimeehylaze~idin-2-one A 5 L, 3-neck round bottom:flask equipped with a ma~1e~ic sti~er, ~ermometer, nitrogen bubbler and addi~ion ~unnel was charged wi~ 88.2 g (0.89 mol) of 4,4-d~nethyl~etidin-2-one (S~ep F), 800 mL
of methylene chloride, 150 mL of triethylamine ~1.08 mol) and 10.9 g (0.089 rnol) of 4-dimethylamirlopyridine. To the stirred solution, at room temperature was added dropwise over 15 minutes a solution of 21a~ 71~l W~ 94tO~34 PCI/US93/07791 ~_ ,, 235 g (1.077 mol) of di-t-butyl-dicarbonate in 300 mL of methylene chloride. The reaction mixture was stirred at room temperature ove~ ht, ~en diluted wi~h 1 L of methylene c~londe arld washed with 500 mL, of satuTated aqueous ammonillm chloride, 500 mL of water, and 500 mL of saturated a~eous sodium chlorid~. Ihe or~anic layer was separated, dried over m?,~n~siurn sulfate, filtered and collcentrated under vacuum to afford 180.3 g of crude product as an orange solid.
The m~tP.ri~l was used direc~lv i~ St~:~ H W~hhUt p~rL~ca~on.
~2001vlHz, CDCl3): ~1.50 (s~ 9H), 1.54 (s, 6H), 2.77 (s, 2H).

Step H: 3-t-Butoxvcarbonvlarnino-3--meth ~lbu~anoic acid A 3 L, 3-neck round bottom llaslc equipped with a magnetic stirrer, theImometer, nitrogen bubbler and addition f lrmel was charged wi~ 180.3 g ~0.89 mol) of N-(t-butoxycarbonyl)-4,4-dimethylazetidin-2-one dissolved in 1 L of tetrahydrofuran. The solution was cooled to 0-5~C and trea~ed dropwise wi~ 890 mL of 1.0 M aqueous lithium hydroxide over 30 ~ utes. The reac~on mixrure was stirred at 0 5~C
~s~rs, ~ ~i}~d ~i~h 1 I, of e~. ~d 1 ~ o~ wa~e~. The la~rs were allowed to separate and the aqueous layer was reextracted with an additional 1 L of ether. The a~ueous layer was ~cî~ified by the addi~on of 1 L of saturated aqueious sodium bisulfate, ~en extracted wi~ lxl L
and 2xS00 ~ of ether. The combined organic layer and ether extracts were washed wi~ iO0 mL of sa~rated aqueous sodiurn chloride, dIied over m~nesium sulfate and coI~centrated under vacuum to give 173 ~
of a yellow oil ~hat solidif~ed upon standî:ng. The mat~rial was slurried with wa~n hexane, then filtered and dried under high vacuum to a~ford 168.5 g (0.77~ mol, 87%) of product as a white solid. lH NMR (200 MHz, CDCl3): ~1.39 (s, 6H), 1.44 (s, 9H), 2.72 (s, 2H). FAB-MS:
calculatedforCloH1gNO4 217; found 218(M~H,54%).
~. .
t Step I: 3-t-Butoxycarbonylamino-3-methyl-N-[2,3,4,5-tetrahydro-2-oxo-1~-1-benzazepin-3(R)-~ butanamide A solution of 8.7Q g ~49.4 mmol) of 3(R)-amino-2,3,4,5-tetrahydro-lH-l-ben~azepin-2-one (Step E) irl 100 mL of methylene .~ :

, .~ - WO 94/05634 21 4 2 7 0 ~ PCI/US93/07791 chloride was treated with 10.73 g (49.4 mmol) of 3-t-butoxycarbonyl-amino-3-me~ylbutarloic acid (Step H) and 13.8 mL of triethyl~mine (10.0 g, 99 mmol, 2 eq.). ~e reaction flask was immersed in an ~: :' . ambient temperature water bath then 26 g of benzotriazol-1-5 ylox~s(dimethylamino)phosphonium hexafluorophosphate (S9 mmol, 1.2 eq) was added all at once and the mixture stirred at room temperature for 2 hours. The reaction mixture was added to 300 mL of e~.vl acet2~ a~d ~asked ~ ee ~ime~ h 5~ aq~leoals cit~ic acid~ twice with sat~rated aqueous sodium bicarborlate and once with saturated 0 aqueous sodium chloride. Ihe organic layer was removed, dried over !~ ~ m~ esillm sulfate, ISitered and the ISltrate concentraled under ~acuum.
T~e residue was purified by preparative high pressure liquid chromatography on silica, eluting with ethyl acetate~hexane (4:1), to ford 17.42 g (46.~ mmol, 94%) of the produc~ as a white solid. lH
15 NMR (200 ~Hz, CDC13): ~ 1.37 (s, 6H), 1.44 ~s, 9H), 1.95 (m, lH), 2.46 (d, 15Hz, lH), 2,.59 (d, lSHz, lH), 2.6-3.0, (m, 3H), 4.53 (m, 1H), 5.30 (br:s, IH), 6.72 (d? 7Hz, l:H), 6.98 (d, 8Hz, 1~I), 7.1-7.3 (m, 3H)~
rs,1~ MS: e~ dforC2o~I2~N3Q1 37~; found 20 376 (M+H,705~o).

Step J: 4-Methyl-2'-nitro-1.1'-biphenyl A vi~orously st~rred mixture of 4-tolylboronic acid (34 g, 0.25 mol) and ~-bromo-1-nitro~enzçne (34 g, 0.168 mol) in a rnixture 3~ of S:~ sodiu~ hydroxide ~l70 mL), w~ter (57 mL), isopropanol (215 'mL~ and benzene (1080 ~) under a nitrogen atmosphere wa~ treated :: wi~ (tetrakis)triphenylphosphine palladium (0) (11.9 g). The stirred bilayer reaction mixture was heated at reflux for 3 hours. l'he cooled i ~: reaction mixture was filtered through Celite and ~e filter cake washed wi~h fresh benzene~ The organic layer was separated and washed with 3 water ~3~), dned over m~nesium sulfate and ~ltered. The ~Sltrate was evaporated under vacuum and the residue (46.1 g) puri~led by preparative high pressure liquid chromatography on silica gel~ elu~ing with hexar~e/ethyl acetate (20:1) gave 28.05 g of the product. EI-MS:
calculated for Cl3H1 lNO2 213; found 213 (M+) lH NMR (400 i ~ .-( v ~
wo 94J05634 Pcr/l~ss3/~77s1.

MHz, CDC13): ~ 2.38 (s, 3H), 7.20 (m, 4H), 7.43 (m, 2H), 7.59 (t, lH), 7.8 (~, 1~).

Step K: 4-Bromometh~1-2'-nitro-1~ bipheny1 A solution of 4-methyl-2'-nitro-l~l'-biphenyl (St~p J) (6.CJ
g, 28.2 mmol~, N-bromosucc~nimide (4.99 g, 28.2 mmol) and AIBN
(653 mg) in 75 mL of carbon tetrachloride was heated at reflux until a ~g~ve po~ssium iodide ~_st w~ o~ined ~l.5 h,. The rea~ion mi~ture was cooled and filtered. The filtrate was evaporated ILnder vacuum to yield 8.41 g of crude produet. l~ NMR revealed ~he product composition was approximatly 75% monobromo and 10%
dibromo, in additivn to 15% of unreacted starting material. lH NMR
(200~Hz, CDC13): ~ 4.53 (s, 2H), 7.2-7.7 (m, 7H), 7.85 (m, llE~). EI-MS: calculatedfor(:~l4HloBrN272; found272,274(~+).
, ~:
Step L.: 4-Ht~dro~vmethy1-2'-ni~ro-l~l' biphen~1 :~ A solution of 4-bromomethvl 2'-nitro-l~l'-biphenyl (~.~ g, 74.~ m ~e.~c ~cld ~ ~T ~f W~ trea~ wi~ po~assi~m 2q aceta~e ~(4.88 g, 49.1 mmol). The reac~ion mixmre was heated at reflux for 2 hours. After cooling, the reaction mixture was fîltered and the precipitate was washed with acetic acid (2x). The ~iltrate was evaporated under vacuum and ~e residue was triturated with ethy1 ether. ~he ethe~ lay~ was washed eoIlsecutîve1y wîth water, s~urated s aqueous sodi~n bicarbonate (3~) and water. ~e organic layer was ~îed over m~nesium suifate, ~lten~d and eva~olated mlder vacu~n.
The residue was dissolved in metharlol (50 mL) and treated with a 5N
methanolic potassium~hydroxide solutîon (5 n~L). After stimng for 1 hour at room tempera~ure, thiII layer chromatography indicated ~e 3~ absence of starting material. The reaction mix~ure was acîdi~led wi~h ace~ic acid ~nd evap~rated under ~acuum. The residue was washed free of acetic acid by washing an etheral solution wî~ aqueous sodîum bicarbonate and water. After drying oveI~ magnesîum sulfate, ~e ethereal solu~ion~ was evaporated under vacuum. The resîdue was purffled by pr~parative high pressure liquid chromatography on silica ~: :
'~

- WO 94/05634 2 1 4 2 7 0 ~ PCr/lJS93/û7791 .

.

gel, eluting wi~ hexane/ethyl acetate (3:1) to give 2'-nitro-1,1'-bi-phenyl-4-carboxaldehyde (620 mg) ~ollowed by 4-hydroxymethyl-~ 2'-ILitro-1,1 '-bipherlyl (3.06 g, 13.4 mmol, 54%~.

5 SteD M: 4-(Tetrahvdro~vranvloxy)meth~1-2'-nitro-1.1'-biphenyl A solutioIl of 4-hydroxymethyl-2'-I~itro-1,1'-biphenyl (3.06 g, 13.4 mmol) and 3,4-dihydropyran (1.8 mL, 20.1 mmol) in il me~hvleIle ~hl~rir1e (50 mL) u~d~r a ~i~ro~en atmosphere was treated ~ with pyndi~ p-toluenesulfonate (336 mg, 1.34 mmol). After stirriIlg for 3 hours at room temperacure, thin layer chromatography indicated that no star~ing malerial reInam~d. rne rea~on ~ Ul~ was diluted with ethyl ether (300 mL). The ether extracts were washed with Y; satllrated aqueous sodium chloride, dried over magnesium sulfate and iltered. :The ISltrate was evaporated under vacuum and the residue 5~ purified by prepa~ative high pressure liquid chromato_raphy on silica gel, eluting wi~ hexane/ethyl acetate (10~ o give 4.47 g of the product.

Step N: 4-~Te~ahydro~yl~lyloxy)methvl-2'-amino-1~ l '-b;phenyl A solution~of'4-(tetrahydropyranyloxy)me~yl-2'-nitro-1,1 '-biphenyI (4.12 g, 13.~ ~mol) in 10~ mL o~ methanol was hydrogenated at 40 psi in ~e presence of 5% palladium on carbon.
After '~. hou~s, up~ke Q~ hydrogen was complete. l~he ~eaction mix~re was filtered ~hrough diatomacious ear~h, and the ISlter cake washed with 2s met:hanol. The:f:iltra~wase~apora~duIldervacu~ntoyield357gof th'e product.

Step O: 4-Hydroxymethyl-2'-(methoxycarbonyl)amiIIo-l~
biphenyl ~ 30 A solution of (~trahydropyranyloxy)methyl-2-amino-1,1'~
biphenyl (500 mg, 1.76 mmol) in pyridi~e (6 mL) was treated with me~yl chloro~olmate (0.41 mL, 5.3 mrnol). I~he reaGtion m~xture was : stirred at room temperature for 48 hours. The reaction mi~ture was evaporated under vacuum. The residue was taken up in ethyl ether and , ~ :

t' ~, . .

1~ 21~s270 ~
WO 94J05~34 PCI'/US93/07791-~

~.

, washed with water (3x). The ether layer was dlied over m~nesium sulfate, filtered and evaporated under vacuum ~o yield 547 mg of crude 4-(tetrahydropyranyloxy)methyl-2'-(methoxycarbonyl)amino-1 biphenyl.
The crude 4-(tetrahydropyranyloxy)methyl-2'-(methoxy-carbonyl)amino-1,1'-biphenyl (2S0 mg) dissolved in 4 mL of methanol was treated with 1 mL of 10% methanolic p-toluenesulfonic acid. The reac~on ~niX~ waS s~irxed a~ room ~mrelq~ for 1 h~ur. ~h~
reaction mixblre was made basic by the addition of saturated aqueous sodium bicarbonate, ~en diluted with e~hyl acetate. The organic layer was washed wi~ water (2x), dried over ma~esium sulfate and evaporated under vacuum. The residue was purified by preparative thin layer chromatography on silica gel, eluting with methylene chloride/me~anol (100:3) to give 137 mg of the product. FAB.-MS
(Li~spike): calculatedforC1sHlsNO3(257); found264(MTLi). lH
NMR (200 MHz,(: DCl3): ~ 3.51 (s, 3H), 4.75 (s, 2H3, 6.62 (br s, 1H), 7.14 (dd, 2H), 7.34 (dd, lH), 7.4 (dd~ 4H).
~, ,~, ~1 20 StepP: 4-Bromomethvl-2'-~methoxv~arbon~l)amino 1~ biphenvl ,~ ~ A solution of 4-hydroxymethyl-2'-(methoxycarbonyl3-aII~ino-1,1'-biphenyl (239 mg, 0.93 mmol) in methylene chloride (4 . mL) was treated with bromo~Time~ylsilane (3.0 mL, 22.7 mmol). The ;eac~on mi~re was sti~red at room temperature for 18 hours. The reaction mixhlre was~diluted wi~ additional me~ylene chloride and washed ~th sanlrated aqueous sodium chloride. Aft~r ~y~g over magnesium sulfate, the filtered organic layer was evaporated under vacuum The residue was purified by preparative thin layer chromatogr~phy on silica gel, eluting with methylene chloride-~i 30 methanol (100:3) to give 190 mg of the product.
~, Step O: N-[1-[[2'-[(Methoxycarbonyl)amino]~1,1'-biphenyl]-4-yl]methyl~2,3 ,4,5-tetrahydro-2-oxo- lH- 1 -benzazepin-3 (R)-.. : ' yll-3-t-butoxycarbonylamino-3-methvlbutanamide .

. ~

- .

WO 94/0~634 PCI/US93/07791 214270~

A solution of 222 mg ~0.594 mmol) of 3-t-butoxycarbonyl-amino-3-methyl-N-~2,3,4,5-tetrahydro-2-oxo-lH-1 -ben7~7epin-3(R)-yl]-bllt~n~mide (Step I) ~n 6 ~ of dry ~limetllyl~ormamide was treated 3û mg of 60% sodium hydride oil dispersion (18 mg NaH, 0.75 mmol~ 1.3 eq). The reaction ~ ur~ was stirred at room temperature for 30 ~ utes. ~ To the soIution was addcd 190 mg (0.594 mmol) of solid 4-bromomethyl-2i-(methoxycarbonyl)amino-1,1' biphenyl. After s~i~ a~ room ~mpera~ ~or 1 ho~, th~ rP~~on mixblre was diluted wi~h eth~1 acetate followed by SO mL of water. The organic layer was washed wi~ water (4 x), dried over m~nesium sulfate, filtered and evaporated under vacuum. The resiaue was purined by preparative thin layer chromatography o~ silica gel, elu~ing with methylerle chloride/me~anol (100:3) to give 231 mg (0.376 mmol, 63%) of ~e product. 1H N~R (400 MHz, CDC13): 8 1.23 (s, 3~I), 1.33 (s, 3H), 1.39 (s, 9H), 1.8j (m, lH), 2.40 (dd, 2H)~ 2.49 (m, lH3, 2.54 (m? 2~), 3.68 (s, 3H), 4.~3 (m, lH)~ 4.94 (d, lH), 5.17 (d, lH), 6053 ~br s, lH3. 6.66 (d, lH), 7.2 (m~ 12H)? 8.09 (d, lH).

Ste~ ~: N-[1-~2'-[(Methoxycarbonyl)a~nino]~l,1'-biphenyl~-4-yl~methyl]-2,3,45-tetrahydro-7-oxo-lH-1-ben7~7epin-3(R)-Yll-3-amiIlo-3-methylbut~n~mide trifluoroaceta~e .
A solution of 86 mg (0.14 mmol) of ~e inteImediate ob~ ed m StPp Q in 2 ~ of me~ylene chloride was treated wi~ 1.0 mL of tri:Eluoroacetic acid. A~e~ stirnng at room temperature for 1 hour, all volatiles wer~ removed under vacuum and ~e residu~ purified by medium pressure li~uid chromatography on C8, eluting with mPthanol/O.l % aqueous trifluoroacetic acid (60:40). The fractions cont~inin~ the product were combined and solvents removed under vacu~m. The residue was lyophilized from w~ter to give 69 mg (0.13 mmol, 96%) of dle ~itle compound as a whi~e solid. FAB-MS:
calculated fsr C30H34N4O4 514; found S15 (M+H). lH NMR (400 ~Hz, CD30D): ~ 1.34 (s, 3H), 1.39 (s, 3H), 2.12 (m, lH~, 2.31 (m, lH), 2.$2 (dd, 2H), 2.6 (m, 2H), 3.54 (br s, 3H), 4.40 (dd~ lH), 5.02 (d, lH), 5.28 (d, lH), 7.30 (m, 12H), 7.5~ (br s, lH).
i c:

, .

2 1 ~ ~ ~ O 7 WO 94/05634 PCI /US93/0779~--,, N-[1-[[2'-[(Me~yl~minocarbonyl)amino][1 ,1 '-biphenyl]-4-yl]methyl]-2,3,4fS-tetrahydro-2-o~o-LH~ n7~7~pin-3(R)-yl]-3-amino-3-methylbutanamide~ tr~fluoroacetate i~ : S~p A~ (? ~ o~ h~ l] A yl3m~thyl~-",3,~
~: 1 0 tetrahydro-2-oxo-1H-1 -bçn~7epin-3(R)-yl~ ~ino-3- methvlbut~n~rnide Prepared from 4-bromomethyl-2'-nitro-1,1'-biphenyl ~F.~m~le 1, Step K) and 3-t-butoxycarbonylamino-3~methyl-~-[2,3,4,5-tetMhydro-2-o~o-1H-1 -ben7.~epin-3(R)-yl]-but~n~mide ~~ : (F~=~mrle 1, Step I) by ~e procedure described ~n E~ample 1, Step Q.
l5 lH NM~ (400 M~ CDC}3): ~ 1.34 (s, 6H), 1.41 (s, 9H), l.83 (m, lH), 2.35-2.70 (m, SH), 4.50 (m, lH), 4.84 (d, 15Hz, lH), 5.23 (d, 15Hz~ 1EI), 5.27 (s, lH), 6.64 (d, 7Hz, lH), 7.1-7.6 (m, 11H), 7.80 (d, 8~1H~. :FAB-MS: ~lc~ t~ or c33~3~4c)6 586; i~und 5~7 (M+H).

Step B: N-[1-[[(2'-Amino)~1,1'-biphenyl~ 4~yl]me~yl~-2,3,4,5-tetrahydro-2-oxo-lH-1-ben~a~epiIl-3~ yl]-3-t-~: buLo~yca~onylamino-3-methylbllt~n~m;de A svlution of 7.79 g (13.23 mmol~ of the intermediate obtained in St~p A iIl 200 mL of me~anol cont~ining (),9 g of 5%
palladium on carbon was hydrogenated at 40 psi. When the uptake of hydrogen was complete, the catalyst was removed by filltration through ' Celi~e. The iiltrate was concentrated under vacuum to yield 6.6 g (11.9 mmol, 90%) of product. FAB-MS: calculated for C33H4N4O4 5S6;
~ound ~57(M~H). ~ lH NMR (400 MHz, CDC13): ~ 1.32 (s, 6H), 1.39 s (s, 9H), 1.87 (m, IH3, 2.51 (dd, lH), 2.S9 (m, lH), 4.51 ~m, lH), 4.89 : ~ (d9 lH), 5.15 (d, lH), 5.32 (br s, lH), 6.71 (d, 1H), 6.81 (s, lH), 7.21 :: (m, 10H).
.
.
,. .

WO 94/05634 21 4 2 7 0 7 PC~JUS93~0779l Step C~ [~2'-[(Methyl~ocarbonyl)~mino~E191'-biphenyl]-4-yl3me~yl]-273,4,5-tetrahydro~ 2-oxo-lH-l~ben7~7epin-3(R)-- yll-3-t-butoxycarbonylamino-3-methylbut~n~mide A solution of 88.4 mg (0.158 mmol) of the illterlnediate S obtained iIl Step B in 4 mL of me~ylene chloride at room tennperature was treated with 0.~ mL of methyl isocyanate (8.5 mmol). The reaction mi~ure was sti~red at room temperature ~or 18 hours, when al] starting m~t~ l was c :~nsl}med as mc~ 4s~l by t,~ laver ch~o~L~Q~hy. The reaction was evaporated under vacuum and the residue passed over silica gel. Elu~on wi~ ethyl aceta~e/n-hexane (3:1) yielded 66 mg (0.1 1 mmol,68%) of product. lH ~ (400 MHz, CDC13j: o 1.21 ~s, 3H), l.X3 (s, 3H), 1.39 (s~ 9H), 1.89 (m, lH), 2.49 (dd, H), 2.60 (m, 2H~, 2.69 ~s, 3H), 4.~0 (m, lH), 4.95 (d, lH), S.06 (d, lH), 5.26 (br s, lH), 6.24 (br s, 1H), 6.70 (d, 1H), 7.22 (m, 11H), ?.71 (d, 1H).

Step D: N-[1-[~2'-[(MethylamiIlocarbonyl)~mino]~ iphenyl]-4-~: ~ yl]me~hyl]-2~3,4,5-tetrahydro-2-oxo-1H-1-ben~azepin-3(R)-yl~ t~ , L~ o~c~t~
' A solunon of 66 mg (0.11 mmol) of ~e ~elmediate ; olbt~ined i~ Step C iIl 2 rnL of me~yle~e chloride was ~eated with '~
~' mL of trifluoroacetic acid. 'rhe reac~ion mi~;~ure was stirred at room t~s~el~Lu~ for 1 hour, when ~hin layer chromatography indîcated that ''; r~ ~g mat~al r~ ;ne~ Ihe reac~on ~ luTe was evaporated to dryness under vacuum and the residue pu~iISed by medium pressure liquid c~ atography on C8, ~lu~:ng ~i~ methanoV0.1% aqueous trifluoroacedc acid (60:40). Fractions cont~inin~ thg product were :: combined and evaporated under vacuum and ~e residue lyophilL~ed ~rom water to give 26 mg (Q.051 ~ol,46%) of the title compound as a whitesolid. FAB-MS: calculatedforC30H35NsO3513; foundS36 (M~Na)O lH NMR (400 MHz~ CD30D); ~ 1.3~ (s, 3H)9 lL.37 (s, 3H), 2.13 (m, lH), 2.39 ~m, lH), 2.54 (dd, lH), 2.63 ~s, 3H), 3.29 (dd, 1H), 4.95 (d, lH), 5.11 (d, lH), 7.22 (m, lOH3, 7.60 (d, lH).

, ~

. .
, j ' .
, .

21~2707 WO 94~05634 PCI'/US93/07791 ;' .

N- [ 1-[ [2'-[(Ethylaminocarbonyl)amino] [ 1,1 '-biphenyl]-4 yl}methyl]-2,3,4,5-te~ahydro-2-oxo-lH-l-benzazepin-3(R)-yl]-3-arnino-3-methyl-S butanamide~ trifluoroacetate i~ .
StepA: N-[1 [[2'-[(Ethylaminocarbonyl)aminoJ[l,l'-b~phenyl]4-~rllmethyl~-23 ~¢.5-tetrahvdro~2-oxo- lH~ P.n7~ 7~pin -3 (R~-yll-3-t-butoxyca~bonylamino-3-methvlbut~n~mide P~epared ~rom ~-[1-[[(2'-amino)[l,1'-bipheIlyl]-4-yl]-methyl]-2,3,4,j-~etrahydro-2-oxo-lH-l-b~n7.~7.epin~3(R)-yl]-3-t-butoxycarbonyl~ino-3~me~ylb~lt~n~mide ~Example 2, Step B) and ~: ethyl isocy~nate by ~he procedure desc~ibed ~n F~rnrle 2~ Step C.

StepB: N [1-[~2'-[~Ethylar~ocarbonyl)am~Ilo][1,1'-biphenyl]~-yl]me~yl]-2,3,4,5-te~rahydro-2-oxo-1H-1-beDzazepin-3(R)-yll-3-~nino-3-methylbut~n~rnide. trifluoroacetate e ti~ c~m~ound wa~ prepared ~~om th~ intemledia~e obtained ~ Step A by ~e proce~ure desc~ibed in 3~ample 2, Step D.
PA13-MS: calculatedforC31H37NsO3527; foundS50~M~Na). lH
NMR (400 MHz, (~D30D): ~ 1.04 (t, 3H), 1.34 (s, 3H), 1.38 (s, 3H), 2.14 (m, lH), 2.34 (m, lH3, 2.52 ~dd, 2~), 2.62 ~m, 2H)7 3.09 (q, 2H), 4.41 ~d~ ), 5.0l (d, lH), 5.24 (d, lH), 7.24 (m, 11H), 7.60 (d, lH).
~ 25~

' ~: N-[1-[[2'-[~2-Propyl~inocarbonyl)aII~ino][l~ biphenyl~-4-yl]methyl]-2,3,4,5-tetrahydro-2-oxo-1H-l-benz~epin-3(R)-yl]-3-amino-3-methyl-but~n~mide~: trifluoroacetate . ~
Step A~ [1-[~2'-[(2-Propylaminocarbonyl)aII~ino]~1,1'-biphenyl]-. ~ ~ - 4~yl]me~yl~-2,3,~,5-tetrahydro-2-oxo-1H-1-benza~epin-3(R)-vll-3-t-butox~rcarbonvlamino-3-meth~lbut~n~mide .:
'';
' "

WO 94/05634 2 1 4 2 ~ 0 7 PCl/VS93/07791 .

- 115~
Prepared ~rom N-[1~[[(2'-aminio)~l ,l '-biphenyl]-4-yl]-rnethyl]-2,3,4,5-tetrahydro-2-o~o-lH-l-benzazepirl-3(R)-yl~-3-t-buto~ycarbonylamino-3-me~ylbllt~n~mide (Example 2, Step B) and isopropyl i50cyanate by ~e procedure described in Example 2, Step C.
lH NMR (400 MHz, CDC13): ~ 1.06 (d, 3H) 1.07 ~d, 3H), 1.32 (s, 3H), 1.39 (s, 9H)j 1.88 (m, lH), 2.48 (dd, lH), 2.50 (m, lH), 2.62 (m, 2H), ~ 3.80 (m, lH), 4.52 (m, lH), 4.98 (d, lH), 5.10 (d, lH), 5.28 (br s, l~I), 5.08 ~b~ s, 1~)9 5.68 ~r ~ 3, 7 ~ lt~.), ''.?0 (d, 1~).

Step B: N-[ 1 -~2'-~(2-PropylaminocarboIlyl)amino] [ 1,1 '-biphenyl] -4-yI~me~yl~-2,3,4,5-tetrahydro-2-oxo-lH-l-benzazepin-3(R)-vll-3-amino-3~methvlbut~n~mide. trifluoroacetate The title compound was prepared f~om the inte~mediate 3 15 obtained in Step A by ~e procedure desc~ibed in E~ample 2, Step D.
F~B MS: calculated for c32H3gNsO3 541; ~ound 541 ~M )- H NMR
(400 MHz, CD3OD): ~1.05 (dd, 6H), 1.34 (s, 3H), 137 (s, 3EI), 2.5 I), 2.34 (rn. lH)~ 25 (m~ lH), 2.64 (m, 2H)~ 3~73 (m~ lH~, 4~41 (dd, ~ , 5.2~ ~d, ~), 7.3 ~m, 12H~, 7.~3 ~d, ~: 2'0 1' ~ EXA~IPLE 5 :
N~ [[2'-[(Aminocarbonyl)amillo][l,l'-biphenylJ-4-yl]methyl]-2~3,4,5-te~ ydro-2-o~o lH-l-bçn~7epin-3(R)-ylJ-3-amirlo-3-methylbutan-25 amide~ trifluoroacetate , Step A: N-[ 1 -[[2'-[(Aminocarbonyl)~nino] [ l, l '-biphenyl]-4-yl]me~yl~-2,3,4,5-tetrahydro-2-oxo-lH-1 -ben~azepin-3(R)-, yll-3-t-butoxycarbonylamino-3-meth~lbut~n~mide A solution of 445 mg (0.80 mmol) of N-[1-~[~2'-amino~-~l,l'-biphenylJ-4-yl]med~ylJ-2,3,4,5 tetrahydro-2-oxo-lH-l ben~epin-3(R)-yl]-3-t-butoxycarbonylamino-3-methylbllt~n~mide (Exa~nple 2, Step B) in 3 mL of me~ylene chlorid~ Imder a nitrogen atrnosphere was treated with 4 mL (29.5 mmol) of trimethylsilyl isocy~ate. The reaction mixture was stirred at room tempera~ure for 18 hours. The ~,~
, .... . ... . . ... .. ..

WO 94/~5634 PCI /US93/07791 !~

reaction mi~ture was evaporated under vacuum and the residue was passed oYer silica gel. Elution wi~ ethyl acetate~exanes (4:1) yielded 211 mg (0.35 ~ol, 44%) of product. ~AB-MS: calculated for C34H41Ns~s 599: found 622 (~+Na). lH NM~ (400 MHz, CDCl3):
~131 ~s, 3H)~ 138 (s, 3H), 139 (s, 9H), 1.9Q (m, lH), 7.~ (dd, 7H), 2.60 (m, 2H), 4.48 (m, lH), 4.95 (d, 1H), 5.08 (d, lH), 5~28 (br s, 1H), 6.66 ( br s, lH), 6.78 (d, lH), 7.22 (m, 11H), 7.72 (d, lH).

Step B: N-[1-[[2'-[(~inocarbonyl)amino]~1,1'-biphenyl]-4-yl~methyl]-2,3,4,5-tetrahydro-2-oxo-lH-1-ben7~7epin-3(R)-yll-3-a~nino-3-meth~rlbut~n~mide~ ~rifluoroacetate The title compound was prepared from the ulte~ ediate ;; obtained in Stsp A by ~the procedure described in F.x~mrle 2, Step D.
5 ~AB-~IS: calculatedforC2gH33NsO3499; ~oundSOO(M+H). 1~I
NMR (400 M~Iz, (:D30D): ~1.34 (s, 3H), 1.37 (s, 3H), 2.14 (m, 1H), 2.34 (m, 1~), 2.50 (dd, 1H), 2.65 (m, 2H), 4.42 (dd~ 1~I), 5.02 (d, lH), 5.25 (d~ lH)~ 7.27 (m, 10? H), 7.60 (d, 1H~
.
; ~0 EXAMPLE 6 N-[l-[[2'-~(Morpholinocal~ollyl)a~ino][1,1'-biphenyl]~-yl].me~yl]-253,4,5-te~ahydro-2-oxo-1H-1-benzazepiIl-3(R)-yl]-3-amino-3-meth~vlbut~n~mlde. trifluoroacet~te s Step A: N-~1-[r(2i-IsocyaIlato)r1,1'-biphenylJ-4-yl]methyl~-2,3,4,5-te~ahydro-2-oxo-lH-1 -benza~epirl-3(R)-yl]-3-t-buto~y-carbonvlamino-3-meth~lbllt~n~mide .~ A solution of 2.0 g (3.6 mmol) of -[1-[[(2'-amino)[l,l'-biphenyl]~-yl]me~yl]-2,3,4,5-tetrahydro-2-oxo-lH-l-benzazepin-3(R)-yl3-3-t-butoxycarbonylamino-3-methylbl-t~n~mide (Fx~mple 2, Step B) and 2.0 mL of trie~yl~mine ~14 mmol) in 40 ~ of me~ylene chloride : under a nitrogen atmosphere was cooled to -10~C and treated with 2.12 g (7.15 mmol) of triphosgene in one por~ion. An exo~eIm occurred.
;~ The reaction was stirred at room temperature ~or 1.5 hours when no j~
i ~.~

' . WO 94/05634 2 1 4 2 7 0 7 Pcr/usg3/~77gl .

. starting amine was detected by thin layer chromatography on silica (hexane/ethyl acetate (1:1)). The reaction mixture was diluted with 40 mL of he~ane and filtered. The filtrate was passed o~er 150 g o~ silica gel arld eluted wi~ hexane/e~yl acetate (1~ o give 1.65 g (2.84 mmol, 79%) OI the product. lH ~ (400 MHz~ CDCl3): ~1.34 (s, ~ ~ ~ 6H)~ 1.39 (s, 9H), 1.84 t(m, lH)~ 2.40 (m~ lH), 2.49 (dd, lH), 2.52 (m, : lH), 4.51 (m, lH), 4.~8 (d, lH), 5.25 (d, lH), 5.34 (b~ s, lH), 6.71 (d, 1~I),7 Q (~ l~I)~

Step~B: N ~ [2'-[~Mo~pholinocarbon~l)amino]~1,1'-biphenyl] 4-yl~me~yI~-2,3,4,~-te~ahydro-2-oxo-lH-1 -ben7~Y.epin-3(R)-vll-3-amino-3-methylbut~n~mide. trifluoroacetate : A soIution of I00 mg (0.17 mmol) of the inte~nediate obtained in Step A in 2 mL of me~ylene chloride was treated with 0.017 ~ of morpholine (0.19 mmol). Irhe reaction mi~tllre was sl;irred at room temperature for 1 hour when ~:in layer chromatography showed no re.rn?~ining isocyanate. TQ the reaction .l~e ~s added l m~ ~f t~lu~ cetic a~i~ The re~eti~n ~0 was s~rred at room tempera~ure for 0.5 hours. The reac$ion ~ L~
b~ was evaporated u~der Yacuum and the residue puIified by preparative me~limn pr~ssllre r~verse phase liquid chromatography on C8, eluting wi~ me~anol/0.1% aqueous ~ uoroacetic acid (65:35). The fractions CO~ he produc~ were c~llb~le~ and ev~porated undér vacuum 25 allcl the residue was lyophili7.e~ i~rom water ~o afford 88 mg (0.15 ~'$ mmol, 88%) of lhe:~itle com~und as a white solid. FAB-MS:
calculat~d for C33H39N5O4 569; found 592 (M~Na). lH NMR (400 MHz, CD30D): ~ 1.35 (s, 3H), 1.39 (s, 3H), 2.12 (m, lH), 2.35 (m, lH), 2.52 (dd, 2H), 2.60 (m, 2H), 3.25 (m, 4H), 3.54 (m, 4H), 4.40 (dd, 0 1H), 4.95 (d,~ IH), 5.30 (d, IH), 7.3 (m, 12H).

j ~:

. 7 1~ i WO 94/05634 PCr/US93/07791--., N-~1-[[2'-~(Pipera~inocarbonyl)~mino]~l~l '-'biphenyl]-4-yl]methyl~-2,3~4,$-tetrahydro-2-oxo-1H-1-be~ 7epin-3(R)-yl]-3-amino-3-me~hyl-butanamide. trifluoroacetate The title compound was prepared from N-[1-[[(2'-isocyarlato)~ 1,1 '-biphenyl]~-yl]methylJ-2,3 ,4,5-tetrahydro-2-oxo- 1H- 1-b~n~7~e~in~3(R~-yll-3-t-but~xy~a~bony~ ~e~hyl~t~n~mi~
piperazine by the methods described iil ~x~mple 6. FAB-M~:
c~lc~ te~l ~or C33~40N6~3 56~; ~ound MHZ7 CD30~ I.Z7 (s, 3H~, 1.30 (s, 3H), 2.07 (m, lH), 2.30 (m, 1EI), 2.4 (dd, 2H), 2.~g ~m, 2H), 3.20 (dd, 4H), 3.30 (dd, 4H), 4.40 (dd, lH), 4.90 (d, lH), ~.33 (d~ lH)7 7.30 (m~ 12H).

.1 . ~ ~ N~ [2'-~[(2-Hydroxyethyl~mino)carbonyl~o~[l~l'~iphenyl]-4-yl~ h~ ,3,4,~te~r~ydr~2~H~ azepi~-3~-y~J-3-a$~ino-20 3-methvlbu~arlamide~ tnfluoroacetate Step A: N~ 2'-~E~2-Hydro~ye~ylaIx~ino)carbonyl]amino][l,l'-! ~ biphe~ylj-4-yl]methyl3-2,3,4,5-tetrahydro-2-o~o-lH-l-berlzazepin-3(R)~yl]-3-t-buto~ycarbonylamino-3-methylb~t~n~mide d ~m ~ (2'-isocyanato)~l,l'-bipheny~
yl]me~yl]-2,3,4,5-tet~ydro-2-oxo lH-l-ben7.~7epin-3(R)-yl]-3-t-butoxycarbonyla~niI}o-3-me~ylbllt~n~rnide and ethanol~mine by the ~ procedure described in P~x~mple 6, Step A. FAB-MS: calculated for C3~H4sNsO6 643; found 666 (M+Na). lH NMR (400 ~z, CDCl3):
~1.29 (s, 3H), 1.31 (s, 3H), 1.38 (s, 9~I), 1.90 (m, lH), 2.5 (dd, 2H3, 2~58 (m, 2H)~ 2.7 (m, lH), 3.21 (t, 2H), 3.S4 ~m, 2H3, 4.49 (m, lH), : ~ 4.88 (d, lH), 5.10 (d, lH), 6.81 (d, lH), 7.21 (m, 1 lH), 7.74 (d, lH).

., .

WO 94/05634 2 1 4 2 7 ~ 7 PCr/US93/07731 Step B: N-[1-~2'-[~(2-Hyd~oxye~yl~mino)carbonyl]amino][1,1'-biphenyi]-4-yl]methyl] -2,3 ,4,5-tetrahydro-2-oxo-1H-1-~ 7.~7~pin-3~R)-yl]-3-amirlo-3-medlylbu~n~mide, trifluoroacetate The title co~pourld was prepa~ed ~rom the inte~nediate obtained in Step A by the procedure described in Ex~nple 6, Step B.
IS: calcul~ted for C31H37N504 543: found S45. 1H NMR (400 M~z. CD301~ 1.34 ( s~ 3H~ 1.37 (s. 3H~. 2.14 (m~ lH), 2.~4 (m, lH), 2.S2 (dd, 2~), 2.64 (m, 2H), 3.20 (t, 2~1), 3.51 ~t, 2H), 4.41 (dd, : l lH)~:5.02 ~d, 1~), 5.20 (d, lH), 7.24 (m, 11H), 7.62 ~d, lH).
. :
EXAh/IPLE 9 : 5 ~ [[2'-~(2-Hydro~ypropyl~mino)c~rbonyl]~mino][1 71'-biphenyl]~-yl]methyl~-2,3,4,5-tetrahydro~2-oxo-1H-l-benzazepin-3(R)-yl]-3~ ~Lno-3-methylbuta~ ide. trifluoroacetate The title co~ ouIldwaspreparedfromN-~ [(2'-ato)~1.1'-b~rhP.nyl~yl~methyI1-2~3,4,5-te~ahydrv-2-oxo lH~1-20: ~n7:~7,~,pm-3(R)~yl]-3-t~ ycd~ nyl~mino-3-me~ylbut~n~mifl~ and 1-amiIlo-2-propaIl~l by th~ procedures described in Px~mrle 6. FAB-P. ~: MS: calcul~ted for C32H3gNsO4 557; fouIld 580 (IM~Na). 1H NMR
- ~ (400 MHz, CD30D): ~ 1.00 ~d, 3H), 1.34 (S9 3H), 1~37 (s, 3H), 2.14 X~ ), 2.34 (m, 1H~ 2.5~ ~dd, 2H), 2.68 ~m, 2H), 3.01 (dd, 1H), 4.41 s (dd, lH), 5.02 (d, lH), 5.21 (d, lH3, 7.25 (m, 11H), 7 62 (d, lEI).

N~ 2'-[[(3-Hydroxypropyl~mino)earbonyl]arnino][1,1'-biphenyl]~-30 yl]methyl]~2,3,4,5~tetr~hydro-2-oxo lH-l-benzazepin-3(R)-yl]-3-aIrLino-3-methylbut~n~mide. tTifluoroacetate 7'he 'dtle compound was prepared ~rom N-[ 1 -E~2~-isocyanato)[1,1'-biphenyl]-4-yl]methyl]-2,374,5-tetrahydro-2-oxo-lH-1-~: ben~7epin-3(R)-yl~-3-t-buto~ycarbonylamino-3-me~ylbut~n~mide and ~: ~ : 3-ami~o-1-propanol by the procedures desc~ibed in Bxample 6. FAB-WO 94/0~34 P~/US93/07791 ~-~

MS: calculated for C32H39N504 557, ~ound 580 ~M+Na)- lH NMR -~400 MHZ7 CD30D): ~ 1.34 (s, 3H), 1.38 (s, 3H), 1.60 (m, 2H), 2.18 (m, lH), 2.35 (m, 1H), 2.52 (dd, 2H), 2.65 (m, 3H), 3.39 (m, 2H), 3.52 ~m, 2H), 4.42 (dd, lH), 5.04 (d~ lH), 5.21 (d, lH), 7.~g (m, 1 lH), 7.59 ~:

:' EXAMP~E 11 ;:
:
N-[1-[[2'-~(2,3-Dihydroxypropylamino)carbonyl]arn1no][1,1'-biphenyl]-4-yl]methyl] 2,3 ,4,5-tetrahydro-2-oxo- lH-1 -benzazepin-3(R)-yl~ ~3-amino-3~methylbutanamide, trifluoroacetate The title compound was prepared ~rom N-[1-[~(2'~iso-cyanato)[l,l'-biphenyl]~-yl]me~yl~-2,3,4,5-tetrahydro-2-oxo-1H~
be~azep~-3(R)-yl];3~t-buto~ycarbonylamino-3-methylbut~n~mide and 3-amino-1,2-propanediol by the procedures described i~ ~xample 6.
FAB~MS: calculatedforC32H3gNsO4557; foundS80(~Na). lH ::
~ (400 MHz, CD30D): â 1.34 (s~ 3H), 1.37 ~s, 3H)7 ~.14 (rll, lH)~
2.34 ~, l~g~, 2.~ d, ~3, 2.66 (m, 2H), ~ m, 1H~, 3.2 (m, 2Hj~
: 20 3.42 ~m, ZH), 3.59 (m, lH), 4.41 (dd, lH), 5.05 (d, lH), 5.17 ~d, lH), 7.25, (m, 10H), 7.59 ~d, lH).

: EXAMPLE 12 2s N-[1-[[2'-[(Me~yl~minocarbonyl)oxy][1,11-biphenyl]-4-ylJme~yl~- ~
2,3,~,5-te~ahydro-2-o~o-lH-1-ben~azepin-3(R3-yl~-3-amino-3-methyl- :
butanamide~ trifluoroaceta~e ~ , .
StepA: 4-Methylphenyl~rime~hylstannane ~: 30 41.4L of l.0 M p-tolylmagnesium brornide in diethyl ether (41.4 mvl) was a~ded dropwise, m~int~ining the temperature below 5~C, over 4 hours to a solution of 546 g (2.79 mol) of trimethyltin chloride in tetrahydrofuran (4 L) under nitrogen at -10~C. The suspension was allowed to warm slowly to room temperature over 12 hours then saturated ammonium ehloride solution (1 L) was added ;:
~ WC) 94/0~634 PCI'/US93/07791 2142~0~

followed by su~ficient water (approximately 1 L) to dissolve the precipitate. The solutiOIl was e~tracted with ether-hexane (1~ 1x4 1~, :
3x2 L). I'he combined organic phases were washed with brine, dried :
over m~ ~nesillm sulfate and the solvents removed uulder vacuum.
pllrific~tion by flash chromatograph~ on silica gel eluting with he~ane/ethyl acetate (95:5) gave a pale yellow oil cont~ining white crystals of 4,4'-d~nethylbiphenyl which were removed by filtration to l~v~ 7113 g (100~ o~prQ~ ~ lH ~LR ~3QO MHz, CDCl3): ~ 0 30 0 (S7 9H), 2.34 (s, 3H), 7.19 (d, 7.7 Hz7 2H)9 7.40 (d, 7.7 Hz, 2H).

Step B: 4-Me~yl-2'-aeet~ lel'-biphe~
A vigorously s~irred solution of 13.2S g (66 mmol) of 2'- ::
bromoacetopheno~e and 22.8 g ~89 mmol) vf 4-methylpheIlyl-trimethylst~nn~ne in 190 mL of dimlethylformamide under a l~itrogen atmosphere was treated wi~ 8.64 g (12 mmol) of bis(triphenylphos~
phine)p~ m(II) chloride and the resulting mixture heated at 150~C ':
~r 6 hours. Ihe reac~on mLxture was cooled~ poured ~nto water (1000 ~ ' d ~.~ Tesu~tar~l s~spension e~t.l~c~d w~ e~yl e~her. The ~-combi:ned e~tracts were washed with water (4x), dried over m~nesium .
sul~te ~d evaporated under vacuum. The residlle was purified by l~
preparanve high pressure li~quid chromatography on silica gel, eluting ~:
wi~h he~anele~yI acetate (10:1) to give 9.8 g (47 ~ol, 71%) of productasanoil. ~I-MS: calculatedforC1sH1~0210: ~ound210 (M+). lH NMR ~200 M~z, CDC13): ~ 1.98 (s~ 3H), 2.37 (s, 3H)~ 7.20 (s, 4H), 7.3-7.~ (m, 4H).

' Step C: 4-Me~hYI-2'-hydroxv-l.l'-bi~hen~l .
A solution of 4.2 g (20.0 mmol) of 4-methyl~ cetyl-1-l'-biphenyl (Step B) in methylene chloride under a nitrogen atmosphere was treated with 8.98 g of 85% m-chloroperbenzoic acid. The resultant su~pellsion was cooled to 0~C and treated dropwise wi~ 1.54 ml, of 'trifluoroa etic acid over a 10 miIlute period. l~e reaction mixture was -~
stiITed at room temperablre for 16 hours. The reaction mixture was diluted with 50 mI, of methylene chloride and the solution was washed ~ .

214270~t WO 94t05634 PCI'/US93/07791 j~' ,, .:
successively with 50 mL of 10~o sodium sulfite, 50 mI, of saturated aqueous potassium earbonate and water (3xS0 mL). The organic layer was removed arld dried over rnagnesium sulfate, ~en evaporated under vacuum to yield 4.1 g of an oil. The oil was dissolved in 20 m~ of methanol and tre~ted with ~.0 mL of 5N aa~ueous sodium hydro.xide.
The reaction mixture was stirred at room temperature for 1 hour. The :pH of ~e solution was adjusted to 5-6 with acetic acid. After the mel:h~ol W2S removed under vac~ zhe ~esidlle was ~en ~
ether, washed with water, dried over m~nesium sulfate, filtered and :~ evaporated uIlder vacuum to yield 3.0 g of cmde product which was ::
purined ~y prepa~a~ive high pressure ~iquid chromatography on silica, eluting wi~ hex~e/ethyl acetate (10:1). In ~is rn~nner~ 1.85 g (10.0 mmol, 50%) of the product was obtained as an oil. lH NMR (200 ~vIHz, ;.
CDCl3): ~ 2.40 (s, 3H), 5.22 (br s, lHj, 6.96 (m, 2H), 7.2-7.4 (m, 6H).
5 EI-MS: calculatedforCl3H120184; found 184(M~,100%).

Step D: 4-Me~vl-2'-ac~toxv-l.1'-biphenvl A soliltiQn o~ 1.0 g (5.4 mmol~ ne~yl~ hyd~o~y-l,lt-biphenyl in 2.0 mL of pyridine was~ treated with 2 mI, of acetic ~ ~ydride. The reaction mixtllre was s~rred at room temperature for S
hours.i ~e sol~ent was removed u}lder vacuum ~o yield 1.11 g (4.9 mrnol, 90%) of the product as an oil. 1H NMR (200 MHz, CDCl3):
2.0? (s, 3H), 2.36 (s, 3H), 7.07 (dd; 3, 8Hz; lH), 7.15 (d, 8Hz~ 2H), 2~i 7-2-7-4 ~

Step E: 4'-Bromomethvl-2-acetoxy-1.1'-biphenvl Prepared from 4-methyl-2'-acetoxy-1,1'-biphenyl by the procedure descnbed in Example 1, Step K. lH NMR (200 M*Z9 CDCl3): ~ 2.05 (s, 3H), 4.50 (s, 2H), 7.08 (m, lH), 7.20-7.45 ~m, 7H).

.

: Step P: ~ N-[1-[[(2'-Acetoxy)[1,1'-biphenyl]4-yl]methyl]-2,3,4~5-::: tetrahydro-2-oxo-1H-1-ben7~7epin-3(R)-yl]-3-t-butoxy- i carbonvlamino-3-methvlbutanamide .

- WO 94/0~634 21 ~ 2 7 0 ~ PCl'/US93/07791 .

123 . ' Prepared from 4-bromomethyl-2'-acetoxy-1,1'-biphenyl and 3-t-butoxycarbonyl~mino-3-methyl-N-[2,3,4,5-tetrahydro-2-oxo~
lH-1-benzazepin-3(R)-yl3-bllt~mide (Example 1, Step I) by ~e procedure descIibed in Ex~nple 1~ Step Q. lH NMR (200 MHz, CDCl3): ~1.38 (s, 6H), 1.45 (s, 9H~, 1.85 (m, lH), 2.02 (s, 3H), 2.35-2.65 (m, SH), 4.S2 ~m, lH), 4.84 (d, 15Hz, lH), 5.30 (d, lSHz, lH), 6.71 (d, 7Hz, lH), 7~1-7.4 (m, 12H).

Step G: N-[i-[[(2'-Hydro~y)[l~l' biphenyl]-4-ylJmethyl]-2,3,4,5-tetrahydro-2-oxo-lH-1-benzazepin-3(R)~yl~-3-t-butoxy-carbonylamino-3-me~hylbu~anarnide A s~lution of 469 mg (0.87 mmol) of ~he ~termediate obtair~ed in Step F ~: 25 ~ of methanol at room temperature was eated with S mL of aqueous SN sodium hydroxide. After stirring at room tempera~ure for 1 hour, ~e reaction mixtllre was evaporated ;~
under vacllum and ~e residue dissolved in methylene chloride, dried oYer m~nesium sul:fate and filt~red. ~he filtrate was e~taporated under u~ um to Yi O mg of ~rude prod~ct whic,h was used in the next ':
p without purifica~ion : ~ ~ : 2 0 Step H: N-[1-~[2'-~(Me~yl~minocarborlyl)oxy}~1,1'-biphenyl]4-yl~-methyl]-2,3,4,5-tetrahydro-2-oxo~ ben7~7epin-3(R)-y!l-3-t-bu~oxyc2~bonvlamino-3-me~hvlbut~n~mide ~; ~ A solution of 100 mg (approx. 0.2 ~nol) of ~e crude 2 : iL~el.~.e~i~t~ obtained in S~ep G in S ~ of methyle:ne chlonde was treated with 1.0 mL of methyl isocya:llate (17 r~ol) and 0.1 mL of 1,8-dia~abicyclo[S.4.0]~dec-7-ene under a nitrogen atmosphere. The reaction mixture was stirred at room temperature for 10 mimltes and 0 ~en evaporated under vacuum to give 146 mg of crude product. 1H
NMR (400 MHz, CDC13): ~ 1.32 (s, 3H,~, 1.33 (s, 3H), 1.39 (s, 9H), 2.12 (m, lH), 2.33 (m, lH), 2.52 (dd, lH), 2.57 (m, 2H), 2.~9 ~s, 3H), 4.38 (dd, lH), 4.8 (d, lH), 5.26 (d, lH3, 7.10 (d, lH), 7.36 (m, lIH).

,~

WO ~4~ 2 1/~ ~ PCT/US93/07791 ~ - 124-~1: N-[1-~[2'-[(Me~yl~minocarbonyl)oxy][1,1'-biphenyl]~-yl]-methyl]-2,3,4,5-tetrahydro-2-oxo-1H-1-benzazepin- :
3(R~-yll-3-amino-3-methylbut~n~mide, trifluoroacetate A solution of 72 mg of ~e crude intennediate obtairled Step H ~ 3.5 mL of methylene chloride was treated with 1.0 mL of ;
trifluoroaeetic acid. After stirring at room temper~ture for 15 minutes, dle reaction mixture was evaporated ~der vacuum aIld the residue p~ied bv reverse ph~se me~lin~ ~ss~ uid chroma~Qgr~phy on :~
(:8, e1uting with me~arlol/0.1% aqueous trifluoroacetic acid (60:40).
: Practions cont~inin~ the product were comb~ed, solvents remo~ed .
xlder vacwm and the residue lyophiIized from water to gi~e 34 mg (0.066 mmol) of ~e title compouI~d as a white solid. FAB-MS:
cal~?ll~t~-~ for C30H34N4O4 514; ~ound 537 (M~Na). lH NMR (400 ~z, CD30D): ~ 1.34 ~s, 3H), 1.38 (s, 3H), 2.12 ~m, 1H), 2.33 (m, IH), X.52 (dd, lH), 2.57 (m, ~H), 2.59 (s, 3H), 4.38 (dd, 1H), 4.8 (d, lH), 5.26 (d, lH), 7.10 (d, l~I)9 7.36 (m, 11H). :
:
- EXA~P~E l~

: N-~1-[12'-[(Methylaminothiocarbonyl)amino]~l,l'-biphenyl]~-yl~-me~yl]-2,3,4,5-tetrahydr~-2-oxo-1H-1-ben~a~epin-3~)-yl~-3-amino-::~ 3-methylbut~n~mide. trifluoroacetate Step A: N-[1-[[(2'-1so~iocyanato)[1,1'-biphenyl~4-yl]me~yl]- :~
2,~,4,5-tetrahydro-2-o~o-1H-1-benzazepin-3(R)-yl3 3-t-butoxycarbonylamino-3-methylbut~n~mide, alld N-[1-~2'-~me~ylaminothiocarbonyl)amino] ~1 ,1 '-biphenyl]~-yl]me~l]-2,3,4,5-tetrahydro-2-oxo~lH-1-ben7.~7.epin-3(R)-~: 30 yll 3-t-butox~vcarbonYlamino-3-methYlbut~n~mide A solu~ion of 300 mg (0.60 mmol) of N-[1-~(2'-amino)[ 1,1 '-biphenyl] -4-yl]me~yl~ -2,3 ,4,5 -tetrahydro-2-oxo- lH- 1 -~,n~7epin-3(R)-yl]-3-t butoxycarbonylamino-3-methylbllt~n~mide mrle 2, Step B) and 1.8 g of methyl isothiocyanate (25 mmol) in 15 mL of beIlzene under a nitrogen atmosphere was heated at reflux for 24 '- WO 94/05634 2 1 4 2 7 0 ~ PCr/USg3/07791 hours. The reaction mi~cure was evaporated under vacuum and ~e residue purified by preparative thin layer chromatography on silica gel, eluting wi~ e~yl acetate~exane (3:1) to give 69 mg of a ~aster moviIlg product iden~i~ied as N-[1-[~(2'-iso~iocyaIlato)[l,1'-biphenyl]-4-~: S yl]me~yl~-2,3,4,5-tetrahydro-2-oxo-lH-1-benzazepin-3~R)-yl]-3-t-:~ butoxycarbonyl~mino-3-methylbnt~n~mide FAB-MS: calculated for C34H3gN404S 598; fo~d 621 (M+Na). lH NMR (400 MHz, Cl~Cl3):
~135 (s, 3H~, ~36 (S? 3H~, 1.40 (s, 9~ lH), ~."8 (dd, "H).
2.52 (m, 3H), 4.50 (m, lH)~ 4.86 (d, lH), j.29 ~d, lH), 6.68 (d, lH), 7.14 (m, lH), 7.30 (M, llH).
The slower moving band yielded 122 mg of material identified as N-[1-[[2'-[(methylaminothiocarbonyl)amino][l,1'-biphenyl]4-yl]me~yl]-2,3,4,5-tet~ahydro-2-oxo-lH-1-benzazepin-3(R)-yl]-3-t-butoxycarbonylamino-3-methylbllt~n~mide. FAB-MS: calculated for C3sH43NjO4S 6~9: found 652 (M~Na). IH NMR (400 MHz, :~ ~ CDCl3): ~1.32 (s, 3H), 1.33 (s, 3H), 1.40 (s~ 9H)~ 1.85 (m, lH), 2.48 (dd~ 2H3, 25~ ~m, 3H), 2.95 ~s, 3H), 4.50 (m. lH), 4.88 (s, lH), 5.20 (s~ l'~, 6.68 ~d,-1O, 7.22 (m, 12 Step B: N~ [~ [~Methylamino~iooarbonyl)amino3[1,1'-bi-phenyl]-4-yl3methyl~-2,3,4,5-tetrahydro-2-oxo-1H-l-ben7~7epin-3(R)-yl]-3-amino-3-methylbllt~n~mide, ;: tri~luoroacetate A solution of 122 mg (0.19 mmol) of N-[1-[[2'-~(rnethyl-an~inothiocarbonyI)amino]~1,1'-biphenyl~-4-yl3methyl~-2,3,4,~-tetra-hydro-2-oxo-lH-l -ben7~7epin-3(R)-yl]-3-t-butoxycarbonylamino-3-methylb~ n~mide in 3 mL of methylene chloride was treated with 1.0 .: mL of trifluoroacetic acid. After 1 hour ~in layer chromatography 30 indicated that no s~a~g material was present. Solvents were removed }nder vacuum and ~e residue purified by reverse phase medium pressure liquid chromatography on C8, elu~Ilg with methanol/0.1%
aqueous tlifluoroacetic acid (60:40). The fractions containing the product were combined, solvents evaporated under vacuum and ~e residue was lyophilized from water to give 84 mg (0.16 mrnol, 84%) of 2 ~ 0 ~
wo s4/0s634 PCr/US93/~7791~ ' .

~e title compound as a white solid. F~B-MS: calculated for -C30H3sN402 529; found 531. lH NMR (400 MHz, CD30D~: ~ 1.32 (s, 3H), 1.38 ~s, 3H), 2.11 ~m, IH), 2.30 (m, lH), 2.5~ (dd, 2H), 2.70 (m, 2H), 2.72 (s, 3H), d"4 (dd, lH), 4.89 (d, lH)9 ~.81 ~d, lH), 7.3 (m, 1~). ' "':

N-[1-~[2'-[(Amino~iocarbonyl)amino~[1,1'-biphenyl]~-yl]methylJ-2,3,4,5-tetrahydro-2-oxo-lH-1-ben~azepin-3(R)-yl~-3-amino-3-methyl-butanamide. tr~fluoroacetate A solu~ion of 100 mg (0.17 mmol) of N.-[1-[[(2'-isothio-cyanato~[1 ,1 '-biphenyl]~-yl]me~yl]-2,3,4,5-te :rahydro ~-oxo~1H-1 -benza~epin-3(R)-yl]-3-t-butoxycarbonyl~mino-3-methylbllt~n~mide (ExaITlple 13, Step A3 in 5 mL of me~anol was ~reated ~th gaseous anh~drous ~on~a for S minu~es. Th~ll layer chromatography revealed no s~ ng iso~iocyana~e was present. T~e reaction ~tllre was e~p{~t~d u}~er ~ um and ~e ~ d~e wa~ dtssolved m 3 ml, of me~ylene chloride alld treated vvi~ 1 mL of trifluoroacetic acid. A~ter 1 hour at room ~emperature the rea~on mix~lre was e~aporated under vacuum and the ~esidue purified by reverse phase medium pressure liquid chromatography on ~8, eluting with methanol/0.1% aqueous $~fluoroacetic acid (60:40). Fractions cont~ining ~e product were combined, solvents removed under ~c~ m and the residue Iyophilized ~m water to give 53 mg of ~he title compound as a white solid. FAB-MS: calculated for C29H33N5O2S SlS; ~ound 516 (M~H). lH NMR
(400 ~z, CD30D): ~1.34 (s, 3H), 1.38 (s, 3H), 2.12 (m, lH), 2.30 (m, lH), 2.54 (dd, 2H), 2.60 (m, 2H), 4.42 (dd, lH), 4.92 (d, lH), 5.26 (d, lH), 7.30 (m, 12H).

.

WO 94/05634 21 4 2 7 0 7 PCr/US93/07791 EXAMPL~ 15 ~-[1-[~2'-~(Dime~ylaminocarbonyl)amino~ biphenyl]-4-yl~methyl~-2,3,4,5-te~ahydro-2-oxo-lH-1 -benzazepin-3(R)-yl~-3-aIxlino-3-methyl-butanamide. trifluoroacetate Step A~: 4-(Tetrahydropyranyloxy)methyl-2'-isocyanato-1,1'-binh~nvl A soludon of 200 mg (0.70 mmol) of 4-(tetrahydropy-ranylox~)methyl-2'~amirlo-1,1'-bipherlyl (Fx~mple 1, StepN) and 0.40 l of trie~yl~rrine in 10 mL o~ me~ylene ehloride urlder a r~itrogen atmosphere was treated with triphosgen~ (420 mg, 0.24 ~nol). T~e reaction mi~ture was stilTed at room temperature for 30 mimltes when ~ layer chromatography on silica ~exane/ethyl acetate; ~:1) revealed no rem~ining amiIle. The reaction mLxture was evaporated under vacuum to yield the crude product which was used in the ne~t step without puri~ic~lion Step B: 4-Hydro~ymethyl-2'-(dime~ylaminocar~onyl)-amino- 1 . l '-biphenvl A sol~tio~ of the cmde illte~ e~i~te from Step A in 4 mL
of me~anol was treated wi~ 4 mL of 40% aqueous dimethylam~ne.
After sti~in~ at roo~ ~el~ly~lature ~or 15 n~utes, the reaction mixture was evaporated uIlder vacuum and the: residue dissolved in 4 mL of me~anol ~d treated wi~ 1 mL of 10% me~olic p-toluenesulfonic a~id. After lS ~;nlltes at ~oom temperacure, the reaction mi~ture was treated with sa~rated aqueous sodium bicarbonate. The mixtur~ was diluted with water then extracted wi~ methylene chloride. The organic layer was dried:and evaporated under vac~um; the residue was purified by ~leyalaliv~ ~n layer chr~matog~phy on silica geI, eluting with h~xane/ethyl acetate:(2:1) $o a~ford 133 mg of product.
~; :
Step C: 4-Bromome~yl-2'-(d~nethylamirlocarbonyl)-~ ~ amino- l ~ l '-biphenyl ,: . : .

h ~ ~ r~ 4 U ~
WO 94/05634 PCI/US93/07791..~, - 12~-A solution of the interrne~i~te obtained in Step B in 4 rnL
of methylene chloride was treated with 0 16 mL (1.21 mmol) of trimethylsilylbromide. The reaction mixture was stirred at room temperature for i 8 hours. The reaction mixture was diluted with me~yleIle chloride then washed wi~ aqueous saturated sodium chloride (2x). The org~nic layer was dried over magnesium sulfate, ISltered and eva~orated under va uum to yield 133 mg of crude product. lH NMR
(400 Hz. CD(~ 2 78 ~s. 6H)~ 45 (s. 2H)~ 6.4 (br s. lH) 7.0~ (~
lH), 7.16 (dd, lH), 7~34 (m, 4H), 7.49 (d, lH), 8.10 (d, lH).
:
S~ep D~ [~2' ~(Dime~ylaminocarbonyljamino][1,1 '-biphenyI]-4-yl]methyl]-2,3,4,5-tetrahydro-2-oxo-lH-1-benzazepin-3(R)-yll-3-amino-3-methylbut~n~mide. tlifluoroacetate A solution of 147 mg (0.39 mmol) of 3-t-butoxycarbonyl-amino-3-methyl-N-~2,3,4,5-tetrahydro-2~oxo-lH-1-benzazepin-3(R)-yl~-bllt~n~mide (Example 1, Step I) in S ~ of dry dimethyli~olmamide was t~eated with 20 mg of 60% sodium hydride/oil dispersion (12 mg ~: Na~IØ5 mmol. :1.3 ecl.~. Ihe re~tion m~ e wa~ stirred at room temperah~re ~or 30 ...i.~.~tes then 133 mg of 4-bromome~yl 2'-(dirnethyl~minocarbonyl)amino-1,l'-biphenyl was added. After stiITing ~'! ' at room temperature for 2 hours, the reaction mix~ure was diluted with e~yl acetate. The mixtllre was washed with water (4x) ~d the organic layer dned over n~nesium sulfate, fil~ered and evaporated under vacuum. The residue was dissolved in 4 mL of me~hylene chloride and treated with 1 ~ of trifluoroace~ic acid~ After stirring at room :; temperature for 1.5 hours, solvents were removed under vacuum and the residue pu~i~ied by reverse phase mediuTn pressure liquid ~ chromatography on C8, eluting with methanol/0.1 ~a aqueous ~~ O trifluoroace~ic acid (65:353. Fractions cont~in;ng the product were combined, solveIlts removed under~vacuum and the residue lyophilized from water to giYe 116 mg of the title eompound as a white solid.
FAB-MS: calculate~ for C31H37NsO3 527; found 529. lH NMR (400 MHz, CD30D): ~ 1.34 (s, 3H), 1.40 (s, 3H), 2.15 (m, lH), 2.34 (m, ;

21~270~

- 12~-lH), 2.54 (dd, 2H), 2.59 (m, 2H), 2.78 (s, 6H), 4.44 (dd, lH), 4.88 (d, lH), 5.38 (d, lH), 7.28 (m, ~l~I), 7.49 (d, lH).

N-~1-[~2'-~[(1,3-Dihydroxyprop-2-yl)aminocarbonyl3arnino][1,1'-biphenyl]4-yl]methyl]~2,3,4,$-~etrahydro-2-oxo~lH-l-ben7.~7.epin- "
3~R~-vll-3-amino-3-methvlbl~t~n~mid~. trifluo~oace~ate Step A: N-[1-[~2'-[(1,3-Dihydroxyprop-2-yl)amirlocarbonyl]-am~no][l,i'-~phenyl]-4-yl~netrlyl]-2,3,4,5-~etrahy~o-2-oxo-lH-l~ 7.~p~n-3(R)-yl]-3-t-blltoxycarborlylamino-3-methylbutarlamide S A solution of 125 mg (0.~3 mmol) of N-[1-~(2'-amino)-biphenyl~-4-yl]methyl]-~,3,4,5-tetrahydro-~-oxo-lH~l-benza~epin-~: 3(R)-yl]-3-t-butoxycarbonylamino-3-methylb~lt~n~mide (E~ample 2, Step B) and 0.10 ml, ~0.72 mmol3 of trie~yl~mine in S mL of met~ylene chloride ~ r a r~itro~ atmosphere was cooled to -lO~C
;~ and treated with 133 mg (0.45 mmol) of tr:iphosg,ene. The reac~ion mi~ture was allowed to wa~n to room temperablre and stirred for 1 hour. l~e reaction mixture was recooled to -10~C and additional trie~yl amine (0.30 mL~ 0.23 mrnol) was added. The reactiorl mixblre was treated w~h: se~inol hydrochlo~de (280 mg, 2 20 mmol) in one 2 por~on. The reac~ion ~ u~ was s~irred: at room tempel~Lule when 5 thin layer chromatography (h~x~n~:/ethyl ~eet~ dica~ed ~o rem~inin~ isocyaIlate. Ihe reaction mix~ure was evapora~d ullder vacuum to give the crude product.

30 :: St~pB: N-[1-~[2'-[[(1,3-Dihydroxyprop-2-yl)aminoearbonyl]-amino~[1,1'-biphenyl~-yl~methyl]-793,4,5-tetrahydro-2-oxo-lH-1-benzazepin-3~R)-yl]-3-amino-3-methyl-butanamide. trifluoroacetate A solution of the crude inteImediate obtained in Step A in 5 mL of methylene chloride was treated wi~ 2 mL of trifluoroacetic acid.

~1~2~9 ~
WO 9~/05634 . PCr/lJS93/07791,~

After stirring at room temperanure for 1 hour, the reaction mixture was evaporated under vacuum and the,:residue purified by reverse phase medium pressure liquid chromatography on C8, eluting with meth~nol/0.1% aqueous trifluoroacetic acid (55:45). Fractions cont~inin~ the product were combiIled, solvents removed under vacuurn and the residue lyophilized from water to give 66 mg (0.096 mmol, 42% over two s~eps) of the title compound as a white solid. FAB-MS:
calculated for C3~H3gNsC)s 573; ~nd 59~ a)- lH N~R (4QQ
M~lz, CD30D): ~ 1.34 ~s, 3H), 1.37 (s, 3H), 2.14 (m, lH), 2.30 (m, lH), 2.48 (dd, 2H), 2.69 ~m, 2H), 3.5~ (m, 4H), 3.70 (m~ lH), 4.40 (dd, lH), ~.05 (d, lH), 5.20 (d, lH), 7.25 (m, 1 lH), 7.62 (d, lH).

N-[1-[[2'-[[[2(R~-Hydro~ylJro~ylamLno]carbonylJamillo][1 ,1 '-biphenyl]~4-yl]methyl]-2,3,4,5-tetrahydro-2-oxo-lH-l-be~
a~e~in-3(R~-vll-3-amino-3-methvlbut~n~mide~ trifluoroacetate he ~iHe com~un~ w~s ~ y~d ~m N-~ 2'-:: 20 isocya~ato)~ iphenylJ-4-yl~melhyIl-2,3,4,5-tetrahydro-2-oxo-lH-1-ben7.~7epin-3(~)-yl~-3-~butoxycarbonylamino-3-methylbut~n~mit?e and :~ (R)-(-)-l-am~no-2-p~panol by ~e me~ods desc~ibed in Example 6.
FAB-MS: calculated for C32H3gNsOq 557; found 580 (M+Na). lH
~ (400 MHz, CD3OD): ~ 1.09 (d, 3H), 1.34 (s, 3H), 1.37 (s? 3H), 2.15 (m, lH), 2.35 (m, lH~, 2.52 (dd, 2,H), 2.65 (m, 2H), 2.95 (dd, lH), 3.16 (dd, lH), 3.7~ (m, lH), 4.82 (dd, lH), 5.02 (d9 lH), 5.20 (d, 1H), J 7.27 (m, llH), 7.61 (d, lH).

EXAMPLE 1~ -:: 30 N-~ r2'-[r~2(S)-HydroxyprQpyla~ o]ca}bonyl]amino][1~ biphenyl]-4-yl]me~yl]-2,3 ,4,5 -tetrahydro-2-oxo- 1 H- 1 -benzazepin-3 (R)-yl] -3 -amino-3-meth~,rlbutanamide. trifluoroacetate The title compound was prepared from N-[1-[[(2'-isocyarlato)[1,1 '-biphenyl]-4-yl3methyl]-2,3,4,S-tetrahydro-2-oxo-lH-l -WO 94/05634 2 1 ~ 2 7 0 7 PCI/US93/07791 benzazepin-3(R) yl~-3-t-butoxycarboIlylamirlo-3-methylbut~n~mide and (S)-(+)-1-amino-2-propanol by the methods descnbed in Example 6.
FAB~MS: calculated ~or C32H3gNsO4 557; f~und 581 (M+Na). lH
N~ ~400 ~Iz, C030D): ~ 1.09 (d, 3H~t 1.34 (s, 3H), 1.37 (s, 3H), ~15 (m? ~ ~~s ~ ), 2 ss (d~? 2~ 68 (m? ~ 3.~2 ~d~ lH~?
3.16 (dd, 1H~, 3.75 (m, lH), 4.41 (dd, lH), 5.06 (d, lH), 5.22 (d, lH), 7.27 ~m, llH), 7.62 (d, lH).

E~A~LE 19 N~ [['2'-[r~[l-Hydroxyprop-2(R)~yl]amino~carbonyl]aminoJ[l,l'-biphenyl~-yl]methyl3-2~3,4,5-tetrahydro-2-oxo-1H-1-benzazep~n-3(R)-vll-3-amino-3-methvlbut~n~mide, trifluoroacetate l~he title compouIld was prepared frorn N-[1-~(2l-isocyanato)~l,1'-biphe~yl3~-yl3methyl]-2,3,4,5-tetrahydro-2-o~o-1H-1-7.~7.epin-3(R)-yl]-3-t-butoxycarbonylamino-3-me~ylbut~n~mi~le arld (R)-2~amino-1~propa~ol by the methods described in Example 6. FAB-~ d ~ ~2~N~4 '57; ~d 580 (~ ,l:~a) 1~ N~.
(400 MHz, CD30D): ~1.07 (d, 3H), 1.34 ~s, 3H), 1.37 (s, 3H3, ~
(m, lH), 2.3~ (m, lH), 2.51 (dd, 2H), 3.41 ~m~ 2H), 3.75 (m, lH)7 4.41 (dd, IH), 5.03 (d,~lH~, 5.21 (d, lH), 7.25 (m, llH)j 7.64 (d, lH).

2'-r(Hydr~in~car~onyl)am~no]~l,l'-biphenyl~-4-yl~methyl~-2,3,4,5-tetrahydro-2-oxo-lH-1-ben7~7epin-3(R)-yl]-3~ ~ino-3-me~hyl-butallamide~ t~ifluoroacetate The title compolmd was prepared from~ (2'-iso~
cyanato)[1,1'-bip~enyl]: 4-yl]me~yl]-2~3~4!5-tetrahydro-2-oxo-1H-1-be.n7~7,epin-3(Rj-yl~-3-t-butoxycarbonylamino-3-me~ylbut~n~micle ~d anhydrous hydrazine by the me~ods described in Example 6. FAB-MS:
~alculated for C2gH3sN603 514: found 537 (M+Na). 1~ NMR (400 MHz, CD30D): ~ 1.35 (s, 3H), 1.38 (s, 3H), 2.29 ~m, 1H), 2.35 (m, wo 92~16~s34 PCI'/US93~07791 ~: lH), 2.57 ~dd, lH), 2.62 (m, 2H), 4.46 (dd, lH), 5.30 (d, lH), 7.29 (m, lOH), 7.73 (d, lH3.

E?XAMPI,E 21 ~-[1-[[2'-[(2,2~1:)ime~ylhydrazinocarbonyl)amino]~1,1'-biphenyl]-4-yl~- :
' me~yl]-2,3,4,5-tetrahydro~2-oxo-lH~l-be}l7~7ep~n-3~R)-yl]-3-amin 3-me~hvl~t~ mid~. ~ifluo~oacetat~
The title compound was prepared from N-~1-[~(2'-: 1 0 isoeyanato)[l ,1 '-biphenyl]~4-yl]methyl]-2,3,4,5-tetrahydro-2-oxo-lH~1-ber~zazepin-3(R)-yl]-3-t-butoxycarbonyl~mino-3-me~ylbu~n~ e and 1,1, d~ne~ylhydrazine by ~he methods descnbed in Px~mrle 6. FAB-~MS: cal~ulated for C3lE~3gN~03 542; found 565 (M~Na). 1H NMR
5 (400 MHz, CD30D): ~1.34 ~s, 3H), 1.38 (s, 3H[), 2.14 (m, lH), 2.30 (s, 6H), 2.36 (m~, 1H)9 2.52 (dd, lH), 2.64 (m, 2~), 4.28 (dd, lH3, 5.00 (dd, lH), 5.30 (~d, lH), 7.26 (m, lûH), 7.~0 (d, lH).

XAMPLE ~
o N~[1-[~2'-~(Carboxvvmethylamino)carbonyl]an~no][~ biphenyl]-4-yl]-methyl]-2,3,4,5-te~ahydro-2-oxo-lH-1-ben7.~7ep~n-3(R)-yl]-3-amino-: 3-methYlbutanamide~ t~ifluoroacetate 2s~ StepA: N-[1-[[2'-[[(t-Butoxycarbonylmet~ylaminQ)carbonyl]- -amino][l~ biphenyl]-4-yl3methyl]-2,3,~ tetrahydro-: ' ~ 2-oxo-lH-1-ben7.~7ep~-3(R)-yl]-3-t-butoxycarbonyl-amino-3-methvlbutanamide :: : Prepared from N-~l ~[[(2'-amino)~l ,1 '-biphenyl]-4-: 30: yl]me~yl]-2,3,4,5-tetrahydro-2-oxo-lH-l-b~,n7.~7,epin-3(R3-yl]-3-t-yca~l~onylamirlo-3-me~ylbllt~n~mide (F.~mrle 2, Step B) arld ~' : : :~ glyc~e: t-butyl ester hydrochloride by the procedure described in Examp}e 16~ Step A.

:. WO~4~05634 21~270~ PCI/U593/~7791 ~tep B: N-[1-[[2'-[[(Carboxymethylamirlo)carbo~yI~arnino~l,1'-biphenyl]-4-yl]methyl~-2,3 ,4,5-tetrahydro-2-oxo-lH- 1-benz~~epin-3(~.)-yl]-3-amiD.o-3-methylbllt~n~mide~ ' trifluoroace~ate" andN-[1-[[2'-~[~Methoxycarbonyl-methylamino)calbonylJamino]~l,1'-biphenyl]-4~yl]methyl]-~: 2,3,4,5-tetrahydro-2-oxo-lH-1-~erlzazepin-3(R)-yl~-3 amino-3-methylbut~nnide~ tri~luoroacetate : ~: A solution of the clude il~te.~ ediate obtained in Step A in 4 : ~ mlL of methylene chlo~ide was treated with 2 mL of ~rifIuoroacetic acid.
After s~ ing~at room temperablre ~or 1 hollr, the reaction mixhlre was evaporated under vacuum and ~e ~sidue p~nfied by r~verse phase medium pressure liquid chromatography on~ C8, eluting~ with ~: meth~nol~0.1~ aqueous $rifluoroacetic acid (55:45). The early ractiorls containin~ the product were combined, solvents remoYed under vacuum and the residue was lyophilized ~rorn water to give 60 : mg:of ~e title compo~d as a white solid. FAB~MS: calculated for C31H3sNsOs 557: fouxld 558 (M+H) lH NMR (400 MHz, CD30D:) s, ~), 1.3~ (s, 3~ .15 (m, 1~ 234 (m lH}~ 2~52 ~d~ 2H~
2.68 (m. 2H), 3 84 (s, 2H), 4 42 (s, 1H), 5 05 (d, 1H), 5.~0 (d, 1H), 7.25 ~m, l lH). 7.64 (d. lH).
Later fractions were combined, solvents removed under vacuum and the residue lyophilized ~r~m water to give 18 mg o~ N-[ 1-2'-~(me~ld~yr,ar~onylmethylamin~)car~onyl]~ o~ biphenyl] 4-. ~ 25 yl]methyl~-2,3,4,5-tet~ahydro-2-oxo-lH-1-ben~a~epin-3(~)~yl~-3-amino-3-m~yll",~ n~ide, trifluoroacetate. PAB-MS: calcuIated for C32~37NsOs 571;: folmd 594 (M+Na). lH NMl~ (400 M~Iz, (:D30D):
1.34 (s, 3H), 1.39 (s, 3H3, 2.15 (m, lH[)t ~.35 (m, lH~, 2.52 ~dd, 2H), 2.66 (m, 2H), 2.71 (s, 3H~, 2.87 (s, ~H), 4.47. (dd, l~ .05 ~d, lH), 30 5.22 (d, lH), 7.~8 (m7 1 lH), 7.61 (d, lH).

~: ~
.
' :

, ~

WO 94/05634 23 ~ ~ n ~ PCI/US93/07791 .

N- [ 1 - ~ [2'- ~ ~ (Methoxycarbonylmethylam~no)carbonyl] arnLno] [ 1 ,1 ' -biphenyl3~-yl]me~yl]-2,3,4,5-tetrahydro-2-oxo-1H-1-benzazepirl-3(R)-vl1-3-amino-3-methylbut~n~mide. trifluoroacetate ~' l~e title compound was prepared from N-[1-~[2'-[(t-buto~carbonylme~yl~mino)carbonyl]amino][l ,l '-biphenyl]-4-yl~me~yl~-2.3,4,$-tetrahydro-2-oxo-1H-1-b~n~7ep~ 3(R)-yl~-3-t bucoxycarbonylan~no-3-me~ylbllt~n~mide by the prQ~edure described in Example 22, Step B. FAB-MS: calculated ~or (:32~37N505 571;
found 59~ (MTN~ H NMR (400 MHz, CD30D): ~1.3~ (s, 3H), 1.39 ~s, 3~I~, 2.15 (m, lH)~ 2.35 (m, lH), 2.52 (dd, 2~I), 2.66 (m, 2H), :;
2.7i (s, 3H), 2.87 (s, 2H), 4.42 (dd, lH), 5.05 (d, 1H), 5.22 (d, lH), 7.28 (m, 11H), 7.61 (d, lH).

EXAMP~E 24 , . .
N~ [2'-[(BeILzylax~L1nocarbo~yl~mino]~ birhPny1]~yl~t~y1~-2s3,4,5-tetrahydro-~-oxo-lH~ n7.~7epin-3(~)-yl]-3-am~o-3-methylbutanamide~ trifllloroacetate he: title compound was prepared ~rom ~-[1-[E(2 -isocya~ato)[l,1'-biphenyl]~-yl]methyl~-2,3,4,5-tetrahydro-2-oxo-1H 1-n~7epin-3(R)-yl]-3-t-butoxycarbonylamino-3-Dle::hylbllt~n~mide and benzyl amine ~y ~e procedures desc~d in F~m~le :6. lH NM~
~1 25 (400~,CD30D~; ~ 134 (s,3H), 1.37 (s,3Hj, 2.13 (m,lH)~ 233 (m,lH), 2.45-2.7û ~m,~H), 4.28 (s,2H), 4.42 (dd,lH), 5.00 (d,lH), 5.25 (d,lH), 701-7.4 (m,I6H), 7.62 (d,1H). FAB-MS: calculated for ~36H39N503, 5~9; found 590 (M+H).

' EXAMPLE 25 N-[1-[~2'-[(Phenylaminocarbonyl)~ino][1,1'-biphenyl]4-yl3methyl]-2,3,4,5-tetrahydro-2-oxo-lH-1-ben~azepin-3(R)-yl]-3-amino-3-methylbu~anamide. trifluoroacetate wo 94/05634 2 1 ~ 2 7 0 J Pcr/us93/077gl The title compound was prepared from N-[1-[~(2'-isocyanato)[ 1,1 '-biphenyl] -4-yl]methyl]-2,3 ,4,5-tetrahydro-2-oxo- lH- 1 -b~n~7epin-3(R)-yl]-3-t-~utoxycarbonyl~mino-3-me~ylbllt~n~mide and ~nilin~ by the procedures described in ~;xample 6. FAB-MS: calculated for C35H37N503, 578; found ~98 (M~Na). lH NM~ (400MHz, CD30D): ~1.32 ~s73~I), I.35 (s~3H), 2.11 (m,lH), 2.30 (m,lH), 2.52 ~m,2~I), 2.65 (m,lH), 4.40 (dd,lH), 5.03 (d,lH), 5.21 (d,1~I), 6.99 (m~I). 7.1S~7.45 ~9H)~ 7.74 (d~lH).
l~XAMPIJE 26 N-[1-[[2'-[~ydroxy~ocarbonyl)amino][l,l'-biphenyll 4-yI3methyl~-2,3,4,5-tetrahydro-2-oxo-lH-l -ben7.~7epLn-3(R)-yl]-3-am~o-3-methYlbu~anam;de. trifluoroacetate The title compou~d was prepared ~rom N-[1-[[(2'-iso-~: ~y~ato)[l,l'-biphenyl]4-yl~me~yl~-2,3,4,5-tetrahydro~2-oxo-lH-l-ben7~7epin-3(R )-yl] -3-t-butoxycarboIlylamino-3~methylbllt~n~ 1e and rim~Jhylsilyl~hyd.ro2tyl~mine by ~e procedures described i~
Exam~le 6~ FAB-~IS: calculated for C~gH33NsO~ 515: fo~d S38 (M~Na)~ lH NMR (400 MHz, CD3C)D): ~1.26 (s, l~I), 1.28 (s, 3H), 2.11 :(m, lH), 2.3~ (m, lH), 2.52 ~dd, 2H), 2 60 (m, 2H), 4.40 (dd, lH), 5.û (d, lH), 5.24 (d, lH), 7.25 (m, 1 lH)~ 8.0 (d, lH).
.
2s ~ EXA~vlPLE 27 N-[1 -[[2'-[~[(Methylaminocal~ollyl)amino]phenoxy][ l ~ l '-biphenyl~-~-yl]me~yl]-2,3~4,5-tetrahydro-2-oxo-lH-1 benzazepin-3(R)-yl]-3-amino-3-methvlbutanamide, trifluoroacetate . ~ .
Step A: 4-Meth~I-2'-(4-nitropheno~v~-1,1'-biphenvl . : A solution of 184mg ~l.Ommol) of 4-methyl-2'-hydroxy-l,l'-biphenyl (Exarnple 12, Step C) in 3mL of dime~ylfolmamide was treated with S5mg of 60% sodium hydri~e (33mg NaH, 1.4mmol). The reaction mixture was stirred at room temperature for 30 minutes then , ~
,........................... ~
''''~

( U
WO 9~/0563'1 P~/US93/077~1 t~

. .
., 13~
treated with 169mg (1.19mmol) of 1-fluoro-4-nitrobenzene. lhe reaction lnî~r~ was heated at 100~C for 2 hours. The reaction e was cooled, poured into 50mL o~;water and the resultant mixture was e~tracted wi~ e~yl ether. The combined e~tracts were washed with water, dried over magllesium sulfate. filtered and evaporated under vacuum. The residue was chromatographed on silica, ~eluting with hexanelethyl ~cet~te (10:1) to give 271mg (0.89m:mol,88%) ~of the product. F~B-MS: calcula~ed for C1gHlsNO~ 305: ~und 306 (M+H). 1H NMR (200MHz,CDC13): ~ 2.28 (s,3H), 6.82 (d,2H), 7.19 (d,3H), 7.2-7.5 ~m,5H), 8.05 (d,2H).

Step B: 4-Bromomethyl-2'-(4~nitrophenoxv)-1.1'-biphenYI
Prepared from 4-methyl-2'-(4-nitro-phenoxy)-1 biphenyl by the procedure described ~ Example 1, Step K. IH N~
(200MHz,CDCI3): ~ 4.43 (s,2H), 6.83 ~d,8Hz,2H), 7.09 (d,8Hz,1H), 7.3-7.5 :(m,7H), 8.0~ (d,8Hz,2H).

~S~2,pC N-E~ 2~ O~Cy)[~ } A y~ J_ ~: ~ 2.0 2,3,4,5-te~ahydro-2-oxo-lH-ber~a~epin-3(R)-yl~amino]-3 -t-butoxvcarbonvlamino 3-methvlbut~n~mide Prepared ~rom 4-bromomethyl~2'-(4-nitrophenoxy)-1,1'-biphenyl and 3-t-buto~ycarbonylamino-3-me~yl-N-[~,3,4,5-tetrahydro-:2-oxo-lH-l-ben~7epin-3~R)-yl]-bllt~n~mide ~xample 1, Step I) ~y ~e 2s procedure descl~bed in:Example l, Step Q. lH NMR (200~~Hz,CDCl3):
1.32 (s,6H), 1.38~(s,9~I), 1.78 (m,1Hj, 2.3-2.7 (m,SH), 4.47 ~rn,1~), 4.75 ~d~15Hz,1H), 5 13 (d,15Hz,1H), 6.63 (d,7~Iz,1H), 6.75 (d,8Hz,2H), 7.05-7.50 (m,l I~I), 7.97 (s,lH), 7.98 (d,8Hz,2H~.

~; 30 Step D: N-[1-~[2'-(4-Aminophenoxy)[l,l'-biphenyl]4-yl]methyl]-2,3,4,5-tetrahydro-2-oxo-lH-b~r~7.~7epin-3(R)-yl]~nino]-3-t-bu~oxycarbonylamino-3 -methvlbutanamide A solution of 282mg (0.415mmol) of ~he in~e~ ediate obtained ~ S~ep C in 30mL of medlanol was hydrogenated at 40psi in the presence of 5% palladium on carbon. After uptake o~ hydrogen was '; .
--~ WO 94/05634 21 4 2 7 0 I PCr/US93/07791 complete, the mi~ture was filtered through Celite and the ISltrate was evaporated under vacuum to yield 264mg of product.

Step E: N-[1-~2'-[4-[(MethylaII~inocarbonyl)amirlo]phenoxy~-~1,1'-biphe~yl]4-yl~methyl]-2~3,4,5-tetrahydro-2-oxo-1H~1-be.n~epin-3(R~-yl~-3-t-butoxycarborlylamino-3-methylbutan~m;de ~ sol~o~ o~ 26Am_ (û.40mmol~ of the in~.rmefli~te obtained in Step D in 5mL of methylene chloride under a nitrogen atmosphere was treated with O.9~nL (1Smunol) of methyl isoeyaIIate.
The reac~ion mi~cure was s~ilTed at room temperature for 18 hours, then all vola~iles were removed unLder vacuum ~d the residue purified by chromatography on silica gel, elut~ng ~th ethyl acetate~exane (3:1) to give 287mg (0.4~ol,100%) of product. lH ~ (400MHz, (:D30D)~ 4 (s,3H), 1.31 ~s,6H), 1.39 (s~9H),2.00 (m,lH), 2.30 (m,1H), 2.42 (m,3~I), 2.50 (dd,lH), 2.73 (s,3H), 4.32 (dd,lH), 4.82 ~; (d,lH)~ 5.24 (d,lH), 6.70 (m,2H), 6.95 (d,lH), 7.2 (m,13H).

St~p F: N-[1-~[2'-E4-[(~ethylaminoca~bonyl)amino]phenoxy]
[1,1'-biphenyl]-4-yl]methyl]-2,3,4,5-tetrahydro-2-oxo-lH-l-benzazepiI1~3(R)-yl]-3-am~o-3-methylbl-t~n~mide~
. trifluoroacetate ~: A solution of 287mg (O.~Ornmo}) of the intermediate obtained in S~ep E in 3mL of methylene chlonde was treated with 2 1.5mL of ~Fifluoroacetic acid. The reac~ioIl mixture was sarred at room tempera~re ~or 1 hour ~en evaporated uIlder Yacuum and ~e residue purified by reverse phase medium pressure liquid chromatography on C8, elu~ing with methanol/0.1% aqueous trifluoro-ace~ic acid (50:50). Fractions conS~ining the product were combined, 3 solv~s r~noved under vacuum and ~e resi~e lyophilized from water to give 165mg (0.23mmol,57%) of the title compound as a white solid.
'~ FAB-MS: calculatedforC36H3gNsO4605; found628(M~Na). ~H
NMR (400~Hz,CD30D): ~1.33 (s,3H), 1.36 (s,3H), 2.06 (m,1H), 2.26 ' ~ ~ L~ ~ ~ V 1~
WO 94/05634i PCI'/US93/0779 (m,lH), 2.48 (m,4H~ 2.74 (s,3H), 4.36 (dd,1H), 4.8 (d,lH), 5.17 (d,lH). ..
.
P~XAMPLE 28 ~: N-[l [~2'-[2-[~Me~ylamirlocarbonyl)~m1no]phenoxy][1,1'-biphenyl~-:~ yl]methyl]-2,3,4,5-tetrahydro-2-oxo-lH-l-benzazepiIl-3(R)-yl]-3-amino-3-me~hvlbutanamide tr~ oroacetate " :
o 4-Methyl-2'-(2-nitrophenoxy)-1.1'-biphenyl l?repared from 4-methyl-2'-hydroxy-1,1'-biphenyl (Examiple 12, Step C) and l-fluoro-2-nitrobenzene by the procedure : described in Example 27, Step A. lH NMR (200MHz,CDCl3): ~ 2.30 (s,3H), 6.74 (dd;2,8Hz;lH), 6.9-7.5 (m,lOH), 7.8~ (dd;2,8Hz;lH).
:
Step B: 4-Bromornethyl-2'-(2-nitrophenoxv)-1 l '-biphenyl Prepa~ed from 4-methyl-2'-(2-I~itrophenoxy)-l,l'-biphenyl by t~e pr~ described m Example 1, Step K. 1~ NM:R
(400~Hz,CD30D): ~ 4.52 (s,2~), 7.4 (m,11H), 7.86 (d,1H).
:
Step C: .N-[1-~2'-(2-Nitrophenoxy)[1,1'-biphenyl~-4-yl]methyl]-~: 2,3,4,$-tetrahydro-2-oxo-lH-ben~a~epin-3(R)-yl~amLno]-3 t-butoxycarbonylamino-3-methylbllt~n~m1d~, Prepared ~rom 4-bromomethyl-2'-(2-nitrophenoxy)-1,1'-biphenyl and 3-t-butoxyca~lJollyla~mo-3-me~y}-N-[2,3, ',5-tetrahydro-2-oxo-lH~l-benzazepin-3(R)-yl]-bllt~n~mide (Example 1, Step I) by the procedure des:cribed in Example 19 Step Q. lH NMR (200MHz,CDCl3~:
~ 1 32 (s,6H), 1.38~(s,9H), 1.78 (m,lH), 2.3-2.7 (m,SH),. 4.47 (m,lH), ': ~ 30 4.75 ~d,lSHz,lH), 5.13 (d,lSHz,lH), 6.63 ~d,7Hz,l~I), 6.75 ~d,8Hz,2H), . ~ 7.05-7.~0 (mJl lH), 7.97 (s,lH), 7.98 ~d,8Hz,2H).
..:
~' Step 0: ~-[1~[~2'-(2-Amirlophenoxy)[1,1'-biphenylJ~-yl]methyl]-2,3,4,5-tetrahydro-2-oxo-lH-benzazepin-3(R)-yl~arnino~-3-.~ t-butoxycarbonylamino-3-methylbutanamide . " ~

;
.... .

., - ~ WO 9~/05~34 2 1 4 2 7 o r7 PCI/US93/07791 - 1~9- :
Prepared ~rom ~e illte~ ediate obtained in Step C by the procedure described in Example 27, Step D.
., Step E: N~ 2'-~2-~Me~ylami~oca~bonyl)~mino]phenoxy][l,l'-biphenyl]-4-yl~methyl]-2,3,4,5-tetrahydro-2-oxo-lH-I-~: . .be~7.~:7.~pin-3(R)~yI]-3-t-butoxycarbonylamino-3 -me~yl-: butanamide Prepared ~rom ~e i~tell11ediate obtained ~n Step D by the : ~ procedure descn~ed irl ~x~mI~Ie 27, ~tep E.
,.
~tep F: N-~ [2'-[2-~(Me~yl~minoca~ yl~mino~phenoxy][l,l'-biphenyl]~-yl3methyl~-2,3,4,5-tetra~ydro-2-oxo-lH-I- :
be~a~epi~-3(R)-yl] -3-am~no-3-me~ylbllt~n~mide~
: ~ : trifluoroacetate lS The title compound was prepared from the ~terrner1t:~te obtaL~ed in Step E by the procedure described i~ Example 27, Step F.
FA~-MS: calculatedforC36H3gNsO46aS; found6~8(M+Na). lH
400 M~,~. ,OD): ~ 1.38 (s, 3H), l ~42 (s~ 3H), 2.08 (m, lH), 20 2.38 ~m, 3H)9 2.54 (dd, 2H), 2.8 ~s, 3H), 4.39 (dd, lH), 4.85 (d, lH), 5.3 (d, lH)~ 6.51 (d, lH), ~.8 dt, lH), 6.84 (dt, lH), 7.00 ~dd, lH), 7.34 ~:~ (m, I2H), 8.94 (dd, IH).

- EXAMP~E 29 N~ 2'-~(Me~yl~min~a~ yl)a~mo~ bip~enyl]~-ylJmethyl]-2,3,4,5~-tetrahydro-2-o~o~l~l-l-ber~azepi~-3(R)-yl~-3-~2(R)-h~ydro~ropyllamino-3-methylbut~n~mide~. trifllloroacetate 30 Step A: N-[1-[~2'-[(Methylan~inocarbonyl)amiIlo][l,l'-biphenyl]-4-yl]methyl]-2,3,~,5-te~ahydro-2-oxo-lH-l-beIl~azepill-3(R)-yl]-3-~2(R)-benzylo~ypropyl~amino-3-rnethylb~ n~mide, trifluoroacetate To a solution of 250 mg (0.399~T~nol) of N-~1-[[2'-~(methy1~minocarbonyl)amino~E l ,~ '-biphenyl]~4-yl]methyl}-2~3,4,5-2142?V i WO 94t0~634 PCI /US93/0779 1 tetrahydro-2-oxo-lH-1-benzazepin-3~ yl]-3-amino-3-methyl-but~n~mide, tnfluoroacetate (Example 2) in 12 mL of methanol was added 1.35 g of powdered 4~ molecular sieves followed by 713 mg (4.34 mmol) of (i~)-2-benzyloxypropanal ~prepared from ethyl D-lactate according to the procedure of ~nessian and Kloss, Tetrahedron Lett., 2,~, 1261-1264 (1985).) in 2 mL of dry me~anol.
After adjusting the pH of ~e suspension to 5.5 with glacial acetic acid, the reaction r~ re was s~red at room tempera~re for 3 hours.
Dropwise, 2.5 mL of 1.0 M sodium cyanoborohydIide in tetrahydrofuran was added and the reaction mixture stirred at room tempeld~ for 18 holLrs. The reaction ~ Lulc~ was fïitered and the filtrate trea~ed wi~ 2.0 IIlL of trifl~oroacetic acid (CAUTION!
evolution of hydrogen cyanide). After stirrin,, for 10 minutes, all volatiles were removed under vacuum ~nd the residue chromato~raphed on silica gel, eluting wi~l methylene chloride/methanol/concentrated ammonium hydroxide (90:5:1) to yield 225 mg (0.339 mmol, 85%) of product. FAB-MS with Li: calculated for C40H47NsO4 661: found ;~ 668 (M+l,i)~ 662 (M+1). lH NMR (400 M~ ~D~OD?: ~ L19 (d~
3H), 1.19 (s, 3H), 1.21 (s, 3H), 2.0j f~m, lH), 2.3 (m, lH), 2.4 ~m. 2H).
2.20 (s~ 3H)~ 2.3 (m~ 2H), 3.64 (m, lH)~ 4.40 (dd, lH), 4.58 (s, lH), 4.62 (d, lH), 5.05 (d, lH), 5.14 (d, lH), 7~23 ~m, 16H), 7.66 (d, lH).

~tep B: N~ [[2'-~(Methyl~minocarbonyl)am~o~ biphe~yl]~-2s yl]me~yl]-2,3,4,5-tetrahydro-2-oxo l~I-1-benzazepin-3(R~-yl]-3-~2(R)-hydro~ypropyl]~o~3-methylbl~t~n~mide, trifluoroacetatc A solution of 225 mg (0.339 ~nol) of the intermediate obtairled in Step A in 5 mL of methanol con~ining 0.2 mL of trifluoroacedc acid was hydrogenated at arnbien$ temperature and 40 psi ~or 2¢ hours over 500 mg of 30% palladium on car~on. The reac~ion .,e was filtered through Celite and the filtrate was evaporated lmder vacuum and the residue purified by reverse phase medium pressure liquid chromatography on C8, elu~ing with methanol/0. 1%
aqueous trifluoroacetic acid (65:35). Fractions cont~inin~ the product r ~ WO 94/05634 2 1 4 2 7 0 7 PCI/US93/07791 ~ 141 ~
were combined, solvents removed under vacuum and ~e residue lyophilized from water to give 160 mg (0.23 mmol, 69%) of ~e title compound as a white solid. FAB-MS: calculated ~or C33Hq lNsO4 571: found S72 (M~H). 1H NMR (400 MHz, CDCl3): ~ 1.20 (d, 1H~, 1.36 (s~ 3H), 137 (s, 3H), 2.15 (~m, lH), 234 (m. lH~. 2.34 (nn. lH)?
2.62 (dd~ 2H), 2.63 (s,~3H), ~.68 (m, 2H), 2.80 (dd, lH), 3.09 (dd, lH), 3.90 (m, lH), 4.40 (dd, lH), S.08 (d, lH), 5.16 (d, 1~, 7.22 (m, 1 lH), 7.6'~ (d, 1H).

: EXAhIPLE 30 N~ 2'-[(~orpholinocarbonyl)amino]~1,1' biphenyl]-4-yl]me~yl]-~ ~ 2,3,4,5-tetrahydro-2-oxo-lH-l-be~azepin-3(R)-yl]-3-~2(R)-hydroxy-;~ 15 propyllamino-3-methylbutanaTnide, trifluoroacetate Prepared f~om N-[1-[[2'-[(mo~pholinocarbonyl)-amino] [ 1,1 '-biphenyl]-4-yl~me~hyl~ -2,3 ,4,5-tetrahydro-2-oxo- lH- 1-ben~azepin-3(R~-yl~-3-amiIlo-3-rne~ylbllt~n~mide. ~ifluoroacetate x~m~ nd ~R~2~yloxyp~ y~e procedure descIi~ed O inEx~nple29. FAB-MS: calcu1atedforC36H4~NsO~627: found 650 (M+Na). 1H NMR (400 MHz~CDCl3) ~ 1.20 (d,3H), 1.36 (s,3H), 1.39 (s,3H), 2.14 (m,lH), 2.34 (m,lH), 2.62 (dd,2H), 2.66 (m,2H, 2.7 (dd,lH), 3.09 (dd,lH), 3.25 (m,4H), 3.63 (m,4H), 3.83 (m,lH), 4.39 (mtlH), s.oj (d~lH), 5.20 (d,lH), 7.29 (m~12H).
2s N~ [[2'-[[(2-Hydroxye~ylamino)carborlyl3aII~ino][1,1'-biphenyl}-~-yl~methyl~-2,3,4,5-tetrahydro-2-oxo-1H-1-be.n~epin-3(R)-yl]-3-[2(R)-; ~ 30 hvdroxypropYllamino-3-methylbut~n~mide~ trifluoroacetatePrepared from N-[1-[[2'-~[(2-hydroxyethylamino)-carbonyl]amino][1,l'-biphenyl]4-yl]me~yl]-2~3,4,5-tetrahydro-2-oxo-lH-l-benzazepin-3(R)-yl]-3-~o-3-methylb~ n~mide, trifluoroacetate (Example 8) and (R)-2-benzyloxypropanal by the procedure described in Example 29. FAB-MS: ca}culated for 21~270 1 WO 94/~5634 PCIIUS93/07791.

C34H43NsOs 601: ~und 602 (M~H). lH NM~ (400 MHz,CD30D): -~ 1.20 (d,3H), 1.36 (s,3H), 1.38 (s,3H), 2.18 (m,lH), 2 35 (m,1H), 2.62 (dd,2H), 2.68 (m,2H), 2.78 (dd,lH), 3.09 (dd~lH), 3.2 (t,2H), 3.52 (t,2H), 3.93 (m,lH), 4.40 (dd,lH), 5.12 (d,lH), 5.18 (d,lH), 7~28 (m,l1~), 7.65 (d,lH).

N-[1-[[2' [(Methylaminocarbonyl)amino][1,1 '-biphenyl]-4-yl]methyl]-2,3,4,~-tetra~ydro-2-oxo-1H-1-benzazepin-3(R)-yl} 3-~2(S),3-dihydrox~propyllamino-3-methvlbutanamide~ trifluoroacetate To a sdrred solution of 368mg (0.716mmol) of N-[1-[[2'-~(me~yl~minocarbonyl)amino][1,1'-biphenyl~-yl]methyl3-2,3,4,5-tetrahydro-2-o~o-1H-1-benzazepin-3(R)-yl3-3-amino-3-metbyl-bllt~n~rnide, trifluoroacetate (Exarnple X) in 12mL of dry methanolunder nitrogen was added 1.35 g of powdered 4A molecular sieves followed by a soludon o~ 0.4 ~ of D-glyceraldehyde ace~onide (used ~de as ~ d according ~o the procedure o~ l,.W. ~erte~, C.S.
Grossman and J.S. Kroin~ 5ynth. Comm., ~" 151-154 (1991).) in 1mL
of dry me~hanol. The pH of the mixt~e was carefillly adjust d to 5.5 with glacial acetic acid and triethylamine. The reaction was stirred at rovm tempera~re for 2 hours at which ~ne 3.0 m~ of a 1.~ M solution of sodium eyarloborohydride in tetra~ydrofurall was added dropwise by syr~nge. The reaction mixture was stirred at room temperature for 18 hours, then filtered ~d the filtrate treated wi~h 9 mL of ~lifluoroacetic acid ~d 9 mL of water. Af~er 1 hour, the reaction mi~ture was evaporated under vacuum and the residue purified by reverse phase medium pressure liquid chromatography on C8, eluting with me~aIlol/0.1% aqueous ~rifluoroacetic acid (60:40). Fractions c~llt~ the product were combined, solvents removed under vacuum and the residue lyophilized f~om water to give 167 mg of the title compound as a white solid. FAB-MS: calculated for C33H41NsOs 587: found 589. ~ 1H NMR (400 MHz, CD3OD): ~ 1.37 (s,3H), 1.39 (s,3H), 2.15 (m,lH), 2.35 (rn,lH), 2.55-2.75 (m,4H), 2.64 (s,3H)~ 2.95 - WO94/05634 214 2 7 0 J PCr/US93/07791 (dd,lH), 3.18 (dd,lH), 3.54 (m,2H), 3.83 (m,lH), 4.42 (dd,lH), ~.08 (d,lH), 5.16 (d,lH), 7.1-7.4 (m,llH), 7.61 (d,lH).

~-[1-[[2'-[(~ninocarborlyl)amino~[l ,1'-biphenyl]~-yl]methyl~-2,3,4,5-tetrahydro-~-oxo-lH-l -benzazepin-3(R)-yl]-3-[2(S),3-dihydroxy-~; prop~l7amino-3-metny~u~a~amide. ~ifluoroacer~l~
The title compound was prepared fr~m ~-~1-[~2'-[(amino-carbonyl)arT~ino] [ 1,1 '-biphenyl~-4-yl]methylJ~2,3 ,4,~-tetrahydro-2-oxo-lH-l-be~azepin-3(R~-yl] 3-amino-3-methylbllt~n~mide, trifluoro-ace~ate (Example 5) and D-glyceraldehyde acetonide according to the ;~ ~ pro~edure desGIibed in Exarnple 32. ~AB-MS: calculated for C32H41NsO4 559: ~ound 561. 1H NMR. (400 MH~, CD3OD): ~ 1.36 ; (s? :lH3, 1.38 (s, 3H), 2.15 (m, lH), 2.34 ~m, lH), 2.62 (dd, 2H)~ 2.68(m, 2H), 2.95 (dd, lH), 3.18 (dd, lH), 3.52 (m, 2H), 3.82 (m, lH), 4.40 :: (dd, lH), 5.05 (d, lH), 5.06 (d, lH), 7.25 (m, 1 lH), 7.60 (d, 1~1).

; ~ 2a EXAMPLE 34 N-[1-[~2'-~[~2-Hydroxye~yl~mino)carbonyl]aIx~ino][l,1'-biphenyl]-4-yl]methyl]-2,3,4,5-tet~ahydro-2-oxo-lH-1-ben~azepin-3(R)-yl]-3-r'~fS)3-dih~drox~ropYllamino-3-me~vlbut~n~mide. trifllloroace~ate ~; 25 ~ The ~tle compound was prepared from N-[1-~2'-[~(2-hydroxye~yl~mino~cdrbonyl]amino}~ 1,1 '-biphenyl]~-yl]me~hyl]-2,3,4,$-tetrahydro-2-oxo-1H-l-benzazepin-3(R)-yl]-3-amino~-methyl-but~n~mi~e, trifluoroacetate (Example 8) and D-glyceraldehyde acetonide according ~o the procedu~e described in Example 32.
~'~ 30 ~: 2-Amino-2-methyl-_-[2,3,4,5-te~rahydro-1-[[2~-[~[(methylamino)-carbonyl]ami~o]methyl][1~ bipheIlyl] 1-yl~methyl]-2-oxo-lH-'.: benzazepin-3~R)-yllpropanamide~ hydrochlolide ,. .

21~2707 WO 94105634 PCr/US93tO7791 o~ .
, , . ,' ! ' Step A: 2-Benzyloxycar~onyl~mino-2-methyl-N-[2,3,4,5-tetra-h~dro-2-oxo-1 H-benzazepin-3(R)-vllpropanamide s Prepared from .N-carboben~yloxy-2-methyl~l~nine ~d 3(R)-ammo-2,3,4,5-~ahydro 1~ epin-2-onv (Exampl~ 1, Step E) subsl;~ benzotMazol-1-yloxytripy~rolidinophasphonium h~fluorophosphate ~r benzotriazol-1-yloxyt~is(dimethylamino)-pnospLIo~ he~o~oph~sphale ac~ording ~o rh~ pr~ adl~e descnbed in Example 1, Step I. IH ~IMR (200 MHz, CDCl3): ~ 1.47 (s, 3H), 1.52 (s, 3~1), 1.82 (m~ lH)~ 2~0-3.00 (m, 3H), 4.4~ (m, lH), 5.05 (s, 2H), 5.37 (s, lH), 6.80-7.40 (m, lOH), 8.65 ~s, 1H). FAB-MS:
calculated ~or C22H2sN3O4 395; found 396 (M~I~100%)-.
Step B: 4-Bromobenzvl-t-butvldiphenvlsilvl ether To a solution of 28.2 g (0.150 mol) of 4-bromvben~yl-alcohol in 470 mL of dry dime~ylfolmamide under nitrogen atmosphe~e was added 31.4 rnL (Q.225 mol) of trie~y}~mTr ~
reaction ~ Lure was sooled to 0~C and:43 mL (0.17 mol~ of t-butyl-chlorodiphenylsilane was added dropwise by addition ~el. The reac~on ~ Lul~ was s~ed a~ a~bient tempera~ure ovemight then pou~ed:into a s~paratory ~nnel Con~inin~ lL of diethyl ether and 500 mL of water. To~is mlxture was added 125 mL of 2N aqueous hy:drochloric acid. T~e l~yers were separated and the aqueous layer was extracted wi~ diethyl e~er (2 x 350 mL). l~e orgaI~ic e~tracts were combined, wash d with water (2 x 250 mL) and dri~d over magIlesium sul~ate. The solids were removed by filtration and the solvent removed under vacullrn to gi~e an oil which crystallized on standing The flask or~ e crude product was placed in the free~r ove~ight then tritura~ed with a minim~l amount of me~aIlol and filtered. The solid was a* dried~for several hours then dr~ed under vaccuum overnight to afford: 59.5 g ~93%) of produ~t as an off-white solid (mp 44-47~C). lH
NMR (200 2~Z? CDC13): ~ 1.15 (s, 9H?, 4.76 (s, 2H), 7.25 ~d, 8Hz, 2H), 7.45 (m, 8H), 7.75 (m, 4H). FAB-MS: calculated for C23H2sBr~si 424; found 425 (M+H, 7%).

:
.
, ., , . ., , . ., . ., ~ ,, . ....... ,.. .... . .. ,.. . ~

w0 s4/0s634 21~ 2 7 0 ~ Pcr/uss3/077s1 Step C: ~-(t-Butyldiphenylsiloxymethvl)phenvlboronic acid To a solu~ion o:f 20 g (47 mmol) of 4-bromoben~yl-t~
butyldiphenyl silyl ether (Step 13) in 200 mL of dry tetrahydrofuran ~md~r a ~ogen a~nosph~ at -78~C was added ~llu~uwise by s~rlnge 19.74 mL (49.35 mmol) of a 2.5M solution of n-butyl lithium in hexaIles over twenty min~ltes~ The resulting mixture was stirred for ~hi~ min~lr~s~ t:hen 11.6 ~ (30.3 rnmolj or l:riisoprop~1 DOlalQ W~IS
added by syr~nge. The reaction mixcure was st~rred at -78~C ~or thirty mirlutes ~e~ slowly w~ed to room temperature and stirred for an additioIlal two hours. The reaction ~ was the~ quenched by t~e addition of 750 ~ of water c~nt~ining 100 mL of concentrated hydrochloric acid ar~d 500 mL of diethyl e~er~ The mî~ture was strirred for one hour and then :the organic layer was separated. The aqueous layer was ex~acted with diethyl ether (2 x 400 mL). The cornlbined ether extracts were washed with saturated aqueous sodium chlorid~ (4 ~ 100 ~), dried over m~nesium sulfa~e ~nd ~iltered. The solvent was removed uIl~er vacuum ~o g~ve ~ o;l which was c~st~lli7ed by dissolving in hexanes and evapora~ion of the solvent der vacuum to affor~ 15.6 g (8$%) of product as a white solid (mp 171-174~(~ H NMR ~200 ~, CDCl3): ~ 1.11 (s, 9H~, 4.86 (S9 2H), 7.40 (m, 6H)? 7.58 (d, 8Hz, 2H3, 7.7û (m, 4H), 8.22 (d, 8Hz, 2H~.
~FAB-MS: calcula~d for C23H27BrO3~i 390; found 37~ lEI2O).

St~p D: N-(t-Butox~carbonyl~-2-bromoben~vlarnine To a slurry of 8.88 g (39.9 mmol) of 2~bromobenzyl~nine hydroGhloride in 100 mL of dry methylene ;chloride Imder a nitrogen atmosphere was added by syIinge 12.24 mL (87.80 mmol) of triethyl-arnine. The resulting: solution was stirred at 0 C for five minutes then treated with 9.6 g (44 mmol) of di-t-butyldicarbonate. The reaction was stirred at room tempera~ure for two hours then diluted with 35~
mL of me~ylene chlonde. The solu~ion was washed wi~ water (2 x 15~ mL), saturated aqueous ammonium chloride (150 mL), saturated aqueous sodium biearbonate (4 x 15~nL) arld saturated aqueous sodium '! ' 21~2~0 1 W~ 94~05634 P(:~/US93/~7791 ~

chloride (150 mL), dried over sod;um sulfate and filtered. The solvent was removed under vacuum to give an oil whic~. was crystallized by dissolving in hot he~anes, ~iltering and cooling the solu~ion. The product was fil~ered and dried under ~ac~ m to a~ford 8.66 g (90~) of ~e product as a w;;n:te solid (mp 51-~3~C). ' lH ~ 200 i~Iz, CDCl3): ~ 1.41 (s, 9H), 4.37 (d, SH~, 2H), 5.00 (s~ lH), 7.10 (m, lH), 7.25 (m, lH), 7.35 (m, 1H), 7.40 (d, 6Hz, 1H). PAB-MS: calculated for C12H~ 3r~(~2 ~; fo~md 286 (~I~H)~

Step E: 2'-~(t-Butoxycarbonylam~no)methyl]-4-~(t-butyldiphenyl-siloxvknethyll- l .1 '-biphenyl To a solution of ~.2 g (8.2 ~nol) of 4-(t-butyldiphenyl-silyoxymethyl)phenylboronic aeid (Step C) Ln 64 mL of ~enzeIle was added 2.2 mL ~f water, 6.4 mL of 5N aqueous sodium hydroxide, and 8.3 mL of isopropanol. TQ thiS mi~ture was added 180 mg (0.16 mmol) of tetrakis(triphenylphosphine) palladium and 2.20 g (7.81 .mmol) of ~t-~utoxycar'oo~1)-~-bromobe~yl~mine (Step D). The resul~ing mL~ture was heated under nitroge~ at reflux for 2 hours then cooled to room temperature. The reaction mixture was diluted with 100 mL of water, transfeITed to a sepa~at~ly fu~ el a~d e~tracted with ether (3 x 150 mL). T~e combined ether extracts were washed wi~
sa~rated aqueous sodium bicarbonate (100 mL ) and saturated aqueous sodium chloride ~100 mL), dried over m~nesiuIn sulfat~ and fil~red.
The solvent was removed under vacuu}n to give a crude product which was purified by column chromatography on silica gel eluting with he~nesle~yl acetate (9:1) to af~ord 4.31 g (100%~ of the product as a ~lear oil. 1H; ~IR (200 MH~, Cl:)C13): ~ 1.11 (s, 9~), 1.41 (s, 9H), 4.2? (d, 6Hz, 2H), 4.45 (m, lH), 4.81 (s, 2H), 7.20-7.49 (m, 14H), 8.72 (m, 4H). FAB-MS: calculated for C35~I41N03Si 551; found 552 (~+H)-St~ F: 2'-[(t-Butoxyca~bonylamino)methyl]-1,1'-bipherlyl-4-methanol :

- WO 94/~5634 P~US93/û7791 214270~

- 1~7 -To a solution of 3.85 g (7.00 mmol) of 2'-[(t-butoxy-ca~bonylamino)me~yl] -4-[(t-butyldiphenylsiloxy)methyl] -1,1 '-biphenyl ~Step E) in 25 mL of dry tetrahydrofuran under a nitrogen atmosphere was added by sy~nge 10.5 mL (0.530 mmol) of a l.OM solution of tet~a-n-butylammonium fluoride iIl tetrahy~Lo~~ . rrh~ rea~on mixture was sti~red for two hours then diluted w~ 700 mL of diethyl eth~r. The mi~re was washed ~th water (3 x 150 mL), sacurated aa~olls so~ O mL), s~lT?ted a~olls soc~m chlonde (50 ~), then dned over m~nesiuIn sulfate and filtered. The solvent was rem~ed under vacuum to give an oil which was puri~ied by co~umn chromatography on silica gel elu~ing wi~ hexanes/ethyl acetate (55:45) to afford 2 02 g (92~b3 of the product as a white solid (mp 89-93~C). lH ~ ~2~0 MHz, CDCl3): ~ 1.40 (s, 9~I), 2.50 (s, 2H), 4.20 s~ 2~I), 4.70 (s, 2H),~7.18-7.45 (m, 8H). FAB-MS: calculated for Cl9H23N~3 313; folmd 314 (M~H).

St~p G: 2'-~t-13u~oxyca~onyl~ni~o)me~hyl~ biphenyl , ~;, ~ .
methanol. methanesulfonate ester To solution: of 53 mg (0.17 ~ol) of 2'-[(t-butoxy-ca~oonylamino)methyl]-l,l'-biphenyl~-me~anol (Step F,) in 1 mL of dry methylen~ chloride under nitrogen atmospheP at 0~C was added by syringe 0.035~mL (0.25 mmol) of triethyl~mine followed by 0.016 mI, (0.20mmol) of m~th~n~fonyl chloride. l~e reac~on mix~ure was stirred for 2:hours at 0~C ~en diluted with 75 mI, of methylelle chloride, washed wi~ water, saturated aqueous sodiurn bicarbonate, saturated aqueous sodium chloride, dned over sodium sulfate and filtered. The ~sblvent was removed under vacuum to give 61 mg (97%) of ~e product as a white solid which was used in ~e next step without fur~er purification. lH NMR (200 MHz, CDCl3)~ 38 (s, 9H), 2.95 (s, 3H), 4.20 (d, 5H[z, 2H~, 4.65 (s, lH)? 5.25 (S, 2H), 7.18-7.50 (m, 8H). FAB-MS: calculated for C2oH25N05S 391; found 392 (M~H).

: :

21~2707 wo 9~/05634 Pcr~US93/0779~.

Step H: 2-Benzyloxycarbonylamino-2-methyl-N-[2,3,4,5~tetra-hydro-2-o~o~1-[~2'-[(t-bu~oxycarbonylarr~ino)methyl]~
[1 ,1.'-biphenyl]~-yl]methyl]-lH-beIlzazepin-3(R)-yl]-propanamide To a soluti~n ~f 819 mg ~.07 mmol) o~ 2-~e~ylo~y-carbonyla~ino-2-methyl-N-[2,3,4,5-tetrahydro-2-oxo-lH-benzazepin-3(R)-yl]p~opanamide (Step A) in 7.0 mL of dry dimethyl~orm~mide m~r ~itro"~n a~ O~C~ was add~d ~ mg ~ 1 mmol~ OI ~CO sQdi~m hyd~deloil dispersion. After st~g for 15 m~nutes7 a sollltion o~ 810 mg (2.1 mmol) of 2'-[(t-bu$oxycarbonylamino)me~yl]-1,1'-biphenyl-4-me~anol, me~anesulfonate ester (Step F) ~ 2.0 mL of dimethyl-faml~mide was added by c~nm~ e flask which originally contained ~e me~h~nesul~ate ester was ~sed wi~ 1.0 mL of dimethyl-fo~ de which was added to ~he reac~ion mL~re. hfter stirr~ng at lS o C for 1~ minutes, the reae~ion mixture was diluted with 400 ml~ of ~: e~yl acetate and 50% saturated ammonium chloride. 'l'he mixture was sferred to a separator~ ~Dnel and ~he a~ueo~ layer was sep~ated.
The o~anic layer was washed wiul IOG m~ of sa~ ed a4ueous sodium bicarbonate and sa~rated aqueous sodium chlolide. The org~nic:layerwasd~edovermagnesiumsul~ate,fil~eredandthesolv~nt removed under vacuum. The residue was purified by flash chromatography on silica gel eluting with ethyl acetate/hexane ~55:45) to a~ord 1.2 g (84%) of ~e product as a white foam. 1H N~ ~200 ~Hz, (:DCl3): ~ 1.38 (s, 9H), 1.48 (s, 3~ 1.52 (s, 3H), 1.78 (s, lH), s 2.35-2.70 (m, 3H), 4.18 (d9 6Hz, 2H), 4.3804.62 (m? 2H), 4.82 (d, 16Hz, 1H~, 5.0~ (s, 2H), 5.25 (d, lbHz, lH), 5.32 (s, lH), 7.08 ~d, 6Hz, lH), ~:~ 7.12-7.43 (m, 18H). FAB-MS: calculated for C41H46N~06 690; found 691(M~H).

3 ~: 2-Benzyloxyc~rbonylamino~2-methyl-N-[2,3,4,5-tetra hydro-2-oxo~ 1 -[[2'-(aminomethyl)[ 1,1 '-biphenyl] 4~yl] -methyl]-lH-ben7~7epin-3(R)-yl]propanarnide, hydro-chloride ,- ' WO 94/05634 2 1 4 2 7 0, PCl/US93/07791 To a solution of 9.83 g (0.5~ mmol) of 2-benzyloxy-carbonyl~o-2-methyl-N-[2,3,4~5-tetrahydro-2-oxo-1 -[~2'-[(~-butoxy-carbonyhmino)me~yl][1,1'-biphenyl]-4-yl~me~yl]-lH-be~ epin-3(R)-yl]propanamide (Step H) in 170 mL of metharlol was added 120 S mL of 9NT a~queous hyd~ochl~c acid. Pe~iodica~I~ lO mL por~oIls o~
~; - me~anol were added to ~e reactioIl lnL.lur~ to dissolve precipitat~s which form during the reaction (50 mL total). The reaction mixture ~as s~ l ovemigm atroom ~mpera~ ~ soiven$ was ~emoved under vacuum. The resulting oil was dissolved in methanoI
and the solvent was removed under vacuum to a~ford 8.57 g (96%) of ~e title compourld as an of~-white foam. lH NMR (200 MHz, CD301~ 1.40 (s, 6~I), 1.90 (m, lH), 2.20-2.65 (m, 3H), 4.02 (s, : ~ ~ 2H), 4.32 ~m, lH), 4.96 (d, 16:Elz, lH), 5.00 (s, 2H~, 5.25(d, 16H2, lH), 7.08-7.65 (m, 17H). FAB-MS: calculated for C36H3gN4O4 590; ~ound S91(M~H, 1~0%).

~p J: 2-Ben~ylo.~yca~bQnyl~mino-2-methy~ 2?3~4~s-~tra ydro-~ 2'-~r~me~ylaII~ino)carbaIly'I7aminojme~yIJ~
biphenyl~ yl]me~yl]-2-oxo-lH-benzazepi~ 3(R)-yl]-~, propanamide To a solu~on of 8.57 g (13.7 mmol) of 2-benzyloxy-:; carbonylamino-2-me~hyl~N-[2,3,4,5-tetrahydro-2-oxo-1-[~2'-(~mino-methyl)[l,l'-biphenyl~-yl~melhyll-lH~ben7~7epiIl-3(R)-yl~-2s ~ arnide, hydrochlQride (S~ep 1) in 75 mL of dry methylene :~: chlorïde under nitrogen a~nosphere was added 2.28 mI, (16.4 mrnol) of ~: triethyl~mine foIIowed by 0.89 mL ~15 mmol) of me~yl isocyanate.
~ter stirring at room temperature for 45 ~iinutes ~e solveIlt was ~: removed under vacuum. The resulting material was dissolved in 3 0 me~ylelle chloride and purified by flash column chromatography on silica gel eluting with ethyl acetate/me~anol (96:4) to a~ford 7.73 g (87%) of product as a white foam. lH NMR (200 ~Iz, CD30D):
~ 1.39 (s, 6H), 1.82 (m9 lH), 2.15-2.60 (m, 3H), 2.63 (s, 3H), 4.13 ~s, 2H)~ 4.36 (m, IH), ~4.g6 (d, l5Hz, lH), 4.85 (s, 2~I), 5.32 (d, l~Hz, lH), .

21~2~07 WO 94/05634 PCr/U593/0779 1~--7.08-7.43 (m, 17H). FAB-MS: calculated ~or C3gH~1NsOs 647; found 648(M~H, 80%).

Step K: 2-Amino-2-methyl-N-~2,3,4,5-tet~ahydro-1-[[2'-[~(methyl-ino)carbonylJaIr~inojme~ylJ[1;1~-b1phenyIJ~-yi~mei~lyl~-2-oxo-lH-ber~azepin-3(R)-~llpropanamide hvdrochloride To a solution of 5.00 g (7.72 mmol) o~ 2-benzyloxy-carbonyl~mino-2-me~hyl-N-~2,3,4,5-te~ahy~ 7'~ (me~yl-amino)carbonyl~ o]methyl][l,l'-biphenyl]-4-yl]methyl]-2-oxo-lH-b~7~7epi~-3~R)-y~ u~ mi~e (Step 3) in 100 rrL of dry me~2nol was added a.so ~ (0.1 equiv. by weight) of p~ m hydroxide. The mi~;ture was stirred ur~der hydrogen atmosphere for 2 hours. T~e ule was ~ltered ~ough Celite. The filter pad was washed wi~h 50 mL of methanol.~ The xSltrate was combined alld the solvent was removedundervacuum. TheresultingoilwasdissolvedinSOmLof me~anol and treated wi~ 17 mL (8.S mmol) of a 0.499N aqueous hydroehlorl~ a~i~ so~ion. I~e solvent was remo~ed u:nde} vacm~:m to give a solid which w~s cryst~ e!l by refluxing in 480 mL of acetonitrile/ethanol (7:1). The mixture was cooled to room temperacure i gentle stimng. After 3 hours ~e solids were filtered and washed with: 80 ~ of ice cold acetor~itrile/ethanol (7:1) and ~en air dlied for 3 ~ours. The: resultiIlg :solid was dissolved in ~0 mL of water, filtered and lyophili7~ over~ight to afford 3.78 g ~89%) OI ~e ~tle comp~und asawhite:solid. lH:N~(400MH~,CD30D): ~1.55(s~3H),1.64(s, 3H), 2.28 (m, 2H), 2.62;(m, 2~I)9 2.67 (s, 3H), 4.16 (dd; 16, 14Hz; 2H), 4.39 (dd; 12, 8Hz; lH), 5.00 (d, lSHz, lH), 5.22 (d, 15Hz, 1H[), 7.14 (d, 7Hz, lH), 7.20-7.¢1 (m, llH). FAB-MS: caiculated for C30H3~NsO3 513; found Sl4 (M+H,: 10V%).
.
~ ' 30 -' WO g~/05~34 2 1 ~ 2 7 0 7 PCr/U~;~3~07791 - 151 - ' .,:

2-Amino-2-methyl-N-[2,3,4,5-te~rahydro-1-~2'-[[[((2-hydroxyethyl)-amino)carbonyl]~mino]me~yl] [ 1,1 ' -biphenyl]-4-yl]methyl]-2-oxo-lH-ben~azepin-3~R~-Yllprop~amide. mfluoroace~a~e Step A: 2-Benzyloxycarbonyl~mino-2-rne~yl-~[2,3,4,5-tetra-:~ hydr~2-o~o-1-r~2'-~inome~hyl)[1,1'-bipheIlyl3 ' ylJ-me~yl]-lH-be~7~7epin-3(R)-yl~propanamide, trifluoroacetate To a solutio~ of 380 mg (0.55 mmol) of 2-ber~ylo~y-car'bonyl~minQ-2-methyl-N-[2,3,4,5-tetrahydro-2-oxo- 1 -~[2'-[(t-butoxy-c~onylamino)me~yl]~l,1'-bipherlyl]-4-yl3rnethyl]-lH-ben7~7epin-3(R)-yl~prop~n~mide (Example 35, Step H) in 2 mL of dry methylene chloride was added S drops of anisole followed by 2 mL of trifluoroaeetic acid. The reaction mix~ure was stirred for 1.5 hours at :~ ~ room tempe~ature at which t~ne ~e solveIlt was remo~ed under vaeuum. The ~resul~ng oil was dissolved ~ S mL of carbon tetrachloride ar~d the solYent was removed under ~acuum. The process was repeated with 5 mL of chlorofonn followed by ~ mL o~ me~ylene chloride to give 427 mg (>100%) of the product cont~inin~ minor amolmt of anisole) as an o~f-white foam. lH NMR (200 MH~ CDCl3):
' ~ I.45 (s, 6H), 1.90 ~m, lH), 2.25~2.65 (m, 3H), ~.12 (s, 2H), 4.38 (m, z5 lEI), 4.85 (d, 16Hz, lH), 4.96 (s, 2H), 5.05 (d~ 16Hz, lH), S.55 (s, lH), 6.91 (m, lH), 7.05-7.60 (m, l9H). FAB-MS: calculated for C36H38N4~4 590; fotmd 591(M+H, 100%).

Step B: 2-Benzyloxycarbonyl~mino-2-methyl-N-[2,3,4,5-tetra-3 0 hydro~ 2' -~[((2-hydroxye~yl)amino)carbonyl]amino]-methyl~[1,1 '-biphenyl]-4-yl]met~ylJ-2-oxo-1H-bén7~epin-~ 3~R)-yllpropanamide !~ To a solution of 160 mg (0~23 mmol) of 2 ben~yloxy-; ~ carbonylamino-2-me~yl-N-~2,3,4,5-tetrahydro-2-oxo-1-[[2'-(amirlo methyl)[1,1'-biphenyl]4-yl]methyl]-lH~ azepin-3(R)-yl]-i ' :

,' j ~

prop~n~mi~e, tnfluoroacetate ~Step A) in 1 mL of dry me~hylene chlolide under Ilitrogen atrnosphere was added O.Q63 mL (0.45 mmol) of triethylamine ~ollowed by 0.039 m~ (0.25 mmol) of 2-isocyanato- ~ i 5 ethyl methacrylate. The reaction mixture was::stirred at room tempera~ure ~or 30 ~ es then ~e so~ent was removed under vacuum.
l'he residue was dissolved in 2 mL o~ tetrahydro-filran/water (3~ d to the resul~mg so~n was added 42 mg (1.0 mmol) of lithillm hydroxide monohydrate. After stirring at room tempera~ure ~or 3 hours ~he r~ac~on mLx~re was dilu~ed wi~h 100 mL
of e~yl acetate and washed with 50 mL of brine. The organic layer was dried over magnesium sulfate, ~lltered and the solvent removed mder va~ to afford I49 nng (97%) of ~e pr~duct as a white foarn.
(200 MHz, CDC13): ~ 1.48 (m, 9H), 1.82 (m, lH), 2.lO-2.70 (m, 3H), 3.05 (ml 2H), 3.1S (t, 4H~, 2H), 2.55 (t, 4H~ 2H), 4.70 (s, 2H)~ 4.45 (mj lH), 4.68 (s, lH), S.0~ (s, 2H), 5.38 (s, lH), 7.05-7.43 m, 19~). FAB-MS: calculated for C3gH43~ ~06 677; found 678(~I+H, 60%) Step C: 2-Amino-2-me~yl-N-[2,3,4,5-tetrahydro-1-[~2'-[[[((2-hydroxye~yl)amino)carbonyl~amino]methyl~[l,l'-biphenyl]~-yl~me~yl~-2-oxo-lH-ben7~7epin-3(R)-yl]-propanamide. ~ luoroacetate 2s T~ a solution of 149 mg (0.22 mmol) of 2-be~zyloxy-~: carbonyl~mino-2-methyl-N-E2,3,4,5-tetrahydro-1-[[2'-~[[(~2~hydroxy-ethyl)amino)carbonyl]a~iIlo]methyl][ l ,1 '-biphenyl]~-yl]methyl]-2-oxo-lH-benzazep~3~)-yl]propanamide (Step B) in 3 mL of dry me~anol was added 30 mg (0.2 equiv. by weight) of palladium hydroxide. The :: ~0 mix*lre was s~rred under hydrogen atmosphere ~or 2 hours. The Luf~ was filtered through Celite. To ~e filtrate was added 3 drops of trifluoroacetic acid and the solvent was removed under vacuum to give a solid which was purified by reverse phase medium pressure liquid chromatography on C-8 eluting with methanol/0.1% aqueous trifluoroacetic acid (60:40) to afford 87 mg ~60~) of the title ..... ... , . . . . ~ .... ............. ....

- WO 94/05634 2 1 ~ 2 7 0 7 P~/US93~07791 compound as a white solid. lH N~R (200 MHz, CD30D): ~ 1.53 (s, 3H), 1.62 (s, 3H), 2.28 (m, 2H), 2.60 (m, 2H), 3.19 (t, 6Hz, 2H), 3.53 (t, 6Hz, 2H), 4.15 (s, 2H), 4.39 ~dd, 12, 8Hz; lH), 4.99 (d, l5Hz, lH), 5.20 ~d, l5Hz, 1H), 7.10-7.41 (m, 12H). FAB-MS: calculated for C31H37NsO4 543; fo~md $44(M+Hr 80%)-EX~MPLE 37 2-~nino-2-methyl-~-[2,3,4,5-tetrahydro-1-[[2'-[[[((2-me~oxyphenyl)-o)ca~bonyl]aII~ino~me~yl]~1,1'-biphenyl]-4-yl]methyl]-2-oxo-lH-:~ benzazepirl-3~R)-yl]prop~n~mide, trifluoroa~etate Step A: 2-BenzyloxycL~bonylamino-2-methyl-N-[2,3,4,5-te~ra-~ hydro-1-[[7'-[[[((2-methoxyphenyl)amino)carbonyl]-~o]me~yl][1,1 '-biphenyl~-yl]methyl]-2-oxo-lH-~: ~ benzazepin-3(R)~yllpropanamide To a so~tian of lOa mg (0.142 mmol~ of ~b~zylo~y-carbonylamino-2-me~yl- -[2,3,4,~-tetrahydro-?-oxo~ '-(amino-methyl)[1,1'-biphenyl]~-yl]me~hyl]-lH-b~7.~7epin-3(R)-yl]-prop~n~mitle, tr~uoroacetate ~F.x~mple 36, Step A) in 2 mI, of dry methylene chloride under nitroaen atmosphere was added 0.040 mL
(0.28 mmol) of triethyl~mine followed by 0.021 mL (0.16 mmol) o~
: 2-me~oxypheI~yl isocyanate The reaction mi~ure was s~ir~d at room 2- mp~r~ture for 30 ~ tes, ~ilute~ with 100 mL of ethyl ~et~te, . ~ washed~ with 25 mL of saturated aqueous amrnonium chloride, 25 mL of saturated aqu~ous sodium bicarbonate and 25 mL of br~ne~ ~e organic layer was dr~ed over m~gnesiunn sulfate, filtered and ~e solvent ~: ~ removed under vacuum to afford 102 mg (97%) of the product as a white foam. 1H N~R (200 MHz, CD30D): ~ 1.38 (S9 6H), 1.80 (m, lH), 2.15-2.50 (m, 3H), 3.80 (s, 3H), 4.19 (s, 2H), 4.27 (m, l~I), 4.68 (d7 16Hz, lH), 5.00 ~s, 2H), 5.30 (d~ 16HZ9 lH), 6~90 (m, 3H), 7.10-7.45 (m, 17H), 7.92 (m, IH). ~ MS: calculated for C~4H4sNsO6 739;
fQund 740 (M~H, 60%).

:~ :

21~270 1 WO 94/05634 PCI'/US93/07791j~

Step B- 2-A~nino-2-methyl~ 2,3,4~5-tetrahYdro-1-[[2'-[[L((2-me~oxyphenyl)aIr~ino)carbollyl]am~no]me~yl3~ 1,1 '-biphenylJ~-yl]methyl3-2-o~o-1H-beILzazepin-3(R)-yl]-propanamide. trifluoroacetate ~h~ ~itle compound wa~ prepared from 2-be~yloxy-carbonyl~mino-2-me~yl-N-[2,3,4,5-tetrahydro-1-[[2'~ [~((2 methoxy-phenyl)amillo)carbonyl]arnino]rnethyl]~1,17-biphenyl~-yl~methyl]-2-o~o-l~-be~azepLn-3(R)-yl~propa:llamide (Step A) accordi~g to -Lh~
procedure described in E~xample 36, Step C. lH NMR (200 MHz, CD30D): ~ 1.52 (s, 3H), 1.61 (s, 3H), 2.22 (m, 2H), 2.65 (m, 2~
3.82 (s, 3H), 4.21 (s, 2H), 4.36 (dd; 12, 8Hz; lH), 4.93 (d, 15Hz, lH), 5.20 (d, 15Hz, lH), 6.78-6.9S (m, 3H), 7.12-7.45 (m, 12H) 7.91 (dd, 4, 1Hz; 1~1). F~-MS: calculated ~or C36H3gNsO4 605; foLuld 15 606(M+H, 100%). ~

~: ~ 2-Amirlo-2-methyl-N-[2,3,4,5~tetrahydro-1-[[2'-[[[((7-hydroxyphenyl)-arnino)car~onyl~amino]me~yl][l,l'-biphenyl] 4-yl]merhyl]-2-oxo~lH-benzazepin-3(R)-yl~propanamide, ~rifluoroaceta~e StepA: 2-Amino-2-me~yl-N-~2,3,4,5-tetrahydro-1-[[2'-L[[((2-,hydroxyphenyl)amino)carbonyl]amino]methyl~Ll,l'-2 5 biphenyl]4-yl~me~yl]-2-o:xo- 1H-ben~a~epin-3(R)-yl~ -propanamide~ trifllloroacetate To a solution of 48 mg (0.067 Ir~nol) of 2-arr~no-2~ ethyl-', ' ' N-[2,3,4,5-tetrahydro-1-~[2'-[[E((2-rnethoxyp'henyl)amino)carbonyl]-amirlo~methyl][1,1 '-biphenyl]-4-yl~methyl]-2-oxo-lH-ben7.~7epin-3(R)-yl~propanamide, trifluoroacetate ~Example 37, Step B) in 2 rnL of dry me~ylene chloride under nitrogen a~nosphere was added 0.33 mL
(0.33 mmol) of a 1.0M solution of boron tribromide in me~ylene chloride. The reaction mixture was stilTed at room temperature for one hour ~d then quenched by the addition Qf 1 mL of water. The solvent was removed under vacuum and the residue was dissolved in 2 i WO 94/05634 ~! 1 4 2 7 0 7 P~/US93~07791 .

~ - 155- ~' . .
mL of methanol and treated with 2 drops of trifluoroacetic acid. I'he solvent was removed under vacllum and the residue was purified by reverse phase mediuna pressure liquid chromatography on C-8, eluting wi~ methanol/ 0.1% aqueous tlifluoroacetic acid (60:40), to afford 37 mg ~60qo) of the i~tle cornpound as a wi~ite solid. 1H N~ (200 MHz, CD30D): S 1.52 (s, 3H), 1.61 (s, 3H), 2.22 (m7 2H), 2.58 (m, 2H), 4022 (s, 2H), 4.36 (dd; 12, 8Hz; lH), 4.93 (d, lSHz, lH), 5.20 (d, 15Hz~
lH), 6.67~.8~ ~m, 3~, 7.12 7.48 (m, 12H) 7.6'' ~m, 1H). FAB-MS:
calculated ~or C3sH37NsO4 591; four~d 592 (M~H, 60%)-EXAl!,/IPLE 39 2-Amino 2-methyl-~-[2,3,4,$-tetrahydro-1-[[2'-[~(amirlocarbonyl) amino]me~yl][l ,1 '-biphenyl]-4-yl]methyl]-2-oxo-lH-be~7~7epin-3~R)-~5 yl]propanamide, trifluoroacetate ~epA: 2-~3e~1O~ycarbonyl.~mino-2-methyl-N ~2,3,~ te~
hydro-1-[~27-~[~amiIlocarbonyl)~mino]me~yl][1,1~-~ ~ 20 birhenyl]~-yl]me~ylJ-2-oxo-lH-ben~azepin-3(R)-yl]-:: propanamilde Prepared ~rom 2-benzyloxycarbonylamino-2-methyl-N-~2,3,4,5-tetrahydro-2-oxo-1 -[[2'-(aminomethyl)[1,1 '-bipherlyl~-4-yl]-methyl~-1H-b~n7~7epin-3(R~yl}prop~n~mi~e, trifluoroac~ate (Example 36? Step A) and t~ethylsilyl isocyanate according to ~e procedure described in Example 37, Step A. lH N~iR (200 MHz, CD3OD): ~
1.40 (s? 6H), 1.82 ~ml 1H), 2.15-2.60 (m, 3H), 4.12 (S9 2H), 4.32 (m, lH), 4.85 ~d, lSHz, lH), 5.00 (s, 2H), 5.32 (d, lSHz, lH), 7.05-7.43 (m, 17H). FAB-MS: calculated for C37H3gNsOs 633; found 644(M~H, 00%).

Step B: 2-Amino-2-methyl-N-[2,3,4,~-tetrahydro 1~[[2'-~[(amirlo-carbonyl)amino]me~yl]~1,1 '-biphenyl]4-yl~me~yl}-2-oxo-lH benzazepin-3(R)-yllpropanarnide~ trifluoroaceta~e ... . . . . . '~ . . .' .' ' ~ ' ' 21~270 ~

The title compound was prepared from 2-benzyloxy-carbonylamino-2-methyl- -[2,3 ,4,~-tetrahydro-1 -[[2'-[[(amino-carbonyl)amino]me~yl~l,l'-biphenyl~4-yl]me~yl]~2-oxo-lH-7~7epin-3(R)-yl]propaIlamide (Step A) accordirlg to dle procedure descn~ed in E~ampie 36, Slep C. lH ~MR (200 M~, C~D30D):
~1.53 (s~ 3H), 1.62 (s,~3H), 2.25 (m, 2H), 2.58 (m, 2H), 4.13 (s, 2H), .37 (dd, 12, 8Hz; lH), 4.97 (d9 lSH~, lH), 5.20 (d, lSHz,lH)7 7.10-7.41(m,12H). FAB-l~S;calculat~diorC~gH33~{)3499; four~d500 o (M+H, 100%).
' 2-~o-2-me~hyl-N-[2,3,4,5-tetrahydro~ [2'-~[[(be~zylamino)-carbonyl]amino]me~yl][1,1'-biphenyl~-yl]methylJ-2-oxo-1H~
azepin-3(R)~yl]propanamide, tTifluoroacetate Step A: 2-Benzyl~yc~LIonyIamino-2-methyl-~-~2,3~4,~-tetra-:~ hydro~ [2'-~(benzylamino)carloonyl]amino~methyl]
~l,1'-biphenyl~-yl]methyl]-2-oxo~lH~ zazepill-3(R)-vllpro~n~rnide Prepared: from 2-benzyloxycal~ollylamino-2-methyl-N-~2,3,4,5-tetrahydro-2-oxo~ [2'-(aminomethyl)[1~ biphenyl~-yl~-me~yl]-lH-~en7~7epm-3(R)-yl}~panamide, trif~uor~acetate (E~ample ~: 2- 36, Step A) and benzyl isocyanate accordin~ to the procedure descnbed in Fx~mple 37, Step A. lH MMR (200 MHz, CD30D): ~ 1.38 ~s, 6H), 1.82 (m, 1H), 2.15-2!55 ~m, 3H), 4.14 (s, 2H), 4.24 (st 2H), 4.32 (m, lH), 4.85 (d, 15Hz, lH), 5.00 (s, 2H), 5.32 (d, l~Iz, lH), 7.05-7.42 (m, 22H). FAB-MS: calculated for C44H4sNsOs 723; found 724 (M~H, 100%).
': Step B: 2-Amino-2-me~yl-N-[2,3,4,5-tetrahy~ro-1-[[2'-~[~(benzyl-amino)carbonyl]~nino]methylJ[1,1'-biphenyl]~-yl]methyl]-2-oxo-lH-ben7.~7epin-3~R)-yl]propanamide, trifluoro-acetate , ., .

WO 94/05634 2 ~ 4 2 7 0 7 P~/US93~07791 The title compound was prepared from 2-b~nzyloxy-carbonylamino-2-me~hyl-N-~2,3,4,5-tetrahydro-1-[[2'-[[[(berlzylaIr~ino)-carbonyl3amino~e~yl][1 ,1 '-biphenyl]~-yl]methyl]-2-oxo-1~-ben~-azepin-3(R~-yl]~ro~amide (Step A) according to the procedure descnbed in E~ample 36, Step C. lH NMR (200 ~Iz, CO3OD~ 3 (s, 3H), 1.62 (s, 3H), 2.2S (m, 2H), 2.$8 (m, 2H), 4.17 (s, 2H), 4.26 (s, 2H), 4.37 (dd, 11, 8H~: lH), 4.96 (d, l5H~, lH)~ 5.20 (d, 15Hz, lH), 7.10-7.~1 ~m, 17H). FA:3-MS: calcu~ated for C36~3gN~O3 389; found 590 (h~+H, 80%) 2-Amino-2-methyl-N-[2,3,4,5-tetrahydro-1-[[2'-[[~ propyl~no)-5 carbonyl]a~ino]methyl][l,l'-biphenyl~-yl~methyl~-2-oxo-lH-ben7~7,epi~:-3~R)-yl]prop~n~mide, trifluoroacetate St~p A: 2-Ber~yloxycarbo~yl~mino-2-methyl-~ 2,3,4~$-te~a-hydro-1~['~'-[E[(1-propylaminc3ca~bollyl~ ~inoJmethyl]
~1,1 '-biphenyl]-4-yl]me~yl]-2-oxo-lH-ben7.~7epin 3(R)-': vllpropanamide Prepared from 2-benzyloxycarbonylarnino-2-methyl-N-[2?3,4,5-tetrahydro-2-oxo-I-[[2'-(aminomethyl)[1 ,1 ~-biphenyl~-4-yl]-~ medlyl]-lH~ .,e~-3(R) yl]propan~ide, ~fluoroace~ate ~Example 2s 36, Step A) and 1-propyl isocyanate according to the procedure ~'' described in E~ample 37, Step A. lH NMR (20Q MHz, CD3OD): ~
0.86 (t, 7.5Hz, 3H), 1.39 ~s, 6H), 1.42 (m, 2H), 1.82 (rn, lH), 2.19-2.55 (m, 3H), 3.01 (t, 7Hz, 2H), 4.12 (s, 2H), 4.32 (m, lH~, 4.85 (d, lSHz, lH3, 5.00 (s, 2H), 5.31 (d, l5Hz, lH), 7.08-7.40 (m, 17H), 7.63 (d, 8Hz, lH). FAB-MS:calcula~edforC40H4sNsOs675;~ound676(M+H, 5~)-: ' ' 21~2~0~
WO 94/05634 PCI'/IJS93J07791 _ , Step B: 2-Amino-2-methyl-N~2,3,4,~-tetrahydro-1-~2'-~[~
b! propylamino)carboIlyl]arnino]methyl][1,1'-biphenyl]~-yl]-methyl]-2-oxo-lH-ben7.~7.epin~.3tR)-yl]propan~mi~le, . trifluoroacetate :I:
The ~itle compound was prepared *om 2-benzyloxy-;: carbonylamino-2-methyl-N-~2"3,4,5-tetrahydro-1-[~2'-~[[(1-propyl-amino)carbonyl]a~ methyl][1~ biphenyl]-4-yl]methyl] 2-oxo-lH-b~-n~epm 3(Rj-yl]~lu~ mide (S~ep A) accor~mg t~ ~e procedu~e :: ~ d~sclibed in Example 36, Step C. lH NMR (200 ~Iz, CD3OD): ~ 0.87 (t, 7Hz, 3H), 1.AA ~dd; 16, 8HZ; 2H), ~.53 (s, 3H), 1 62 (s, 3~), 2.25 ~m, 2H), 2.58 (m, 2H)~ 3.08 (t, 7Hz, 2H), 4.14 ~s, 2H), 4.37 (dd; 12, 9Hz;
1~), 4.97 (d, l5H~, lH), 5.20 (d, 15Hz, lH), 7.1007.41 (m, 12H). FAB-MS: calculated for C32H3gNs~3 541; ~ound S42 (M~H, 100%).
~.
~ 15 2-~o-2-m~thyl-N~ 4~-t~ahy~ro~ 2'-~ m~thyle~yl)-aminoJca~ yl]-amLno]me~yl][1,1~-biphenyl}~Lyl~me~yl~2~xo-lH-;20 ~z;az~pin-3(R)-yl~prop~n~mid~, trifluoroacetate Step A: 2-Be~zyloxycarbonylamino-2-methyl-N-[2,3~4,5-tetra-: hydra-1-[~2'-~[~ methylethyl)amino~rbonyl]a~nol-~: : me~ylJ[l,l'-biphenyl]-4-yl~me~yl3-2-o~o~1H-berl7~epiIl-2s 3(R)-vllp}op~n~rnide Prepared from 2~ber~yloxyc~rbonylamirlo-2-methyl-N-[2,3,4,5-tetrahydro-2-oxo-1-[[2'-(aminomethyl)[1,1'-biphenyl]-4-yl]
methyI~-1H-bcn7~7epin-3(R)-yl]propanamide, ~rifluoroacetate (Example 3 6, ~tep A) and isopropyl isocyanate according to the procedure 30 ~descIibed ~ F.x~mrle 37, ~tep ~ 1H NMR (700 ~, CD30D): ~
1.06 (d, 6~5Hz? 6H), 1.39 (s, 6H), 1.82 ~m, 1H), 2.19-2.58 (m, 3H~, 3.74 ~m, lH), 4.12 (s, 2H),:4.32 (m, 11H), 4.87 (d, l5Hz, lH), 5.01 (s, 2H), 5.31 (d~ 15Hz, lH), 7.08-7.40 (m, 17H). FA~MS: calculated for C40H4$NsOs 675; ~und 676(M~H, 80%).

":, . ' ., .

- WO 94~05634 2 1 ~ 2 7 0 7 PCr/US93/07791 - 15~
Step B t 2-~ino-2-me~yl-N-[2,3,4,5-te$rahydro-1-[[2'-[[[[(1-me~yle~yl)amino~carbonyl]amino]methyl3[1,1 '-biphenyl]-yl~me~yl3-2 oxo-lH-benzazepin-3~ yl]propanamide, trifluoroacetate :~ 5 Ihe tid~ compound was prepareâ ~rom 2-~nzylo~y-carbonylamino-2-Me~yl-N-[2,3,4,5-tetrahydro-1-~[2'-[[[[(1-methyl-e~yl)~mino]car~ony~mino]methyl~ biphenyl]~-yl]me~yl~-2-oxo-lH~ n~7~pin~ ylJ~s~ amide ~Step A) accor~ing to ~}e procedure desc~bed irl Example 36, Step ~. lH NMR (2~ l~Iz, CD3C)D): ~ 1.06 (d, 6.5Hz, 6H), 1.53 (s, 3H~, 1.62 (s, 3Hj, 2.2S ~m, 2H), 2.58 (m, 2H), 3.74 (m, lH)9 4.14 (s, 2H), 4.37 (dd, 1~, 8Hz; lH~, 4.97 (d, 15H7" lH), 5.20 (d, 15~, lH), 7.10-7.41 (m9 12H). F~B-MS:
calcul$ed for C32H3~NsO3 541; found 542 ~M~H~
s E~MPLFJ 43 :: 2-Amino-2-methyl- -[2~3~4~s-te~ahydro-l-[[2~-~[~(e~}yl~mmo) carbonyl]:amino3methyl][1 ,1 '-biphenyl]~-yl]methyl]-~-oxo-lH-2 ben~azepin-3(R)-ylJ~o~,amide, ITifluoroacetate :~ ~
StepA: ~ 2-BeIlzyloxycarbonyl~mino-2-methyl~N-[293,4,5-tetra-hydro-1-[[2'-~[[(ethylamino)earboIlyl]amino]methylJ-~1,1 '~iphenyl}~yl~methyl~-2-oxo-lH-~ç,.r~ 3~R~yl]-propanamide Prepared from 2-benzyloxy~arbonylamino-2-methyl-N-[2~314,5-tetrahydro-2-oxo-l-[~2'-(aminome~hyl)[l,l'-biphenylJ-4-yl]-me~yl]-lH-bel~7~7epin-3(R)-yl]prop~n~mi~e, trifluoroacetate (E3xample 36, Step A) ~nd ethyl isocyanate according to ~e procedure descIibed in Example 37, Step A~ lH NMR (200 MHz, CD3OD): ~ 1.03 (t, 7Hz, 3H)~ 1.39 (s, 6H), 1.82 (m, lH), 2.18 2.~8 (m, 3H), 3.07 (q, 2H), 4.12 s, 2~), 4.32 (m, lH), 4.87 (d, 15Hz, IH), 5.00 (s, 2H), 5.31 (d, 15Hz, lH), 7.08~7.40 (m, 17H). FAB-MS: calculated for C3gH43N$Os 661;
found 662 ~M+H, 100%).

2142~0 ~
WO 94/05634 P~/U~;~3/~7791.--Step B: 2-Amino-2-melthyl-N-[2,3,4,5-tetrahydro~ [2'-[[[(1-ethyl-amino)carbonyl]~LnoJmethyl][1 ,1 '-biphenyl]4-yl]me~ylJ-2-oxo-lH-betlzazepin-3(R)-~l]~ro~amide, .
~rifluoroacetate The ~itle compound was prepared f~om 2-~enzylo~y-carbonylamino-2-methyl- -~2,3 ,4,5-tetrahydro-1~[[2'-~[[( 1 -e~ylamino)-carbonylJ~minoJm0thyl][1,1'-biphenyl]~yl]me~yl]-~-oxo-lH-ben~-azepin~ ylJplu~amide (S.ep A) according to~ proeedu~
described in Example 36, Step C~. lH NMR (200 MH~, CD30D): ~ 1.05 (t, 7H~, 3H), 1.53 (s, 3H), 1.52 (s, 3H), 2.25 (m, 2H), 2.58 (m, 2~)7 3.09 (q, 2H)i 4.14 (s~ 2H), 4.37 (dd, 11, 8Hz; lH), 4.97 (d, 15Hz, lH), 5.20 (d, 15Hz, lH), 7.10-7.41 (m, 12H). FAB-MS: calculated for C31H37NsO3 527; found 528 (M~H, 100%).

Amino-2-methyl~N-r2,3,4,;-tetrahvdro~ r2~ (N,N-d~rle~yl-am~no)carb~yl]~i~o~methyl~ biphenyl}~~yl3me~yl]~2-oxo-1H-20 benzazepin-3(R)-yl]prop~n~mi~le, trifluoroacetate : StepA:~ 2-Benzyloxycarbonylamino-2-methyl-N-[2,3,4,5-tetra-hydro~ [2'-~[~(N,N--limethylaminojcar~onyl~o]-: me~yl]~1,1'-b~p~enyl] ' yl]me~yl]~ o-1H-benzazepm-3(R)-vllprop~namide p~r~fs;d ~rom 2-benzylo~ycarbonylamirlo-2~me~hy~-N-~; [2,3,4,5-tetrahydro~2-oxo-1-[~2'-(aminomethyl)[l,1'-biphenyl~-4-yl]-methylJ-lH~ 7~7~pill-3(R)-yl]prop~n~mi~le, hydrochloride (Exarnple 35, Step I) and ~limethylcar~amyl chloride according to the procedure 30 ~ described in F.x~mrle 37, Step A. lH NMR (200 MH~, CD30Dj: ~ 1.39 :~ ~ (s, 61H), 1.82 (mS lH~, 2.18-2.58 (m, 3H), 2.81 (s, 6H)~ 4.20 (d7 SHz, 2~I), 4.32 (m, lH), 4.86 (d, l5Hz, lH), 5.01 (s, 2H)j 5.31 (d, 15Hz, 1H), 6.40 (t, SH~, lH~, 7.06-7.40 (m, 17H). FAB-MS: calculated for C3gH43NsOs 661; found 662 (M+H7 80%).
, ,.

,, ~ WO 94/05634 214 2 70 s PCr/US93~07791 ~ ~ - 161 -Step B- 2-Arnin~-2-methyl~ ~2,3,4,5-tetrahydro~ 2'-[[[(NfN-: ~ ~ime~ylam1no)caIbonyl3an~inoJmethyl][l,l '-biphenyl]4-~l]me~yl~-2-oxo-lH-ben~azepin-3(R) yl]~ro~ ide, tri~luoroacetate S : The ~itle compQund was prepared ~rn 2-benzyloxy-:~ carbo~ylamino-2-me~yl-~-[2,3,4,5-tetrahydro-1-[[2'-[[~(N,N-dimethyl-amino)carbonyl3~mino]me~yl][1,1'-biphenyl]~4-ylJmethyl]-2-oxo-lR-3(R3-yl~ e (5tep A) accol~lu~g tO th~ proc~:~u~e described in Example 36, Step C. lH NMR (200 MHz, CD30D3: ~ 1.53 (s, 3~H), 1.62 (s, :3~ 2.25 (m, 2~), 2.58 (m, ~lH), 2.83 (s, 6H~, 4 ?? ~S7 2H), 4.38 (dd, l l, 9Hz; lH), 4.98 (d, 15Hz, lH), 5.20 (d, lSHz, lH), 7.10 (m, lH), 7.17-7.37 ~m, llH). FAB-~IS: calculated for C3lH37NsO3527 folLnd528(M+H,100%).

2-A~ino-2-methyl N-[2,3,4,5-te~ahydro l E~ (4-morphoiiIlo)-carbonyl~ moJme~yl~ biphenyl]~-ylJmethyl]~2-oxo-lH-2 0 ~ ~ benzazepin-3(R)-yl]prop~n~mi(le, trifluoroacetate Step A: 2-Berlzyloxycarborlylamino-2-methyl-N-[2,3~49~-tetra-hydro-1-[[2'-~[~(4~morpholillo)carbonyl]amiIlo~me~lyl]-[l,l'-~phenyl]-4-yl]methyl~-2-oxo-lH~ azepm-3(R)-yl~-:2s ~: ~ propanamide Prepared from 2-benzyloxycarbonylam~no-2-methyl-N
X,3,4,5-tetrahydro. 2-oxo-1-[~2'-(aminome~yl3[1,1'-biphenylJ4-yl]-;~: methyl~-lH-b~n7.~epin-3(R)-yl]propanamlde, hydrochloride (Example 35, Step I) and 4-mo~pholinocarboIl:yl chloride according to the 30 procedure described iIl F.~ le 37, Step A lH N~ (200 MHz.
CDC13): S ~1.45 (s, 3H)~ 1.47 (s, 3H), 1.80 (m9 lH), 2.35-2.68 (m, 3H), 3.14 (t, SHz, 2H), 3.5~ (t, 5Hz, 2~I), 4.32 (d, 5~Iz, 2H), 4.45 (dd; 12, 7 ~; lH), 4.86 (d9 15Hz, 1~), $.03 (s, 2H)~ 5.20 (d, lSHz, 1~), 5.43 (s, lH), 6.40 (t, SHz, 1~), 7.05-7.42 (m, l9H). FAB-MS: calculated for :~ : : C41H4sN$O6703; found704(M~H,80%).

21427~)7 WO 94/05634 PCl ~US93/07791 ~-' ~ - 162-., .
Step B: 2-Amino-2-methyl-~-~2,3,4,5-tetrahydro-1-[[2'-[~[(4-morpholino)carbonyl]am~no]methyl][1,1 '-biphenylJ~-yl]- r methyl]-2-oxo-lH-berLzazepin-3(R)-yl~prop~n~mi~lç, ~rifluoroaceta~e The title compourld vras prepared from 2-benzyloxy-carbonyl~mino-2-methyl-~,-[293,4,5-tetrahydro-1-[~2~-[[[(4~ orph lmo)c~lJol~yl~nnolme~Lyl]~l,l ?-bipheIIylJ~-yl~ed~ -2-o~o-1~
~zepin-3(R)~yl]prop~n~mi~e (Step A) according to the procedure o described in F~rnrle:36~ S~ep C. lH NMR (7~ MH~, CD30~
153 (s, 3H), 1.62 (s, 3H), 2.25 (m, 2H), 2.S8 (m, 2H), 3.27 (t, SHz, 2H), 3.58 (t, SHz, 2H)? 4.24 (s, 2H), 4.37 (dd; 11, 8Hz; 1H), 4.99 (d~
lSHz, lEI), 5.19 (d, l~H7" lH), 7.10 (m, llE~), 7.17-7.40 (m, llH).
MS: calculated for C33H3gNsO4 569; found 570 (M~, lOO~o).

Amino-2-methyl-N~2,394,5-t~trahydro~ 2'-~E[~(e~hoxycarbonyl)-2q Inethylamirlo]carbonyl]amino~me~yl]~191'-biphenyli4-yl3me~yl]-2 oxo-lH-benzazepin-3(R~-yl]propanamide, trifluoroa~eta~e ~:: Step A: 2-Be~zyloxycarbo~ylamino-2-methyl-N-~2t3~4,5-tetra-:~ hydro-1-~2'-~[~e~io~yc~onyl)me~ylarnino~car~onylJ-;~ : 2s : amirlo~methyl~ biphenylJ 4-yl]methyl~-2-oxo-1H-~: benzazepin-3(R)-yllpropanamide To a slurry of 200 mg (0.284 mmol) of 2-benzyloxy-carbonyl~mino-2-methyl-N-[2,3,4,5-tetrahydro-2-o~o-1-~[2'-(amino-methyl)[1~1'-biphe~yl~-yl]methyl]-lH~ zazepin-3(R)-yl]-3~ ~r~)a~mirle, t~ifluoroacetate (Example ~6, Step :A) in 1.0 mL of dry mefflylene chloride under a ~itrogen a~osphere was added 0.080 mL
(0.57 ~ol) of trie~yi~minç. The mixture was stirred at room temperature for 30 minutes (mi~ture A).
~: In a separate flask was placed 59.4 mg (0.426 mmol) of glyc~ne ethyl ester hydrochloride in 2.0 mL of dry methylene chloride , ~ .

WO 94/0563'~ 2 1 ~ 2 ~ t~ 7 PCr/US93/07791 .

uIlder a nitrogen atmosphere. To ~is sluITy was added 0.080 mL (0.57 mmol) of triethyl~mine. After S minlltes~ 69 mg (0.43 mmol) o~ 1,1'-carbonyl~iimi~la7ole was added. The resulting mi~ture was stirred at room temperature for lS minlltes then the previously prepared amine 5 solu~o~ (~L~lLL~e A) was add~d l~ia c~nn~ to the r~ac'do~ mL~ e.
After st~g ~or 24 hours at room temperature, ~e reaction m~xture was diluted wi~ lOO.mL of ethyl acetate, washed wi~h 2~ mL of sa~rated aqueou3 ~mm~nium chloride, 25 mL G. saturat~d sou~m bicarbonate ~d 25 mL of b~e. The organic layer was removed, dried over m~nesium sulfate, ~ltered and the solven~ removed under vacuum. The resultiIlg material was purif1ed by flash CQl~
~llrolllatography on silica gel eluting with ethyl acctate~exarles (90:10) to ~ford 149 mg (73%) of the product as a white f.oam. lH NMR ~200 ~z, CD30D): ~1.22 (t, 7Hz, 3H), 1.39 ~s, 6H), ~.82 (m, lH), 2.15-15 2.55 (m, 3H), 3.81 (s, 2H), 4.13 (m, 4H), 4.32 (m, lH), 4.g6 (d, l51HziH), 5.01 (s, 2H), 5.32 ~d, l5H2, lH), 7.08-7.43 (m, 17H). ~AB-MS:
calculated~orc4lH4sNso77l9; f~Und720(M~H'5o%) 20 Stel) B: 2-A~ino-2-methyl~N-[2,3,4,5-tetrahydro-1-[[2'-[[[[(ethoxy-c~l,ol.yl)methyl~mino]ca,l,o~yl]~o]me~yl][1 ,1 '-bi-phenyl~-yl]me~hyl]~2-oxo-1H-ben~7ep~-3(R~-yl]-prop~n~mide, ~Tifluoroacetate The ~itle compound was prep~ed from 2-benzyioxy-call,ollyl~min~-2-methyl-N-[2,3,4,5-tetrahydro-l -[[29-~[(etho~y-25 ~uo-~yl)mel~lylA"~ o3carbonyl]~o]me~ylJ~ phenyl~-4-yl~-methyl]-2-oxo-lH-b~ epin~3(R)-yl]propar~amide (Step A) accordmg to ~e procedure described in Exanaple 36, Step C. lH NMR (200 ~, CD30D): ~1.22 (t, 7~1z, 3H), 1.53 ~s, 3H), 1.62 (s, 3H), 2.25 (m, 2H), 2.58 (m, 2,H), 3.82 (s, 2H), 4.24 (m, 4H), 4.38 ~dd; 12, 9Hz; lH), 4.97 (d, l5Hz, lH~, 5.20 (d, lSHz, lH), 7.10-7.40 (m, 12H). FAB-MS:
calculated ~or C33H3gNsOs 585; folmd 586 (M+H, lOO~o).

' 21~270~
' WO 94/05634 PCI/lJS93/07791 ~,, , - 1~4-2-Amino-2-methyl-N-[2,3,4,5-tetr~hydro-1- [[2'-[[~[(carboxymethyl)-am~no]carloonyl~amirlo~methylJ[1,1 '-biphenyl]~-yl]methyl]-~-oxo-lH-5 ben~a~epin-3(R)-yl]propanamide, t~i~1uoroac~t~te Step A: 2-Be~zyloxyc~bollylamino-2-methyl-N-[2,3,4,5-tetra-hy~ [~'-r[~ o~yl,m~ylaI~:Lino~-carbonyl]amino]me~yl][1 ,1 '-biphenyl]-4-yl]methyl]-2-oxo-l~-benzazepin-3(R)-yllpropaIlamide Prepared ~rom 2-benzyloxycarbonylamino-2-methyl-N-~2,3,4,5-tetrahydro-2-oxo-1 -~2'-(aminome~yl)[ 1,1 '-biphenyl~-4-yl]-me~yl]-lH-bçn7.~7epin-3(R)-yl]propanamide, t~uoroacetate (Example 36, Step ~) and glyc~e benzyl ester hydrochlonde according to th:e procedure described in Example 46, Step A. lH NMR (200 MHz, CD30D): ~1.38 (s, 6H), 1.82 (m, lH)7 2.18-2.60 (m, 3H), 3.86 (s, 2H), 4.13 (s~ 2H), 432 (m, 1H)~ 4.84 (d, 15Hz, lH); 4.~9 (s, 2H), 5.11 s,2H~,~.30~d,153E~, lH),7.~5-,.A~ ~m,~H). FAB-~fS~ la~d ~: for(:~6H47NsO7781; found782(M~H,9oC'o).
~ ~ 20 Step B~ ~ino-2-methyl-N-[2,3,4,~-tetrahydro~ [2'-[[~[(earbo~yme~yl)~o]carbonyl]amino3me~yl]-~1,1 '~ biphenyl3-4-yl3me~yi]-2-oxo-lH-ben7.~7~opin-3(R)~-yllpropanamide. trifluoroacetate The t~tle compouIld was p~pared from 2-'~1l~yloxy-carbonyl~mino-2-rne~yl-N-[2,3,4,5-tetrahydro-l ~[2'-~[~(benzyloxy-carb~nyl)me~yl~minoJcarbollyl~amino~methyl][1,1'-bipheIlyl]-4-yl]-me~yl]-2-oxo-lH-b~n7~7epin-3(R)-yl]propanamide (Step A) according to ~e procedure described in Examp~e 36, Step C. lH NMR (200 MHz, 30 CD3OD): ~ 1.53 (S7 3H), 1.62 (s, 3H), 2~25 (m, 2H), 2 59 (m, 2H)~
3.82 ~s, 2H), 4.15 (s, 2H~, 4.38 (dd; 12, 9Hz; 1H~, 4.97 ~d, lSHz, 1H), : 5.19 (d, 15Hz, lH), 7.10-7.43 (m, 12H). FAB-MS: calculated for C31H3sNs~s 557; found 558 (M~H, 25%).

WO 94/05634 21~ 2 7 0 7 P~/US93/07791 - 165- ' EXAMPLE~ 48 3-Amino-3-methyl-N-~2,3,4,5-tetrahydro-1-[~2'-[[[(me~hylamino)-carbonyl~o]me~yl][l,l'-biphenyl]4-yl]methyl]-2-oxo-lH-~nzazepin--3(R~y!]b lt~n~mi~e, trifluoroacet~t~

Step A: 2~2-Dime.thylbutanedioic acid. 4-methYI ester 2~2~ yls~ ~nic acid (20 g~ 1~ mmol~ diss~l~ed i~
200 mL of absolute m~.tll~nol at 0~ was treated dropwise wi~ 2 mL of conceIltrated sulfuric acid. A~ter the addition was completet the - mixture was allowed to w~n to room temperature and stirred ~or 16 hours.
~: The ~i~ was concentrated und~r vacuum to S0 mI, and slowly treated wi~ 2~ mI, of saturated aqueous sodiurrl bicarbonate.
The mixt-lre was washed wi~ hexane (3x) and the aqueous layer ; removed and cooled in an iee bath. The mixture was acidified to pH 2 by slow addi~on of 6N HCI ~hen ex~racted with ether (8x). The combmed ~AI~d~ts were washe~ wi~ briIle, dried o~er m~
sulfate, fil~ered and solvents removed under vacuum. l~e residue was 2 dried at:room tempera~e under vacuum to af~ord 14.7 g (91.8 ~nmol~
67~o) of a viscous oil that slowly solidified upon st~n~in~. lH NMR
analysis indicates ~e product is a mi~ture of the desired compouIld and 15% of the isomeric 292-dime~ylbut~ ioic acid, l-me~yl est~r.
NMR (200MHz, CDCl3) of desired compourld: ~ 1.29 (s, 6H), 2.60 ~s, 2H~, 3.66 (s, 3H). NhlR (200MHz, CDC13) isomer: ~1.28 (s, 6H), 2.63 (s, 2H)" 3.68 (s, 3H)~

:~ Step B: 3-[Berlzyloxycarbonylamino]-3-me~ylbutanoic acid, methyl ester To 14.7 g (91.8 mmol) of 2,2-dimethylbutanedioic acid-4-me~yl ester (Step A), co~t~ &; 15% of ~e isomenc l-methyl ester compound, in 150 mL of benzeIle was added 13 mL of trie~ylamine ~ ~: (9.4 g, 93 mmol,: 1.01eq) followed by 21.8 mL of diphenylphosphoryl azide (27.& g, 10~1 mmol, 1.1 eq). The mixture was heated under , 214270"~
WO 94/05634 PCl'/US93/07791 _ nitrogen at reflux ~r 45 minutes then 19 mL (19.9 g, 184 mmol, 2 eq) of benzyl alcohol was added and refluxing continued for 16 hours.
The ~ ul~ was cooled, ~ilt~red and the filtrdte coneentrated to a ~ ,n volume un~ vacuurn. The residue was 5 r~dissol~d in 250 m~ of ethyl ace~a~, w~s~ed wi~h water, sa.~rat~d aqueous sodium bicarbonate (2x) and brine. I~e organic layer was removed, dried over m~nesium sulîate, filtered ~d the ~1ltrate CoI~ dtl:;d to a ~ vo~me underva~ ~h~ crllde pro~uct was puri~1ed by me~ m pressure liquid chromatography Oll silica, ~; ; 10 elu~g wi~ hexane/e~yl acetate (4:1), to a~ord 18,3 g (68.9 mmol, 75~) of ~e product as a pale yellow liquid in addition to a small amount of pure 3-[benzyloxycarbonylamino]-292-dimethylpropanoic acid,:methylester. IHNMR(200MHz,CI~C13)ofmajorproduct:
5: 1.40 (s, 6H3, 2.69 (s, 2H), 3.63 (s, 3H), S.OS (s, 2H), S.22 (br s, lH), 7.32 (s, ~H)~ lH NlvlR (200MHz, CDC13) of 3-[benzylo~ycarbonyl amino]-2,2-dimethylpropanoic acid, methyl ester (200MHz, CDCl3):
l 1g (s, 6~), 3.30 (d, 7Hz, 2H; resonance collapses to smglet m CD30D), ~.67 (S9 3~FI)~, ~.09 (s, 2H), 5.22 (br s, 1~; resonance absent in 20 CD30D), 7-3 (br s,SH).
:~ StepC: 3-Benzyloxycar~onylamino-3-methylbut~noic acid A solutton of 18.3 g (68.9 mmol) of me~yl 3-benzyloxy-yl~o-3-methylbu~anoate (Step 13) in 20 mL of me~anol at 5 room~temperature was treated dropwise with 51 mL of 2N NaC)H (102 mmol, ~1.5 eq).: The ~ ure was stirred at room temperature for 16 ;: hours ~en transfelTed:to a separatory furmel and washed with he~ane (3x3. The aqueoùs layer was removed, cooled to 0~ and slowly acidified to pH ~ (paper) by dropwîse addition of 6N H(: l. This mixtuFe was ~:: 3 ~ extrac~ed with ether (6x); combined extracts were washed with lN H(: l and b~e, ~}en diied over m~ sium sulfate, ~lltered and solvent remoYed under vacuum to afford 17.3 g (68.7 mmol, 99%) of the product. 1~ ~MR (200~IHz, CDC13~: â 1.42 (s, 6H), 2.77 (s, 2H), 5.06 (s, 2H), 5.2 (br~s, lH), 7.3 (s, SH).

WO g4/05634 2 1 4 2 71~ 7 PCI/US93/07791 S~ep D: 3-Benzyloxycarbonylamino-3-methyl-N-[2~3,4,5-tetra-hydro-2-oxo-lH-benzazepin-3(R)-yllbut~n~mide Ple~ared ~rom 3-benzyloxycarbonyhmino-3-methyl-butanoic acid (Step C) and 3(R)-~o-2,3,4,S~etrahydro-lH-benz- .
:: S az~pin-2~e (Example ~, S~ep E) Sul~sl~L~ g benzot~ ol-1-yloxytri-py~rolidinophosphoI~ium he~afluorophosphate ~r benzotriazol-1-yloxy-tris(d1methylamino)phosphol~ium he~afluorophosph~te according to the procea~e described m ~ le 1, Step I. lH ~ (200 ~
CDC13): ~ 1.37 (s, 6H), 1.82 (m, lH), 2.45-2.75 (m, 4H), 2.86 (m, lH), 4.49 (m, IH), S.OS (dd; 10, 6Hz; 2H), S.SS (s, lH), 6.73 (s, lH), 6.96 (d, 4Hz, lH), 7.10-7.40 (m, 8H) and 8.68 (s, lH). FAB-MS:
calculated for C23H27N30~ 409; found 410 (M~H, lOO~o)-Step E: 2'-[(t-Butoxycarbonyl~mino)rnethyl]-1,1'-bipherlyl-4-methanol. acetate ester To solution of 500 mg (1.60 mmol) of 2'-[(t~butoxy-yl~mino)me~yl~ biphenyl~-me~anol (Example 35, Step E) m ~ mL of dTy ~ yhlle c~ e tmder:~ n~oge$I a~ln~s~ a~
room temperature was added by synnge 0.267 mI~ ~1.91 mmol~ of 20: triethyl~min~ followed by 0.165 mL (1.76 mmol) of acetic anhydride.
~: Ihe reaction mixtu~ was s~d for 1 hour then diluted with 150 mL
: of ethyl acetate, washed with sa~ated aqueous ammonil}m chlo~ide, sat~ated aqueous so~ bicarbonate, saturated aqueous sodium chlonde9 d~ied over m~nesium sulfate and ~ltered. The solvent was :~ removed under vacuum to give 583 mg (~10()%, cr",~ a minoramount of e~yl ~retAte) of ~e product as a white solid which was used ~: in ~e next step withdut ~urther purification. lH NMR (200 MHz, CDCl3): ~1.39 (s, 9H), 2.10 (s, 3H), 4.22 (d, 6Hz, ~H), 4.65 (s, lH), 5.12 (s, 2H), 7.18-7.48 ~m, 8H). FAB-MS: calculated for C21H2sNO4 30 355; fouIld 356:(M+H).

Step F: 2'-A~inornethyl-1,1'-biphenyl-4-methanol? acetate ester, trifluoroacetate :~ ' :

: :

21~270~
wc) s4/0s634 PCrlU~93/077gl ~_ Prepared from 2'-[~t-butoxycarbonylamino)methyl]-1,1'-biphenyl-4-methanol, acetate ester (Step E) according to ~e procedure described in Example 36, Step ~ Nl~ (200 MHz, CDCl3): ~ 2.03 :~ 5 (s, 3H), 3.98 (s, 2H), 5.07 (s, 2H), 7.18-7.48 (m, 8H), 7.75 (s, 3H).
:PAB-MS: calculated ~r C16H~7NO2 255; fo~d ~56 (.~H, 80~~c~.
, Step G: 2'-~[(Methylam~rlo)carbonyl~amino]methyl-1,1'-biphenyl-4-methanol~ ac~at~ ester Prepared from 2'-arninomethyl-1 71~-bipherlyl-4-met i: acetate ester, trifl~oroacetate (Step F;) accord~ng to the procedure described in Example 37, Step A. 1H NMR (200 MHz, CDCl3): ~ 2.10 (s, 3H), 2.65 (d, 4.8H~, 3H), 4.27 (d, 4.8Hz, 2~), 4.52 (m, lH), 5.12 (s, 2H), 7.18-7~48 (m7 8H). FAB-MS: calculated for C1gH20N2O3 312;
lS fouIld 313 (M~H, 100%).
! ;-~: Step H: 2'~[[(Meth~lamino)carbonyl]am~o]me~yl-1,1'-biphenyl-4- methanol ; ~ To a solution of 498 m~ (1.60 mmol) o~ 2'-~(mPthyl-amino)carbonyl~amirlo~ ethyl-1,1'-biphenyl~-methanol7 acetate ester (S!tep G) in I0 mL of THF/water (3:1) was added 335 mg (7.98 mmol) of li~ium hydroxide monohydrate. A~ter stining at room temperature ,: for 16 hours the reaction ~ U1e was diluted with 150 mL of ethyl ~c~t~te and was~ed wi~ brine (~ ~ 50 mL). ~e organic layer w~s r~, ~S dried over m~gnesilLnn sulfate, ISltered and the solvent removed under ~; vacuum ~o ~ord 411 mg (95%) of the product as a white solid. 1H
N~R (20a MHz, CD30D): ~ 2.64 (s, 3H), 4.20 (s, 2H~, 4.62 (s, 2H), ' ' ' 7.12-7.45 (m, 8H). FAB-MS: calculated for C16Hl~N202 270; fowld 271 (M+H, 100%).

Step 1: 2'-[[~Methylamino)carbonyl]amino]methyl-1,1'-biphenyl-4-~: me~hanol~ methanesulfonate ester To solution of 100 mg (0.17 mmol) of 2'-[~(met~ylamino)-carbonyl]amino]rnethyl-1,1'-biphenyl-4-methanol (Step H) in S mL of dry methyleI~e chloride and 1 mL dry dimethylformamide under a h 1~_ WO 94/05634 214 2 7 0 7 PCI'/US93/07791 nitrogen a~nosphere at 0~(: was added by syringe 0.077 mL (0.56 mmol) of triethyl~mine followed by 0.034 mL (0.44 mmol) of me~nesulfonyl chloride. The reaction mixture was stirred ~or 30 mimlte.S at 0~C ~en diluted with 75 mL o~ methylene chloride, washed ~i~h water~ s~l~sed aque~us sodium bica~bonate, sa~ate~ aqueous sodium chloride then dried over sodium sullCate aIld ~lltered. The sol~ent was removed under vacuum to give 128 mg (100%) of the pro~ct as a while so~d ~nich was llsed m ~the ne~t SEp ~IhClUt ~r pulilScation. lH N~ (200 MHz, CDC13): â 2.66 (d, 4Hz, 3H), 2.97 (s~ 3H~, 4.26 (d, SHz, 2H,), 4.42 (m~ 1H), 5.26 (s, 2H). 7.18-7.48 ~m, 8H). FAB MS: calculated for C17H20N204S 348; ~und 349 (M~H, 100%).
,.
StepJ: : 3-Benzyloxycarbonyl~mino-3-methyl-N-[2,3,4,5-tetra-hydro-1-[[2'-[~(methylamino)ca~l~o~yl]am~no]methyl]-[1,1 '-bipheny}]-4-yl]methyl]-2-oxo~1H-benzazepiI1~3(R)-yl~-butanam;de Prepa~ed from 3-benzyloxycarbonylamirlo~3-methyI-N- :
~2,3,4,5-tetrahydro-2-oxo~lH-ben7.~7epi~-3(R)-yl]bllt~n~mide (Step D) d 2'-[[(me~yl~mmo)call,ullyl~am;mo]me~yl-1,1'-biphenyl-~-methanol, m~th~npsulfoIlate ester (Step I) accordi~g to the procedure descnbed in Egample 35, S~ep H. IH ~ (200 MHz, CDCl3): ~ 133 (s ,6H), 1.78 (m, lH), 2.37-2.63 (m, 3H), 2.60 (d, 5Hz, 3H), 4. 0 (d, 6Hz, 2H), 4.52 (m, 2H), 4072 (t, 6H~, lH~, 4.86 (d, i6~, lH)~ 4.89 (s, 2H), 5.10 (d, 15Hz, lH), 5.69 (s, lH), 6.73 (d, 7.5Hz, lH), 7.08-7.35 ~m, 16H) 7.40 ~m, lH). FAB-MS: calculated for C3gH43NsOs 661;
found 662 (M~H, 40%).

Step K: 3 Amino-3-methyl-N-[2,3,4,5-tetrahydro-1-L~2'-~[(methyl-amino)ca~ yl]amino]me~yl]~1,1'-biphenyl]4-yl]methyl]-2-oxo-1H-benzazepin-3(R)-vlIbut~n~mide. tn~luoroacetate The title compound was prepared from 3-benzyloxy carbonyl~mino-3-methyl-N-~2,3,4,5-~etrahydro-I -[[2'-[[[(Tnethylamino)-carbonyl]amino]methyl][1,1 '-biphenyl]~-yl3methyl] 2-oxo-lH-21~2~ 0~
WO g~/05634 PCI'/US93/0779t --- ;

benzazepin-3(R)-ylJbut~n~mide (Step J) according to the procedure described in F.~m~le 36, Step C. lH NMR (200 MHz, CD30D): ~ 1.32 (s, 3H), 1.35 (s, 3H), 2.0-2.35 (m, 2~ .40-2.62 (m, 4H), 2.65 (s, 3H), 4.14 (dd; 17, lSHz; 2H), 4.40 (dd; 12, 8Hz; lH), 4.97 (d, 15Hz, lH), 5.21 ~d, 1~Hz, lH), 7.10-7.41 (m, 12H). FAB-MS: calculatedfor ::
(:3 1H37NsO3 527; folmd 528 (M~H, 100%), .:

3-[2(R)-Hydroxypropyl~amirlo-3-methyl-N-[2,3,45-tetrahydro-1-[~2'-[~(methyl~mino)car'oonyl]amulo]me~yl][1 ,1 '-biphenyl]~-yl]methyl]-2-oxo-1H-ben7.~epin-3(R)-yllb~lt~n~mide, trifluoroacetate LS Step A: 3-Amino-3-methyl-N-[2,3,4,5-tetrahydro-2-oxo-1H-benza~epin-3(R)-~ but~n~mide. t~ifluoroacetate To a solution of 150 mg (0.40 mmol~ of 3-t-butoxy-car'Donyl~Tntno-3-methyl-N-~2,3,4,5-tetrahydr~-2~o~ ben7~7e~n-3(R)-ylJ~ 1e (Example 1, Step I) in 2 mL of methyIene chIoride 0 at 0~C was added 2 mL of trifluoroacetic acid and the ~ us~ stirred at room le~ fo~ 1 hour. All vol~tiles were removed under vacuum to give 130 mg (0.33 mmol, 84%) of ~e product. 1H NMR
~200MHz, CD30I)~: ~ 1.33 ~s, 3H), 1.37 (s, 3H), 2.12 (m, lH), 2.3-2.6 (m~ 3H3, 2.6-3.0 (m, 2H), 4.37 (dd; 8, 12~; lH), 7.02 (d, 8H~, 1H), 7.1-7.3 (m, 3H). l~ MS: calculated ~o~ C15H21N30~ 275; found ;~ 276 (M~H, 100%).

Step B: 3-[2(R)~ Benzyloxypropyl]am~o'-3-methyl-N-12~3,4,5-tekahydro-2-oxo-lH-ben7~7epin-3(R)-yl~bllt~n~mide~
tr~luoroacetate To a soluti~n of 1.0 g (2.6 mmol) of 3-amino-3-methyl-N-[2,3,4,5-tetrahydro-2-oxo-lH-ben~azepiIl-3(R)-yl]but~n~mide, trifluoroacetate ~Step A) in 25 mL of dry methanol was added 3.0 g of dry 3~ powdered molecular sieves followed by a solution of 2.~ g (17 mmol) of (R)-2-ben~yloxypropallol (prepared from methyl D-lactate - - WO 94/0563~ 2 1 ~ 2 7 0 7 PCI'~US93J~7791 ~;

, according to the proeedllre of Hanessian and Kloss, Tetrahedron Lett., ~, 1261-1264 (1985)~) In S mL of dry methanol. The pH of the mi~Lule was carefully adjusted to 6 by the addilion of t~ifluoroacetie acid. ~e reaction was stirred for 2 hours at room temperature at wl~ch ~me ~5.4 mL (15.4 mmol) of a 1.0 ~vI solution of sodium ~:
cyanoborohydride in tetrahydrofuran was added by syr~nge. ~he reaetion was s~ed for 72 hours then ~lltered through a pad of ~elite. .;
To th~ e was added S mL of tri~or~ace~c acid (~AliTIO~tl , evohltion o~ hydrogeIl cyanide) and ~e resulting m~x~ure was stirred ~:
~~: for ~ree hours. The solvent was rernoved under vacuum to a~ford a clear oil which was puri~led by reverse phase medium pressure liquid ch~omatography on ~-8, elu~ing with methanol/0.1% aqueous triiluoroacetic acid (60:40), to af~ord 1.27 g (2.36 ~nol, 92%) oi~ the product as a white solid. lH ~ (200 MHz, CD30D~: ~ 1.31 (d, 6Hz, 3H), 1.40 (s, 3H), 1.43 (s, 3H), 2.17 (m, lH), 2.30 (m, lH), 2.6- :
3.1 (m, SH3, 3.22 (dd; 3, 12Hz; lH), 3.86 (m, lH), 4.48 (dd; J, 12Hz;
lH), 4.50 (d, 1'~, lH)~ 4.70 ~d. 1'~Iz, 1H)~ 7.11 (d, 8Hz, lH~, 7.15-7.~5 ~m, 8~. FAB~MS: calcu}at~f~2sH~3N3O3 A23; fo~md ~24 (M~H, 100%).

Stép C: 3-[2(R)~Benzyloxyp~opyl]am~no-3-methyl-N-[2,3,4,~-: tetrahydro-2-oxo-l H-benzazepin-3(R)-~ llbutanamide To a solu~on of 2.034 g (3.788 mmol) of the intermediate obtained in Step B in 40 mL of methylene chloride was added 40 mL of ~~ c water. The llli~Ul~ was s~irred vigorously while s~cient solid potassium carbonate was added to adjust the pH of the aqueous layer to 10-11. Stirrirlg was discontinued and the layers allowed to separate.
The organic layer was removed and the aqueous lay~r extracted twice more wi~ methylene chloride. The combincd extracts were dried over potas~ium c~l~ol~ate, fi1ltered aIld solvents removed under vacuum to afford 1.53 g (3.62 mmol, 95%) of the product as a white solid.

Step D: 3-[2(R)-Benzyloxypropyl]~n~o-3-methyl-N-[2,3,4,5-tetrahydro-1-[[2'-[~[(methylamino)carbonyl~arninoJ-~ , , . , ., ~ ", .. .. . .. ..... . .. ... . .

2,1~2~i7 WO 94/05634 P~lUS93107791t -' .:

methyl][l, l '-biphenyl~-4-yl~methyl~-2-oxo-lH-ben~azepin~
3(R~-yllbutanamide Prepared from 3-[2(R)-benzyloxypropyl]amino-3-methyl- ~ :
~-[2,3,4,$-tetrahydro-2-oxo-lH-be.n7.~7.epin-3(~)-yl3bllt~n~mide (Step C~ ~d ~'-[[(me~yl~minok~onylJamino~e~yl-1,1'-~iphenyl-4- . :.:
methanol, methanesulfollate ester ~Examplë 48, Step I) according to the :::
procedure described iIl E~ample 35, Step H. lH NMR (200 MHz, (:D30D): ~1.10 (s, 3H~ ? (S, 3H)~ ~.13 (d,~Hz.3H), 1.95 ~m. 1~
2.12-2.39 (m, 31E~), 2.40-2.63 (m, 3H), 2.63 (s, 3H), 3.70 (m, lH), 4.13 (s, 2~), 4.42 (dd; 12, 8~z; lH), 4.46 (d, 12Hz~ lH), 4.59 (d, 12Hz, lH), 4.93 (d, lSHz, lH), 5.2~ (d, 15Hz, lH), 7.V2-7.40 (m, 17H). FAB-MS:
calculated foI' C4lH4gNsO4 675; ~ound 676 (M+H, 100%). .
:
~ i Step E: ~ 3-~2(R)-Hydro~ypropyl]amîno-3-methyl-~ 2~3,4,5-tetra-hydro-1~ 2'~ (methylamino)carbonyl]amino]methyl]~
bi~phenyl] 4 yl~methyl]-2-oxo-lH-ben7i~7epin-3(R)-yl]-but~n~r~ide. tnfluoroacetate : ::
To a solu~ion OI 233 mg ~0.34~ mmol) OI ~-~2~R~-benzyl-oxypropyl3an~ino-3-methyl-N-[2,3,4,5-te~ahydro-1-~[2'-~[[(methyl-amino)~arbonyl]amino]me~yl]~ 1"1 '-biphenyl~yl~methyl~-2~xo-1H-n7.~7ep~-3(R)-yl]b~-t~n~mide (Step D) in S m~ methanol was added 5 drops of concentrated hydrochloric acid. The result~g mixture was hydroge~ated at ambien~ ~emperacure over S0 mg of 30~o palladium on ~bon ca~alyst at $0 psi ~or 24 hours. The mixture was ~lltered :25 ~rough (:elite. To the filtrate was added 3 drops of trifluoroacetic acid and the solvent was ~removed under vacuum to give a solid which was p~ fied by reverse phase medium pressure ~iquià chromatography on : C-8, eluting wi~ methanollO.1% aqueous trifluoroacetic acid (5S:45), to ford 157 mg (65%) of the title compound as a white solid. lH NMR
30 (200 MHz, CD30D): ~ 1.18 (d, 6H2, 3H), 134 (s, 3H), 1.36 (s, 3H), 2.02-2.22 (m, IH), 2.~2-2.43 (m, lH), 2.~8~2.65 (m, 5H), 2.65 (s, 3H), 2.78 (m, lH), 3.90 (m, lH), 4.16 (s, 2H), 4.38 (dd; 12, 8Hz; lH), 5.03 (d, lSHz, lH), ~.17 (d, lSHz, lH), 7.10-7.40 (m, 12H). FAB-MS:
calculated for C34H43NsO4 585; found 586(M+H? 40%)-:: : :

- wo s4tos634 2 1 4 2 7 0 1 PC~/U~93~077gl :~

- 173 - :

.
EXAMPLE 50 i :
3-[2(S),3-Dihydroxypropyl~amino-3-methyl-N-[2,3,4,5-tetrahydro- 1 -~2'-~L~(met'.ly~mmo)c~ yl]amino]me~hyl]~ -biphenyl~ ~' yl~-methyl]-2-oxo-lH-ben7~7epirl-3(R)-yl]bllt~n~mide7 trifluoroac~ate !~
. . .
St~p A: 3~Amino-3-me~yl-~ ,5-cetr~hydlo-~-o~o~
0 : ben~azepin-3(R)-yllbut~namide.
: ~: To a solution of 502 mg (1.34 mmol) of 3~t-butoxy-carbonylamiDo-3 me~hyl-~-~2,3,4,5-tetrahydro-2-oxo-lH-be~7~7epin-3~R)-yl]~ ide (Ex~ple 1, Step 1) in 3 mL of me~ylene chloride at 0~C was added 0.160 mL (1.47 mmol) of ~nisole followed by 3 mL
of t ifluoroacetic acid. The mixture stir~ed at room temperature ~or 3 hours. All vola~les were removed under vacuum ~o giYe ~ oil which was~ dissolved in lO:mL of water. To ~is solution was added 268 mg (6.7 mmol) o~ sodium hydroxid~ and the resultirlg mi~ture was s~drred all ~e solids wer~ dissolved. T~e so~on ~ras t~nsfemed to a separatory ffinnel a~ld the aqueous layer was e~tracted with chlorofo~n (3 x 50 mL). The comb~ed orga~ic ex~acts were washed with brine, d:ried~over sodium sulfate and filtered. The solyeIlt was removed under vacuum to afford:368 mg (100%) of the product as a white solid. lH
N~ (200MH~, CDCl3): ~ 1.27 (s, 6H), 195-2.30 (m, ~H), 2.37-2.75 (m? 3H), 2.80-3.Q2 ~m~, lH), 3.48 ~s, 2~), 4.52 (m, lH~, 6.97 (m, 1H), 7.1-7.27 ~m, 3H), :7.98 ~s, lH), ~.29 (d, 7Hz, l~I). FAB-MS: calculated for Cl~H21N3O2 275; found 276 (M~H, 100%).

Step B- 3-~2,2-Dimethyl-1,3-dioxolan-4(S)-yl]methyl]amino-3-3 ~ ~ methy l-N- ~2,3 ,4 ,5-tetrahydro-2-oxo- l H-benzazepin-3 (R) - yllbutanam1de, To a solution of 368 mg (1.34 rr~n~l) of 3-amino 3-methyl-N-~2,3,4,5-tetrahydro-2-oxo-1H-ben7~epin-3(R)-yl~bllt~n~mide ~Step A) in 10 mL of dry methanol was added 1.5 ~ of dry 4~ powdered molecular sieves ~llowed by a solution of 520 mg (4.0 mmol) of ' 214270~1 WO g4/05~34 PCr/U~;93/07791 D-glyceraldehyde acetonide (used crude as prepared according to the procedure of L.W. Hertel, COS. Gr~ssrnan and J.S. Kroin, Syn. Comm.
1991, 21, 151-154.) in 5 mL of dr~y methanol. The pH of ~e mixture ~~
was carcfully adjusted to 6 by the addition of 3 drops of acetic acid.
The ~action was stirred ~r S hours at room ~Lemp~d~ at uhich time 4.0 mL (4.0 mmol) o:f a 1.0 ~ solution of sodium cyanoborohydride in .;:
tetrahydr~ru~ was added by syringe. The reaction was stirred for 16 .
homs then fil~red ~oug~ a pad of C~li~. ~n~ soive~ was rem~ved ~der vacuum to afford a clear oil which was purified by flash columrl :
chromatography on silica gel eluting with chlorofoml/10% aqueous ammonium hydroxide ~33%) in methanol (92:8) to afford 387 mg (78%) of ~e product as a white solid. lH N~ (200 MHz, CD30D):
1.10 (s, ~H), 1.28 (s, 3H), 1.34 ~s, 3H), 2.08 (m, lH), 2.26 (dd; 16, 15~z; 2H3, 2.44 (m, lH), 2.58-2.75 (m, 3H), 2.87 (m, lH), 3.63 (dd; 8, 7Hz; 1H), ~.05 (dd; 8, 7Hz; lH), 4.20 (m, lH), 4.38 (dd; 12, 8 Hz; 1 4.84 (s, lH), 7.00-7.40 (m, 4H). FAB~MS: calculated for C21H31N30 389; found 390 (MlH, 100 Step C: 3-[[2,2-Dimethyl-1,3-dioxolan4(S)-yl~methyl]amino-3- .
methyl-N~2,3,4,5-te~hydro-1 -~[2' -[~[(me~ylamino)-carboIlyl3am~o3methyl]~1,1'-biphenyl~-yl3methyl]-2-oxo- ;' 1H-benzazepin-3~R)-yllbutanamide Prepared ~rom 3-~2,~-dimethyl-1,3-dioxolan-4(Sj-yl]-me~yl]arx~ino-3-methyl-l~I-[2,3,4,5-tetrahydro-2-oxo-1H-berlzazepin-3(R)-yl~bllt~n~mide (S~ep B) a~d 2'-[[~me~ylamino~carbonyl]amino~-met}~yl-1,1'-biphenyl~-methanol, me~anesulfonate ester (Example 48, Step I) according to ~e procedure described in Example 35, Step H.1H
NMR (200 MHz, CD30D): ~ 1.14 (s, 6H), 1.28 (s, 3H), 1.34 (s, 3H), 2.07 (m, lH), ~.20-2.~2 (m, 3H), 2.48-2.76 (m, 4H), 2.64 (s, 3H), 3.64 dd; 8, 6Hz; lH3, 4.05 ~dd; 8, 6Hz; 1H), 4.14 (s, 2H), 4~20 (m, llH)9 4.40 (dd; 12, 8Hz; lH), 4.94 (d, lSHz, lH~, ~.27 (d, 15Hz, lH), 7.10-7.40 (m, 12H). FA:3~MS: calculated for C37H46Ns~s 641; found 642 ~M+H, 80%).

:

W0 ~4/0563~. 2 1 ~ 2 7 ~ ~ PCI/US93/07791 "

Step D: 3-[2(Sj,3-Dihydroxypropyl]amino-3-methyl-N-[2,3~4,5-tetrahydro-l-~[2'-[~(methyl-aIx~ino3carbonyl~amino]- ' ' methyl~l,1'-biphenyl~-4-yl~methyl]-2-oxo-lH-be~7.~7epin-3(R~-yllbutanamide. trifluoroacetate To a s~lution o~ 137 mc, (0.~13 mmol) of 3~ ,7-dimethyl-1,3-dioxoIan-4(S)-yl3me~yl]amino-3-methyl-N-[2,3~4,5-tetrahydro-1-~[2'-[[[(methylamino~carbonyl]a~o3methyl~[1,1'-biphenyl3 4-yl]-me~hy~j-7-Q~o-l~-~n7~7~pin-3~R~-yl~ ";d~ (~p Cj in ~ m:L, of me~anol was added 2.0 mL of SO~o aqueous trifluoroacetic acid. The 0 resulting solution was sti~Ted at room temperature for 3 hours at which ~:
time the solvent was removed Imder vacuum to ~i~e a solid which was purified by reverse phase medium pressure liquid chromato,~raphy on C-8, eluting u~h me~anol/~.1% aqueous triflusroacetic acid (55:45), to a~rd 108 mg (70%) of the title compound as a white solid. lH N~
(200 MHz, CD30D)- ~ 1.3~ (s, 3H), 1.37 (s, 3H), 2.02-2.22 (m, lH), 2.~2-2.43 (m, lH), 2.50-2.70 (m,4H), 2.64 (s73H)~ 2.94 (dd~ 12, 9Hz;
lH~, 3.17 (dd~ 12, 3~; 1~), 351 (m, 2H), 3.82 (m7 lH), 4.16 (s, 2H)~
4.38 ~da, lZ~ 8~;:1H~, 5.~3 (d7 1~, lH), 5.14 ~d, I5Hz, lH), 7.1~-7.40(m,12H). FAB-~S:calculatedforC34H~3NsOs601;found 602 20: (M+H, 40%).

~ 2-Amin~-2-me~yl-N-[2~3~4~s-getrahyd~o~ 2~ E(cyclopropylamino) 2s carbonyI~minojmethyI]~[I,I9-biphenyl]4-ylJmethyIJ~2-oxo-lH-benzazepin-3(R)-yllpropanamide~ tT~ifluoroacetate ' 3 0 ' , , 2~42~07 : :
W0 94/05634 P~lUS93/07791 ~

Step A: 2-Benzylo~ycarbonylamino-2-methyl-N-[2,3,4,5-tetra- ~ ::
hydro-1-[[2'-~[[(cyclopropyl~mino)carbonyl]arnino~methyl]- :'[1,1'-biphenyl]-4-yl]methyl~ 2-oxo-lH-benzazepin-3~1R)-yl]-propanamide . ~ .
~repa~ed fr~n 2-benzylo~ycar~onyl~mo-2-methyl-~-[2,3,4,5-tetrahydro-2-axo-1-[~2'-(aminome~yl)[1,1'-biphenyl]-4-yl]-me~ylJ-1H-berl7.~epin-3(O-yl]propanarnide, hydrochloride (Example ~: 3~ Step 1) arld ~yclopropyl amLne ac~oraiIlg IO ~ proc~re desc~i~d :
:~ in Example 46, ~tep A. lH NM~ (200 MHz, CD3OD~. ~ 0.39 (m9 2H), 0.61 (m, 2H), 1.38 (s, 6H), 1.82 (m, lH), 2.18-25g (m, 4H), 4.18 (s~
2H), 4.32 (m, !H), 4.86 (d, 15Hz, lH), 5.00 (s, 2H), 5.21 (d, 15Hz, lH), 7.10 (m9 lH), 7.14-7.40 (m, 16H). F~3-~S: calculated for ~ ;~
C40H43N505 673; found 674 (~I~H, 70%).

Step B: 2-Amino-2-me~yl-N-[2,3,4,5-tetrahydro-1-[[2'-[[[(cyclo- ~
~:~; propylamino)carbonyl]amino]methyl3~1,1'-bipheIlyl]4-yl]- ;.
:; ~ methy~3-~-oxo-lH-benzaze~in-3(3~)-yl]~ mi~e, , . ..
~: ~ trifluoroacetate : The title compound was prepar~d fr~rn 2-berlzyloxy-a~bonylammo-2-methyl-N-~2~3,4,5-~etrahydro-1-[[2-E~E(cyelopropyl-amino)caroonyl]amino]me~yl~1 ,1 '-biphenyl]-4-yl]methyl]-2-oxo-lH-benz~7epin-3(Rj-yl3propanamide (Step A) according ~o the procedure described L~ F,~mp]e 36, S~ep C. lH NMR ( 00 M~, CD30D): ~ 0.39 (m, 2H3, 0.62 (m, 2H), 1.~3 (s, 3H), 1.62 (s, 30, 2.10-2.45 (m, 3H~, ' 2.S8 ~m, 2H), 4.19 (s, 2H), 4.37 (m, lH), 4.98 (di 15Hz, lH), 5.20 (d, ~SHz,lH)?7.08-7.40(m,12H)~ FAB-MS:calcula~edforC32H37NsO3 539; found 540 (M+H, 80%).
:

: , : 2-Amino-2-met~yl-N-[2,3,4,5-tetrahydro- 1 -[~2'-~[(methyl~ino)-carbonyl]amino]methyl]-3-bromo-~ 1,1 '-biphenyl]4-yl]methyl]-2-oxo-: IH-benzazepin-3(R)-yllpropanamide .

~: WO 94/05634 2 1 4 2 7 0 7 P~tUS93107791 - ~

Step A: 4-Methvlphenvltnmethvlstannane To a solu~on of 546 g (2.74 mol) of trimethyltin chloride in tetrahydrofurall (4L) under nitrogen at -10~C was added dropwise, m~int~ining ~e ~emperature b~low 5~C over 4 hours, 4 14 L of 1.0 M .~ .
5 ~tolylr~eciuI;l bromide ~ diethyl ethe~ (4.14 moI, 1.S eq.). The suspension was allowed to waIm slowly to room temperature over 12 ~::
hours then saturated ammor~ium chloride solution (1~) was added :.
fol~owea by s~ imr wa~r (a~ le~y lL) to dissolYe the precipitate~ Thé solution was extracted with ether-hexane (1:1) (1 x 4L, ~;
3 x 2L). The ~ombined organic phases were washed with bline, dried over m~gnesium sulfate and the solvents removed under vacuum~
Purification by flash chromatography on silica gel eluting with hexa~}e~e~yl acetate (95:5) gave a pale yellow oil conl,~;ni~g white crystals of 4,4'-dimethylbiphenyl which were removed by fl1ltration to leave~ 698 g (100%) of product. 1H NMR (300MHz~ CDC13): ~ 0.30 (s, ' ~;
9H), 2.34 (s, 3H)~ 7.19 (d, 7.7Hz, 2H), 7.40 (d, 7.7Hz, 2H).

Soep B: ~'-hlethvl~ bipnenvl-2-n~rile A solu~ion of 2.00 g (11.0 mmol) of 2-bromobenzonitrile, 2.93 g (~1.5 mmol) o~ ~me~hylphenyltrimethylst~nn~ne (Step A) and 0.3g5 g (0.550 ~ol) of bis-triphenylphosphine palladium (II) chloride :~: in 50 mL o~ dry dimethylformamide under nitrogen was heated at ~;
lOO~C for 5.5 hours. I~he reachon was ~ooled to room temperanure, ~
:: : poured into 150 mL, of water and extracted Wi~1 e~er (3 x 150 mL).
:~ 25 ~e combined:ether extracts were washed with water (4 x 100 mL) and brine (100 mL), dried over m~nesium sulfate, filtered ~d the solv~nts '' remove~ u~der vacuum. Purification by fl~sh ehromatography on silica gel? eluti~g wi~ hexane/ether (85:15), afforded 1.69 g (80%) of the product cont~min~ted with about 10% of 2-methylben~onitrile. lH
3~ ~ (200MHz, CDCl3): ~ 2.40 (s, 3X), 7.27 (d~ 7Hz, 2H3, 7.30-7.6~ ;
(m, SH), 7.72 (d, 6Hz, lH). EI-MS: calculated for C14HllN 193;
found 193 (M~, 100%).
.

2 1 4 2 ~ 0 ~
~O 94/0~634 P~/US93/07791 ~_ Step C: 3'-Bromo-4'~methvl~ biphenyl-2-rlitrile A solution of 5.2 g (~7 mmol) of 4'-methyl-1,1'-biphenyl- :
2-nitrile (Step lB).Ln 60 mL of methylene chloride ~t 0 C was treated with 6.7 g of silver trifluoroacetate (30 mmol). W~en all the silver s triflu~roace~ate was dissolved, 1~5 mL of ~iu~ e was added dmpwisa (4.95 g, 31 mmol) wi~ vigorous stirring. After two hours, the reaction mixture was filtered and dle solid washed wi~ methylene chloride. The com~ed OI~Ili~ layers were washed onc~ wirh dim~ (<1~j aq~eous : sodium hydroxide and once with br~ne. The organic layer was removed, dried over magnesium sulfate, fi1ltered and coneentrated under vacuurn. The residue was puri~led by preparative high pressure liquid :~
chromatography on silica, eluting with 10% ether/hexane to give 3 g (41%) of product. 1~ N~ (200~IHz, CDCl3): ~ 2.46 (s, 3H), 7.2-7.8 (m, 7H). ~ :

Step D: 3~Bromo-4'-bromometh~ 1 '-biphenyl-2-nitrile ~::: A solution of loO g (3~7 mmol) of 3~romo ~'methy~
blphenyl-2-nit~iIe (Step C) in 1~ mL of carbon tetra~hloride under a 20 nitrogen a~nosphere was treated wi~ 0.720 g (4.~ mmol) of :~ ~ N-bromosucei~ ide followed by 60 mg ~0.37 mmol) of azobisisobutyrv~ e (AIBN). The reaction mixtur~ was heated at .: reflux for four hours, cooled to room temper~ture and ~iltered throu~h : ~ Celite. The sol~ent was removed u~der v~c.nllm ~d th~ residue was ' 2s ~di~s~lved in methylene :chlonde and treated with decoloIizirlg carbon.
The solid:s were filtered through Celite and the solvent removed under va~uum. The resulting solid was triturated with cold ether, filtered and :~ ' ; air dried to afford 920 mg (71 %) of ~e product as an of~-white solid.
lH NMR (2û0MHz, CDCl3): ~ 4.~4 (s, 2H), 7.4-7.8 (m, 7H). EI-MS:
~; 3 0 c~lculated for C14HgBr2N 35 1 ; found 35 1 (M+, 20%); 27 1 (M-Br, 1 00%)-:
:
StepE: 3'-Bromo-4'-acetoxymethyl-1.1'-biphenY1 2-nitrile To a solution of 662 mg (1.89 ~nol) of 3'-bromo-4'-::: bromomethyl-l,it-biphenyl-2-nitrile (Step D) in 10 mL of dry dimethyl WO 94/05634 PCl/US93/07791 ~:
214270~

formamide was added 92S mg (9.43 mmol) of potassium acetate. The reac~ion mix :ure was heated at 50 C for 2 hours then diluted with 100 mL of water. The mixture was extracted with ethyl acetate (3 x 100 ' mL). The organi~ extracts were combined, washed with water (100 mL), sah~ ed aqueous sodium bicar~onate ~100 mL) alld bnn~ (100 rnL). rhe solution was dried over magnesium sulfate, filtered and the solvent removed under vacuwn to give an oil which was purified by flash co~ chTomatogTaphy on si~ica gel, ~iuii~ ~ h~
acetate (7S:25), to afford 4~ mg (64%) of the product as a white solid.
lH NMR (200MHz, CDC13): ~ 2.14 (s, 3H), S.22 (s, 2H), 7.4-7.8 (m, :
7H). EI-MS: calcula~ed ~or C16H12BrNO2 329; found 329, 331 (M~?
7%); 270, 272 (M-Br, 100%).
, Step F: 3'-Bromo-4'-hvdroxymethvl-1 .1'-b;phenvl-2-nit~le ~: .
Prepared fronn 3'-bromo-4i-acetoxymethyl-1,1'-biphenyl-2-nitrile (Step E) according to the procedure described in Example 48, :~
Stsp ~. lH N~iR (2~)MHz, CDCl3): ~ 2.04 (s, lH), 4.19 (s, 2H), 7.35~
7.8(m,7H). ElMS:calculatedforC14HIoBrNO287,289; ~ound ~:
287, 289 (M~, 5~o), 269, 271 (M-H20, 100%).

Step G: ~ 3'-Bromo-4'-t-butyldiphenylsilyloxymethyl-1,1 '-biphenyl-2-nitrile To a so~ution of 670 mg ~2.35 mmol) of 3'-bromo~'- ::
2s hydroxymethyl-1~1'-biphenyl-2 nitlile (Step F) in 5 mL of dry dimethyl~orm~mide Imder a nit~ogen atmosphere was added 237 mg (3.49 mmol) o~ imidazole. The r~action mix~ure w~s cooled to 0~C and 0.73 mL (2.8 mmol) o~ t-butylchlorodiphenylsilane was added dropwise by syringe over S minutes. The resulting solu~ion was s~imed at 0 C
3~ ~or 15 ~ s then at room temperature for 2 hours. The reaction mi~re was poured into 100 rnL of water and extracted with e~er (3 x :: 75 ~). The combined ether extracts were washed with water (75 mL), saturated aqueous sodium bicarbonate (75 mL~ and brine (7~ mL).
The organic layer was dried over magnesium sulfate, filtered and ~he solvent removed under vacuum to give an oil which was punfied by 21~27~
WO 94/05634 PCI'/US93/07791~--' flash column chromatography on silica gel, eluting with hexanes/ethyl .
acetate (9:1), to afford 1.24 g (100%) of the product as a clear oil. lH
NMR (200MHz, CDC13): ~ 1.13 (s, 3H), 4.80~(s, 2H), 7.30-7.50 ~m, ~ ~
9H), 7.55-7.80 (m, 7H), 7.86 (d, 8Hz, lH). F~B-MS: calculated for ~.
C3~H2gBr~JOSiS26; found527,528~271 (60%) :

StepH: 2'-AminomethYl-3-bromo 1 1'-biphenvl-4-methanol To a solution of 13~ mg (0~ mmol) ol ~'-b~Qmo~'-~-but;yldiphenylsilyloxymethyl-1,1'-biphenyl-2-~itrile (Step G~ in 3 mL of dry methylene chloride under a nitrogen a~nosphere was added 199 mg (0.775 mmol) of tetra~n-butylamrnonium borohydride. The reaction mixture was heated at reflux ~or 8 hours, cooled to room tempe~ature, poured Lnto 25 mL of water and extracted with e~yl acetate (3 x 35 :~:
~). The combined organic e~tracts were washed with water (25 mL), saturated aqueous sodium bica~bonate (25 mL~ and brine (25 mL). The organic layer was dried over magnesium sulfate, fi1ltered and the solvent removed uIlder vacuum to give an oil which was dissol~ed in 3 mL of tet~ y~ an and treated ~ i mL of 6N aque~s hy~rochloric ~:
acid ~be resulting solution was heated at reflux ~or 4 hours, cooled in an ice b~ d quenched with 10 mL of lN aqueolls sodium hydroxide~
The mL~ture was extracted with ethyl acetate (3 x 35 ~). l'he organic ..
ext~acts were washèd wi~ water (25 mL), sarurated aqueous sodium bicarbonate (25 mL) arld brine (25 mL). ~ne or_a~c layer was dried over sodium sulfate, filtered arld ~e solvent removed under vacuum to 2s gIve an oiI which was purified by flash columrl chromatography on silica gcl, eluting with chlorofoIm/10% amunonium hydroxide (33%) in me~anol (9:1), to af~ord 43 mg (57%~ of the product as an off-white solid. lH NMR (200MHz, CD30D): ~ 3.69 (s, 2H), 4.68 (s, 2H), 7.16 30 (dd; 7, 6Hz; 1~I), 7.21-7.41 (m, 4H), 7.47 (dd; 9, 8 Hz; lH), 7.58 (d~
8Hz, lH). FAB-MS: calcula~ed for Cl4Hl~BrNO ~92; found 292, 293 (50%) .

~: 2'-[~(Methylamino)carbonyl] amino~methyl-3 -bromo- 1, l '-. biphenvl-4-methanol WO 94/05634 21 ~ 2 7 0 7 P(~/US93/077~1 ~
' ~'~'.

, . .

To a solution of 68 mg (0.23 mmol) of 2'-aminomethyl-3-bromo-1,1'-biphenyl-4-me~hanol (Step H) in 3 mL of dry methylene --chlorid~ and 1 rnL of dry dimethylfoIm~mide under ni~rogen a~nosphere at 0~C was added 0.015 mL ~0.25 mmol) of methyl i~ocyanate. 'rh~ rea~ion ~ e was st~ d ~or 30 mmlltes at 0~C then diluted with 100 mL of ethyl acetate, washed with water, sa~rated 1l.
aqu ous sodium bicarbonate, saturated a~ueous sodium chloride, dried over m~sitlm s~ e a~d filte~ rne soi~7e~t was removed Imder vacuum ~o give 71 mg ~88%) of the product as a white solid which was used ir~ ~e next step wi~out ~urther puri~lcation. 1H ~MR (200 MHz, CD3OD): ~ 2.64 (s, 3H), 4.20 (s, 2H), 4.69 (s, 2H), 7.16 (m, lH), 7.22- ~
7.43 (m, 4H), 7.50 (d, 2Hz, lH), 7.58 (d, 8 Hz, lH). FAB-MS: ;
calclllated ~r cl6Hl7BrN2o2 349; f~UIld 349' 3sl ( ) Step J: 2'-[~Methylan~ino)carbonyl~am~o]methyl-3~bromo-1,1'-biphenyl-4-methanol~ metharlesul~onate ester Prepared from 2'-~(methylaminio)~onyl~aminio~methyl~
3-bromo~ bipnenyI-4-methanoI (Step 1) ~ccording to the procedure described in Exarnple 48, Step I.: FAB-MS: calculated for C17Hl9BrN2O4S 427; found 427, 429 (ao%)~

Step K: 2-t-Butoxyc~rbonylamino-2-methyl-N-~2,3,4,5-tetrahydro-2-oxo-l H-ben~azepin-3(R~-vllp~op~nide Prepared from N-t-butoxycarbonyl-2-methyl~l~nine and 3~ amino-2,3,~,~-tetrahydro-lH-I-ben7~7epin-2-one (Example 1, Step E) SUbSLiL~ g benzotriazol-l-yloxytripyrrolidinophosphonium hexaifluQrophosphate for benzotna~ol-1-yloxytris(dimethylamino)-phosphoI~ium :hexafluorophosphate according to the procedure dessribed in Example 1, Step I. lH NMR (200 MHz, ~DCl3): ~ 1.47 (s, 3H), 1.52 ~s, 3H), 1.82 (m, lH), 2.50-3.00 (m, 3H), 4.45 (m, lH), 5.05 (s, 2H), ~.37 ~s, lH)t 6.80-7.40 (m, 10H) and 8.65 (s, lH). FAB-MS:
calculated for C22H~sN3O4 395; ~ouIid 396 (M+H, 100%).

:
.

21~270~l WO ~4/0563q PCI/US93/07791~ ~ ' .. ..
',;'~', - 182- :
Step L: 2-t-Butoxycarbonylamino-2-me~hyl-N-[2,3,4,5-tetrahydro-1-[[2' -~[~(me~ylamino)carbonyl~aTnino]methyl]-3-bromo- ~:
~1,1 '-biphenyl]-4-yl~methyl]-2-oxo-l;H-ben~azepin-3(R)-yï~
prnpanamide Prepa}ed ~m 2-t~buto~ycar~ony}~ino-2-meffiyl-~-[2,~,4,~-tetrahydro-2~oxo-lH-be~7.~7.epin-3(R)-yl~ amide (Step K) alld 7'-[[(methylamino)carbonyl~amino3methyl-3-bromo-1, 1'-biphenyl- :
~ me~anol, me~nesulfo~at~ ester (S~ep ~) accor~ing t~ ~e pr~cedure described in Example 3S, Step H. lH NMR (~00 MHz, CDCl3): ~ 1.39 ~;
(s, 1~), 1.41 (s, 3H)~ 1.92 (m, lH), 2.48-2.75 ~m, ÇH), ~.20 ~d, 6H~, 2~), 4.52 (m, 2H), 4.70 (m, lH)~ 4.92 (m, 2H), 7.08-7.3S ~m, lOH) 7.42 (m, lH).

Step M: 2-Arnlno-2-methyl-N-~2,3,4~5-tetrahydro-1-[[2'-~[(methyl-amino)carbonyl3amino3me~yl~-3-bromo-L1,1'-biphenyl3-4- ':
yl]me~yl~-2-oxo-lH-be~zepin~3(R)-yl]proparlamide, tnfluoroacetate To a solution of 146 mP (0.211 mm~l) of 2-t-buto~y-carbonylaInino-2-methyl-N-[2,3,4,~-tetrahydro~1-[[2~ (me~yl- ~.
amino)carbonyl~amirlo~methyl~-3-bromo-[1,1 '-biphenylJ~-yl~methyI~-2- ,', oxo-lH-be~ epin 3(R)-yl~b~lt~n~mide (Step L~ in S mL of methylene chloride was added S drops of anisole followed by 5 mL of tIifluoro-ace~e acid~ The reaction lni~L~I~ was s~i}Ted at room temperature ~or hour then the solvent was removed under vacuum. The residue was purified by reverse ~phase medium pressure liquid ch~omatography on C-8l eluting wi~h methanol/0.1% aqueous t~ifluoroace~ic acid (60:40), to ;.
afford 87 mg (58%) of the title compound as a whilte solid. 1H ~MR
(200 MHz, CD30D): ~ 1.52 (s, 3H), 1.S9 (s, 3H), 2.32 (m, 2H), 2.60-:3.02 (m, 2H), 2.65 (s, 3H), 4.17 (dd; 18, 14Hz; 2H), 4.43 (dd; 12, 9H~;
lH), 4.90 (d, 16~Iz, lH), 5.34 ~d, 16Hz, lH), 7.10~7.42 ~m~ 8H), 7.50 m, 3H). FAB-MS: calculated for C30H34BrNsO3 592; found S93, 595 (100%~.
.;

~: .

:

' WO 94/~634 ~ 1 ~ 2 ~ ~ P~/US93/07791 , ~

EX~MPL~ 53 2-Arr~irlo~2-rnethyl-N-~2,3~4,5-tetrahydro 1-[[2'-~2-~methylamino-carbonyl]~nino]ethyl]~ biphenyl]4-yl~methyl]-2 oxo-lH-ben7~ pm-3(R~-yl~p~op~n~mt~e, ~ifluo~oaceta~e S~ep A: 2'-(2-cy~noe~yl)-1,1'-biphenyl-4-methanol, t-butyl-diphenvlsilyl e~ner To a solution of 1.50 g (3.84 mmol) of 4-(t-butyldiphenyl-silyoxymethyl)phenylboro~ic acid (Example 35, Step C) in 8 mL of dry ' dimethylf~na~ide was added 220 mg (0.19 mmol) of tetralcis-(t~phenylphosphine)palladiumt 1.2 g (5.8 mmol) of tripotassium phosphate and 0.791 g (4.03 mIr: ol) of 2-bromophenylacetonitrile. The resulting mi~ture was heated under nitrogen a~ l~0 C for 3 hours then cooled to room temperature. The reac~ion mixture was diluted with 100 mL of saturated aqueous ammonium chlor~de, ~ sferred ~o a separa~o~y ~nn~l and ~x~racted with e~her ~3 x 150 ml ). I~e co~ned ether extracts were washed with sa~urate~ aqueous sodium icarb~nate (lO0 mL) and saturated aqueous sodium chloride (100 mL), .:
2 dri d over magnesiu~ ~ul~ate and.~ltered. 'rhe solvent was remo~ed under vacuum to give a crude product which was puIified by flash column chromatography on silica gel eluting with hexanes/ethyl acetate (9:1) to ~ord 1~3 g (73%) of tbe product as a clear oil. lH NMR (200 MHz, CDCl3): ~ 1.10 (s9 9H), 3.82 (s, 2H), 4.82 (s, 2H)9 7.18-7.47 (m, 2_ 11H~, 7.50-7.62 ~'~m, 3H), 7.73 (m, 4H). PAB-MS: calculated ~or C31H31NOSi 461; ~und 462 (M~H, 2G%).

Step B: 2'-(2-(:yanoe~h~ biphenyl-4-methanol 3a Prepared from 2'-(2-cyanoethyl)-1,1 '-biphenyl-4-methanol, t-butyldiphenylsilyl ether (Step A) according to the procedure described in Ex~mple 35, Step F. lH NMR (200MH%, CDC13): ~ 1.93 ~s, lH~, 3.60 (s, 2H), 4.73 (d, 4~Iz, 2H), 7.27 (m, 3H), 7.33-7.63 (m, SH). FA.B-MS: ca}culated for C1sH13NO 223; found 222 (M-lH)r 20~5 (M-H20 100%).

7 PCI/US93/07791,_ - 184- :

StepC: 2~-(2-cy~noethy~ biphenyl-~-me~hanol~ t-butyl-dimethvlsilvl ether Prepared ~rom 2'-(2-cyanoethyl)-1, 1 '-biphenyl-4-methanol ~:
S (Step B) substi~ ," t-butyldim~ylsilyI chloridz for t-but~rl~hlo~
diphenylsilane accordin~g to the procedure descnbed ~n Example S2, Step G. lH Nl~ (200 MHz, CDC13): ~ 0.94 (s, 9H), 3.60 (s, 2H), 4.77 ~S, ','~ ), 7,~A (m, 3H), 7.~'0 (m, 4~), 7.52 ~m, 1~ AB-:~IS: c~lcula~ed for C2,1H27NS)Si 337; ~ound 336 (M-H, 10%), 206 (1~0%).
, Step D: 2'-(~-Aminoethvl)-1~ biphen~1-4-methanol ':
Prepared ~om 2i-(2-cyanoethyl)-191'-biphenyl-4-metharlol, t-butyldimethylsilyl ether (Stzp C) according to ~e procedur~ descnbed in E~ample S2, Step H.: lH ~ (200MHz, CD30D): ~ 2.63 (m, 2H), :: 2.75 (m, 2~I), 4.63 (s, ~H), 7.~0-7.32 (m, 6H), 7.39 ~d, 8Hz, 2H). PAB-MS: calculated~rCIsHl7NO227; found242(M~2Li,100%).
..
Ste~ E: 2'-~2-~Me~yl~minocarbonyl]~o~e~vl-l,l'~biphenyl4- ;
; ~ 20 methanol Prepared ~rom 2'-(2-aminoethyl)-1 ,1'-biphenyl-4-methanol (Step D) accnrding to the procedure described in Example 52, Step I.
H NMR (200 MHz, CDC13): ~ 2.56 (d, 5Hz, 3H), 2.70 (t, 8 Hz, 2H)~
2,89 (t~ ~, lH), 3.10 (m7 2H), 4.37 (m, l~I), 4.~2 (t, 6Hz, 1H), 4.67 (d, ~ H~, 2H~, 7.12-7.3Q (I~n, 6H), 735 (d 8Hi!? lH). FAB-MS:
calculated ~or C17H20N202 284; fouu~d 285 (M~H, 100%).

Step F: 2'-[2-[Methylaminocarbonyl]amino]ethyl-1,1'-biphenyl-4-methanol, methanesul~onate ester Prepared from '~ me~ylaminocarbonyl]amino~ethyl-:: ~ 1,1'-biphenyl-4-me~anol ~Step E) accordin~ to the procedure described in Example 48, Step 1.

W094/~S63~ 27~ PCI/US93/07791 , . ;

"',~
- lgS - ', Step G: 2~t-Butoxycarbonylamino-2-methyl- -[2,3,495-tetrahydro-1 -[~2'-[2-[[me~ylaminoearbonyl]amino~ethyl]~l ,l '-biphenyl]~-yl~me~yl~2-oxo-lH-ber~7.~7epin-3(0-vllpropaIlamide , .
Prepar~d from 2-t-~uto~ycar~onyl~m;n~2-m~thyl N-~2,3,4yS-tetrahydro~2-oxo-lH-benzazepin-3(R)-yl~proparlamide ;::
(Example 52, Step K.) and 2'-~2-~methylaminocarbonyl]amino]e~yl-l.l'-~phe~yl~-metha~oL me~esulfonat~ es~er (~tep ~) ~C~ g to the procedure described in Example 35, Step H. 1~ NMR (200 MHz, CDC13): ~ 1.39 (s, 12H), 1.41 (s, 3H), 1.8S (m, lH), 2.40-2.80 (m, 8H), 3.13 (m~ 2H), 4.25 (m, 2H), 4.47 (m, lH), 4.94 (d, 16Hz, lH), 4.96 (s, lH), 5.11 (d, 16Hz, lH), 7.08-7.20 (m, 12H). FAB-MS:
cal~ulated for C36H4sNsos 627; ~ound 628 (~I~H, ZO~o), 528 (100~)-Step H: 2~Amino-2-methyl-~-~2,3,4,5-tetrahydro~ 2'-~2~ t.' knethyl~minoc~rbonyl]amirlo]e~hyl][l,l '-bipherlyl'14- ' ' ylJme~yl]-2~xo-lH-b~n7~epin 3(R)-yl}prop~n~micle~
tr;fl~oroacetate The title compound was prepared from 2-t-butoxy-carbvrylamino-~-me~yl- -~2,3,4,5-tetr~hydro-1-[[2'-[2-[[methyl~ino-c~ol~yl]amirlo3edlyl][1,1'-biphenyl]~-yl~rne~yl3-2~oxo-lH-benz-: azepin-3(R)-yllprop~namide (S~ep G) according to ~le procedure described in Example 52. Step M. ~H N~R (200 ~z, (~D3013):
:~ 1.53 (s, 3H), 1.62 (s, 3H), 2.25 (m, 2H), 2.59 (m, 5H), 2.67 (t, 7Hz, 2H), 4.37 (dd; 12, 9Hz; lH), 4.96 (d, lSH~,lH), 5.21 (d, 15H~, lH), 7.08-7.38 (m, 12H). FAB-MS: calculated for C31H37N~O3 527; found 528 (M~H, 100%).
:
3~ XAMPLE 54 : ~ 2-Amino-2-me~hyl-N-[2,3,4,5-tetrahydro-5-[~2'-[[~(methylarr~ino)-carbonyl~ ~ino~methyl][1,1'-biphenyl]~-yl]methyl]-4-oxo-1,5-benzothiazepin-3(S)-yllpropanamide. trifluoroacetate 21~27 0~
WO 94/OS63~, P~/US93/077~--- 1 ~6 - ; :
Step A: 2-t Butoxycarbonylamino-2-methyl-N-[2,3,4,5-tetrahydro-4-oxo-SH- 1 .5-benz~thiazepin-3 (S)~vllpropanarnide Prepared from 3(S)-amino-2,3,4,5-tetrahydro-1 ,S-ben~o-~iazepin~5H)-one (prepared ~rom D-cysteine (S-cysteine) and 2-5 ~uoro-l~itrobe~ ,ne ~y ~e ;nethod of Slade, e1 A~l, J. A~ed. Chem., ~, 1517-1521 (1985)) and ~-t~butoxycarbonyl-2-mëthyl~l~nine by the procedure descri~ed in Example 1, Step I. lH NMR (200~Iz, CDCl3): . -1,2Z (s, l~I), 2.86 ~t, I2Hz, 1~, 3.8~ (dd; 11, 7~z; IH), 4.6~ (m, lH), ~.93 (s, lH), 7.07 ~dd; 8, 6Hz; lH), 7.10-7.40 (m, 3H), 7.60 (dd; 8, 6Hz; lLH), 8.0 (br s, lH). FAB-MS: calculated for ClgH2sN3OdS 379;
~und 380 (M~H, 45%). , :

Step B: 2-t-Butoxycarbonylamino-2-methyl-N~2,3,4,5-tetr~hydro-5 ~ 5-[~2'-[[[(methylamino)carbonyl]arnino]methyl][l,l'-biph~nyl3~-yI]methyl]4-oxo-1,5-ber~o~iazepLn-3(S)-yl]-propa~amide P~ d from 2-t-butoxycar~nyl~mino-~-methyl- -~2,3,4,5-tetrahydro~-oxo-SH-1,5-ben~ot~i~7epin-3(S)-yl~propanamide 0: (Step A) and 2'-[[(methyl~mino)carbonyl3amL~o]methyI-1,1'-biphenyl~- !~
met~ ol, methanesulfona~e ester (E~ample 48, Step 1) a~cb-d,.lg to the procedure desc~ibed in E~ample 35, Step H. 1 H NMR (200MHz, CDCl3): ~ 1.34 (s, 15H), 2.6Q (d, SHz, 3H), 2.78 (t, 12Hz, lH), 3.77 ~: (dd; 11~ 7Hz; lH), 4.20 (d, 4Hz, 2H), 4.62 (m~ lH), ~.93 ~s, 1H~, 4.98 25: ~d, 16Hz, lH), S.15 ~d, 16Hz~ lH), 7.10-7.47 (m, 11H), 7.58 (dd; 8, 6Hz; lH3. ~AB-MS: calc~ e~forC34H41NsOsS 631; found 632 (M~H, 20%).

Step C: 2-~mmo-2-methyl-N-[~,3,4,5-tetrahydra-5-[~2'-~[~(methyl-3 0 : amino)carbonyl]amino]me~yl~ biphenyl]-4-yl]me~yl~-4-oxo- 1 ~5-benzothiazepiIl-3(S)-yllpropanamide he title connpound was prepared ~rom 2-t-butoxy-call,ollylamino-2-methyl-N-[2,3,4,5-tetrahydro-$-~[2'-[~(methylamino)-~arbonyl]amino]methyl][ 1,1 '-biphenyl]~-yl]methyl]-4-oxo-1,5-benzothiazepin-3(S)-yl~propanamide (Step B~ according to ~e WO 94/05634 ~ 1 ~ 2 7 0 7 P~/US93~07791 :;

-187- ' procedure described in E~ample 52, Step M. lH NMR (200MHz, CD30D): ~ 1.5Z (s, 3H), 1.59 ~s, 3H), 2.64 (s, ~H), 3.17 (t, 12Hz, lH), 3.56 (dd; 12, 8Hz; lH), 4.14 (s, 2H), 4.57 (dd; 12, 8H~; lH), ~.05 (d, 16Hx, lH), 5.20 (d, 16~z, lH), 7.08-7.50 (n[l9 llH), 7.62 (d, 7Hz; lH). i:
FAB-MS calculat d~rc2~H33NsO3ss3l; fo~dS32( 100%). ' ", 2-Amino-2-me~yl-N-~2~3,4~5-tetrahydro-5-~2'-~(methylamino)-carboIlyl~arr~ino~methyl~[l,l '-biphenyl]-4-yl]methyl~-8-fluoro-4-oxo-1,5-benzothiazepin-3(S~-yllpropanamide trifluoroacetate Step A: 2-t-Bu~oxycarbonylamino-2-methyl-N-~2,3,4,5-tetrahydro-8-~luoro~-oxo-SH-1,5-benzo~hiazepi:n-3(S)-yl]propa : ~ ~ amide Prepa~ed from 3(S)-aminQ-8-fluoro-~,394,5-tetrahydro-othia~ep~4(5H)-one (prepared from D-cyste~ne (S-cysteine) ;~ 2~ and 2,4-difluoro-1-nitrobelLzene by ~e me~hod of Slade, et al, J. Med.
Chem., 28, 1~17-lg21 (1985) used for the preparation o~ 3(S)-arnino-2,3,4,5-tetrahydro-1,5-benzothia~epin~(5H)-one) and N-t-butoxy-carbonyl-2-me~hyl~lanine by the procedure described in Example 1, Step I. lH NMR (20~)M~ COC13): ~ 1.42 (s, 15H), ?.90 (t, 12Hz, lH), 3.83 (dd; 11, 7Hz; lH), 4.63 (m, lH), 4.97 (s, lH), 7.04 (m, 2H), 7.31(m,2H),8.33(s91H). FAB-MS: calcula~ed~orClgHE2sF~3O4S
: 397; found 398 (M+H, 45%).

Step E~: 2-t-Butoxycarbonylamino-2-methyl-N-[2~3,4,5-tetrahydro-~0 5-[~ [~1(~ethyl~mino)carbonyl]amino~methyl][1,1'- ;
biphenyl~-4-yl]methyl~-8-fluoro-4-oxo-1 ,S-ber~o~iazepin-- 3(S)-yllpropanamide Prepared from 2-t-butoxycarbonylarrlino-2-methyl-N-[2,3,4,5-tetrahydro-8-fluoro-4-oxo-5H-1,5~ben~othiazepin 3(S)-yl]-propanamide (Step A) and 2'-[~(methylamino)carbonyl~amino]me~yl-21~270 7 WO 94/05634 PCr/US93/0779l--1,1'-biphenyl-4-methanol, methanesulfonate ester (F.xample 48, Step I) ...
according to the procedure desc~ibed in Example 35, Step H. 1H NMR . ::
(200MHz, CDC13): ~ 1.39 (s, 15H), 2.62 (d, SHz, 3H), 2.80 (t, 12Hz,.
1H), 3.75 (dd; 11, 7Hz; lH), 4.22 (d, 4Hz, 2H), 4.48 (m, lH), 4.68 (rn, .
lH), 4.92 (s, lH), 4.96 (d, 15~, lH), 5.08 (~1, 16Hz, lH), 7.10-7.''7 ~;n, ~;
11H). FAB MS: calculated for C34H40FNsOsS 649; found 650 ~M~H, 15%).
. .
Step C: 2-Amino-2-methyl-N-[2,3,4,5-tetr~hydro-5-[[2'-~[[(me~hyl- ~;
a~r~ino)carbonyl]~nino]methyl] ~ l ,1 '-biphenyl]~-yl]methyl]-8-fluoro-4-oxo- 1 ,5-benzothiazepin-3(S)-yl]propanamide, .
trifluoroacetate The title compound was prepared ~rom 2-t-butoxy-carbonyl~mino-2-methyl-N-~2,394,~-tetrahydro-5-[~2'-[[[~me~hylamino)-15 carbonyl]amino]methyl~[l,1'-biphenyl]-4-yl~methyl]-8-fluoro~-oxo-1,5-benzo~iazepin-3(S)-yl~r~allamide (Step B) according to the proced~re described in Example 52, Step M. lH NMR (200~Iz, D3~D): ~ 1.53 ~s, 3~, ~.60 ~s, 3H), 2.~4 ~s, 3H~, 3.19 ~t, ~2E~z, 1~)~
3.59 (dd; 12, 8Hz; lH), 4.14 (s, 2H), 4.57 (dd; 12, 8H~; lH), 5.00 (d, ~ 16Hz, 1~), 5.~.2 (d7 16Hz, lH), 7.08-7.43 (m, 1ûH), 7.59 ~dd; 9, SE~
lH). FAB-MS: calculatedforC2gH32FNsO3S5~g; f~undSjO~M+H, 60%).

2s 2-Amino-2-me~yl-N-[7-fluoro-2,3,4,5-tetrahydro-1 -~2' -[E~(me~yl-amino)carbonyl]aIxlinoJmethyl][l,1'-biphenyl]-4-yl]me~yl]-2-oxo-lH-benzazepin-3(R~ llpropanamide. hydrochloride :
3 St~p A: 3(R)-amino-7-nitro-2,3,4,5-tetrahydro-1H-1-benzazepin-2-one To a solution of 440 mg (2.50 mmol) of 3(R)-amino-293,4,5-tetrahydro-lH-l-benzazepin-2-one (Example l, Step E) in S rnL
of concentra~ed sulfuIic acid at 0~C was added 265 mg (2.63 mmol) of WO 94/0~634 21~ ~ 7 ~ 7 PCI/IJS~3/07791 , ....
potassilLm nitrate. The resulting yellow solution was stirred for 30 ~.
minutes at then at room temperature for 24 hours. The reaction :' ule was poured carefully i~to 100 g of ice and the pH of ~e resulting mixture was adjusted to 11 by the portionwise addition of so~ium carb~nate. The ~ , was transfe~Ted to a s~para~ory ~ el and extracted ~oroughly with ethyl acetate (4 x 100 mL). The organic extracts were combined, washed with brine (100 mL), dried over sodilIm suIfa~ ~d fil~er~d. Th~ soiveIlt was removed lmder ~-a~ to ~.
a~ford 3~5 mg (70%) of the product as a yellow solid. lH NMR (200 L~
MHz, CDCl3): ~ 1.58 (S? 2H), 1.98 (m, lH)~ 2.47-2.70 (n, lH), 2.72-3.05 (m, 2H), 3.40 (dd; 11, 8Hz; lH), 7.07 (d, 8Hz, lH), 7.92 (s, lH), :
arld8.10(m,'1H). FAB-MS: calcula~dforCloHllN303221; found 222 (~H,100%).

Step B: 2-Benzyloxycarbonylamino-2-me~yl-N-[7-nitro-2,3,~,5-tetrahvdro-2-oxo-lH-l-benzazepin-3~ yllp~opanamide Prepared f~m N-carbobe~yl~xy-2-methylalanine and 3(R)-amino-7~ ro-2,3,4,j-te~anydro-1H-l-b~.n~7epin-~-one ~S~p ~4 subs~ g benzotriazol-1-yloxytripyrrolidinophospho~ium hexa-fluor~phosphate ~or bellzotliazol-1-yloxy~s(dimethylamino)-phosphonium hexafluorophosph~e according to the procedure described in Fx~m~?le 1, Step I. lH NMR (400 MHz, CDCl3): ~ 1.48 (s, 3H), 1.49 (S7 3H), '~ m, 1H), ~73 (m, 2H), 2.9'~ ~m, lH), 4.45 (~ 1H)~
5 07 (s, 2H), S.30 (s, lH), 7.05 (d, 8 Hz~ lH), 7.30 (m, 6H), 8.06 (dd; 8, 6Hz; lH)7 8.13 (d~ 2.5Hz7 lH), 8.35 (s, lH). FAB-MS: calclllated for C22H24N4O6 424; found 425 (M+H, 100%).

Step C: 2-Ber~yloxycarbonylamino-2-me~hyl-N-~7-amino-2,3,4,5-;. , .
3 0 tetrahvdro-2-oxo-l H-l -benzazepirl-3(R)-~llpropanamide To a solution of 310mg {0.73mmol) 2-benzyloxyearbonyl-amino-2-methyl-N-[7-nitro-2,3,4,5-tetrahydro-2-oxo-1H-1-benzazepiII-3(R)-yl3propanamide (Step B) in 20 m~ of methanol was added 78 mg (1.5 mmol) of ammonium chlolide followed by 669 mg (10.2 mmol) of zinc dust. The resul~g mixture was heated at reflux for four hours.

21~27~ ~
~
W0 94/05634 P~/US93/a7791 .~
' ~

.,.
The solids were removed by ~iltration ~hrough Celite. The filter pad was washed with 30 mL of hot me~anol. The filtrate was combined and ~e solvent was removed under vacuum. ~The residue was dissolved ~ ;
in 10 mL of lN aqueous hydrochloric acid and the solids were ~iltered 5 aw~. To the result~g so~ution was added suf~cient 5~ aqueous sodium hydroxide until ~he pH was approx~mately 12. The solutivn was extracted with e~yl a¢etate ~3 x 50 mL). The combined organic ~a~s were washed ~ waler ~n~n DriIle, dried over m~es1um ~: sul~ate and filtered. The svlvent was removed under vacuum to afford 256 mg (85%) of ~e p~oduct as a white solid. 1H N~IR (400 MHz, CDCl3): ~ 1.48 (s, 3H), 1.50 (s, 3~I), 1.78 (m, lH), 2.~7 (m, lH), 2.71 ~' ~m, 1H), 2.82 (rn, lH)9 3.67 (s, 2H), 4.44 (m, lH)7 5.05 (s, 2H), 5.39 (s, 1H), 6.50 (m, 2~I3, 6.74 (d, 8Hz, lH), 7.04 (d, 7Hz, lH), 7.32 (m, 6~
: ~ PAB-MS: calculated ~or ~22H26N4O4 410; found 411 (M~H, 100%). l S
Step D: 2-Amino-2-melthyl-N-~7-fluoro-2,3,4,5-tetrahydro-2-oxo-lH-l-benza~epin-3(R~-YIl-~ropan~mide ~' : To a solunon of 2~6 mg (O.Ç24 mmol) of 2-benzyloxy-carboaylamino-2~methyl-N-[7-amino-2,3 ,4,5-tetrahydro-2-oxo~
ben7.~7epin-3(R)-yl]propanamide ~Step C) in 1.2 mL of water was added 0.171 mL:of concentrated hydrochloric acid. The resulting mixture was stiIIed until all ~e solids were dissolved then ~e solution was ~ ~ cooled to 0~~. To ~his solution was added a solu~on of 5'~ mg tO.75 :; mmol) of sodium nitnte in a minim~l amounk of water. After 30tes at 0~C~ O.I56 mL (1.06 mmol) of 60 weight percent aqueous hexafluorophosphoric acid was added dropwise. Immediately a white precipitate formed. The solids were filtered and washed with ice cold water, dlen air: dried. The resulting solid was dried under vacuum 3 0 over~ ht. ~ ~
T~e solid was slunied in S mL of mesitylene and the flask equipped wi~ a I~itrogen purge was placed in a 165~C oil bath for 5 mimlteS. Rapid gas evolution was observed. The mixture was cooled ~o room temperature and diluted with lQ0 mL of ethyl acetate. The resulting solution was washed with sodium bicarbonate then brine, dried .

WO ~4/05634 2~ ~ g; 2 7 1~ ~i Pcr/US93/0779t ,' ~

.
~ - 191 - .
over magnesium sulfate and ~e solvent was removed under vacuum.
The residue was puriISed by flash col~nn chromatography on silica gel elutLng with chlorofo~m/10% arnmonium hydroxide (33~o) in methanol to a~ford 33 mg (23%) o~ ~e product as an off-white solid. lH NMR
5 (200 MHz, CDC13): ~ 1.30 (s, 6H), 2.10 (m, lH), ?,5Q (m7 lH~, ~73 ~m, 1H), 2.89 (m, lH) 4.32 ~dd; 12, 8Hz; 1H), 5.05 (s, 3H), 7.05 (m, ~: 3H). FAB MS: calculated for C14HlgFN3O2 279; found 280 ~M~H, l~O~o).

StepE: ~-BeIlzyloxycarbonylamino-2-methyl-N-~7 I~uoro-2,3,4,5-tetrahvdro-2-oxo-lH-l-benzazepin-3~R~-vllpropanamide To a solution of 33 mg (0.12 mmol) of 2-amino-2-methyl-N-[7-fluoro-2,3,4,5-tetrahydro-2-oxo-1H-1-benzazepin-3(R)-yl]propan- ~:
amide (Step D) in 1 mL of me~ylene chloride was 32 rng (0.13 mmol) of N-(ben~yloxyca~onyloxy)succinirnide. The sou~ion was stirred at room temperature for 24 hours then ~uenched wi~ 5 drops of 33~o a4ueous:~mmonillm hyd~oxi~. lhe solYent was lemo~ed u~der vacuu n and t~e residue was pur~ed by fiash column chromatog~phy on silica gel eluting with ethyl acetate~exar~es (75:25) to af~ord 25 mg (46%) of the product as an off-white solid. lH NMR ~400 MHz, CDC13): ~ 1.48 (s, 3H), 1.50 (s, 3H), 1.82 (m, lH), 2.56 (m, lH), 2.71 :
(m, lH), 2.86 (m, lH), 4.42 (m, 1H), 5.05 (s, 2H), 5.43 (s, lH), 6~90 (m9 2H), 7.~9 (d, 8~ 1H), 730 ~m~ ~H), 8.09 ~s, lH). FAB-MS:
calculated ~or C22H24PN3O4 413; found 414 (M~, 100%).
2s ~ep F: 2-Benzyloxycarbonylamino-2-methyl-N-[7-fluoro-2,3,4,5-tetrahydro-2-oxo-1-~2'-[(t-butoxycarbonylamino)methyl]-191'-biphenyl~-yl]methyl]-lH-benzazepin-3~R)-yl]-propanamide :~ Prepared ~rom 2-ben~yloxycarbonylamL o-2-me~yl-N-~7-fluoro-2,3,4,5-tetrahydro-2-oxo- lH- 1 -benzazepin-3(R)-yl]propanamide (S~ep E) and 2'-[(t-butoxycarbonylamino)methyl3-1,1'-biphenyl-4-methanol, me~anesulforlate ester (Example 35, Step G) according to the procedure described in Exarnple 35, Step H. lH NMR (200 MHz, 21~270~
WO 94/0~634 PCI'/US93/07791 CDCl3): ~1.39 (s, 9H), 1.48 ~s, 3~), 1.51 (s, 3H), 1~78 (m, 1H), 2.35- .
2.70 (m, 3H), 4.18 (d, 7Hz, 2H), 4.42 ~m, 1H~, 4.58 (m, 1H~, 4.7S (d, ;.
16Hz, lH~, 5.05 ~s, 2H), 5.27 (d, 16Hz, lH), 5.35 (s, lH), 6.88 (dd; 8, 6Hz, lH), 6.98 (m, lH), 7.09 (d, 6Hz,1 H), 7.14-7.35 (m, 13H), 7.40 (d, S 8HZ9 lH). F~-~IS: calculated for C41H4 ~406 708; found 709 (M~
.
Step G: 2-Benzyloxycalbony~amino-2-methyl-N-[7-fluoro-2,3,4,5-tetrahydro-2-oxo-1-~2'-(aminome~yl)[l,l'-biphenyl]-4- ::
yl]methyl]-lH-ben7.~7ep~-3(R)-yl]prop2~amide, trifluoroacetate Prepared ~rom 2-benzyloxycarbonylamino-2-methyl-N-~7- :
fluoro~2,3,4,5-tetrahydro-2-oxo-1-[[2'-[(t-butoxycarbonylamino)-methyl]~l,1'-biphenyl~-4-yl]methyl]-lH-berlzazepiIl-3(R)-yl]propan-amide (Step F) according to the procedure described in Example 36, Step A. lH NMR (200 MHz7 CDC13): ~ 1.40 (s, 6H), 1.90 (m, lH), 2.25--2.6~ (m, 3H~? 4.05 (s, 2~I), 4.3$ ~m~ 1~), 4~78 (d, 16~z? 1H), 4 96 (s, 2~), 5.0S (d, 16H~, lH), 5.55 ~s, lH), ~.90 (m, 3H), 7.00-7.50 (m, 17H), 7.80 (s, lH). FAB-MS: calculated for C36H37FN~04 608;
found 609 (l!~H, 100%).

Step H: 2-BeIlzyloxycarbonylamirlo-2-methyl-N-~7-fluoro-2,3,4.5-tetrahydro~ [2'-[[~(me~yl~no3caIbonyl]a~ixlo]me~yl~-~1,1'-biphenyl~-4~yl~methyl~-2-oxo-1H b~n7~7epin-3(R)-yllpropanamide Prepared from 2-benzyloxycarbonylamino-2-methyl-N-~7-fluoro-2,3,4,5-tetrahydro-2-oxo-l -[~2'-(aminornethyl)[1 ,1'-biphenyl]-4-yl~me~hyl]-lH-ben7.~7epin-3(R)-yl]propanamide, ~rifluoroacetate (Step G) and me~yl isocyanate accord~g to 'che procedure described in Ex~nple 35, Step I. lH NMR (400 MHz, CDCl3): ~ 1.44 (s, 3H), 1.45 ~s, 3H), 1.78 (m, lH), 1.85 (s, lH), 2.30-2.60 (m,3H), 2.57 (d, 4Hz, 3H), 4.18 ~d, 5Hz, 2H), 4.40 (m, lH), 4.62 (m, lH), 4.80 (m, 2H), 5.00 (s, 2H), 5.17 (d, 1$Hz, lH), S40 (s, lH), 6.85 (m, lH), 6.96 (m, lH), W0 94/05634 ~ 7 ~ ?t PCl /US93/07791 ,.~,;,', - 193 - , .
, .. ..
7~08 7.3~ (m, 13H), 7.39 (m, lH). FAB-MS: calculated ~or C3gH40FNsC)s 665; folmd 666 (M~H, 100%).
.. .
Step I: 2-Amirlo-2-methyl-N-Z7-fluoro-~,3,4,5-tetrahydro-1-[~2'-[[~(me~tlyl~minQ)car~onyl]amiIlc]meth~ll[l,l'-biphenyl~
yl]methyl}-2-oxo~lH-benza~epin-3(R)-yl]propanamide, trifluor~acetate 2~B~yloxyca~onyi~mmo-~-me~nyl-~ ~7-i~uoro-~,3,~,$~
tetrahyd~ [2~[[[(methylamino)carbonyl]-amino~methyl] L 1,1 '-biphenyl~ylJme~yl]-2-oxo-lH-ben;~a~e~ -3(R)-yl~propanamide (30 ~:
mg, 0.045 mmol) (Step H) was dissolv~d ~ 1 mL of 30~o hydro~romic ~::
acid in acetic acid. ~e mixture was stirred at room temperature ~r 1 hour~ The solYent was remo~ed urlder vacullm to give a solid which was purified by reverse phase medium pressure liquid chromatography on C-8 eluting wi~ me~anoV0.1% aqueous trifluoroacetic acid (60:40) to a~ford 27 mg ~93%) of the title compound as an of~-white solid. lH
400 MH~ CD30D): ~155 (s, 3H), 1.64 (s~ 3H). 2.28 (m, ZH), 2.62 ~m, 2H), 2.~7 (s, 3H), 4.16 ~s, 2H~, 4.39 (dd; 12, 8Hz; XH), ~.96 :~
(d, 15Hz, lH), 5.25 (d, 15Hz, lH), 7.0~-7.19 (m, 3H), 7.20-7.39 (m~
6H), 7.40 (m, 2~3. ~AB-MS: calculated for C30H34F~lsO3 531; folLnd 532 (M~H, 100%).

EXAMPL~ ~7 3-~2(R)-Hydroxypropyl]amino-3-me$hyl-N-~2,3)4,j tetrahydro-~me~yl~mino)carbollyl]amino]methyl]~1,1'-biphenyl]~-yl]me~yl]-4-oxo-1.5-benzothiazepin-3(5)-vllbutanamide Step A: 3-~2(R)-Benzyloxypropyl]amino-3-methyl-N-[2,3,4,5-tetra-hydro-5-[[2'-[[~(methylamino)carbonyl~amino]me~hyl~[1,1 '-biphenyl34-yl3me~yl~-oxo-1,5-benzothiazepin-3(S)-yl3-bu~anamide Prepared from 2-amino-2-methyl-N-[2,3,4,5-tetrahydro-5-~[2'-[[[~ethylamino)carbonyl]amino]me~yl][1,1'~biphenyl3~~
-21~2~0~
WO 94105634 PCI'/US93/07791 --.
:,..

yl]methyl]-4-oxo-~75-benzo~iazepill-3(S)-yl]pr~pallamide, trifluoroacetate (Exa~nple 54) and (R)-2-benzylox~ropanal (prepared ; :~
~rom methyl D-l~r,t~te according to ~e procedure of Hanessian and ~ I;
Kloss, Tetrahedron Lett., 2~, 1261-1264 (1985) according to the procedure d~scnbed in Ex~nple Ag, Step B.. ' ::
., ~
Step B: 3-[2(R)-~rdroxypropyl]an~ino-3-methyl-N-~2,3,4,5-tetra-hydro-S-lt t~ nyi~mino)ca~ ~nojmei~y}311,1 biphenyl~4-yl3me~yl]4-oxo-1,5-benzothîazepin-3~S)-yl]- ~.
butanamide The ti~le compound is prepared from 3-~2(R)-ben~yl-oxypropyl]amillo-3 -rnethyl-N-[2,3 ,4,S-tetrahydro-5-E[2' -[[[(methyl-ami$1o)car~onyl]amirlo]methyl][1,1 '-biphenyl]~-yl]methyl]~-oxo-1 ,5-benzo~iazepin-3(S)-yl]but~n~nide (Step A) by the procedure described in :Example 49, Step E.

: ' : EXA~PLE 5 - ~ ~
3-[2(S),3-Dihydroxypropyl]amino-3-methyl-N-[2,3,475-tetrahydro-5- ;.
~ ~2'-~[~(me~ylamirlo)car~onyl]~i~o]me~hyl]{1,1'-biphenyl] ' yl~-methyll4-o~o-l.5-benzothiazepin-3(S)-yllbutanamide Stev A:: 3-[[2,2-Dimethyl~1,3-dioxolan-4~5~-yI~me$hyl~mino-3-me~yl-N-[2,3,4,5-tetrahydro-5-[~2'-~[(methyl~ino)-carbonyl]amino]me~yl]~ biphenyl]-4-yl~methyl~-4-oxo-~ benzothiazepin-3(S~-vllblltanamide Prepared from 2-amir~o-2-methyl-N-~2,3,4,5-tetrahydro-5-2'-~(me$hylamino)carbonyl]amino~me~yl][ 1,1 '-biphenyl~-4-yl]-met~iyl1-4-o~o-1,5-benzothiazepin-3~S)-yl]propa~de, trifluoroacetate (Fx~mrle 54) and D-glyceraldehyde acetonide (used cmde as prepared according to the procedure of Hertel, L.W.; Grossm~n, C.S.; Kroin, J.S~
~: Syn. Cornm., 1991, 21, 151-154) by the p~ocedure described in : ~ Example 50, Step B.

wo 94/0s634 2 ~ ~ 2 7 0 7 PC~/USg3/07791 ' ..

- 195 ~
.:
Step B: 3-~2~5~,3-Dihydroxypropyl]amino-3-methyl-N-[2,3,475-tetfahydro-5-~2'-[[[(me~ylamino)carbonyl]amino]methyl]-~1,1'-biphenyl]~-ylJme~ylJ4-oxo-1,5-benzothiazepin-3($)-yllbutanamide s ~ itle compound is ptepared ~rom 3-~q,2~im~hyl-1,3- -dioxolan-4(S)-yl]me~yl]amino-3-methyl-~J ~2,3,4~5~etrahydro-5-~2'-[~(me~ylamino)c~l)ollyl]amino]methyl~[l ,l '-biphenyl]~-yl3~ne~ylJ~4- ,:, o~o-15~ zo~pin-3(~)-yl~bnr~n~rnide (Step A) by ~ne procea~
descnbed in Example 50, Step D.

EXAMPL~ 59 ~:

~: 2-~mi~o-2-methyl-N-[2,3,4,5-tetrahydro-1-[[2'-[~methoxycarborlyl)-amino]me~yl][l,l'*iphenyl]-4-yl~methyl]-2~oxo-lH-benzazepin-3(R)-, : yl]propanamide,:trifluoroacetate .
: ~ :
Ste~ A: 3(R~t-B~toxyearbonylamin~2,3,4,5-~etrahydro-lH-1-benzazepin-~-one To a suspensiorl o~ 576 mg (3.27 mmol) of 3(R) am~no- ~.
273,4,5-tetxahydro-lH-I-b~n7.~7,~pin-2~ne (Examp}e 1, Step B) in SmL
me~ylene chloride at room tempeld~u~ was added 0.46 mL (334 mg, 3.3 mmol, 1.0 eq.~ of trie~yl~mine ~ollowed by 0.75 mL ~712 mg, 3~27 . mmol, 1~1eq) of di-t-butyldicarbonate. The mi:xture was s~irred for 4 hours~ at room temperaffire then added ~o 50 mL of ethyl acet~te and 25 ~ ~ washed with 5% aqueous citric acid ~3~), saturated aqueous sodium bicarbonate and saturated aqueous sodium chloride. The organic layer was removed~ dried over nl~nesi~n sulfate, filtered and solven~s : ~ ~ removed un~er vacuum to give 884 mg (3.20 mmol, 98%) o~ ~ product as a whi~e solid. lH NM~ (200~Iz, CD~13~: ~ 1.40 (s, 9H), 2.00 (m, 30 lH), 2.65 (m, 2H), 2.95 (m, lH), 4.2Q (m, lH), 5.42 (br d, 8Hz, lH)9 6.97 (d, 7Hz, 1H), 7.2 (m, 3H), 7.50 (br s, 1H).

StepB~: 3(R)~t-Butoxycarbonylamino-2~3,49~tetrahydro-1-[[2'-cvanoJ 1~ biphenvll-4-~1lmethyll- 1 H-benzazepin-2-orle WO 94/05634 PCrtUS93/07'791i~

- 196 - :
..:.
Prepared from 4'-bromomethyl-1,1'-biphenyl-2-rlitrile ~ , ' (prepared by ~e method of M. Fisher, et al, U.S. 5,206,235) and 3(R)~
t-butoxycarbonylamino-2,3,4,5 ~ tetrahydro- lH- l -benzazep~-2-one (Step A) by ~e procedure described in Fx~mple 19.Step Q. lH NM~ (400 ~:
MH~,CDC13~: ~139(s,9H~,1.90~m,l~),2.'~2.60~ml3~ 8 (m, IH~, 4.94 (d, 15Hz, 1H), 5.20 (d, 15Hz, lH), 5.43 (d, 7Hz, lH), 7.1-7.3 (m, 4H), 7.33 (d, 8Hz, 2H), 7.35-7.50 (m, 4H)9 7.60 (t, 8~Iz, lH), 7.72 (d~ 8H~ ~; calculat~d for C2gH~gN3O3 467; rouDd 468 ~M~H, 15%), 368 ~M-BOC, 100%).
a ,.
Step C: 3(R)-t-Butoxycarbonylamino-2,3,495-tetr~ydro-1-~[2'-aminomethyl[l,l'-biphenyl]~-yl3me~hyl~-lH-benzazepin-2-one To a solution o~ 200 mg (0.43 mmol) o~ the intermediate 15 obtained in Step B in S ml, of ethanol was added 5 mL of liquid ammonia arld the result~ng mixture hydrogenated at 200-400 psi and 80~C f~r 6 hours over 60 mg of Ra~ey ~i~kel. The re~ction ~ e was ca~tiously vent~d and al~ voIat~Ies removed by a steady stream of : nitrogen. l~e residue was redissolved in chloroform, filtered through elite :and ~he lSltrate concen~ated u~der vacuum to gi~,e 1~9 mg (0.32 mmol, 74%) of the product as a white fo~ which was used without puAfication.

Step D: 3(R)-t-ButoxyearbonylamiIlo-2,3,4,~-tetrahydro-1-E~2'-?5 ~ ~ ~[(methoxycaIbonyl)at~lino~methyl][~ bipheIlyl~-4-yl]
methyll-1 H-~enzazepin-2-one A solutiotl of 31 mg (0.066 ~ol) of ~e inteImediate obtained in Step C in 1 mL of methylene chloride at room temperature was treated with 1 drop of triethylamine followed by 5 ~L ~6 mg, 0.067 mmol, 1 eq.) of methyl ~hlorofolmate. The mi~ture was stirred at room temperature for 1 hour then diluted in~o 10 ml;, of ethyl acetate ~' ' : and washed with 5% aqueous citric acid ~and saturated aqueous sodium chloride. The organic layer was removed, dried over m~nesium sulfate, filtered and solvents removed under vacuum. The residue was :. ~
~ .

W~ 94/05634 2 ~ ~ 2 7 ~ 7 ~/US93/07791 - 197- ~
puri~ied by medium pressure liquid chromatography on silica, eluting :
with S~o methanol in ethyl acetate, to give 33 mg ~ 0.062 mmol, 95%) of ~e product as a colo~less glass. lH NMR (400 MH~, CDC]3):
~1.38 (s, 9H), 1.91 (m, lH), 2.43-2.60 (m, 3H), 3.62 ~s, 3H), 4.26 ~m, 3H3, 4.68 ~Dr t, 1~), 4.93 (d, l~ ), 5.18 (d, lSHz, lH), S.A~ (~r d, 7Hz, lH), 7.13-7.35 (m, 1 lH), 7.41 (d, 8Hz, lH). FAB-MS: calculated . ::
for C31H35N3Os 529; ~und 530 (M~H, 25%), 430 (M-BOC, 100%). ' Step E: 2-t-Butoxycarbonylamino-2-methyl-N-~2,3,4,5-tetrahydro-0 1 ~2'~ me~oxycarbonyl)amino]methyl]~1,1'-biphenyl]~-vllme~vll-2-oxo-1H-benzazepin-3(R~-vllpropanamide A solution of 33 mg ( 0.052 ~ol) of ~e intennediate ~;
obtamed in Step D in 2 mL of methanol at room temperature was treated with 0.5 mL of concentrated hydrochloric acid. After 2 hours~
solvents were removed uhder vacuum and the residue further d~ied under high vacuum for 1 hour.
The ~e hyd~hlonde obtained abo~re w~s taLen up in 1 : ~: mL o~ me~ylene chloride an~ treated wi~h 13 mg ~ 0.064 mmoI, 1 .~J3 eq.) of N-t-butoxycarbonyl-a-methyl~l~n;ne, 26 ,uIJ of tnethyl~îne (19 mg, 0.19 mmol, 3 eq.~ and finally, 49 mg (0.094 mmol, l.S eq.) of :~ benzotriazol-1-yloxytripyrrolidinophosphonium hexafluorophosphate.
A~er stimng at room temperature for 1 hour, the reaction mixtl; re was diluted i~to 10 ~ of ethyl actetate and washed ~7ith 5% a~u~ous citric acid, saturated aqueous sodiurn bicarbonate and saturated aqueous S sodium chIoride. The organic layer was rcmoved, dried over m~nesium sulfate, filtered and solvents removed under vacuum. The residue was pùrified by m~dium pressure liquid chroma~ography Oll : :~ silica, eluting wi~ e~yl. acetatc, to give 37 mg ( 0.060 xnmol, 96%) of the product as a clear glass. lH NMR (400 MHz, CDC: 13): ~ 1.41 (s, 9H), 1~42 (s, 3H), 1.44 (s, 3H), 1.84 (m, lH), 2.40-2.6~ (m, 3H), 3.61 (S9 3H), 4.24 (d, 6 Hz, 2H), 4.48 (m, 1H), 4.68 (br t, lH), 4.89 (d, lSH~, lH), 4.91 (br s, lH), 5.2~ (d, 15Hz, lH), 7~15-7.35 (rn, 11H), 7.40 (d, 8Hz, lH). FAB-MS: calculated for C3sH~2N4O6 614; folLnd 615 (M+H, 5%), 515 (M-BOC, 100%).

:

2~ 9~490~63-~ PCI/U593/07791._ ,''~
Step F: 2-Amino-2-methyl N-~2,3,4,5-tetrahydro~1-[[2'-[[(me~oxycarbonyl)amino~me~yl~[1,1'-biphenyl]~-yl]- - ~:
methyI]-2-oxo-1H-ben7.~7.epiIl-3~R)-ylJprop~n~mide, trifluoroacetate ::
A solution of 35 mg ( 0.057 mmol) of ~e intermediate o~tained in Step E in 1 mL of methanol at room temperatllre was l,:
~a$ed with 0.~ mIJ of conc~n~rated hyd~oc~lor.c acid. A*~r 3 nours, solvents were removed urlder vacuum and the residue puri~ied by medi~n pressure liquid chromatography on C8? elut~ with ::
me~anol/0.1 % aqu~ous trifluoroacetic acid (65:35), to give 35 mg ~0.055 mrnol, 98%) of ~he title compourld as a colorless glass. lH NMR
(400 MHz, (:D3C)D): 8 1.55 (s, 3H), 1.64 (s, 3H), 2.27 (m, 2H), 2.61 (m, 2H), 3.60 (s, 3H), 4.14 (s, 2H), 4.40 (m, lH), 5.02 (d, 15H~, lH), 5.22 (d, l~Hz, IH), 7.14 (d~ ~ H~, lH), 7.20-7.40 (m, 11H), 8.22 (br d, 8Hz, lH). FAB-MS: c~lculated for C30H34N40~, 514; ~und 515 ~-(~H, 5~%).
1 .-.
,.
; ~ ~ 20 . EXAMPLE 60 :: 2-Amino-2-methyl-N-~2,3~4,5-tetrahydro-l-[E2'-[~(berLzyloxycarbonyl)-amino~me~yl][l,1'-biphenyl] 4-yl3methyl~-2-oxo-lH-bPn7~7epirl-3(R)-: ~ ' yl~prop~n~mide, trifluoroacet~

; 25 ~ep A 3(R)-t-Butoxycarbonylamino-2,3,4,5-tetrahydro-1-~2'-[[(benzyloxycarbonyl)am~o]me~yl][1,I'-biphenyl]~-yl]-methy1l- 1 H-ben~azepin-2-one A snlution of 64 mg (0.14 mmol) of 3(R)-t-butoxy-O carbonylam}no-2,3,4,5-tetrahydro 1-[[2'-aminomethyl[1,l'-bipheIlyl]-4-3 yl]methyl~-lH-ben7~7epin-2-one ~Example 59, Step C) in 1 mL of methylene chloride at room temperature was $reated with 1 drop of triethyl~mine followed by 36 mg (O.ld, ~nol, 1 eq.) of N-(benzyloxy-carbonyloxy)succiI~imide and 5 mg of N-hydroxybenzotriazole~ The mixture was stirred at room temperature for 1 hour ~en added to 10 wo g4105634 2 1 4 2 7 0 7 PCI/US~3/077~1 .

- 199~
mL of ethyl ~cetate and washed with 5~ aqueous citric acid, saturated aqueous sodium bicarbonate and saturated aqueous sodium chloride. ::
The organic layer was removed, dned over magnesium sulfate, ~1ltered aIld solv~nts removed under vacuum. The residue was purilSed by medium pressure li~uid chromatography on silica. eluting wi{h ethyl acetate/hexanes (2:1), to give 68 mg ( 0.11 mmol, 83%) of the produc~
as a white, crusty foa}n. lH NMR (400 MHz, CDCl3): ~ 1.38 (s, 9H), 1.89 (m~ 60 (m, 3H), 4.27 (m, 3H), 4.75 (br t~ lH~. ~.
15Hz, lH), 5.05 (s, 2H), 5.18 (d, 15Hz, lH), 5.44 (br d, 7Hz, lH), 7.10-o 7.35 (m, 11H~ 7.40 (d~ 8Hz, lH). FAB-MS: calculated for C37H39N305 605; found 606 (M+H, 2%), ~06 ~M-BOC, 100%).

Step B: 2-t-Butoxycarbonylarnino-2-methyl-N-~2~3,4,5-~etrahydro-1-[~2'-[[~nzyloxycarbonyl)amino3methyl~ biphenyl~-4-yllme~yll~2-oxo-lH-ben~a~epin 3(R)-vllpropanamide ;, P~pared from ~e intennediate obtained in ~tep A and N-t-~' ~ butoxycarbonyl-oc-methylalanine by the procedure described in ~, F.~r~rnple 59, Step ~ lH NMR (400 M~ CDCl3~: ~ 1.41 (~ ~H~ lA2 :~
(s, 3H), ~.44 (s, 3H), 1.82 ~m, lH), 2.38-2.65 (m~ 3H), ~.27 (d, 6 Hz, 2H), 4.47 (m, lH3, 4.74 (br t, lH), 4.87 (d, lSHz, 1H~, 4.92 ~br s~ lH), : ~ 5.05 (s, 2H), 5.~1 (d~ 15Hz, lH), 7.10-7.35 (m, 1 lH), 7.40 (d, 8Hz, lH)~
FAB-MS: calculated ~r C41H46N40~ 690; found 691 (M~H, 3%), ..
591 (M-BOC, 100%).

s Step C: 2-Amino-2-methy1-N-~2,3,4,5-tetrahydr~1-~12'-~(benzyl-oxycarbonyl)~n~ino~methyl][ 1,1 '-biphenyl~-4-yl]methyl~-2- :
oxo-lH-benzazepin-3(R)-yl7propanamide. trifluoroacetate The title compound was prepared ~rom ~he inte~nediate ob~ained in Step B by the procedure descnbed in Example 59, Step F.
I~ MR (400 MHz, CD30D): ~1.54 (s, 3H), 1.6~ (s, 3H), 2.27 (m, 2H), 2.60 (m, 2H), 4.16 (s, 2H), 4~39 (dd; 7, 11 Hz; lH), 5.00 ~d, 15Hz, lH), 5.05 (s, 2H), 5.22 (d, 15Hz, lH), 7.14 (d, 8 Hz, lH), 7.20-7.40 (m, 1 lH). FAB-MS: calculated for C36H3gN4O4 590; found 591 (M~H, 100%).

WO94/05634 PCI/US93/0779~

200- ;
EXAMPLE 61 . I;

Utilizi~g ~e procedures des~ribed in Examples 1 to 60 and - ;
general methods of organic syr~esis described in the chemical s literature and ~mili~r to one skilled în the ar~ ~he following compounds of Formula 1 can be prepared from the appropr~ately substituted starting mater~als ~nd reagents.
, ,.

Rl '' ~ 6 ~4 8 ~ N-C -A--N/

~: 15 .

WO 94/05634 2 1 4 2 7 (~ ~ PCI/U~;~3/û7791 , .~.
:. .

EXAMPLE 61 (Cont'O
....

R R9 A F:~4 H ~ H

H -NH-c-NHcH3 -C~2~ CH2~CH-CH-CH20H ~, ~ R ~ ~3&H3 0 H -NH-C-NHCH3 -CH2-~-- -CH2CH20H H
O C~3~ H3 I H
H -NH-C-NHCH3 -CH2-C-- -Cl J2C(~3)2 H
11 C~ H3 IH
H -NH-C~NHCH3 - CH2-C-- -CH2CH2CHCH3 H

-NH-C-NHCH3 CH2-C-- Cl~
C~&H3 H -NH-C-NHCH3 -CH2-C-- -CH2CH2CH ~ H
O ~ ~ CH~3~ H3 OH

2s H~ -NH-C-NHCH3 -C~2-C-- --CH2~CH-CH3 H

3 ~ ~

::

21~2~0~
WO 94/05634 P~/US93/0779~
. ~'.

.
EXAMPLE 61 (Cont'd) .. ..
R~1 R9 A R4 R
~ :-R ~3 ,CH3 6-F -NH-C-NHCH3 -CH2-C-- H H ' '.
1"
~ C~3&H3 7-F ~NH~C NHCH3 -CH2-C~ H H

7-CF, ~NH-C-NHCH3 -CH \C~ H H

15~ C~3~C~I, 7-OCH3 -NH-C-NHGH3 -C~2-C-- H H ,' 7-GH -NH-C NHCH3 C;H~ C
: :' 20~
' ~ ~ ' : ' ~'' ' ' , ' .
' ' ' ~ ~ ' :

~ j . ~., , . ~ , i , .

:

::~ : :

. . wo 94/05634 ~ ~L 4 2 7 ~ s Pcr/usg3/o7791 ~ :

EXAMPLE 61 ~Cont'd) ::

: 5 R9 A R4 Rs ~:) CH~ CH3 7 SCH3 -NH-C-NHCH3 -CH2-\C/ H H

CH3 Cr~3 7~S(O~CH3 -NH-C-NHCH3 -CH2-C-- H H

1I C~ CH3 8-OCH3 -NH-C-NHCH3 -~H2-C-- H H

; ~ ~ C~3~ H3 8-CI -NH-C-NHCH3 CH~ ~ H3 ~:~ ~ & 3 ; 8-1 -NH-C NHCH3 -CH2-( _ H H

:
~ .
:~ 30~ ~

, ' ~ ~ . . ' ' : :

- - ~ - .... -.-.. -~ i~2~07 W0 94/0563~ PCI/US93tO7791 ,~

. ' EXAMPLE 61 (Cont'd) i~ .
R1 R9 A .;' ~4 R5 .
ll C'~3~ H~
-NH-C-NHCH3 C- H H ;

", ~H~
H -NH-C~NHCH3 -~- H H ~;

H -NH-C NHCH3 C ,,3C~H H H

H, ~CH20H
: H -NHC-NHCH~ ~C- H H

H3 ~CH20H
N~i-C-t~th'Ct i3 --C--1.
~:

,;
:
, : :
: :

- .

:

:~
, ' ~

:: I

~: :

WO 94~05634 2 1 4 2 7 0 7 P~/US93/0779~

EXAMPLE 61 (Cont'd~

R1 R9 A R4' R .'.

jl H, ~CH3 H -NH-C-NHCH3 --C-- c~3 H
: ~ ~ &~2~~
H NH-C-NHt::H3 -CH2-C~ H H

NH-C-NHCH~ -CH2-'C~ H
~ ll HOCH2 ,~CH3 OH
H -NH-C-NHCH3 -CH2 "C-- CH2CHCH3 H

~l HOCH2 ~CH3 OH
H -NH-G-NHCH3 " --,H2C;HC'r~2t~3H

.

~ 2 5 :
~ :

:
:

;, 21~07 wo g4/05634 PCr/US93/0779t~;--EXAMPLF, 61 (Cont'd) s ..

H -NH-C-NHCH3 --'C/-- ~ H H

O H, ,~2~H

: N~

;H2~,lN .
H -NH-C-NH~H3 ~C-- H H
' ~ 2~
f NH
H -NH-C-NHCH3 ,~J

H ~NH-G-NHCH3 ~ NH

O
: ~ 30 ~ fL~
~:~ H -NH-C-NHCH3 ~ ,N

:

:

WO 94/0~634 2 1 ~ 2 7 1) 7 PC'r/US93/07791 Utili7.ill~ ~e procedures described in Ex~mples 1 ~o 60 and general methQds of organic synthesis described ~n the chemical 5 literab~re and ~mili?~r ~o one skilled i~ the alt, the ~llowing compounds of Formula I can be prepared from the a~ o~liately ~;
substituted start~g m~terials and reagents.

~N-C-A-N~ , ~

~ ~ 15 ~

~ , ~o , ;
L

~ ~ 25 : ~ 30 21~2707 WO 94/05634 PCI/US93/07791 -- :

EXAMPLE 62 (Cont'd) ~ -R9 A . ~ :~4 ::

H -NH-C-NH2 ' H
11 CH~ / n~

H -NH-C-NH2 - CH2-\C/ -CH2CHCH3 ll \ & OH
: H -NH-C-NHCH3 -CH2-C-- -CH2CHCH3 H-NH~C-NHCH2CH20H --CH2-C-- -CH~C;H2CHCH3 CH3 ~CH3 (:)H
H -NH-C-NHCH~ -CH2-\C_ -CH2CHCH~

~: 25 :

~ , , ~ ' :
-~: ~ 3 0 ..

,, .

W~ ~4/0~34 2 1 ~ ,PCl'/US93/0'7791 - ~0~ -:'~
..
EXAMPLE 62 ~Cont'd) :, R1 Rg A R4 Il ~ & I ,'',:
H ~ -NH-C NHCH3-CH2-C-- : -CH~CHCH3 : 11CH3 ~Gtl3 OH
:; 7~F -NH-C-NHCH3-CH2-C-- -CH2CH~H3 11CH3 &H3 OH
7-CF3 -NH~ NHCH3-CH~-C-- -CH2CHCH3 1 ~ ~ }.
CH3 ~CH3 OH
7-OCH -NH-C-NHCH3-CH2-C-- ~CH2CHCH3 :~:
\ & OH
2 o 7-~SCH3 -NH-C-NHCH3--CH2-C-- ~CH2CHCH3 ,, - :
~ : :

' ~:
.
~ ~ 30 ': :;
:: .

214270 ~
WO94/0563'1f PCr/VS~3/07791r.

- EXAMPLE 62 (Cont'd ) ~: ''. ' R1 ~9 A " F~4 .
Il H, ~CH3 7-F -NH-C-NHCH~ --C~ H

o H, &~2OH
: ~ ~ 10 7-F -NH-C-NHCH3 -C~2-C~ H
,.
o CH3 &H2OH
7-F -NH-C-NHCH3 -CH2-C ~ t I f 5 ~ ll HOCH2 ~H3 ~: 7-F -NH-C NHCH3 - C:H2- C-- H
HOCH2 &H3 OH
7-r -~Jh-C-NHCh'3 - ~H2-~-- -CH2Ci-iCH3 .~
2~0 ~ HOCH2 ~CH3 OH

7-CF3 -NH-5-NHCH3 -CH2~C-- -CH2CHCH2OH

HOCH2 ~CH3 ~H
25 ~ 6-1: NH-C-NHCH3 -CH2-G~ -CH2CH2::HCH3 : :

. .
f;

, ~ .
~ ~ , ",;
~ S

WC) 94/0S~34 2 1 ~ 2 7 0 7 PCI/US93/0779~

. .
,: .
EX~l~IPLE 63 .:

Uti1izing ~e procedures described in Examples 1 to 60 and 5 gene~al me~ods of orgaI~ic syIlthesis described in the chemic~l literature and f~mili~r to one ~kille(l in ~e art, the following compounds of Forrnula I can be prepared from the a~ro~.iately 1 .
su~st~tuted star~g ~elials and reaFents.
10(X)n~(CH2~p ~( ~N-C--A--NHR4 : ~ ,,.
.

: ' ' ,.

~.

: ~5 :

.

:' 2142~0-1 WO 94/05634 PCI/U593/07791 ~~' - 2~2 ~
EXAMPLE 63 (Cont'd) ;

X n p R9 A ~4 0 3 -NH-C-NHCH3 --CHz-C-- H

Il C;h3 ,~CH3 ~~ ~ ;
10 ~ - O 3 -NH-C-NHCH3 CH2~ CH2CHCH3 , & '' O 1 -NH-C-NHCH3 --CH2-C-- 1-1 ' 1S R CH3 ~CH3 OH
o 1 NH-C-NHCH3 --CH2 ( -CH2~CH3 1I CH3 ~CH3 - O û -NH-C-NHCH3 --CH~-C-- H

CH3 ~CH3 t: H
O O ~: -NH C-NHCH3 --CH2-C~ H2cHcH3 .

, ~: 30 ,..
~.:

~, WO94/05634 2~ 7~ PCI~ ;93/0779~ ' ''''.

EXAMPIJE 63 fCont'd~ !:',' '~ ' . ~,.,~
X n p R9 A R4 1I CH3 ~CH ~ VH
C C), 1 1 -NH-C-NHCH3 --CH2~ CH2CHCH3 ....

H3 t:)H
~:~ l0 CHOH 1 1 -NH-C-NHCfl3 --CH~-C-- -CH2CHCH~, ~ CH3 ~CH3 S 1 0 -NH-C-NWCH3 ~ CH2-C~ H

S ll ~s ~ 3S 1 0 ~NH-C-NHCH2CH~OH --C~ H
,.
C~ &H~ ~H
S 1 0 -NH-C-NHCH3 --CH2-C-- -CH2~HC~3 Clt3 ~CI13 SO 1 0 -NH-C-NHCH3 ~ ~H2-C-- H

' , ! , :';;, :
' ~ 3 0 '': :
~ , " .
,'::
y .
~, . , ~, .
.~ , , .

21~270 ~
WO 94/05634 P~/US93/07791.

~ 214 -. .
EXAMPLE 63 (Cont'd) ~ .
~,., -,.
X n p R9 . A R4 .
ll CH~ ~CH~
SO 1 0 -NH~C-NHCH3 --C~ H
, CH3 ~CH~ OH

.~ .,, o 5 OH
SO 1 0 -NH-C-NI ICH3 -CH2-(-- -CH2CHCH20H

~; lS ll CH3" &H3 Q :;Hq CH~
S 1 2 -NH-C-NHCH ~ --C-- H

C H3 & H3 ~::: S 1 2 -NH-C-NHCH3 --CH2-C-- -CH2~HCH3 2s ~ O CH3 ~CH3 OH
S 1 2 -NH-C-NHCH3 -CH2~C-- -CH2~HCH2~ )~
':' : .' :
~ ~ . ' ' . , 3~
:

::: ::

.
. .

WO 94/Q~634 PCI'/US93/07791 ~
2112707 ~

....

EXAMPLE 63 (Cont'd) ,'.
X n p R9 C1 13 ~13 ~: S 1 2 -NH-C-NHCH3 -CH2-C-- H
: .
1I CH~ ~CH3 S 1 2 -NH~ NHCH3 --c~ H
',, 11 CH3 ~CH3 OH
S ~ NH-C-NHCH3 --CH2~C~ -CH2~HCH3 CH3. &H3 8H

S 1 2 -NH-C NltCH3 -CH2--C-- -CH~HCH20H

.
2 o ~ ll CH3 ~CH3 ~ 1 1 -NH-C-NHCH3 --CH2-C ~ H

13 ~CH3 ; O 1 ~ NH-.,-NHCH3 - -C-- H
2~
~3,. &H3 OH
: Q 1 1 ~ -NH-C-NHCH3 -CH2-C-- -CH2~HCH3 ~:
: : :
. .
~ CH~, ~H3 OH
O 1 1 -NH-C-NHCH3 --~H2-C ~ -CH2CHCH20H

~' ' .
, , 21g2~7 WO 94/~5634 P~/~JS93/07791 : .

, . ~
:';., Utilizing ~e procedures descnbed in Exatnples 1 to 60 and general me~ods of organic synthesis described in ~e chemical ~:
litera~e and ~mil;~r ~o one skilled in the ar~, ~e follo~
compounds of Formul~ I can be prepared ~rom the a~ro~ria~ly substi'~uted starting materials and reagents.

R1 ~( ))m a ~ ~ N-C-(CHz)~NH~

, .

.

~ ' :
,~; 25 ~ ' ~ 30 r ~:

WO 94/05634 21~ 2 7 0 r~ PCI'/US93/07791 : ~

~'.',~
EXAMPLE 64 (Con~'d3 ,, . .
R1 X m R9 ~4 ll OH
H 1 0 -NH-C-NHCH3 -CH2~HCH3 ll OH
H 1 0 -~IH-C-NHCH3 -CH2 HCH3 ~ OH ::
H 1 O NH-C-NHCH3-CH2~H~H 2OH

11 , 1;
H : O O -NH~C-NHCH ~ H

ll I H
H û ' O -NH-GNHCH3 -CH2CH2CHCH3 ., :

: 30 ~ .

~W1~94~/05634 PCI'/U593/07791 ...

EXAMPLE 64 (Cont'd) S R~ x m R9 . R4 11 C)H
H 1 1 -NH-C-~IHCH3 -C~12~HCH3 0 ll OH
H 1 1 -NH-C-NHCH3 -CH2C~HCH20H

~l O~H
H 1 1 -NH-C-NHCH3 -CH2 tlCH3 7~ ~ OH
H 1: 1 -NH-C-NHCH3 -~ H2CHzCHCH3 ~ 20 ll I CH3 '~: H 1 0 -NH-C-NHCH3 -CH2CHCH3 :
.

,~ , :: 2s !

~: 30 :

.

WO 9~/05634 2 1 ~ 2 7 ~ ~ PC~/US93/0779t - ~19 -....
EXAMPLE 64 (Cont'd) , .
R1 x m R9 R4 : R OH , 8~F 1 o -NH-C-NHCH3 -CHz~H~~H3 I;
, .
1l OH
8-CF3 1 0 -NH-C-NHCI 13 -CH2~HC~H3 .

8-(: CH3 1 0 -N~i-C-NHCI 13 -~H2~HCH3 8-SCH3 1 O -NH-C~NHCH~ -CH2CHCH3 : : , O OH
: ~ :, 11 . ,:
2 0 9-F 1 0 -NH-C-NHCH3-CH~CHCH3 : . ' ~ , :
: : ~

, . ..., ~, _ 2 ~,~ 9247~5634 PCI /US93/07791 - 2~0 -~ .
EXAMPLE 64 (Cont'd) ~...
Rl x m h9 R4 .. .
O I H
~-F 1 ~ -NH-C-NHCH3 -CH2~::(CH3)2 ~l I H I H ~ .
: 10 8-F 1 0 -NH-C-NHCH3 -CH2CH-CH-CH3 :~ ;
O
H 1 0 -NH-C-NHCH2CH2t:)H H
; .
~ ~ o OH
0 . -NH-C-NHCH2CH20H , CH2CHCH3 ~ OH
H 1 1 -NH-C-NHCH2Ctl20H CH2CI-ICH3 .,.
: : .

25~ ~:

.
~ ~ 30 :, ~' , ., .. ., ., . , .... . .... ,.. , .. . ,.. ..... ,. . ~, . ~. .. ... .. .

WO 94/05634 2 1 ~ 2 7 0 7 PCI/US93/07791 ~

- ~!2~
' ':
EXAMPLE 64 ~Cont'd) , .. , ~ .
R1 x m R9 R4 ,~
~ OH i:

O OH
Il I "
H 1 0 -NH-C-NHCH2CH2OH -CH2CH2CH-C;H3 O OH
~ Il I
H 0 0 ~NH-C-NHCH2CH2OH -CH2CH2CI I-CH3 lS j o OH OH

H 1 0 -NH-C-NHCH2CH2C)H -CH~CH-CH-CH3 , ~ OH
8-F 1 0 -NH-C~NHCH2CH2OH -CH2CHCH3 , ~ ~

:::

~ :
30:
:: ~:

, : .

21~2 107 WO g~/0~634 P(:~/US~3/07791~--- 222.-,: ;
: : : E~AMPLE~64 (Cont'd) . . .

.
F~1 x m R9 : R4 O OH
Il .. .
8-CF3 1 0-NH-C NHCH~CH20H -CH2CHCH3 Ol OH :~
~ 8-OCH3~ 1 0-~IH C-NHCH2CH20H -CH2CHCH3 ,:
OH
8 F~ 1 0 ~NH-C-NHCH2CH~OH -CHzC;HCH3 : 20:
. .

~, ~; i, , i ;

30: ~

:.: : ~ :

~: .
~. . .

~, :

WO 94J05634 2 1 4 2 7 0 . PCI /US93/07791 ,, ~XAMPLE 65 :
Utilizing ~e procedures described in Fx~mrles 1 to 60 and :' general me~ods o~ organic syn~esis described in ~e chemical lit~ratu~e a~d ~mili~r to ~e s~illed in tbe ar~, the ~ollowi~
compounds of Fo~nula 1 can be prepar~d from the a~ iately substihlted star~ing nnaterials and reagents.

: ~ lo R1 6 ~N-~ O

20:
'~

~, : : , :

~ ~ : 25 ,~ ~

: ~ ~' . ' :
; ::

21~270 ~
wo 94/0~634 PCr/~JS93/077~

'~ ~
~3XAMPLE 65 (Cont'd) . ':
.~.'.
R1 R9 A R4 ' ~,.;
11 C~3~CH3 IH Ol~l H -CH2NH-C-~H2 -CH~-C --Cl l;~-CH-CH CH2OH
':
0 1 C1~3 &H3 H -CH2NH-C-NH~ - CH2 G -CH2GH2OH
, : : ~ ~3~ 3 I H
H -CH2NH-C-~H2 - CH2-C-- -CH2C~C~3)2 ~ C~3 &H3 I H
CH2Nlt~ 2 ~ r~ !z5U2Cu.CH3 ll C~3 &H3 : H -CH2NH-C-NH2 -CH2-C-- -CH2 :; ' ~: 25 ~ ~ ~ & 3 ~"; H -CH2NH-C-NH2 -CH2~ H2CH2CH3 C~3 &H3 H -CH2NH-GNH~ H2-C-- -CH3 ~:~ 30 ~:

wo 9410s634 2 ~ ~ 2 7 0 7 Pcr/us~3tn7791 . - .
EXAMPLE 65 (Cont'd) HCH2NH~C-NHCH3 H, ~CH3 H

10 ~ CH3 ~H
H-CH~NH C~NHCH3 --C~ H ;

:: ~
H, ~CH2OH
: ~: 15 H-Cl 12NH~C-NHCH3 --C-- tl ..

HOCH ~ ~H
2NH~ 3 --C--~ o CH3 ~CH2OH
H-~H2NH-C-NHCH3 --C~ H

O CH3 ~CH2OH
~; H-CH2NH-C-NHCH3 -~H2-C~ H
:

~ 2" & 3 H-~H2NH-C-NHCH3 -CH2-C~ H
3 0:

:

, ' 2142707 ;
WO 94/05634 PCT~US93/07791 ,.-~ :

- 2~6 -~: EXAMPLE 65 (Cont'd~

.. ~:
~ H, ~CH3 OH
H -CHzNH-C-NHCH2CH3 --C-- --CH2-CH-CH3 1I CH3 ~H OH
H -cH2NH-c-NHcH2~}~3 --C-- ~CH2-CH-C:H3 ~ , .
H, &~2~H OH
H -CH2NH-C NHCH2CH3 ~ CH2-CH-C~3 ' H -CH2NH-C~NHCH2CH3 ~C-- --CH2-CH-CH3 CH, :~CH2OH OH
,~H ~ H -CH2NH-C-NHCH2CH3 --C-- --CH2-CH-CH3 25 ~ : CH3 ~CH2OH OH
H -CH2NH-C~NHCH2CH3 ~CH2-C-- - CH2-CH~CH3 i ,i ~ , ~ .
O HOCHz ~H3 Ol-l H -cH2NH-c-NHcH2cH3 -CH2-C-- --CH2-cH-ctl3 , ; . .

~ , .. .. ....

WO 94/05634 ~ 1 ~ 2 7 0 lPCrJU~i~3107791 EXAMPLE 65 (Cont'd~

~ H, ~CH3 C)H
H-CH2NH-~-NHCI 12Ph C-- ~CH2-CH-CH2OH
~ . ~
CH3 ~H OH
-CH2NH-(:~-NHCH2Ph --C-- --CH2-CH-CH2(:)H

~ H, ~CH2OH OH
~: 15 H-CH2Ntl-C-NtlCH2Ph --C-- --CH2-CH-CH2OH

-CH~NH-~-NHCH2Ph ~C-- ~CH2-CH-CH20H
.
; ' 2 0 CH?, ~CH2OH OH
GH2NH-C-NHCH2Ph --G-- CH2- CH- CH2QH
:~ :
2s ~) CH3 ~CH20H OH
H -CH2NH-C-NHCH2Ph -CH2-C-- --CH2-CH-CH20H

.
~;~ O HOCH2 J&H3 OH

30 -CH2NH-C-NHCH2Ph -CH2-C-- --CH2-CH-CH~OH

,,;~

.

2 i 4 2 7 O 7 w~ 94/0563~ Pcr/uss3/077s~

. .

EXAMPLE 65 (Cont'd) .

, .
~: ~ R C~3&H3 ~ 6-F ~CH2NH-C-NH2 -CH2-C-- H
: .
o R C~3&H3 6~0CH3 -CH2NH-C~H2 ~CH2-~-- H

: 1l C~3 &~3 7-Br -CH2NH-C~NH2 -CH2-C~ H
, ,~
;
R ~ &H3 7-CI -CH2NH-C-NH2 -C~2~
::: : :
O C~3 C~H3 7-CH3~ ~-CH2NH~C-NH2 ~CH2-C~ H

~ ~3 & 3 2s ~ ~ 8-CI ~-CH2NH-C-NH2 ~ C~2~C ~ H

R ~3 &H3 8-I ~ -CH2NH-C-NH2 - CH2-C-- H
3 0 :

j ~ : :
. :

i, i/, ;

r '~:
'~ ~
:

.- WO94/05634 21~2707 PCIIUS93/07791 ' ;

'';
EXAMPLE 65 (Cont'd) s 1I C~3 &H3 : ~ ~ H -CH2NH-C-N(CH3)2 -CH2~

o H -cH2NH-c-NHcH(cH3)2 -CH2-C-- H

C~ ~ H3 ~; CH3 ~ C~3 &H3 H -CH2NH-C-N)tClt2Ph ~-CH2-C~ H

; R C~3~CH3 H ' -CH2NH-C-N3 ~ CH2~C ~ It ~ CH~3 &H3 H -CH2NH-GN ~O - CH2~ H
Ij :
R ~ ~ &
H -CH2NH-C-N~NH -CH2-C~ H
i , :

~f~

~ r ;~ ~

21Q~2~l0 ~
W~ 94/05634 PCI/U!i93/07791 ~-~

EXAMPLE 56 ~ ;

Utilizing ~e procedures described in Examples 1 ~o 60 and general methods of orgaIlic synthesis descri~ed in ~e chemical literatur~ ~nd ~mili~r to one skill~d in ~ àrt, the following comp~unds of Folmula I can be prepared from the a~r~liately substituted starting materials and reagents.

~ / (x)n- (C ~l2)p N-C--/~ NHR4 N ~o :: : 20 X n p : R9 A R4 CH3 ~~13 ;~ ~ 25 - ~ 3 -CH2NH-C-NHCH3 --C~ H

CH3 ~CI 13 OH
o 3 -CH2NH-C-NHCH3 -CH2-C -CH2CHGH3 ~ CH3 ~H~ OH
- 0 3 CH2NH-G~NHCH3 -CH2-C-- -5H2CHCH20H

: ::

WO 94/05634 214 2 7 ~ 7 PCT/US93/07791 lEXAhIPLE 66 (~ont'd) ' X n p R9 A R4 ~ CH3 ~H3 ~: O 1 -(~H2NH-C-NHCH3 C-- H
: ~ CH3 ,~,~H3 OH
o 1 -CH2NH-C-NHCH3 -CH2-C-- -CH2CHCH3 H3 ~CH3 OH
- O 1 -CH 2NH-C-NHCH3 --CH2-C--. -CH2CHCH2OH

~ e ~ CH3 ~H3 0 0 -CHzNH-C-NHCH3 --C ~ H

- O CH3 ~CH3 ~: : 20 - ~ O H2NH-C-NHt:~H3 ~CH2~C-- -CH2CH~H3 CH3 &H3 8H

0 ~ O -CHzNH-C-NHCH3 ~ --CH2-~ -CH2CHC!t2OH
~ ll CH3, &H3 OH
~: : C=O 1 1 -CH2NH-C-NHCH3 -CHz-C-- -CH2t:~HCH3 Clt3 ,f,CH3 OH
CHOH 1 1 : -CH2NH-C-NHCH3 - CH2-G~ H ~CH(~H3 3 ~

; ~ : : :~ : :

i:: :
:: :
~ ' .

::
. ... . , .. , .. ,, ., .. , .. ~.. ;. -.. .. .

21~2707 W~ 94/05634 PClrlUS93/07791 --.

,',~

-232- ~:
EXAl~fPLE 66 (Cont'd) ~:

X n p ~ Fl9 ~' A R4 10 -CH2NH-C-NHC2Hs --CH2-"C~-- H

R CH3 ~ÇH3 S 10 -~H2NH-C-NHCH2C:H2OH -C-- H
.
11 CH3 ~CH3 OH
S 1 0 -CH~NH-C-NHCH~, --CH2-C-- -CH2t:~HCH3 20~ ~ ~ SO 1 0 -CH2NH-C-NH2 --C~ H

CH3 ~CH3 OH
: SO 1 0: -C HzNH C-NH2 -CH2-C~ ~CH2CHCH3 ~;; 2~5 :: ll 3~. & 3 OH
SO 1 0 -CH~NH-C-NH~ ~ CH2-C-- -CH2CHCH2OH

: : !
~ .
; ' 3 0 .:~ ' . .

.; ~ . WO 94/05634 21 4 2 7 0 7 PCI/US93/07791 EXAMPLE 66 tCont'd) X n p R9 A R4 s 8 C~3 ~H3 ~:
1 2 -CH2NH-C-NHz CH2-C-- H

8 CH3 ~,CH3 S 1 2 -CH2NH-~-NH2 --C-- H
: : :
ll 3~ & 3 OH
S 1 2 -Ctl2NH-C-NH2 -CH2'-C~ -CH2~:;H~H3 1I Cl-13 ~H3 OH
S 1 2 -CH2NH-C-NH2 -CH2~C~ -CH2CHCH20H
~ .

3~. & 3 S 1 2 -CH~NH-C~NH2 - CH2-C H
~: 2Q
CH3 &H ~
S: 1 2 -CH2NH-C-NHCH2Ph - C-- H

25 ~

~,; ! . I ! ~

:: : :

A ~ , '~ ~

:: : ~

21~'~7~ ~
WO ~/0~634 P~/USg3/07791 ~, EXAMPLE.66 (Cont'd) X n p R9 A R4 s ~
CH~ ~CH3 Ol l S 1 2CH2NH-C-NHC2H5 - CH~-C-- -CH2CHCH3 ~ : ....
~ C~t3 ~CH3 OH
~ S 1 2 ~ -CH2NH-C-NHPh -CH2-C-- -CH2CHCH2OH

CH3 ~CH3 ~: O 1 1 -CH2NH-C-NHCH3 -CH2-C~ H

CH~ CH3 O 1 1: -CH2NH-C-NHCH3 --C H

~ ll CH3 ~CH3 OH
Q 1 1 -CH2NH-C-NH2 -CH2-C~ -CH~t~HCH3 . ~ ~
CH3 ,~CH3 OH
O~ CH2NH-C-NHCH3 --CH2-C~ H2CHc~20 ~ .
!, :~: ::: ~ :

:: :

..... ~ . .. ...

Claims (29)

WHAT IS CLAIMED IS:
1. A compound having the formula:

where L is .

:

n is 0 or 1;
p is 0 to 3;
q is 0 to 4;
w is 0 or 1;

X is C=O, O. S(O)m m is 0 to 2;
R1 R2 R1a, R2a, R1b and R2b are independently hydrogen, halogen, C1-C7 alkyl, C1-C3 perfluoroalkyl, C1-C3 perfluoroalkoxy, -S(O)mR7a, cyano, nitro, R7bO(CH2)v-,R7bCOO(CH2)V-, R7bOCO(CH2)v,R4R5N(CH2)V-, R7bCON(R4)(CH2)V-, R4R5NCO(CH2)v-, phenyl or substituted phenyl where the substituents are from 1 to 3 of halogen, C1-C6 alkyl, C1-C6 alkoxy, or hydroxy;
R7a and R7b are independently hydrogen, C1-C3 perfluoroalkyl. C1-C6 alkyl, substituted C1-C6 alkyl, where the substituents are phenyl or substituted phenyl; phenyl or substituted phenyl where the phenyl substituents are from 1 to 3 of halogent C1-C6 alkyl C1-C6 alkoxy. or hydroxy and v is 0 to 3;

R3a and R3b are independently hydrogen, R9, C1-C6 alkyl substituted with R9, phenyl subsbtituted with R9, or phenoxy substituted with R9 with the proviso that eitber R3a or R3b must be a substituent other than hydrogen;

R9 is R4bR12bNCON(R12a)(CH2)v-, R4bR12bNCSN(R12a)(CH2)v-, R4bR12CNN(R12b)CSN(R12a)(CH2)v-, R4bRl2CNN(R12b)CON(R12a)(CH2)v-, R4bR12CNN(R12b)COO(CH2)V-,R4bR12bNCOO(CH2)v-orR13OCON(R12a)(CH2)v-, where v is 0 to 3;
.
R12a, R12b and R12C are independently R5a, OR5a, or COR5a; R12a and R12b, or R12b and R12C, or R12a and R12C, or R12b and R4b, or R12C and R4b, or R13 and R12a can be taken together to form -(CH2)r-B-(CH2)S- where B is CHR1, O, S(O)m or NR10, m is 0, 1 or 2, r and s are independently 0 to 3 and R1 and R10 are as defined;

R13 is: C1-C3 perfluoroalkyl, C1-C6 alkyl, substituted C1-C6 alkyl, where the substitutents are hydroxy, NR10R11, carboxy, phenyl or substituted phenyl; phenyl or substituted phenyl where the substituents on the phenyl are from 1 to 3 of halogen, C1-C6 alkyl, C1-C6 alkoxy or hydroxy;

and v is as defined above;
R4, R4b, R5 and R5a are independently hydrogen, phenyl, substituted phenyl, C1-C10 alkyl, substituted C1-C10 alkyl, C3-C10 alkenyl, substituted C3-C10 alkenyl, C3-C10 alkynyl, or substituted C3-C10 alkynyl where the substituents on the phenyl, alkyl, alkenyl or alkynyl are from 1 to 5 of hydroxy, C1 -C6 aLkoxy, C3-C7 cycloalkyl, fluoro, R1, R2 independently disubstituted phenyl C1-C3 alkoxy, R1, R2 independently disubstituted phenyl, C1-C20-alkanoyloxy, C1-C5 alkoxycarbonyl, carboxy, formyl or -NR10R11 where R10 and R11 are independently hydrogen, C1-C6 alkyl, phenyl, phenyl C1-C6 alkyl, C1-C5-alkoxycarbonyl or C1-C5-alkanoyl-C1-C6 alkyl; or R4 and R5 can be taken together to form -(CH2)r-B(CH2)s-where B is CHR1, O,S(O)m or N-R10, r and s are independently 1 to 3 and R1 and R10 are as defined above;

R6 is hydrogen, C1-C10 alkyl, phenyl or phenyl C1-C10 alkyl;

A is where x and y are independently 0-3;
R8 and R8a are independently hydrogen, C1-C10 alkyL trifluoromethyl, phenyl, substituted C1-C10 alkyl where the substituents are from 1 to 3 of imidazolyl, indolyl, hydroxy, fluoro, S(O)mR7a, C1-C6 alkoxy, C3-C7 cycloalkyl, R1, R2 independently disubstituted phenyl C1-C3 alkoxy, R1, R2 independently disubstituted phenyl, C1 alkanoyloxy, C1-C5 alkoxycarbonyl, carboxy, formyl, or -NR10R11 where R10 and R11 are as defined above; or R8 and R8a can be taken together to form -(CH2)t-where t is 2 to 6; and R8 and R8a can independently be joined to one or both of R4 and R5 to form alkylene bridges between the terminal nitrogen and the alkyl portion of the A group wherein the bridge contains from 1 to 5 carbon atoms;
and pharmaceutically acceptable salts thereof.
2. A compound of Claim 1 wherein:

n is o or 1;
p is 0 to 3;
q is 0 to 2;
w is 0 or 1;

X is O, S(O)m m is 0 to 2;
R1, R7, R1a, R2a, R1b a:nd R2b are independently hydrogen, halogen, C1-C7 alkyl, C1-C3 perfluoroalkyl, -S(O))mR7a, R7bO(CH2)v-, R7bCOO(CH2)v-,R7bOCO(CH2)v-,phenyl or substituted phenyl where the substituents are from 1 to 3 of halogen, C1-C6 alkyl, C1-C6 alkoxy: or hydroxy;
R7a and R7b are independently hydrogen, C1-C3 perfluoroalkyl, C1-C6 alkyl, substituted C1-C6 alkyl, where the substituents are phenyl; phenyl and v is 0 to 2; :
R3a and R3b are independently hydrogen, R9, C1-C6 alkyl substituted with R9, phenyl substituted with R9, or phenoxy substituted with R9 with the proviso that either R3a or R3b must be a substituent other than hydrogen;

R9 is R4bR12bNCON(R12a)(CH2)v-, R4bR12bNCSN(R12a)(CH2)v-, R4bR12cNN(R12b)CON(R12a)(CH2)v-R4bR12cNN(R12b)COO(CH2)v-, R4bR12bNCOO(CH2)v-or R13OCON(R12a)(CH2)V-, where v is 0 to 3;

R12a, R12b and R12c are independently R5a, OR 5a, or COR5a; R12a and R12b, or R12b and R12c, or R12a and R12c or R12b and R4b or R12c and R4b, or R13 and R12a can be taken together to form -(CH2)r-B-(CH2)s- where B is CHR1, O, S(O)m or N10, m is 0, 1 or 2, r and s are independenltly 0 to 3, R1 is as defined above and R10 is hydrogen, C1-C6 alkyl, phenyl C1-C6 alkyl or C1 C5 a1kanoyl-C1-C6 alkyl;

R13 is C1-C3 perfluoroalkyl, C1-C6 alkyl, substituted C1-C6 alkyl, where the substituents are hydroxy, NR10R11, carboxy, phenyl or substituted phenyl; phenyl or substituted penyl where the substituents on the phenyl are from 1 to 3 of halogen, C1-C6 alkyl,C1-C6 alkoxy or hydroxy;
where v is as defined above;

R4, R4b, R5 and R5a are independently hydrogen, phenyl, substituted phenyl, C1-C10 alkyl, substituted C1-C10 alkyl, where. the substituents on the alkyl or phenyl are from, 1 to 5 of hydroxy, C1-C6 akoxy, C3-C7 cycloalkyl, fluoro, R1, R2 independently disubstituted phenyl C1-C3 alkoxy, R1, R2 independently disubstituted phenyl, C1-C20-alkanoyloxy, C1-C5 alkoxycarbonyl, carboxy or formyl;
R4 and R5 can be taken together to form (CH2)r-B(CH2)s-where B
is CH1, O, S(O)m or N-R10, r and s are independently 1 to 3 and R1 and R10 are as defined above;

R6 is hydrogen. C1 -C10 alkyl or phenyl C10 alkyl;

A is where x and y are independently 0-2;
R8 and R8a are independently hydrogen, C1-C10 alkyl, substituted C1-C10 alkyl where the substituents are from 1 to 3 of imidazolyl, indolyl, hydroxy, fluoro, S(O)mR7a, C1-C6 alkoxy, R1, R2 independently disubstituted phenyl, C1-C5-alkanoyloxy, C1-C5 alkoxycarbonyl, carboxy, formyl,-NR10R11 where R10 and R11 are independently hydrogen, C1-C6 alkyl or C1-C5 alkanoyl-C1-C6 alkyl;
or R8 and R8a can be taken together to form -(CH2)t-where t is 2 to 4;
and R8 and R8a can independently be joined to one or both of R4 and R5 to form alkylene bridges between the terminal nitrogen and the alkyl portion of the A group wherein the bridge contains from 1 to 5 carbon atoms;
and pharmaceutically acceptable salts thereof.
3. A compound of Claim 2 wherein:

n is 0 or 1;
p is 0 to 2;
q is 0 to 2;
w is 0 or 1;
X is S(O)m or:-CH=CH-;
m is 0 or 1;
R1, R2, R1a, R2a, R1b, and R2b are independently hydrogen, halogen, C1-C7 alkyl, C1-C3 perfluoroalkyl,-S(O)mR7a, R7bO(CH2)v-, R7bCOO(CH2)v-,R7bOCO(CH2)v-, phenyl or substituted phenyl where the substituents are from 1 to 3 of halogen, C1-C6 alkyl, C1-C6 alkoxy, or hydroxy;

R7a and R7b are independently hydrogen, C1-C6 a1kyl or substituted C1-C6 alkyl where the substituents are phenyl and v is 0 to 2;
R3a and R3b are independently hydrogen, R9, C1-C6 alkyl substituted with R9, phenyl substituted with R9 or phenoxy substituted with R9 with the proviso that either R3a or R3b must be a substituent other than hydrogen;. -R9 is R4bR12bNCON(R12a)(CH2)v-, R4bR12bNCSN(R12a)(CH2)v-, R4br12cNN(R12b)CON(R12a)(CH2)v-, R4bR12cNN(R12b)COO(CH2)v-, R4bR12bNCOO(CH2)v-orR13OCON(Rl2a)(CH2)v-, where v is 0 to 2;

R12a, R12b and R12c are independently R5a OR 5a, or COR5a; R12a and R12b, or R12b and R12c, or R12a and R12c, or R12b and R4b, or R12c and R4b, or R13 and R12a can be taken together to form -(CH2)r-B-(CH2)s-where B is CHR1, O,S(O)m or NR10, m is 0, 1 or 2, r and s are independently 0 to 2, R1 is as defined above and R10 is hydrogen, C1-C6 alkyl or C1-C5 alkanoyl-C1-C6 alkyl;

R 13 is C1-C6 alkyl, substituted C1-C6 alkyl, where the substituents are phenyl or substituted phenyl; phenyl or substituted phenyl where the substituents on the phenyl are from 1 to 3 of halogen, C1-C6 alkyl, C1-C6 alkoxy or hydroxy;
R4, R4b, R5 and R5a are independently hydrogen, C1-C10 alkyl, substituted C1-C10 alkyl, where the substituents on the alkyl are from 1 to 5 of hydroxy, C1-C6 alkoxy, fluoro, R1, R2 independently disubstituted phenyl, C1-C20-alkanoyloxy, C1-C5 alkoxycarbonyl or carboxy;

R6 is hydrogen or C1-C10 alkyl;
A is where x and y are independently 0-2;
R8 and R8a are independently hydrogen, C1-C10 alkyl, substituted C1-C10 alkyl where the substituents are from 1 to 3 of imidazolyl, indolyl, hydroxy, fluoro, S(O)mR7a, C1-C6 alkoxy, R1, R2 independently disubstituted phenyl, C1-C5-alkanoyloxy, C1-C5 alkoxycarbonyl, carboxy; or R8 and R8a can be taken together to form -(CH2)t- where t is 2; or R8 and R8a can independently be joined to one or both of R4 and R5 to form alkylene bridges between the terminal nitrogen and the alkyl portion of the A group wherein the bridge contains from 1 to 5 carbon atoms; and pharmaceutically acceptable salts thereof.
4. A compound of Claim 3 wherein:

n is 0 or 1;
p is 0 to 2;
q is 1;
w is 1;
X is S(O)m or-CH=CH-;
m is 0 or 1;
R1, R2, R1a, R2a, R1b and R2b are independently hydrogen, halogen, C1-C7 alkyl, C1-C3 perfluoroalkyl, -S(O)mR7a, R7bO(CH2)v-, R7bCOO(CH2)v-, phenyl or substituted phenyl where the substituents are from 1 to 3 of halogen, C1-C6 alkyl, C1-C6 alkoxy or hydroxy;
R7a and R7b are independently hydrogen, C1-C6 alkyl, substituted C1-C6 alkyl, where the substituents are phenyl and v is 0 or 1;
R3a and R3b are independently hydrogen, R9, or C1-C6 alkyl substituted with R9 with the proviso that either R3a or R3b must be a substituent other than hydrogen;

R9 is R4bR12bNCON(R12a)(CH2)v-, R4bR12cNN(R12b)CON(R12a)(CH2)v-, R4bR12cNN(R12b)COO(CH2)v-, R4bR12bNCOO(CH2)v-or R13OCON(R12a)(CH2)v-, where v is 0 or 1;
R12a, R12b and R12c are independently R5a, OR5a, or COR5a; R12a and R12b, or R12b and R12c, or R12a and R12c, or R12b and R4b, or R12c and R4b, or R13 and R12a can be taken together to form -(CH2)r-B-CH2)s- where B is CHR1, O, S(O)m or NR10, m is 0, 1 or 2, r and s are independendly 0 to 2, R1 is as defined above and R10 is hydrogen, C1-C6 a1kyl or C1-C5 alkanoyl-C1-C6 alkyl;

R13 is C1-C6 alkyl, substituted C1-C6 alkyl, where the substituents are phenyl or substituted phenyl; phenyl or substituted phenyl where the substituents on the phenyl are from 1 to 3 of halogen, C1-C6 alkyl, C1-C6 alkoxy or hydroxy;

R4, R4b, R5 and R5a are independently hydrogen, C1-C10 alkyl, substituted C1-C10 alkyl, where the substituents on the alkyl are from 1 to 3 of hydroxy, C1-C3 alkoxy, fluoro, R1, R2 indeperldently disubstituted phenyl, C1-C20 alkanoyloxy, C1-C5 alkoxycarbonyl or carboxy;

R6 is hydrogen;

A is where x and y are independently 0-1;
R8 and R8a are independently hydrogen, C1-C10 alkyl, substituted C1-10 alkyl where the substituents are from 1 to 3 of imidazolyl, indolyl, hydroxy, fluoro, S(O)mR7a, C1-C6 alkoxy, R1, R2 independently disubstituted phenyl, C1-C5-alkanoyloxy, C1-C5 alkoxycarbonyl, carboxy; or R8 and R8a can be taken together to form -(CH2)t- where t is 2; and R8 and R8a can independently be joined to one or both of R4 and R5 to form alkylene bridges between the terminal nitrogen and the alkyl portion of the A group wherein the bridge contains from 1 to 5 carbon atoms;
and pharmaceutically acceptable salts thereof.
5. A stereospecific compound of Claim 1 having the following structural formula:

where R1, R2, X, n, p, q, L, w, R1a, R2a, R3a, R4, R5, R6 and A are as defined in Claim 1.
6. A compound of Claim 1 which is:

N[1-[[2'-(Methoxycarbonyl)amino][1,1'-biphenyl]-4-yl}methyl]-2,3,4,5-tetrahydro-2-oxo-1H-1-benzazepin-3(R)-yl]-3-amino-3-methylbutanamide;

N-[1-[[2'-(Methylaminocarbonyl)amino][1,1'-biphenyl]-4-yl]methyl]-2,3,4,5-tetrahydro-2-oxo-1H-1-benzazepin-3(R)-yl]-3-amino-3-methyl-butanamide;

N-[1-[[2'-[(Ethylaminocarbonyl)amino][1,1'-biphenyl]-4-yl]methyl]-2,3,4,5-tetrahydro-2-oxo-1H-1-benzazepin-3-(R)-y1]-3-amino-3-methyl-butanamide;

N-[1-[[2'-[(2-Propylaminocarbonyl)amino][1,1'-biphenyl]-4-yl]methyl] -2,3,4,5-tetrahydro-2-oxo-1H-1 -benzazepin-3(R)-yl]-3-amino-3-methyl-butanamide;

N-[1-[[2'-[(Aminocarbonyl)amino][1,1'-biphenyl]-4-yl]methyl]-2,3,4,5-tetrahydro-2-oxo-1H-1-benzazepin-3(R)-yl]-3-amino-3-methyl-butanamide;

N-[1-[[2'-[(Morpholinocarbonyl)amino][1,1'-biphenyl]-4-yl]methyl]-2,3,4,5-tetrahydro-2-oxo-1H-1-benzazepin-3(R)-yl]-3-amino-3-methyl-butanamide;

N-[1-[[2'-[[(2-Piperazinocarbonyl)amino][1,1'-biphenyl]-4-yl]methyl]
2,3,4,5-tetrahydro-2-oxo- 1H-l -benzazepin-3(R)-yl]-3-amino-methyl-butanamide;

N-[1-[[2'-[[(2-Hydroxyethylamino)carbonyl]amino][1,1'-biphenyl]-4-yl]methyl]2,3,4,5-tetraydro-2-oxo-1H-1-benzazepin-3(R)-yl]-3-amino-3-methylbutanamide;

N-[1-[[2'-[[(2-Hydroxypropylamino)carbonlyl]amino][1,l'-biphenyl]-4-yl]methyl-2,3,4,5 -tetrahydro-2-oxo-1H-1 -benzazepin-3 (R)-yl] -3-amino-3-methylbutanamide;

N-[1-[[2'-[(Methylaminocarbonyl)oxy][l,1'-biphenyl]-4-yl]methyl]-2,3,4,5-tetrahydro-2-oxo- 1H-1-benzazepin-3(R)-yl]-3-amino-3-methyl-butanamide;

N-[l-[[2'-[(Dimethylaminocarbonyl)amino][l,l'-biphenyl]-4-ylmethyl]-2,3,4,5-tetrahydro-2-oxo-1H-1 -benzazepin-3(R)-yl]-3-amino-3 methylbutanamide;

N-[1-[[2'-[[(2(R)-Hydroxypropylamino)carbonyl]amino][1,1'-biphenyl]-4-yl]methyl]-2,3,4,5-tetrahydro-2-oxo-1H-1-benzazepin-3(R)-yl]-3-amino-3-methylbutanamide;

N-[1-[[2'-[[(2(S)-Hydroxypropylamino)carbonyl]amino][1,1'-biphenyl]-4-yl]methy]-2,3,4,5-tetrahydro-2-oxo-1H-1-benzazepin-3(R)-yl]-3-amino-3-methylbutanamide;

N-[1-[[2'-[[[[1-Hydroxyprop-2(R)-yl]amino]carbonyl]-amino][1,1'-biphenyl]-4-yl]methyl]-2,3,4,5-tetrahydro-2-oxo-1H-1-benezazepin-3(R)-yl]-3-amino-3-methylbutanamide;

N-[1-[[2'-[4-[(Methylaminocarbonyl)amino]phenoxy][1,1'-biphenyl]-4-yl]methyl]-2,3,4,5-tetrahydro-2-oxo-lH-1-benzazepin-(R)-yl]-3-amino-3-metylbutanamide;

N-[1-[[2'-[2-[(Methylaminocarbonyl)amino]phenoxy][1,1'-biphenyl]-4-yl]methyl]-2,3,4,5-tetrahydro-2-oxo-1H-1-benzazepin-3(R)-yl]-3-amino-3-methylbutanamide;

N-[1-[[2'-[(Aminocarbonyl)amino][1,1'-biphenyl-4-yl]methyl]-2,3,4,5-tetrahydro-2-oxo-1H-l-benzazepin-3(R)yl]-3-[2(R)-hydroxypropyl]-amino-3-methylbutanamide;

N-[1-[[2'-[(Aminocarbonyl)amino][1,1'-biphenyl]-4-yl]methyl]-2,3,4,5-tetrahydro-2-oxo-1H-1-benzazepin-3(R)-yl]-3-[2(S),3-dihydroxy-propyl]amino-3-methylbutanamide;
N-[1-[[2'-[(Methylaminocarbonyl)amino][1,1'-biphenyl]-4-yl]methyl]-2,3,4,5-tetrahydro-2-oxo-1H-1-benzazepin-3(R)-yl]-3-[2(R)-hydroxy-propyl]amino-3-methylbutanamide;

N-[1-[[2'-[(Methylaminocarbonyl)amino][1,1'-biphenyl]-4-yl]methyl]-2,3,4,5-tetrahydro-2-oxo-1H-1-benzazepin-3(R)-yl]-3-[2(S)-hydroxy-propyl]amino-3-methylbutanamide;

N-[1-[[2'-[(Methylaminocarbonyl)amino][1,1'-biphenyl]-4-yl]methyl]-2,3,4,5-tetrahydro-2-oxo-1H-1-benzazepin-3(R)yl]-3-[2(S)-di-hydroxypropyl]amino-3-methylbutanamide;

N-[1-[[2'-[(Morpholinocarbonyl)amino][1,1'-biphenyl]-4-yl]methyl]-2,3,4,5-tetrahydro-2-oxo-1H-1-benezazepin-3(R)-yl]-3[2(R)hydroxy-propyl]amino-3-methylbutanamide;

N-[1-[[2'-(Morpholinocarbonyl)amino][1,1'-biphenyl]-4-yl]methyl]-2,3,4,5-tetrahydro-2-oxo-1H-1-benzazepin-3(R)-yl]-3-[2(S),3-di-hydroxypropyl]amino-3-methylbutanamide;

N-[1-[[2'-[[(2-Hydroxyethylamino)carbonyl]amino][1,1'-biphenyl]-4-yl]methyl]-2,3,4,5-tetrahydro-2-oxo-1H-1-benzazepin-3(R)-yl]-3-[2(R)-hydroxypropyl]amino-3-methylbutanamide;

N-[1-[[2'-[[(2-Hydroxyethylamino)carbonyl]amino][1,1'-biphenyl]-4-yl]methyl]-2,3,4,5-tetrahydro-2-oxo-1H-1-benzazepin-3(R)-yl]-3-[2(S)-hydroxypropyl]amino-3-methylbutanamide;

N-[1[[2'-[[2-Hydroxyethylamino)carbonyl]amino][1,1'-biphenyl]-4-yl]methyl]-2,3,4,5-tetrahydro-2-oxo-1H-1 -benzazepin-3(R)-yl]-3-[2(S),3-dihydroxypropyl]-amino-3-methylbutanamide;

N-[1-[[2'-[(Methylaminocarbonyl)amino][1,1'-biphenyl]-4-yl]methyl]-2,3,4,5-tetrahydro-2-oxo-1H-1-benzazepin-3(R)-yl]-2-amino-2-methyl-propanamide;

N-[1-[[2'-[(Aminocarbonyl)amino][1,1'-biphenyl]-4-yl]methyl]-2,3,4,5-tetrahydro-2-oxo-1H-1-benzazepin-3(R)-yl]-2-amino-2-methyl-propanamide;

N-[1-[[2'-(Morpholinocarbonyl)amino][1,1'-biphenyl]-4-yl]methyl]-2,3,4,5-tetrahydro-2-oxo- 1H-1-benzazepin-3(R)-yl]-2-amino-2-methyl-propanamide;

N-[1-[[2'-[(Piperazinocarbonyl)amino][1,1'-biphenyl]-4-yl]methyl]-2,3,4,5-tetrahydro-2-oxo-1H-1-benzazepin-3-(R)-yl]-2-amino-2-methyl-propanamide;

N-[1[[2'-[[(2-Hydroxyethylamino)carbonyl]amino][1,1'-biphenyl]-4-yl]methyl]-2,3,4,5-tetrahydro-2-oxo- 1H-1-benzazepin-3(R)-yl]-2-amino-2-methylpropanamide;

N-[1-[[2'-[(Methylaminocarbonyl)oxy][1,1'-biphenyl]-4-yl]methyl]-2,3,4,5-tetrahydro-2-oxo-1H-1-benzazepin-3(R)-yl]-2-amino-2-methyl-propanamide;

N-[1-[[2'-[[(Methoxycarbonylmethylamino)carbonyl]amino][1,1'-biphenyl]-4yl]methyl]-2,3,4,5-tetrahydro-2-oxo-1H-1-benzazepin-3(R)-yl]-2-amino-2-methylpropanamide;

N-[1-[[2'-[(Hydroxyaminocarbonyl)amino][1,1'-biphenyl]-4-yl]methyl]-2,3,4,5-tetrahydro-2-oxo-1H-1-benzazepin-3(R)-yl]-2-amino-2-methyl-propanamide; . .

N-[1-[[2'-[(Methoxycarbonyl)amino][l,1'-biphenyl]-4-yl]methyl]-7-fluoro-2,3,4,5-tetrahydro-2-oxo-1H-1-benzazepin-3(R)-yl]-3-amino-3 methylbutanamide;

N-[1-[[2'-[(Methylaminocarbonyl)amino][1,1'-biphenyl]-4-yl]methyl]-7-fluoro-2,3,4,5-tetrahydro-2-oxo-1H-1-benzazepin-3(R)-yl]-3-amino-3-methylbutanamide;

N-[1[[2'-[(Methylaminocarbonyl)amino][1,1'-biphenyl]-4-yl]methyl]-7-trifluoromethtyl-2,3,4,5-tetrahydro-2-oxo-1H-1-benzazepin-3(R)-yl]-3-amino-3-methylbutanamide;

N-[1-[[2'-[(Morpholinocarbonyl)amino][l,l'-biphenyl]-4-yl]methyl]-7-trifluoromethyl-2,3,4,5-tetrahydro-2-oxo-1H-1-benzazepin-3(R)-yl]-3-amino-3-methylbutanamide;

N-[1-[[2'-[[(2-Hydroxyethylamino)carbonyl]amino][1,1'-biphenyl-4-yl]methyl]-7-trifluoromethyl-2,3,4,5-tetrahydro-2-oxo-1H-1-benzazepin-3(R)-yl]-3-amino-3-methylbutanamide;

N-[1-[[2'-[[(2-Hydroxyethylamino)carbonyl]amino[l,l'-biphenyl]-4-yl]methyl]-7-fluoro-2,3,4,5-tetrahydro-2-oxo-1H-1-benzazepin-3(R)-yl]-3-amino-3-methylbutanamide;

N-[1-[[2'-[(Methylaminocarbonyl)oxy][l,1'-biphenyl]-4-yl]methyl]-7-fluoro-2,3,4,5-tetrahydro-2-oxo-1H-1-benzazepin-3(R)-yl]-3-amino-3-methylbutanamide:

N-[1-[[2'-[2[(Methylaminocarbonyl)amino]phenoxy][1,1'-biphenyl]-4-yl]methyl]-7-trifluoromethyl-2,3,4,5-tetrahydro-2-oxo-1H-1-benzazepin-3(R)yl]-3-amino-3-methylbutanamide;

N-[1-[[2'-[(Methylaminocarbonyl)amino][1,1'-biphenyl]-4-yl]methyl]-7-fluoro-2,3,4,5-tetrahydro-2-oxo-1H-1-benzazepin-3(R)-yl]-3-[2(R)-hydroxypropyl]amino-3-methylbutanamide;

N-[1-[[2'-[(Morpholinocarbonyl)amino][1,1'-biphenyl]-4-yl]methyl]-7-fluoro-2,3,4,5-tetrahydro-2-oxo-1H-1 -benzazepin-3(R)-yl]-3-[2(R)-hydroxypropyl]amino-3-methylbutanamide;

N-[1-[[2'-[(Morpholinocarbonyl)amino][1,1'-biphenyl]-4-yl]methyl-7-fluoro-2,3,4,5-tetrahydro-2-oxo-1H-1-benzazepin-3(R)-yl]-3-[2(R)-hydroxypropyl]amino-3-methylbutanamide;

N-[1-[[2'-[(Morpholinocarbonyl)amino]1,1'- biphenyl-4-yl]methyl]-7-fluoro-2,3,4,5-tetrahydro-2-oxo-1H-1-benzazepin-3(R)-yl]-3-[2(S),3-di-hydroxypropyl]amino-3-methylbutanamide;

N-[l-[[2'-[[(2-Hydroxyethylamino)carbonyl]amino][1,1'-biphenyl]-4-yl]methyl]-7-fluoro-2,3,4,5-tetrahydro-2-oxo-1H-1-benzazepin-3(R)-yl]-3-[2(R)-hydroxypropyl]amino-3-methylbutanamide;

N-[1-[[2'-[(Methylaminocarbonyl)amino][1,l'-biphenyl]-4-yl]methyl]-7-fluoro-2,3,4,5-tetrahydro-2-oxo-1H-1-benzazepin-3(R)-yl]-2-amino-2-methylpropanamide;

N-[1-[[2'-[(Morpholinocarbonyl)amino][1,1'-biphenyl]-4-yl]methyl]-7-fluoro-2,3,4,5-tetrahydro-2-oxo-1H-1-benzazepin-3(R)-yl]-2-amino-2-methylpropanamide;

N[1-[[2'-[(Piperazinocarbonyl]amino][l,1'-biphenyl]-4-yl]methyl]-7-fluoro-2,3,4,5-tetrahydro-2-oxo-1H-1-benzazepin-3(R)-yl]-2-amino-2-methylpropanamide;

N-[1-[[2'-[[2-Hydroxyethylamino)carbonyl]amino][l,l'-biphenyl-4-yl]methyl]-7-fluoro-2,3,4,5-tetrahydro-2-oxo-1H-1-benzazepin-3(R)-yl]-2-amino-2-methylpropanamide;

N-[1-[[2'-[(Methylaminocarbonyl)oxy][1,1'-biphenyl-4-yl]methyl]-7-fluoro-2,3,4,5-tetrahydro-2-oxo-1H-1-benzazepin-3(R)-yl]-2-amino-2-methylpropanamide;

2-Amino-2-methyl-N-[2,3,4,5-tetrahydro-1-[[2'-[[[(methylamino)-carbonyl]amino]methyl][l,1'-biphenyl]-yl]methyl]-2-oxo-1H-benzazepin-3(R)-yl]propanamide;

2-Amino-2-methyl-N-[2,3,4,5-tetrahydro-1-[[2'-[[[(methylamino)-carbonyl]amino]methyl][1,1'-bipnenyl]-4-yl]methyl]-7-fluoro-2-oxo-1H-benzazepin-3(R)-yl]propanamide;

2-Amino-2-methyl-N-[2,3,4,5-tetrahydro-1-[[2'-[[[(methylamino)-carborly]amino]methyl][1,1'-biphenyl]-4-yl]methyl]-7-methoxy-2-oxo-1H-benzazepin-3(R)-yl]propanamide:

2-Amino-2-methyl-N-[2,3,4,5-tetrahydro-1-[[2'-[[[(methylamino)-carbonyl]amino]methyl][1,1'-biphenyl]-4-yl]methyl]-7-methylthio-2-oxo-1H-benzazepin-3(R)-yl]propanamide;

2-Amino-2-methyl-N-[2,3,4,5-tetrahydro-1-[[2'-[[[(methylamino)-carbonyl]amino]methyl][1,1'-biphenyl]-4-yl]methyl]-7-trifluoromethyl-2-oxo-1H-benzazepin-3(R)-yl]propanamide;

3-Amino-3-methyl-N-[2,3,4,5-tetrahydro-1-[[2'-[[[(methylamino)-carbonyl]amino]methyl][1,1'-biphenyl]-4-yl]methyl]-2-oxo-1H-benzazepin-3(R)-yl]butanamide;

3-Amino-3-methyl-N-[2,3,4,5-tetrahydro-1-[[2'-[[[(methylamino)-carbonyl]amino]methyl][1,1'-biphenyl]-4-yl]methyl]-7-fluoro-2-oxo-1H-benzazepin-3(R)-yl]butanamide;

3-Amino-3-methyl-N-[2,3,4,5-tetrahydro-1-[[2'-[[[(methylamino)-carbonyl]amino]methyl][1,1'-biphenyl]-4-yl]methyl]-7-methoxy-2-oxo-1H-benzazepin-3(R)-yl]butanamide;

3-Amino-3-methyl-N-[2,3,4,5-tetrahydro-1-[[2'-[[[(methylamino)-carbonyl]amino]metyl][1,1'-biphenyl]-4-yl]methyl]-7-methylthio-2-oxo-1H-benzazepin-3(R)-yl]butanamide;

3-Amino-3-methyl-N-[2,3,4,5-tetrahydro-1-[[2'-[[[(methylamino)-carbonyl]amino]methyl][1,1-biphenyl]-4-yl]methyl]-7-trifluoro-methyl-2-oxo-1H-benzazepin-3(R)-yl]butanamide;

3-[2(R)-Hydroxypropyl]amino-3-methyl-N-[2,3,4,5-tetrahydro-1-[[2'-[[[(methylamino)carbonyl]amino]methyl][1,1'biphenyl]-4-yl]methyl]-2-oxo-1H-benzazepin-3(R)-yl]butanamide;

3-[2(R)-Hydroxypropyl]amino-3-methyl-N-[2,3,4,5-tetrahydro-1-[[2'-[[[(methylamino)carbonyl]amino]methyl][1,1'-biphenyl]-4-yl]methyl]-7-fluoro-2-oxo-1H-benzazepin-3(R)-yl]butanamide;

3-[2(R)-Hydroxypropyl]amino-3-methyl-N-[2,3,4,5-terahydro-1-[[2'-[[[(methylamino)carbonyl]amino]methyl][1,1'-biphenyl]-4-yl]methyl]-7-methoxy-2-oxo-1H-benzazepin-3(R)-yl]butanamide;

3-[2(R)-Hydroxypropyl]amino-3-methyl-N-[2,3,4,5-tetrahydro-1[[2'-[[[(methylamino)carbonyl]amino]methyl][l,1'-biphenyl]-4-yl]methyl]-7-methylthio-2-oxo-1H-benzazepin-3(R)-yl]butanamide;

3-[2(R)Hydroxypropyl]amino-3-methyl-N-[2,3,4,5-tetrahydro-1-[[2'-[[[)(methylamino)carbonyl]amino]methyl][1,1'-bipheny]-4-yl]methyl]-7-trifluoromethyl-2-oxo-1H-benzazepin-3(R)-yl]butanamide;

3-[2(S),3-Dihydroxypropyl]amino-3-methyl-N-[2,3,4,5-tetrahydro-1 -[[2'-[[[(methylamino)carbonyl]amino]methyl][1,1'-biphenyl]-4-yl]-methyl]-2-oxo-1H-benzazepin-3(R)-yl]butanamide;

3-[2(S),3-Dihydroxyropyl]amino-3-methyl-N-[2,3,4,5-tetrahydro-1-[[2'-[[[methylamino)carbonyl]amino]methyl][1,1'-biphenyl]-4-yl]-methyl]-7-fluoro-2-oxo-1H-bezazepin-3(R)-yl]butanamide;

3-[2(S),3-Dihydroxypropyl]amino-3-methyl-N-[2,3,4,5-tetrahydro-1 -[[2-[[[(methylamino)carbonyil]amino]methyl][1.1'biphenyl]-4-yl]-methyl]-7-methoxy-2-oxo-1H-benzazepin-3(R)-yl]butanamide;

3-[2(S),3-Dihydroxypropyl]amino-3-methyl-N-[2,3,4,5-tetrahydro-1 -[[2'-[[[(methylamino)carbonyl]amino]methyl][1,1'-biphenyl]-4-yl]-methyl]-7-methylthio-2-oxo-1H-benzazepin-3(R)-yl]butanamide;

3-[2(S),3-Diydroxypropyl]amino-3-methyl-N-[2,3,4,5 tetrahydro- 1-[[2'-[[[(methylamino)carbonyl]amino]methyl][1,1'biphenyl]-4-yl]-methyl]-7-trifluoromethyl-2-oxo-1H-benzazepin-3(R)-yl]butanamide;

2-Amino-2-methyl-N [2,3,4,5-tetrahydro-1-[[2'-[[(aminocarbonyl)-amino]methyl][1,1'biphenyl]-4-yl]methyl]-2-oxo-1H-benzazepin-3(R)-yl]propanamide;
.

2-Amino-2-methyl-N-[2,3,4,5-tetrahydro-1-[[2'-[[(aminocarbonyl)-amino]methyl][1,1'-biphenyl]-4-yl]methyl]-7-fluoro-2-oxo-1H-benzazepin-3(R)-yl]propanamide;

2-Amino-2-methyl-N-[2,3,4,5-tetrahydro-1-[[2'-[[(aminocarbonyl)-amino]methyl][1,1'biphenyl]4-yl]methyl]-7-methoxy-2-oxo-1H-benzazepin-3(R)-yl]propanamide;

2-Amino-2-methyl-N-[2,3,4,5-tetrahydro-1-[[2'-[[(aminocarbonyl)-amino]methyl][1,1'-biphenyl]-4-yl]methyl]-7-methylthio-2-oxo-1H-benzazepin-3(R)-yl]propanamide;

2-Amino-2-methyl-N-[2,3,4,5-tetrahydro-1 -[[2'-[[(aminocarbonyl)-amino]methyl][1,1'-biphenyl]-4-yl]methyl]-7-trifluoromethyl-2-oxo-1H-benzazepin-3(R)-yl]propanamide;

3-Amino-3-methyl-N-[2,3,4,5-tetrahydro-1-[[2'-[[(aminocarbonyl)-amino]methyl][1,1'-biphenyl]-4-yl]methyl]-2-oxo-1H-benzazepin-3(R)-yl]butanamide;

3-Amino-3-methyl-N-[2,3,4,5-tetrahydro-1-[[2'-[[(aminocarbonyl)-amino]methyl][1,1-biphenyl]-4-yl]methyl]-7-fluoro-2-oxo-1H-benzazepin-3(R)-yl]butanamide;

3-Amino-3-methyl-N-[2,3,4,5-tetrahydro-1-[[2'-[[(aminocarbonyl)-amino]methyl][1,1'-biphenyl]-4-yl]methy]-7-methoxy-2-oxo-1H-benzazepin-3(R)-yl]butanamide;

3-Amino 3-methyl-N-[2,3,4,5-tetrahydro-1-[[2'-[[(aminocarbonyl)-amino]methyl][1,1'-biphenyl]-4-yl]methyl]-7-methylthio-2-oxo-1H-benzazepin-3(R)-yl]butanamide;

3-Amino-3-methyl-N-[2,3,4,5-tetrahydro-1-[[2'-[[aminocarbonyl)-amino]methyl][1,1'-biphenyl]-4-yl]methyl]-7-trifluoromethyl-2-oxo-1H-benzazepin-3(R)-yl]butanamide;

3-[2(R)-Hydroxypropyl]amino-3-methyl-N-[2,3,4,5-tetrahydro-1-[[2'-[[aminocarbonyl)amino]methyl][1,1'-biphenyl]-4-yl]methyl]-2-oxo-1H-benzazepin-3(R)-yl]butanamide;

3-[2(R)-Hydroxypropyl]amino-3-methyl-N-[2,3,4,5-tetrahydro-1-[[2'-[[(aminocarbonyl)amino]methyl][1,1'-biphenyl]-4-yl]methyl]-7-fluoro-2-oxo-1H-benzazepin-3(R)-yl]butanamide;

3-[2(R)-Hydroxypropyl]amino-3-methyl-N-[2,3,4,5-tetrahydro-1-[[2'-[[(aminocarbonyl)amino]methyl][1,1'-biphenyl]-4-yl]methyl]-7-methoxy-2-oxo-1H-benzazepin-3(R)-yl]butanamide;

3-[2(R)Hydroxypropyl]amino-3-methyl-N-[2,3,4,5-tetrahydro-1-[[2'-[[(aminocarbonyl)amino]methyl][1,1-biphenyl]-4-yl]methyl]-7-methyl-thio-2-oxo-1H-benzazepin-3(R)-yl]butanamide;

3-[2(R)-Hydroxypropyl]amino-3-methyl-N-[2,3,4,5-tetrahydro-1-[[2'-[[(aminocarbonyl)amino]methyl][1,1'-biphenyl]-4-yl]methyl-7-tri-fluoromethyl-2-oxo-1H-benzazepin-3(R)-yl]butanamide;

3-[2(S),3-Dihydroxypropyl]amino-3-methyl-N-[2,3,4,5-tetrahydro-1-[[2'-[[(aminocarbonyl)amino]methyl][1,1'-biphenyl]-4-yl]methyl]-2-oxo-1H-benzazepin-3(R)-yl]butanamide;

3-[2(S),3-Dihydroxypropyl]amino-3-methyl-N-[2,3,4,5-tetrahydro-1-[[2'-[[(aminocarbonyl)amino]methyl][1,1'-biphenyl]-4-yl]methyl]-7-fluoro-2-oxo-1H-benzazepin-3(R)-yl]butanamide;

3-[2(S),3-Dihydroxypropyl]amino-3-methyl-N-[2,3,4,5-tetrahydro-1-[[2'-[[(aminocarbonyl)amino]methyl][1,1-biphenyl]-4-yl]methyl]-7-methoxy-2-oxo-1H-benzazepin-3(R)-yl]butanamide;

3-[2(S),3-Dihydroxypropyl]amino-3-methyl-N-[2,3,4,5-tetrahydro-1-[[2'-[[(aminocarbonyl)amino]methyl][1,1'-biphenyl]-4-yl]methyl]-7-methylthio-2-oxo-1H-benzazepin-3(R)-yl]butanamide;

3[2(S),3-Dihydroxypropyl]amino-3-methyl-N-[2,3,4,5-tetrahydro-1-[[2'-[[aminocarbonyl)amino]methyl][1,1'-biphenyl]-4-yl]methyl]-7-trifluoromethyl-2-oxo-1H-benzazepin-3(R)-yl]butanamide;

2-Amino-2-methyl-N-[2,3,4,5-tetrahydro-1-[[2'-[[[(ethylamino)-carbonyl]amino]methyl][1,1'-biphenyl]-4-yl]methyl-2-oxo-1H-benzazepin-3(R)-yl]propanamide;

2-Amino-2-methyl-N[2,3,4,5-tetrahydro-1-[[2'-[[[(ethylamino)-carbonyl]amino]methyl][1,1'-biphenyl]-4-yl]methyl]-7-fluoro-2-oxo-1H-benzazepin-3(R)-yl]propanamide;

2-Amino-2-methyl-N-[2,3,4,5-tetrahydro-1-[[2'-[[[(ethylamino)-carbonyl]amino]methyl][1,1-biphenyl]-4-yl]methyl-7-methylthio-2-oxo-1H-benzazepin-3(R)-yl]propananmide, 2-Amino-2-methyl-N-[2,3,4,5-tetrahydro-1-[[2'-[[[(ethylamino)-carbonyl]amino]methyl][1,1'-biphenyl]-4-yl]methyl]-7-methylthio-2-oxo-1H-benzazepin-3(R)-yl]propanamide;

2-Amino-2-methyl-N-[2,3,4,5-tetrahydro-1[[2'-[[[(ethylamino)-carbonyl]amino]methyl][1,1'-biphenyl]-4-yl]methyl]-7-trifluoromethyl-2-oxo-1H-benzazepin-3(R)-yl]propanamide;

3-Amino-3-methyl-N-[2,3,4,5-tetrahydro-1-[[2'-[[[(ethylamino)-carbonyl]amino]methyl][1,1'-biphenyl]-4-yl]methyl]-2-oxo-1H-benzazepin-3(R)-yl]butanamide;

3 Amino-3-methyl-N-[2,3,4,5-tetrahydro-1[[2'-[[[(ethylamino)-carbonyl]-amino]methyl][1,1'-biphenyl]-4-yl]methyl]-7-fluoro-2-oxo-1H-benzazepin-3(R)-yl]butanamide;

3-Amino-3-methyl-N-[2,3,4,5-tetrahydro-1-[[2'-[[[(ethylamino)-carbonyl]amino]methyl][1,1'-biphenyl]-4-yl]methyl]-7-methoxy-2-oxo-1H-benzazepin-3(R)-yl]butanamide;

3-Amino-3-methyl-N-[2,3,4,5-tetrahydro-1-[[2'-[[[(ethylamino)-carbonyl]amino]methyl][1,1'-biphenyl]-4-yl]methyl]-7-methylthio-2-oxo-1H-benzazepin-3(R)-yl]butanamide;

3-Amino-3-methyl-N-[2,3,4,5-tetrahydro-1-[[2'-[[[(ethylamino)-carbonyl]amino]methyl][1,1'-biphenyl]-4-yl]methyl]-7-trifluoromethyl-2-oxo-1H-benzazepin-3(R)-yl]butanamide;
.
3-[2(R)-Hydroxypropyl]amino-3-methyl-N-[2,3,4,5-tetrahydro-1-[[2'-[[[(ethylamino)carbonyl]amino]methyl][1,1'-biphenyl]4-yl]methyl]-2-oxo 1H-benzazepin-3(R)-yl]butanamide;

3-[2(R)-Hydroxypropyl]amino-3-methyl-N-[2,3,4,3-tetrahydro-1-[[2'-[[[(ethylamino)carbonyl]amino]methyl][1,1'-biphenyl]-4-yl]methyl]-7-fluoro-2-oxo-1H-benzazepin-3(R)-yl]butanamide;

3-[2(R)-Hydroxypropyl]amino-3-methyl-N-[2,3,4,5-tetrahydro-1-[[2'-[[[(ethylamino)carbonyl]amino]methyl][1,1'-biphenyl]-4-yl]methyl]-7-methoxy-2-oxo-1H-benzazepin-3(R)-yl]butanamide;

3-[2(R3-Hydroxypropyl]amino-3-methyl-N-[2,3,4,5-tetrahydro-1-[[2'-[[[(ethylamino)carbonyl]amino]methyl][1,1'-biphenyl]-4-yl]methyl-7-methylthio-2-oxo-lH-benzazepin-3(R)-yl]butanamide;

3-[2(R)-Hydroxypropyl]amino-3-methyl-N-[2,3,4,5-tetrahydro-1 [[[(ethylamino)carbonyl]amino]methyl][1,1'biphenyl]4-yl]methyl]-7-trifluoromethyl-2-oxo-1H-benzazepin-3(R]-yl]butanamide;

3-(2(S),3-Dihydroxypropyl]amino-3-methyl-N-[2,3,4,5-tetrahydro-1-[[2'-[[[(ethylamino)carbonyl]amino]methyl]1,1'-biphenyl]-4-yl]methyl]-2-oxo-1H-benzazepin-3(R)-yl]butanamide;

3-[2(S),3-Dihydroxypropyl]amino-3-methyl-N-[2,3,4,5-tetrahydro-1-[[2'[[[(ethylamino)carbonyl]amino]methyl[[1,1'-biphenyl]-4-yl]methyl]-7 fluoro-2-oxo-1H-benzazepin-3(R)-yl]butanamide;

3-[2(S),3-Dihydroxypropyl]amino-3-methyl-N-[2,3,4,5-tetrahydro-1-[[2'-[[[(ethylamino)carbonil]amino]methyl]1,1'-biphenyl]-4-yl]methyl]-7-methoxy-2-oxo-1H-benzazepin-3(R)-yl]butanamide;

3-[2(S),3-Dihydroxypropyl]amino-3-methyl-N-[2,3,4,5-tetrahydro-1-[[2'-[[[(ethylamino)carbonyl]amino]methyl][1,1'-bipherlyl]4-yl]methyl]-7-methylthio-2-oxo-lH-benzazepin-3(R)-yl]butanamide;

3-[2(S),3-Dihydroxypropyl]amino-3-methyl-N-[2,3,4,5-tetrahydro-l-[[2'-[[[(ethylannino)carbonyl]amino]methyl][1,1'-biphenyl]-4-yl]methyl]-7-trifluoromethyl-2-oxo-1H-benzazepin-3(R)-yl]butanamide;

2-Amino-2-methyl-N-[2,3,4,5-tetrahydro-1-[[2'-[[[[hydroxyethyl)-amino])carbonyl]amino]methyl][1,1'-biphernyl]-4-yl]methyl]-2-oxo-1H-benzazepin-3(R)-yl]propanamide;

2-Amino-2-methyl-N-[2,3,4,5-tetrahydro-1-[[2 -[[[[(hydroxyethyl)-amino]carbonyl]amino]methyl][1,1'-biphenyl]-4-yl]methyl]-7-fluoro-2-oxo-1H-benzazepin-3(R)-y1]propanamide;

2-Amino-metyl-N-[2,3,4,5-tetrahydro-1-[[2'-[[[[(hydroxyethyl)-amino]carbonyl]amino]methyl][1,1'-biphenyl]-4-yl]methyl]-7-methoxy-2-oxo-1H-benzazepin-3(R)-y1]propanamide;

2-Amino-2-methyl-N-[2,3,4,5-tetrahydro-1-[[2'-[[[[(hydroxyethyl)-amino]carbonyl]amino]methyl]1,1'-biphenyl]-4-y1]methyl]-7-methyl-thio-2-oxo-1H-benzazepin-3(R)-y1]propanamide;

2-Amino-2-metyl-N-[2,3,4,5-tetrahydro-1-[[2'-[[[[(hydroxyethyl)-amino]carbonyl]amino]methyl][1,1'-biphenyl]4-y1]methyl]-7-trifluoromethyl-2-oxo-1H-benzazepin-3(R)-y1]propanamide;

3-Amino-3-methyl-N-[2,3,4,5-tetrahydro- 1 -[[2'-[[[[(hydroxyethyl)-amino]carbonyl]amino]methyl][1,1'-biphenyl]-4-y1]methyl]-2-oxo-1H-benzazepin-3(R)-y1]butanamide;

3-Amino-3-methyl-N-[2,3,4,5-tetrahydro-1-[[2'-[[[[(hydroxyethyl)-amino]carbonyl]amino]methyl][1,1'-biphenyl]-4-y1]methyl]-7-fluoro-2-oxo-1H-benzazepin-3(R)-yl]butanamide;

3-Amino-3-methyl-N-[2,3,4,5-terrahydro-1-[[2'-[[[[(hydroxyethyl)-amono]carbonyl]amino]methyl][1,1'-biphenyl]-4-y1]methyl]-7-methoxy-2-oxo-lH-benzazepin-3(R)-y1]butanamide;

3-Anino-3-methyl-N-[2,3,4,5-tetrahydro-1-[[2'-[[[[(hydroxyethyl)-amino]carbonyl]amino]methyl][1,1'-biphenyl]4-y1]methyl]-7-methyl-thio-2-oxo-1H-benzazepin-3(R)-yl]butanamide;

3-Amino-3-methyl-N-[2,3,4,5-tetrahydro-1-[[2'-[[[[(hydroxyethyl)-amino]carbonyl]amino]methyl][1,1'-biphenyl]-4-y1]methyl]-7-trifluoro-methyl-2-oxo-1H-benzazepin-3(R)-y1]butanamide;

3-[2(R)-Hydropypropyl]amino-3-methyl-N-[2,3,4,5-tetrahydro-1-[[2'-[[[[(hydroxyethyl)amino]carbonyl]amino]methyl][1,1'-biphenyl]-4-y1]-methyl]-2-oxo-1H-benzazepin-3(R)-yl]butanamide;

3-[2(R)-Hydroxypropyl]amino-3-methyl-N-[2,3,4,5-tetrahydro-1-[[2'-[[[[(hydroxyethyl)amino]carbonyl]amino]methyl][1,1'-biphenyl]-4-y1]-methyl]-7-fluoro-2-oxo-1H-benzazepin-3(R)-yl]butanamide;

3-[2(R)-Hydroxypropyl]amino-3-methyl-N -[2,3,4,5-tetrahydro-1-[[2'-[[[[(hydroxyethyl)amino]carbonyl]amino]meyhyl][1,1'-biphenyl]-4-y1]-methyl]-7-methoxy-2-oxo-1H-benzazepin-3(R)-y1]bultanamide;

3-[2(R)-Hydroxypropyl]amino-3-methyl-N-[2,3,4,5-tetrahydro-1-[[2'-[[[[(hydroxypropyl]amino-3-methyl-N-[2,3,4,5-tetrahydro-1-[[2'-methyl]-7-methylthio-2-oxo-1H-benzazepin-3(R)-y1]butanamide;

3-[2(R)-Hydroxypropyl]amino-3-methyl-N-[2,3,4,5-tetrahydro-1-[[2'-[[[[hydroxyethyl)amino]carbonyl]amino]methyl][1,1'-bi-phenyl]-4-y1]-methyl]-7-trifluoromethyl-2-oxo-1H-benzazepin-3(R)-y1]butanamide;

3-[2(S),3-Dihydroxypropyl]amino-3-methyl-N-[2,3,4,5-tetrahydro-1-[[2'-[[[[(hydroxyethyl)amino]carbonyl]amino]-methyl][1,1'-biphenyl]-4-yl]methyl]-2-oxo-1H-benzazepin-3(R)-y1]butanamide;

3-[2(S),3-Dihydroxypropyl]amino-3-methyl-N-[2,3,4,5-tetrahydro-1-[[2'-[[[[(hydroxyethyl)amino]carbonyl]amino]-meyhyl][1,1'-biphenyl]-4-y1]methyl]-7-fluoro-2-oxo-1H-benzazepin-3(R)-y1]butanamide;

3-[2(S),3-Dihydroxypropyl]amino-3-methyl-N-[2,3,4,5-tetrahydro- 1 -[[2'-[[[[(hydroxyethyl)amino]carbonyl]amino]-methyl][1,1'-biphenyl]-4-yl]meyhyl]-7-methoxy-2-oxo-1H-benzazepin-3(R)-y1]butanamide;

3-[2(S),3-Dihydroxypropyl]amino-3-methyl-N-[2,3,4,5-tetrahydro-1-[[2'-[[[[(hydroxyethyl)amino]carbonyl]amino]-methyl][1,1'-biphenyl]-4-y1]methyl]-7-methylthio-2-oxo-1H-benzazepin-3(R)-yl]butanamide;

3-[2(S),3-Dihydroxypropyl]amino-3-methyl-N-[2,3,4,5-tetrahydro-1-[[2'-[[[[(hydroxyethyl)amino]carbonyl]amino]-methyl][1,1' biphenyl]-4-y1]methyl]-7-trifluoromethyl-2-oxo-1H-benzazepin-3(R)-yl]butanamide;

N-[5-[[2'-[(Methoxycarbonyl)amino][1,1'-biphenyl]-yl]methyl]-2,3,4,5-tetrahydro-4-oxo-1,5-benzothiazepin-3(S)-y1]-3-amino-3-methylbutanamide;

N-[5-[[2'-[Methylaminocarbonyl)amino][1,1'-biphenyl-4-y1]methyl]-2,3,4,5-tetrahydro-4-oxo-1,5-benzothiazepin-3(S)-y1]-3-amino-3-methylbutanamide;
.
N-[5-[[2[(Morpholinocarbonyl)amino][1,1'-biphenyl]-4-y1]methyl]-2,3,4,5-tetrahydro-4-oxo-1,5-benzothiazepin-3(S)-y1]-3-amino-3-methylbutanamide:

N-[5-[[2'-[[(2-Hydroxyethylamino)carbonyl]amino][1,1'-biphenyl]-4-y1]methyl] -2,3,4,5-tetrahydro-4-oxo-1,5-benzothiazepin-3(S)-yl]-3-amino-3-methylbutanamide;

N-[5-[[2'-[(Methylaminocarbonyl)amino][1,1'-biphenyl]-4-yl]methyl]-2,3,4,5-tetrahydro-4-oxo-1,5-benzothiazepin-3(S)-y1]-3-[2(R)-hydroxy-propyl]amino-3-methylbutanamide;

N-[5-[[2'-[(Morpholinocarbonyl)amino][1,1'-biphenyl]-4-y1]methyl]-2,3,4,5-tetrahydro-4-oxo-1,5-benzothiazepin-3(S)-y1]-3-[2(R)-hydroxy-propyl]amino-3-methylbutanamide;

N-[5-[[2'-[[(2-Hydroxyethylamino)carbonyl]amino][1,1'-biphenyl]-4-yl]methyl]-2,3,4,5-tetrahydro-4-oxo-1,5-benzothiazepin-3(S)-yl]-3-[2(R)-hydroxypropyl]amino-3-methylbutanamide;

N-[5-[[2'-[(Methylaminocarbonyl)amino][1,1'-biphenyl]-4-y1]methyl]-2,3,4,5-tetrahydro-4-oxo-1,5-benzothiazepin-3(S)-yl]-3-[2(S),3-di-hydroxypropyl]amino-3-methylbutanamide;

2°-Amino-2-methyl-N-[2,3,4,5-tetrahydro-5-[[2'-[[[(methylamino)-carbonyl]amino]methyl][1,1'-biphenyl]-4-yl]methyl]-4-oxo-1,5-benzo-thiazepin-3(S)-yl]propanamide;

2-Amino-2-methyl-N-[2,3,4.5-tetrahydro-5-[[2'-[[[(methylamino)-carbonyl]amino]methyl][1,1'-biphenyl]-4-yl]methyl]-8-fluoro-4-oxo-1,5-benzothiazepin-3(S)-yl]propanamide;

2-Amino-2-methyl-N-[2,3,4,5-tetrahydro-5-[[2'-[[[(methylamino)-carbonyl]amino]methyl][1,1'-biphenyl]-4-yl]methyl]-8-methoxy-4-oxo-1,5-benzothiazepin-3(S)-yl]propanamide;

2-Amino-2-methyl-N-[2,3,4,5-tetrahydro-5-[[2'[[[(methylamino)-carbonyl]amino]methyl][1,1'-biphenyl]-4-yl]methyl]-8-methylthio-4-oxo-1,5-benzothiazepin-3(S)-yl]propanamide;

2-Amino-2-methyl-N-[2,3,4,5-tetrahydro-5-[[2'-[[[(methylamino)-carbonyl]amino]methyl][1,1'-biphenyl]-4-yl]methyl]-8-trifluoromethyl-4-oxo-1,5-benazothiazepin-3(S)-yl]propanamide;

3-Amino-3-methyl-N-[2,3,4,5-tetrahydro-5-[[2'-[[[(methylamino)-carbonyl]amino]methyl][1,1'-biphenyl]-4-y1]methyl]-4-oxo-1,5-benzo-thiazepin-3(S)-yl]butanamide;

3-Amino-3-methyl-N-[2,3,4,5-tetrahydro-5-[[2'[[[(methylamino)-carbonyl]amino]methyl][1,1'-biphenyl]-4-yl]methyl]-8-fluoro-4-oxo-1,5-benzothiazepin-3(S)-y1]butanamide;

3-Amino-3-methyl-N-[2,3,4,5-tetrahydro-5-[[2'-[[[(methylamino)-carbonyl]amino]methyl][1,1'-biphenyl]-4-y1]methyl]-8-methoxy4-oxo-1,5-benzothiazepin-3(S)-yl]butanamide;

3-Amino-3-methyl-N-[2,3,4,5-tetrahydro-5-[[2'-[[[(methylamino)-carbonyl]amino]methyl][1,1'-biphenyl]-4-y1]methyl]-8-methylthio-4-oxo-1,5-benzothiazepin-3(S)-yl]butanamide;

3-Amino-3-methyl-N-[2,3,4,5-tetrahydro-5-[[2'-[[[(methylamino)-carbonyl]amino]methyl][1,1'-biphenyl]-4-y1]methyl]-8-trifluoromethyl-4-oxo-1,5-benzothiazepin-3(S)-y1]butanamide;

3-[2(R)-Hydroxypropyl]amino-3-methyl-N-[2,3,4,5-tetrahydro-5-[[2'-[[[(methylamino)carbonyl]amino]methyl][1,1'-biphenyl]-4-y1]methyl]-4-oxo-1,5-benzothiazepin-3(S)-y1]butanamide;

3-[2(R)-Hydroxypropyl]amnio-3-methyl-N-[2,3,4,5-tetrahydro-5-[[2'-[[[(methylamino)carborlyl]amino]methyl][1,1'-biphenyl]-4-y1]methyl]-8-fluoro-4-oxo-1,5-benzothiazepin-3(S)-y1]butanamide;

3-[2(R)-Hydroxypropyl]amino-3-methyl-N-[2,3,4,5-tetrahydro-5-[[2'-[[[(methylamino)carbonyl]amino]methyl][1,1'-biphenyl]-4-y1]methyl]-8-methoxy-4-oxo-1,5-benzodiazepin-3(S)-y1]butanamide;

3-[2(R)-Hydroxypropyl]amino-3-methyl-N-[2,3,4,5-tetrahydro-5-[[2'-[[[(methylamino)carbonyl]amino]methyl][1,1'-biphenyl]-4-yl]methyl]-8-methylthio-4-oxo-1,5-benzothiazepin-3(S)-yl]butanamide;

3-[2(R)-Hydroxypropyl]amino-3-methyl-N-[2,3,4,5-tetrahydro-5-[[2'-[[[(methylamino)carbonyl]amino]methyl][1,1'-biphenyl]-4-yl]methyl]-8-trifluoromethyl-4-oxo-1,5-benzothiazepin-3(S)-yl]butanamide;

3-[2(S),3-Dihydroxypropyl]amino-3-methyl-N-[2,3,4,5-tetrahydro-5-[[2'-[[[(methylamino)carbonyl]amino]methyl][1,1'-biphenyl]-4-yl]-methyl]-4-oxo-1,5-benzothiazepin-3(S)-yl]butanamide;

3-[2(S),3-Dihydroxypropyl]amino-3-methyl-N-[2,3,4,5-tetrahydro-5-[[2'-[[[(methylamino)carbonyl]amino]methyl][1,1'-biphenyl]-4-yl]-methyl]-8-fluoro-4-oxo-1,5-benzothiazepin-3(S)-yl]-butanamide;

3-[2(S),3-Dihydroxypropyl]amino-3-methyl-N-[2,3,4,5-tetrahydro-5-[[2'[[[(methylamino)carbonyl]amino]methyl][1,1'-biphenyl]-4-yl]-methyl]-8-methoxy-4-oxo-1,5-benzothiazepin-3(S)-yl]butanamide;

3-[2(S),3-Dihydroxypropyl]amino-3-methyl-N-[2,3,4,5-tetrahydro-5-[[2'-[[[(methylamino)carbonyl]amino]methyl][1,1'-biphenyl]-4-yl]-methyl]-8-methylthio-4-oxo-1,5-benzothiazepin-3(S)-yl]butanamide;

3-[2(S),3-Dihydroxypropyl]amino-3-methyl-N-[2,3,4,5-tetrahydro-5-[[2'-[[[methylamino)carbonyl]amino]methyl][1,1'-biphenyl]-4-yl]-methyl]-8-trifluoromethyl-4-oxo-1,5-benzothiazepin-3(S)-yl]-butanamide:

2-Amino-2-methyl-N-[2,3,4,5-tetrahydro-1-[[2'-[[(aminocarbonyl)-amino]methyl][1,1'-biphenyl]-4-yl]methyl]-4-oxo-1,5-benzothiazepin-3(S)-yl]propanamide;

2-Amino-2-methyl-N-[2,3,4,5-tetrahydro-5-[[2'-[[(aminocarbonyl)-amino]methyl][1,1'-biphenyl]-4-yl]methyl]-8-fluoro-4-oxo-1,5-benzothiazepin-3(S)-yl]propanamide;

2-Amino-2-methyl-N-[2,3,4,5-tetrahydro-5-[[2'-[[(aminocarbonyl)-amino]methyl][1,1'-biphenyl]-4-yl]methyl]-8-methoxy-4-oxo-1,5-benzothiazepin-3(S)-yl]propanamide;

2-Amino-2-methyl-N-[2,3,4,5-tetrahydro-5-[[2'-[[(aminocarbonyl)-amino]methyl][1,1'-biphenyl]-4-yl]methyl]-8-methylthio-4-oxo-1,5-benzothiazepin-3(S)-yl]propanamide;

2-Amino-2-methyl-N-[2,3,4,5-tetrahydro-1-[[2'-[[(aminocarbonyl)-amino]methyl][1,1'-biphenyl]-4-yl]methyl]-8-trifluoromethyl-4-oxo-1,5-benzothiazepin-3(S)-yl]propanamide;

3-Amino-3-methyl-N-[2,3,4,5-tetrahydro-5-[[2'-[[(aminocarbonyl)-amino]methyl][1,1'-biphenyl]-4-yl]-4-oxo-1,5-benzothiazepin-3(S)-yl]butanamide;

3-Amino-3-methyl-N-[2,3,4,5-tetrahydro-5-[[2'-[[(aminocarbonyl)-amino]methyl][1,1'-biphenyl]-4-yl]methyl]-8-fluoro-4-oxo-1,5-benzo-thiazepin-3(S)-yl]butanamide;

3-Amino-3-methyl-N-[2,3,4,5-tetrahydro-5-[[2'-[[(aminocarbonyl)-amino]methyl][1,1'-biphenyl]-4-yl]methyl]-8-methoxy-4-oxo-1,5-benzo-thiazepin-3(S)-yl]butanamide;

3-Amino-3-methyl-N-[2,3,4,5-tetrahydro-5-[[2'-[[(aminocarbonyl)-amino]methyl][1,1'-biphenyl]-4-yl]methyl]-8-methylthio-4-oxo-1,5-benzothiazepin-3(S)-yl]butanamide;

3-Amino-3-methyl-N-[2,3,4,5-tetrahydro-5-[[2'-[[(aminocarbonyl)-amino]methyl][1,1'-biphenyl]-4-y1]methyl]-8-trifluoromethyl-4-oxo-1,5-benzothiazepin-3(S)-y1]butanamide;

3-[2(R)-Hydroxypropyl]amino-3.methyl-N-[2,3,4,5-tetrahydro-5-[[2'-[[(aminocarbonyl)amino]methyl][1,1'-biphenyl]-4-y1]methyl]-oxo-1,5-benzothiazepin-3(S)-y1]butanamide;

3-[2(R)-Hydroxypropyl]amino-3-methyl-N-[2,3,4,5-tetrahydro-5-[[2'-[[(aminocarbonyl)amino]methyl][1,1'-biphenyl]-4-y1]methyl]-8-fluoro-4-oxo-1,5-benzothiazepin-3(S)-y1]butanamide;

3-[2(R)- Hydroxypropyl]amino-3-methyl-N-[2,3,4,5-tetrahydro-5-[[2'-[[(aminocarbonyl)amino]methyl][1,1'-biphenyl]-4-y1]meyhyl]-8-methoxy-4-oxo-1,5-benzothiazepin-3(S)-y1]butanamide;

3-[2(R)-Hydroxypropyl]amino-3-methyl-N-[2,3,4,5-tetrahydro-5-[[2'-[[(aminocarbonyl)amino]methyl][1,1'-biphenyl-4-y1]methyl]-8-methyl-thio-4-oxo-1,5-benzothiazepin-3(S)-y1]butanamide;

3-[2(R)-Hydroxypropyl]amino-3-methyl-N-[2,3,4,5-tetrahydro-5-[[2'-[[(aminocarbonyl)amino]methyl][1,1'-biphenyl]-4-y1]methyl]-8-trifluoromethyl-4-oxo-1,5-benzothiazepin-3(S)-y1]butanamide;

3-[2(S),3-Dihydroxypropyl]amino-3-methyl-N-[2,3,4,5-tetrahydro-5-[[2'-[[(aminocarbonyl)amimo]methyl][1,1'-biphenyl]-y1]methyl]-4-oxo-1,5-benzothiazepin-3(S)-y1]butanamide;

3-[2(S),3 -Dihydroxypropyl]amino-3-methyl-N- [2,3,4,5-tetrahydro -5-[[2'-[[(aminocarbonyl)amino]methyl][1,1'-biphenyl]-y1]methyl]-8-fluoro-4-oxo-1,5-benzothiazepin-3(S)-y1]-butanamide;

3-[2(S),3-Dihydroxypropyl]amino-3-methyl-N-[2,3,4,5-tetrahydro-5-[[2'-[[(aminocarbonyl)amino]methyl][1,1'-biphenyl]-4-y1]methyl]-8-methoxy-4-oxo-1,5-benzothiazepin-3(S)-y1-butanamide;

3-[2'(S),3-Dihydroxypropyl]amino-3-methyl-N -[2,3,4,5-tetrahydro-5-[[2'-[[(aminocarbonyl)amino]methyl][1,1'-biphenyl]-4-y1]methyl]-8-methylthio-4-oxo-1,5-benzothiazepin-3(S)-y1]-butanamide;

3-[2(S),3-Dihydroxypropyl]amino-3-methyl-N-[2,3,4,5-tetrahydro-5-[[2'-[[(aminocarbonyl)amino]meyhyl][1,1'-biphenyl]-4-y1]methyl]-8-trifluoromethyl-4-oxo-1,5-benzothiazepin-3(S)-y1]-butanamide;

2-Amino-2-methyl-N-[2,3,4,5-tetrahydro-5-[[2'-[[[(ethylamino)-carbonyl]amino]methyl][1,1'-biphenyl]-4-y1]methyl]-4-oxo-1,5-benzothiazepin-3(S)-y1]propanamide;

2-Amino-2 methyl-N-[2,3,4,5-tetrahydro-5-[[2'-[[[ethylamino)-carbonyl]amino]methyl][1,1'-biphenyl]-4-y1]methyl]-8-fluoro-4-oxo-1,5-benzothiazepin-3(S)-y1]propanamide;

2-Amino-2-methyl-N-[2,3,4,5-tetrahydro-5-[[2'-[[[(ethylamino)-carbonyl]amino]methyl][1,1'-biphenyl]-4-y1[methyl]-8-methoxy-4-oxo-1,5-benzothiazepin-3(S)-y1]propanamide;

2-Amino-2-methyl-N-[2,3,4,5-tetrahydro-5-[[2'-[[[(ethylamino)-carbonyl]amino]methyl][1,1'-biphenyl]-4-yl]methyl]-8-methylthio-4-oxo-1,5-benzothiazepin-3(S)-y1]propanamide;

2-Amino-2-methyl-N-[2,3,4,5-tetrahydro-5-[[2'-[[[(ethylamino)-carbonyl]amino]methyl][1,1'-biphenyl]-4-y1]methyl]-8-trifluoro-methyl-4-oxo-1,5-benzothiazepin-3(S)-y1]propanamide;

3-Amino-3-methyl-N-[2,3,4,5-tetrahydro-5-[[2'-[[[(ethylamino)-carbonyl]amino]methyl][1,1'-biphenyl]-4-y1]methyl]-4-oxo-1,5-benzothiazepin-3(S)-y1]butanamide;

3-Amino-3-methyl-N-[2,3,4,5-tetrahydro-5-[[2'-[[[(ethylamino)-carbonyl]amino]methyl][1,1'-biphenyl]-4-y1]methyl]-8-fluoro-4-oxo-1,5-benzothiazepin-3(S)-y1]butanamide;

3-Amino-3-methyl-N-[2,3,4,5-tetrahydro-5-[[2'-[[[(eyhylamino)-carbonyl]amino]methyl][1,1'-biphenyl]-4-y1]methyl]-8-methoxy-4-oxo-1,5-benzothiazepin-3(S)-y1]butanamide;

3-Amino-3-methyl-N-[2,3,4,5-tetrahydro-5-[[2'-[[[(ethylamono)-carbonyl]-amino]methyl][1,1'-biphenyl]-4-y1]methyl]-8-methylthio-4-oxo-1,5-benzothiazepin-3(S)-y1]butanamide;

3-Amino-3-methyl-N-[2,3,4,5-tetrahydro-5-[[2'-[[[(ethylamino)-carbonyl]amino]methyl][1,1'-biphenyl]-4-y1]methyl]-8-trifluomethyl-4-oxo-1,5-benzothiazepin-3(S)-y1]butanamide;

3-[2(R)-Hydroxypropyl]amino-3-methyl-N-[2,3,4,5-tetrahydro-5-[[2' -[[[(ethylamino)carbonyl]amino]methyl][1,1'-biphenyl]-4-y1]-methyl]-4-oxo-1,5-benzothiazepin-3(S)-y1]butanamide;

3-[2(R)-Hydroxypul]amino-3-methyl-N-[2,3,4,5-tetrahydro-5-[[2'-[[[(ethylamino)carbonyl]amino]methyl][1,1'-biphenyl]-4-y1]methyl]-8-fluoro-4-oxo-1,5-benzothiazepin-3(S)-y1]butanamide;

3-[2(R)-Hydroxypropyl]amino-3-methyl-N-[2,3,4,5-tetrahydro-5-[[2'-[[[(ethylamino)carbonyl]amino]methyl][1,1'-biphenyl]-4-y1]methyl]-8-methoxy-4-oxo- 1,5-benzothiazepin-3(S)-y1]-butanamide;

3-[2(R)-Hydroxypropyl]amino-3-methyl-N-[2,3,4,5-tetrahydro-5-[[2'-[[[(ethylamino)carbonyl]amino]methyl][1,1'-biphenyl]-4-y1]methyl]-8-methylthio-4-oxo-1,5-benzothiazepin-3(S)-yl]-butanamide;

3-[2(R)-Hydroxypropyl]amino-3-methyl-N-[2,3,4,5-tetrahydro-5-[[2'-[[[(ethylamino)carbonyl]amino]methyl][1,1'-biphenyl]-4-yl]-methyl]-8-trifluoromethyl-4-oxo-1,5-benzothiazepin-3(S)-yl]-butanamide;

3-[2(S),3-Dihydroxypropyl]amino-3-methyl-N-[2,3,4,5-tetrahydro-5 -[[2'-[[[(ethylamino)carbonyl]amino]methyl][1,1'-biphenyl]-4-yl]methyl]-4-oxo-1,5-benzothiazepin-3(S)-yl]-butanamide;

3-[2(S),3-Dihydroxypropyl]amino-3-methyl-N-[2,3,4,5-tetrahydro-5-[[2'-[[[(ethylamino)carbonyl]amino]methy][1,1'-biphenyl]-4-yl]methyl]-8-fluoro-4-oxo-1,5-benzothiazepin-3(S)-yl]butanamide;

3-[2(S),3-Dihydroxypropyl]amino-3-methyl-N-[2,3,4,5-tetrahydro-5-[[2'[[[ethylamino)carbonyl]amino]methyl][1,1'-biphenyl-4-yl]methyl]-8-methoxy-4-oxo-1,5-benzothiazepin-3(S)-yl]butanamide;

3-[2(S),3-Dihydroxypropyl]amino-3-methyl-N-[2,3,4,5-tetrahydro-5-[[2'-[[[(ethylamino)carbonyl]amino]methyl][1,1'-biphenyl]-4-yl]methyl]-8-methylthio-4-oxo-1,5-benzothiazepin-3(S)-yl]butanamide;

3-[2(S),3-Dihydroxypropyl]amino-3-methyl-N-[2,3,4,5-tetrahydro-5-[[2'-[[[(ethylamino)carbonyl]amino]methyl][1,1'-biphenyl]-4-yl]methyl]-8-trifluoromethyl-4-oxo-1,5-benzo-thiazepin-3(S)-yl]butanamide;

2-Amino-2-methy}-N-[2,3,4,5-tetrahydro-5-[[2'-[[[[(hydroxyethyl)-amino]carbonyl]amino]methyl][1,1'-biphenyl]-4-yl]methyl]-4-oxo- 1,5 -benzothiazepin-3(S)-yl]propanamide;

2-Amino-2-methyl-N-[2,3,4,5-tetrahydro-5-[[2'-[[[[(hydroxyethyl)-amino]carbonyl]amino]methyl][1,1'-biphenyl]-4-y1]methyl]-8-fluoro-4-oxo-1,5-benzothiazepin-3(S)-y1]propanamide;

2Amino-2-methyl-N-[2,3,4,5-tetrahydro-5-[[2'-[[[[(hydroxyethyl)-amino]carbonyl]amino]methyl][1,1'biphenyl]-4-y1]methyl]-8-methoxy-4-oxo-1,5-benzothiazepin-3(S)-y1]propanamide;

2-Amino-2-methyl-N-[2,3,4,5-tetrahydro-5-[[2'-[[[[(hydroxyethyl)-amino]carbonyl]amino]methyl][1,1'-biphenyl]-4-y1]methyl]-8-methyl-thio-4-oxo-1,5-benzothiazepin-3(S)-y1]propanamide;

2-Amino-2-methyl-N-[2,3,4,5-tetrahydro-5-[[2' -[[[[(hydroxyethyl)-amino]carbonyl]amino]methyl][1,1'-biphenyl]-y1]methyl]-8-trifluoro-methyl-4-oxo-1,5-benzothiazepin-3(S)-y1]propanamide;

3-Amino-3-methyl-N-[2,3,4,5-tetrahydro-5-[[2'-[[[(hydroxyethyl)-amino]carbonyl]amino]methyl][1,1'-biphenyl]-4-y1]methyl-4-oxo-1,5-benzothiazepin-3(S)-y1]butanamide;

3-Amino-3-methyl-N-[2,3,4,5-tetrahydro-5-[[2'-[[[[(hydroxyethyl)-amino]carbonyl]amino]methyl][1,1'-biphenyl]-4-y1]methyl]-8-fluoro-4-oxo-1,5-benzothiazepin-3(S)-y1]butanamide;

3-Amino-3-methyl-N-[2,3,4,5-tetrahydro-5-[[2'-[[[[(hydroxyethyl)-amino]carbonyl]amino]methyl][1,1'-biphenyl]-4-y1]methyl]-8-methoxy-4-oxo-1,5-benzothiazepin-3(S)-y1]butanamide;

3-Amino-3-methyl-N-[2,3,4,5-tetrahydro-5-[[2'-[[[[(hydroxyethyl)-amuino]carbonyl]amino]methyl][1,1'-biphenyl]-y1]methyl]-8-methyl-thio-4-oxo-1,5-benzothiazepin-3(S)-y1]butanamide;

3-Amino-3-methyl-N-[2,3,4,5-tetrahydro-5-[[2' -[[[[(hydroxyethyl)-amino]carbonyl]amino]methyl][1,1'-biphenyl]-4-y1]methyl]-8-trifluoro-methyl-oxo-1,5-benzothiazepin-3(S)-y1]butanamide;

3-[2(R)-Hydroxypropyl]amino-3-methyl-N-[2,3,4,5-tetrahydro-5-[[2'-[[[[(hydroxyethyl)amino]carbonyl]amino]methyl][1,1'-biphenyl]-4-y1]-methyl]-4-oxo-1,5- benzothiazepin-3(S)-y1]-butanamide;

3-[2(R)-Hydroxypropyl]amino-3-methyl-N-[2,3,4,5-tetrahydro-5-[[2' -[[[[(hydroxyethyl)amino]carbonyl]amino]methyl][1,1'-biphenyl]-4-y1]-methyl]-8-f1uoro-4-oxo-1,5-benzothiazepin-3(S)-y1]butanamide;

3-[2(R)-Hydroxypropyl]amino-3-methyl-N-[2,3,4,5-tetrahydro-5-[[2' -[[[[(hydroxyethyl)amino]carbonyl]amino]methyl][1,1'-biphenyl]-4-y1]-methyl]-8-methoxy-4-oxo-1,5-benzothiazepin-3(S)-y1]butanamide, 3-[2(R)-Hydroxypropyl]amino-3-methyl-N-[2,3,4,5-tetrahydro-5-[[2 '-[[[[(hydroxyethyl)amino]carbonyl]amino]methyl][1,1'-biphenyl]-4-y1]-methyl]-8-methylthio-4-oxo-1,5-benzothiazepin-3(S)-y1]butanamide;

3-[2(R)-Hydroxypropyl]amino-3-methyl-N-[2,3,45-tetrahydro-5-[[2'-[[[[(hydroxyethyl)amino]carbonyl]amino]methyl][1,1'-biphenyl]-4-y1]-methyl]-8-trifluoromethyl-4-oxo-1,5-benzo-thiazepin-3(S)-y1]-butamimide;

3-[2(S),3-Dihydroxypropyl]amino-3-methyl-N-[2,3,4,5-tetrahydro-5-[[2'-[[[[(hydroxyethyl)amino]carbonyl]amino]-methyl][1,1'-biphenyl]-4-y1]methyl]-4-oxo-1,5-benzothiazepin-3(S)-y1]butanamide;

3-[2(S),3-Dihydroxypropyl]amino-3-methyl-N-2,3,4,5-tetrahydro-5-[[2'-[[[[(hydroxyethyl)amino]carbonyl]aminino]-methyl][1,1'-biphenyl]-4-y1]methyl]-8-fluoro-4-oxo-1,5-benzo-thiazepin-3(S)-y1]butanamide;

3-[2(S),3-Dihydroxypropyl]amino-3-methyl-N-[2,3,4,5-tetrahydro-5-[[2'-[[[[(hydroxyethyl)amino]carbonyl]amino]-methyl][1,1'-biphenyl]-4-yl]methyl]-8-methoxy-4-oxo-1,5-benzo-thiazepin-3(S)-y1]butanamide, 3-[2(S),3-Dihydroxypropyl]amino-3-methyl-N-[2,3 ,4,5-tetrahydro-5-[[2'-[[[[(hydroxyethyl)amino]carbonyl]amino]- methyl][1,1'-biphenyl]-4-y1]methyl]-8-methylthio-4-oxo-1,5-benzothiazepin-3(S)-y1]butanamide;

3-[2(S),3-Dihydroxypropyl]amino-3-methyl-N-[2,3,4,5-tetrahydro-5-[[2'-[[[[(hydroxyethyl)amino]carbonyl]amino]-methyl][1,1'-biphenyl]-4-y1]methyl]-8-trifluoromethyl-4-oxo-1,5-benzothiazepin-3(S)-y1]-butanamide;

2-Amino-2-methyl-N-[2,3,4,5-tetrahydro-1-[[2'-[2-[[(methylamino)-carbonyl]amino]prop-2-y1][1,1'-biphenyl]-4-y1]methyl]-2-oxo-1H-benzazepin-3(R)-y1]propanamide;

2-Amino-2-methyl-N-[2,3,4,5-tetrahydro-1-[[2'-[[(methylamino)-carbonyl]amino]ethyl][1,1'-biphenyl]-4-y1]methyl]-2-oxo-1H-benz-azepin-3(R)-y1]propanamide;

2-Amino-2-methyl-N-[2,3,4,5-tetrahydro-1-[[2'-[[(methoxycarbonyl)-amino]methyl][1,1'-biphenyl]-4-y1]methyl]-2-oxo-1H-benzazepin-3(R)-y1]propanamide:

3-Amino-3-methyl-N-[2,3,4,5-tetrahydro-1-[[2'-[[(methoxycarbonyl)-amino]methyl][1,1'-biphenyl]-4-y1]methyl]-2-oxo-1H-benzazepin-3(R)-y1]butanamide;

3-[2(R)-Hydroxypropyl]amino]-3-methyl-N-[2,3,4,5-tetrahydro-1-[[2'-[[(methoxycarbonyl)amino]methyl][1,1'-biphenyl]-4-y1]-methyl]-2-oxo-1H-benzazepin-3(R)-y1]butanamide;

3-[2(S),3-Dihydroxypropyl]amino-3-methyl-N-[2,3,4,5-tetrahydro-1-[[2'-[[(methoxycarbonyl)amino]methy][1,1'-biphenyl]-4-yl]methyl]-2-oxo-1H-benzazepin-3(R)-yl]butanamide;

2-Amino-2-methyl-N-[2,3,4,5-tetrahydro-5-[[2'-[[(methoxycarbonyl)-amino]methyl][1,1'-biphenyl]-4-yl]methyl]-4-oxo-1,5-benzothiazepin-3(S)-yl]propanamide;

3-Amino-3-methyl-N-[2,3,4,5-tetrahydro-5-[[2'-[[(methoxycarbonyl)-amino]methyl][1,1'-biphenyl]-4-yl]methyl]-4-oxo-1,5-benzothiazepin-3(S)-yl]butanamide;

3-[2(R)-Hydroxypropyl]amino-3-methyl-N-[2,3,4,5-tetrahydro-5-[[2'-[[(methoxycarbonyl)amino]methyl][1,1'-biphenyl]-4-yl]-methyl]-4-oxo-1,5-benzothiazepin-3(S)-yl]butanamide;

3-[2(S),3-Dihydroxypropyl]amino-3-methyl-N-[2,3,4,5-tetrahydro-5-[[2'-[[(methoxycarbonyl)amino]methyl][1,1'-biphenyl-4-yl]methyl]-4-oxo-1,5-benzothiazepin-3(S)-yl]-butanamide;

2-Amino-2-methyl-N-[2,3,4,5-tetrahydro-1-[[2'-[[[(methylamino)-carbonyl]oxy]methyl][1,1'-biphenyl]-4-yl]methyl]-2-oxo-1H-benzazepin-3(R)-yl]propanamide;

3-Amino-3-methyl-N-[2,3,4,5-tetrahydro-1-[[2'-[[[(methylamino)-carbonyl]oxy]methyl][1,1'-biphenyl]-4-yl]methyl]-2-oxo-1H-benzazepin-3(R)-yl]butanamide;

3-[2(R)-Hydroxypropyl]amino-3-methyl-N-[2,3,4,5-tetrahydro-1-[[2'-[[(methylamimo)carbonyl]oxy]methyl][1,1'-biphenyl]4-yl]-methyl]-2-oxo-1H-benzazepin-3(R)-yl]butanamide;

3-[2(S),3-Dihydroxypropyl]amino-3-methyl-N-[2,3,4,5-tetrahydro 1-[[2'-[[[(methylamino)carbonyl]oxy]-methyl] [1,1'-biphenyl]-4-y1]methyl]-2-oxo-1H-benzaze-pin-3(R)-y1]butanamide;

2-Amino-2-methyl-N-[2,3,4,5-tetrahydro-5-[[2'[[[-(methylamino)carbonyl]oxy]methyl][1,1'-biphenyl]-4-y1]-methyl]-4-oxo-1,5 benzothiazepin-3(S)-y1]propan-amide;

3-Amino-3-methyl-N-[2,3,4,5-tetrahydro-5-[[2'[[[-(methylamino)carbonyl]oxy]methyl[1,1'-biphenyl]4-y1]-methyl]-4-oxo-1,5-benzothiazepin-3(S)-y1]butanamide;
or 3-[2(S),3-Dihydroxypropyl]amino-3-methyl N-[2,3,4,5-tetrahydro-5-[[2'- [[[( methylamino)carbonyl]oxy]-methyl]-4-oxo-1,5-benzothiazepin-3(S)-y1]butanamide, or a pharmaceutically acceptable salt thereof.
7. A process for the preparation of compound of claim 1, which comprises reacting a compound having a formula:

, III
where R1, R2, R6, X, n and p are as defined in claim 1, with a compound having the formula:

IV

- where R5 and A are as defined in Claim 1 and G is a protecting group;
which step is either followed by or preceded by the treatment of the compound with where R1a, R2a, R3a, L, w and q are as defined in Claim 1 and Y is a leaving group, followed by the replacement of the protecting group G
with R4.
8. The process of Claim 7 where compound III is first reacted with compound IV followed by reaction with compound VI.
9. A process for the preparation of a compound of Claim 1 which comprises reacting a compound having a a formula:

V

where R1, R2, R5, R6, X, A, n and p are as defined in claim 1, and G is a protecting group, with a compound having the formula:

where R1a, R2a, R3a, L, w and q are as defined in claim 1, and Y is a leaving group, followed by replacement of the protecting group G with R4.
10. The process of claim 9, where the protecting group G is t-butoxycarbonyl or benzyloxy-carbonyl and Y is chlorine, bromine, iodine, O-methanesulfonyl or O-(p-toluenesulfonyl) .
11. 2-Amino-2-methyl-N-[2,3,4,5-tetrahydro-1-[[2'-[[[methylamino)carbonyl]amino]methyl][1,1'-biphenyl]-4-y1]methyl]-2-oxo-1H-benzazepin-3(R)-y1]-propanamide; or a pharmaceutically acceptable salt thereof.
12. 2-amino-2-methyl-N-[2,3,4,5-tetrahydro-1-[[2'-[[[(methylamino)carbonyl]amino]methyl][1,1'-biphenyl]-4-y1]methyl]-2-oxo-1H-benzazepin-3(R)-y1]propanamide.
13. The hydrochloride salt of the propanamide of claim 12.
14. A composition useful for increasing the endogenous production or release of growth hormone in a human or an animal which comprises an inert carrier and an effective amount of a compound of claim 1, 2, 3, 4, 5, 6, 11 or 12, or a pharmaceutically acceptable salt thereof.
15. A composition useful for increasing the endogenous production/release of growth hormone in a human or an animal which comprises an inert carrier and an efective amount of a compound of claim 1, 2, 3, 4, 5, 6, 11 or 12, or a pharmaceutically acceptable salt thereof or growth hormone releasing factor (GRF) or one of its analogs or IGF-1 or IGF-2.
16. A composition according to claim 15, wherein said composition contains at least one growth hormone secretagogue selected from GHRP-6, GHRP-1, GHRP-2 and B-HT 920.
17. A composition for the treatment of obesity which comprises an inert carrier and a compound of claim 1, 2, 3, 4, 5, 6, 11 or 12, or a pharmaceutically acceptable salt thereof in combination with an .alpha.2 adrenergic agonist or .beta.2 adrenergic agonist.
18. A composition for the treatment of osteoporosis which comprises an inert carrier and a compound of claim 1, 2, 3, 4, 5, 6, 11 or 12, or a pharmaceutically acceptable salt thereof in combination with parathyroid hormone or a bisphosphonate.
19 A composition for the treatment of the catabolic effects of nitrogen wasting which comprises an inert carrier and a compound of claim 1, 2, 3, 4, 5, 6, 11 or 12, or a pharmaceutically acceptable salk thereof in combination with insulin-like growth factor I (IGF-I).
20. A growth hormone release-promoting pharmaceutical composition comprising an acceptable growth hormone release-promoting amount of a compound of claim 1, 2, 3, 4, 5, 6, 11 or 12, or a pharmaceutically acceptable salt thereof in association with a pharmaceutically acceptable carrier.
21. A growth hormone release-promoting pharmaceutical composition comprising an acceptable growth hormone release-promoting amount of the hydrochloride of claim 13, in association with a pharmaceutically acceptable carrier.

.
22. A compound defined in claim 1, 2, 3, 4, 5, 6, 11 or 12, for a pharmaceutically acceptable salt thereof, for use in promoting the release of growth hormone.
23. Use of a compound defined in claim 1, 2, 3, 4, 5, 6, 11 or 12, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of obesity, osteoporosis or catabolic effects of nitrogen wasting.
24. Use of a compound defined in claim 1, 2, 3, 4, 5, 6, 11 or 12, or a pharmaceutically acceptable salt thereof as a growth hormone release-promoting agent.
25. The hydrochloride of claim 13, for use in the treatment of obesity, osteoporosis or catabolic effects of nitrogen wasting.
26. A method for increasing levels of endogenous growth hormone in a human or an animal which comprises administering to such human or animal an effective amount of a compound of claim 1.
27. A method for the treatment of obesity which comprises administering to an obese patient a compound of claim 1, in combination with an .alpha.2 adrenergic agonist or .beta.2 adrenergic agonist.
28. A method for the treatment of osteoporosis which comprises administering to a patient with osteoporosis a compound of claim 1, in combination with parathyroid hormone or a bisphosphonate.
29. A method for the treatment of the catabolic effects of nitrogen wasting which comprises administering to such patient a compound of claim 1, in combination with insulin-like growth factor I
(IGF-1).
CA002142707A 1992-08-28 1993-08-18 Benzo-fused lactams promote release of growth hormone Expired - Fee Related CA2142707C (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/936,975 US5283241A (en) 1992-08-28 1992-08-28 Benzo-fused lactams promote release of growth hormone
US936,975 1992-08-28

Publications (2)

Publication Number Publication Date
CA2142707A1 CA2142707A1 (en) 1994-03-17
CA2142707C true CA2142707C (en) 1997-12-30

Family

ID=25469291

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002142707A Expired - Fee Related CA2142707C (en) 1992-08-28 1993-08-18 Benzo-fused lactams promote release of growth hormone

Country Status (19)

Country Link
US (3) US5283241A (en)
EP (1) EP0659179B1 (en)
JP (1) JPH08504178A (en)
KR (1) KR950702966A (en)
AT (1) ATE209185T1 (en)
AU (1) AU674348B2 (en)
CA (1) CA2142707C (en)
CZ (1) CZ52695A3 (en)
DE (1) DE69331197T2 (en)
ES (1) ES2166363T3 (en)
FI (1) FI950894A (en)
HU (1) HUT72053A (en)
NO (1) NO950730L (en)
NZ (1) NZ255818A (en)
PL (1) PL310601A1 (en)
RU (1) RU95107663A (en)
SK (1) SK26095A3 (en)
WO (1) WO1994005634A1 (en)
ZA (1) ZA936310B (en)

Families Citing this family (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4208304A1 (en) * 1992-03-16 1993-09-23 Merck Patent Gmbh 2-OXOCHINOLINDERIVATE
EP0612319A1 (en) * 1992-08-20 1994-08-31 Otsuka Pharmaceutical Co., Ltd. Benzoheterocyclic compounds as oxytocin and vasopressin antagonists
US5283241A (en) * 1992-08-28 1994-02-01 Merck & Co., Inc. Benzo-fused lactams promote release of growth hormone
US5430144A (en) * 1993-07-26 1995-07-04 Merck & Co., Inc. Benzo-fused lactams promote release of growth hormone
US5434261A (en) * 1993-07-26 1995-07-18 Merck & Co., Inc. Benzo-fused lactams promote release of growth hormone
US5545735A (en) * 1993-10-04 1996-08-13 Merck & Co., Inc. Benzo-Fused Lactams promote release of growth hormone
US5492920A (en) * 1993-12-10 1996-02-20 Merck & Co., Inc. Piperidine, pyrrolidine and hexahydro-1H-azepines promote release of growth hormone
US5492916A (en) * 1993-12-23 1996-02-20 Merck & Co., Inc. Di- and tri-substituted piperidines, pyrrolidines and hexahydro-1H-azepines promote release of growth hormone
US5494919A (en) * 1993-11-09 1996-02-27 Merck & Co., Inc. 2-substituted piperidines, pyrrolidines and hexahydro-1H-azepines promote release of growth hormone
US5721251A (en) * 1993-12-10 1998-02-24 Merck & Co., Inc. Piperidine, pyrrolidine and hexahydro-1H-azepines promote release of growth hormone
US5721250A (en) * 1993-12-23 1998-02-24 Merck & Co. Inc. Di-and tri-substituted piperidines, pyrrolidines and hexahydro-1H-azepines promote release of growth hormone
US5798337A (en) * 1994-11-16 1998-08-25 Genentech, Inc. Low molecular weight peptidomimetic growth hormone secretagogues
US20020111461A1 (en) * 1999-05-21 2002-08-15 Todd C. Somers Low molecular weight peptidomimetic growth hormone secretagogues
US5731317A (en) * 1995-03-10 1998-03-24 Merck & Co., Inc. Bridged piperidines promote release of growth hormone
US5559128A (en) * 1995-04-18 1996-09-24 Merck & Co., Inc. 3-substituted piperidines promote release of growth hormone
ES2268713T3 (en) 1995-12-13 2007-03-16 MERCK &amp; CO., INC. ESSAYS OF RECEPTORS OF SECRETAGOGOS OF THE HORMONE OF GROWTH.
US6531314B1 (en) 1996-12-10 2003-03-11 Merck & Co., Inc. Growth hormone secretagogue receptor family
WO1997036873A1 (en) * 1996-04-03 1997-10-09 Merck & Co., Inc. Piperidines, pyrrolidines and hexahydro-1h-azepines promote release of growth hormone
US6635632B1 (en) * 1996-12-23 2003-10-21 Athena Neurosciences, Inc. Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
US6683075B1 (en) 1996-12-23 2004-01-27 Athena Neurosciences, Inc. Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use
WO1998046220A1 (en) * 1997-04-14 1998-10-22 Merck & Co., Inc. Combination therapy for the prevention and treatment of osteoporosis
US6211174B1 (en) 1997-10-31 2001-04-03 Merck & Co., Inc. Naphtho-fused lactams promote release of growth hormone
US6657063B1 (en) * 1998-04-30 2003-12-02 Pfizer Inc. Combinations of β3 agonists and growth hormone secretagogues
US6958330B1 (en) 1998-06-22 2005-10-25 Elan Pharmaceuticals, Inc. Polycyclic α-amino-ε-caprolactams and related compounds
US6509331B1 (en) 1998-06-22 2003-01-21 Elan Pharmaceuticals, Inc. Deoxyamino acid compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
US6552013B1 (en) 1998-06-22 2003-04-22 Elan Pharmaceuticals, Inc. Deoxyamino acid compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
US6569851B1 (en) * 1998-06-22 2003-05-27 Elan Pharmaceutials, Inc. Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
US6774125B2 (en) * 1998-06-22 2004-08-10 Elan Pharmaceuticals, Inc. Deoxyamino acid compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
US6528505B1 (en) 1998-06-22 2003-03-04 Elan Pharmaceuticals, Inc. Cyclic amino acid compounds pharmaceutical compositions comprising same and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
US6682908B1 (en) 1998-07-10 2004-01-27 Merck & Co., Inc. Mouse growth hormone secretagogue receptor
WO2000002919A1 (en) 1998-07-13 2000-01-20 Merck & Co., Inc. Growth hormone secretagogue related receptors and nucleic acids
NZ525513A (en) 1998-08-07 2004-09-24 Pont Pharmaceuticals Du Succinoylamino lactams as inhibitors of Abeta protein production
HRP990246A2 (en) 1998-08-07 2000-06-30 Du Pont Pharm Co Succinoylamino benzodiazepines as inhibitors of a beta protein production
JP2002522058A (en) 1998-08-10 2002-07-23 メルク・アンド・カンパニー・インコーポレーテッド Canine growth hormone secretagogue receptor
JP4445133B2 (en) 1998-08-20 2010-04-07 大日本住友製薬株式会社 Oxindole derivatives
US6194402B1 (en) * 1998-09-02 2001-02-27 Merck & Co., Inc. Enhancement of return to independent living status with a growth hormone secretagogue
US6380184B1 (en) 1998-10-28 2002-04-30 Bristol-Myers Squibb Co. Benzoazepines and analogs thereof useful as growth hormone secretagogues
CA2347671A1 (en) * 1998-12-24 2000-07-06 Dupont Pharmaceuticals Company Succinoylamino benzodiazepines as inhibitors of a.beta. protein production
JP2002542151A (en) 1999-02-18 2002-12-10 科研製薬株式会社 Novel amide derivatives as growth hormone secretagogues
US6525203B1 (en) 1999-03-12 2003-02-25 Bristol-Myers Squibb Company Heterocyclic aromatic compounds useful as growth hormone secretagogues
US6518292B1 (en) 1999-03-12 2003-02-11 Bristol-Myers Squibb Co. Heterocyclic aromatic compounds usefuls as growth hormone secretagogues
DE19937537A1 (en) 1999-08-09 2001-03-08 Gruenenthal Gmbh Substituted 2-dialkylaminoalkylbiphenyl derivatives
US6503902B2 (en) 1999-09-13 2003-01-07 Bristol-Myers Squibb Pharma Company Hydroxyalkanoylaminolactams and related structures as inhibitors of a β protein production
US6960576B2 (en) 1999-09-13 2005-11-01 Bristol-Myers Squibb Pharma Company Hydroxyalkanoylaminolactams and related structures as inhibitors of Aβ protein production
CA2384544A1 (en) 1999-10-08 2001-04-19 Bristol-Myers Squibb Pharma Company Amino lactam sulfonamides as inhibitors of a.beta. protein production
CA2391498A1 (en) * 1999-11-18 2001-05-25 Antexpharma, Inc. Substituted 1-benzazepines and derivatives thereof
WO2001060826A2 (en) 2000-02-17 2001-08-23 Bristol-Myers Squibb Pharma Company SUCCINOYLAMINO CARBOCYCLES AND HETEROCYCLES AS INHIBITORS OF Aβ PROTEIN PRODUCTION
US6495540B2 (en) 2000-03-28 2002-12-17 Bristol - Myers Squibb Pharma Company Lactams as inhibitors of A-β protein production
AU2001253090A1 (en) * 2000-04-03 2001-10-15 Bristol-Myers Squibb Pharma Company Cyclic lactams as inhibitors of abeta protein production
BR0110051A (en) 2000-04-03 2004-12-07 Bristol Myers Squibb Pharma Co Compound, Compound Use, Pharmaceutical Composition and Method of Treatment of Alzheimer's Disease
CA2404273A1 (en) * 2000-04-11 2001-10-18 Bristol-Myers Squibb Pharma Company Substituted lactams as inhibitors of a.beta. protein production
US20100009966A1 (en) * 2001-04-11 2010-01-14 Bristol-Myers Squibb Pharma Company Substituted lactams as inhibitors of abeta protein production
BR0110638A (en) 2000-05-11 2003-03-25 Bristol Myers Squibb Co Tetrahydroisoquinoline analogues useful as growth hormone secretagogues
US6878363B2 (en) * 2000-05-17 2005-04-12 Bristol-Myers Squibb Pharma Company Use of small molecule radioligands to discover inhibitors of amyloid-beta peptide production and for diagnostic imaging
EP1268450A1 (en) * 2000-06-01 2003-01-02 Bristol-Myers Squibb Pharma Company Lactams substituted by cyclic succinates as inhibitors of a-beta protein production
IL143690A0 (en) * 2000-06-19 2002-04-21 Pfizer Prod Inc The use of growth hormone secretagogues to treat systemic lupus erythematosus and inflammatory bowel disease
IL143942A0 (en) * 2000-06-29 2002-04-21 Pfizer Prod Inc Use of growth hormone secretagogues for treatment of physical performance decline
US7468365B2 (en) * 2000-11-17 2008-12-23 Eli Lilly And Company Lactam compound
US7186745B2 (en) 2001-03-06 2007-03-06 Astrazeneca Ab Indolone derivatives having vascular damaging activity
US20090062256A1 (en) * 2001-06-01 2009-03-05 Bristol-Myers Squibb Pharma Company LACTAMS SUBSTITUTED BY CYCLIC SUCCINATES AS INHIBITORS OF Abeta PROTEIN PRODUCTION
EP1312363A1 (en) * 2001-09-28 2003-05-21 Pfizer Products Inc. Methods of treatment and kits comprising a growth hormone secretagogue
US6649606B1 (en) 2001-11-09 2003-11-18 Bristol-Myers Squibb Co. Tetrahydroisoquinoline analogs as modulators of chemokine receptor activity
US7342884B2 (en) * 2002-03-13 2008-03-11 Harmonic, Inc. Method and apparatus for one directional communications in bidirectional communications channel
US20030199514A1 (en) * 2002-03-27 2003-10-23 Fryburg David A. Methods for improving efficacy of treatment with growth hormone secretagogues
US20050192265A1 (en) * 2003-03-20 2005-09-01 Thompson Richard C. Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds
WO2005027913A1 (en) * 2003-09-19 2005-03-31 Pfizer Products Inc. Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and a growth hormone secretagogue
UA87854C2 (en) 2004-06-07 2009-08-25 Мерк Энд Ко., Инк. N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators
FR2878528B1 (en) * 2004-11-29 2008-05-16 Aventis Pharma Sa 2-ALCOXY-3,4,5-TRIHYDROXY-ALKYLAMIDES, PREPARATION THEREOF, COMPOSITIONS CONTAINING SAME AND USE THEREOF
FR2878525B1 (en) * 2004-11-29 2007-02-23 Aventis Pharma Sa BENGAMIDES HAVING SUBSTITUTED CAPROLACTAM CYCLE, PREPARATION METHOD, COMPOSITIONS CONTAINING SAME AND USE THEREOF
KR101155335B1 (en) * 2005-01-07 2012-06-11 엘지전자 주식회사 Multimedia message service operating method for mobile communication terminal
US7989441B2 (en) * 2005-06-08 2011-08-02 Novartis Ag Organic compounds
FR2901554B1 (en) * 2006-05-24 2011-04-01 Sanofi Aventis 2-ALCOXY-3,4,5-TRIHYDROXY-ALKYLAMIDE-BENZAZEPINE, PREPARATION THEREOF, COMPOSITIONS CONTAINING SAME AND USE THEREOF
FR2901556A1 (en) * 2006-05-24 2007-11-30 Sanofi Aventis Sa 2-ALCOXY-3,4,5-TRIHYDROXY-ALKYLAMIDE DERIVATIVES, THEIR PREPARATION, COMPOSITIONS CONTAINING SAME AND USE THEREOF
FR2901555A1 (en) * 2006-05-24 2007-11-30 Sanofi Aventis Sa 2-ALCOXY-3,4,5-TRIHYDROXY-ALKYLAMIDE-BENZOTHIAZEPINE, THEIR PREPARATION, COMPOSITIONS CONTAINING SAME AND USE THEREOF
WO2008134828A2 (en) 2007-05-04 2008-11-13 Katholieke Universiteit Leuven Tissue degeneration protection
JP2012517997A (en) * 2009-02-17 2012-08-09 Msd株式会社 1,4-benzodiazepin-2-one derivatives
BR112012001363A2 (en) * 2009-07-22 2016-11-08 Ipsen Pharma Sas igf-1 analog, pharmaceutical composition, and method for treating conditions or diseases mediated by igf-1 receptor binding
WO2013190520A2 (en) 2012-06-22 2013-12-27 The General Hospital Corporation Gh-releasing agents in the treatment of vascular stenosis and associated conditions
EP2872490B1 (en) * 2012-07-13 2018-02-07 F. Hoffmann-La Roche AG Antiproliferative benzo[b]azepin-2-ones
US9119832B2 (en) 2014-02-05 2015-09-01 The Regents Of The University Of California Methods of treating mild brain injury
SG11201609050UA (en) 2014-05-30 2016-12-29 Pfizer Carbonitrile derivatives as selective androgen receptor modulators
WO2017075535A1 (en) 2015-10-28 2017-05-04 Oxeia Biopharmaceuticals, Inc. Methods of treating neurodegenerative conditions
JP6974331B2 (en) 2016-02-05 2021-12-01 デナリ セラピューティクス インコーポレイテッドDenali Therapeutics Inc. Compounds, compositions and methods
HUE058802T2 (en) 2016-12-09 2022-09-28 Denali Therapeutics Inc Compounds useful as ripk1 inhibitors
BR112020024292A2 (en) 2018-06-06 2021-03-02 Massachusetts Institute Of Technology circular rna for translation into eukaryotic cells
CN115867291A (en) 2019-05-22 2023-03-28 麻省理工学院 Circular RNA compositions and methods
CN115052635A (en) 2019-12-04 2022-09-13 奥纳治疗公司 Circular RNA compositions and methods
WO2023275715A1 (en) 2021-06-30 2023-01-05 Pfizer Inc. Metabolites of selective androgen receptor modulators

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3239345A (en) * 1965-02-15 1966-03-08 Estrogenic compounds and animal growth promoters
US4411890A (en) * 1981-04-14 1983-10-25 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
US4036979A (en) * 1974-01-25 1977-07-19 American Cyanamid Company Compositions containing 4,5,6,7-tetrahydrobenz[b]thien-4-yl-ureas or derivatives and methods of enhancing growth rate
EP0166357A3 (en) * 1984-06-26 1988-10-26 Merck & Co. Inc. Benzofused lactams and pharmaceutical compositions containing them
US4692522A (en) * 1985-04-01 1987-09-08 Merck & Co., Inc. Benzofused lactams useful as cholecystokinin antagonists
CA1334092C (en) * 1986-07-11 1995-01-24 David John Carini Angiotensin ii receptor blocking imidazoles
US4820843A (en) * 1987-05-22 1989-04-11 E. I. Du Pont De Nemours And Company Tetrazole intermediates to antihypertensive compounds
CA1338238C (en) * 1988-01-07 1996-04-09 David John Carini Angiotensin ii receptor blocking imidazoles and combinations thereof with diuretics and nsaids
US4970207A (en) * 1988-07-07 1990-11-13 Fujisawa Pharmaceutical Company, Ltd. Benzodiazepine derivatives
US5206235A (en) * 1991-03-20 1993-04-27 Merck & Co., Inc. Benzo-fused lactams that promote the release of growth hormone
US5283241A (en) * 1992-08-28 1994-02-01 Merck & Co., Inc. Benzo-fused lactams promote release of growth hormone
US5583130A (en) * 1992-09-25 1996-12-10 Merck & Co., Inc. Benzo-fused lactams promote release of growth hormone
US5317017A (en) * 1992-09-30 1994-05-31 Merck & Co., Inc. N-biphenyl-3-amido substituted benzolactams stimulate growth hormone release
US5374721A (en) * 1992-10-14 1994-12-20 Merck & Co., Inc. Benzo-fused lactams promote release of growth hormone
US5284841A (en) * 1993-02-04 1994-02-08 Merck & Co., Inc. Benzo-fused lactams promote release of growth hormone
US5434261A (en) * 1993-07-26 1995-07-18 Merck & Co., Inc. Benzo-fused lactams promote release of growth hormone
US5430144A (en) * 1993-07-26 1995-07-04 Merck & Co., Inc. Benzo-fused lactams promote release of growth hormone
US5438136A (en) * 1993-11-02 1995-08-01 Merck & Co., Inc. Benzo-fused macrocycles promote release of growth hormone

Also Published As

Publication number Publication date
WO1994005634A1 (en) 1994-03-17
JPH08504178A (en) 1996-05-07
EP0659179A4 (en) 1995-08-09
ATE209185T1 (en) 2001-12-15
NO950730L (en) 1995-04-24
DE69331197D1 (en) 2002-01-03
CZ52695A3 (en) 1996-02-14
FI950894A0 (en) 1995-02-27
NO950730D0 (en) 1995-02-27
US5968924A (en) 1999-10-19
FI950894A (en) 1995-02-27
AU674348B2 (en) 1996-12-19
US5672596A (en) 1997-09-30
KR950702966A (en) 1995-08-23
NZ255818A (en) 1997-05-26
HU9500599D0 (en) 1995-05-29
HUT72053A (en) 1996-03-28
PL310601A1 (en) 1995-12-27
ES2166363T3 (en) 2002-04-16
DE69331197T2 (en) 2002-06-27
US5283241A (en) 1994-02-01
SK26095A3 (en) 1995-08-09
ZA936310B (en) 1994-10-19
EP0659179B1 (en) 2001-11-21
EP0659179A1 (en) 1995-06-28
AU5080593A (en) 1994-03-29
CA2142707A1 (en) 1994-03-17
RU95107663A (en) 1996-11-20

Similar Documents

Publication Publication Date Title
CA2142707C (en) Benzo-fused lactams promote release of growth hormone
US7279573B2 (en) Amide derivatives
KR100288722B1 (en) Dual action inhibitors
WO1995009633A1 (en) Benzo-fused lactams promote release of growth hormone
CA2147503A1 (en) Substituted dipeptide analogs promote release of growth hormone
JPH07108901B2 (en) Norcyclostatin polypeptide
BG61448B1 (en) Benzocondensated lactams increasing the release of the growth hormone
WO1995003289A1 (en) Benzo-fused lactams promote release of growth hormone
EP0711287A1 (en) Benzo-fused lactams promote release of growth hormone
US20060014701A1 (en) Novel amide derivatives as growth hormone secretagogues
SE447250B (en) NEW ENCAPAL INGREDIENTS
WO1999045029A1 (en) New salt forms of (2e)- 5-amino-5- methylhex-2- enoic acid n-methyl-n-((1r)-1-(n- methyl-n-((1r)-1-(methylcarbamoyl)-2- phenylethyl)carbamoyl)-2- (2-naphtyl)ethyl)amide
US5726319A (en) Biphenyl substituted dipeptide analogs promote release of growth hormone
US5817654A (en) N-substituted naphthofused lactams
GB2272439A (en) Benzo-fused lactams that inhibit the release of growth hormone
US5654294A (en) Spiro lactam dual action inhibitors
US6211174B1 (en) Naphtho-fused lactams promote release of growth hormone
HU211894A9 (en) Benzo-fused lactams promote release of growth hormone

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed